Word	Tag	Begin-End
This	O	0-4
can	O	5-8
translate	O	9-18
into	O	19-23
global	O	24-30
effects	O	31-38
on	O	39-41
cellular	O	42-50
health	O	51-57
and	O	58-61
differentiation	O	62-77
state	O	78-83
. 	O	83-85

Recently	O	0-8
,	O	8-9
several	O	10-17
reports	O	18-25
have	O	26-30
identified	O	31-41
crucial	O	42-49
roles	O	50-55
for	O	56-59
miRNAs	O	60-66
in	O	67-69
controlling	O	70-81
the	O	82-85
production	O	86-96
,	O	96-97
differentiation	O	98-113
,	O	113-114
and	O	115-118
health	O	119-125
of	O	126-128
myelinating	O	129-140
cells	O	141-146
of	O	147-149
the	O	150-153
mammalian	O	154-163
nervous	O	164-171
system	O	172-178
. 	O	178-180

As	O	0-2
single	O	3-9
miRNAs	O	10-16
are	O	17-20
often	O	21-26
predicted	O	27-36
to	O	37-39
target	O	40-46
up	O	47-49
to	O	50-52
hundreds	O	53-61
of	O	62-64
individual	O	65-75
transcripts	O	76-87
,	O	87-88
miRNAs	O	89-95
are	O	96-99
able	O	100-104
to	O	105-107
broadly	O	108-115
affect	O	116-122
the	O	123-126
overall	O	127-134
protein	O	135-142
expression	O	143-153
state	O	154-159
of	O	160-162
the	O	163-166
cell	O	167-171
. 	O	171-173

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
will	O	19-23
discuss	O	24-31
how	O	32-35
individual	O	36-46
miRNAs	O	47-53
regulate	O	54-62
these	O	63-68
various	O	69-76
processes	O	77-86
,	O	86-87
and	O	88-91
also	O	92-96
how	O	97-100
miRNA	O	101-106
production	O	107-117
in	O	118-120
general	O	121-128
is	O	129-131
required	O	132-140
for	O	141-144
several	O	145-152
stages	O	153-159
of	O	160-162
myelin	O	163-169
generation	O	170-180
and	O	181-184
maintenance	O	185-196
.   	O	196-200

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
a	O	23-24
class	O	25-30
of	O	31-33
small	O	34-39
(	O	40-41
approx	O	41-47
.	O	47-48
22	O	49-51
nt	O	52-54
)	O	54-55
noncoding	O	56-65
RNAs	O	66-70
that	O	71-75
are	O	76-79
capable	O	80-87
of	O	88-90
post	O	91-95
-	O	95-96
transcriptionally	O	96-113
silencing	O	114-123
mRNAs	O	124-129
that	O	130-134
contain	O	135-142
sequences	O	143-152
complementary	O	153-166
to	O	167-169
the	O	170-173
miRNAs	O	174-180
'	O	180-181
7	O	182-183
-	O	183-184
to	O	185-187
8	O	188-189
-	O	189-190
bp	O	190-192
'	O	193-194
seed	O	194-198
'	O	198-199
sequence	O	200-208
. 	O	208-210

MicroRNAs	O	0-9
in	O	10-12
oligodendrocyte	O	13-28
and	O	29-32
Schwann	O	33-40
cell	O	41-45
differentiation	O	46-61
.  	O	61-64

Our	O	0-3
data	O	4-8
suggests	O	9-17
that	O	18-22
down	O	23-27
-	O	27-28
regulation	O	28-38
of	O	39-41
miRNA	B	42-47
-	I	47-48
128	I	48-51
may	O	52-55
contribute	O	56-66
to	O	67-69
glioma	O	70-76
and	O	77-80
GBM	O	81-84
,	O	84-85
in	O	86-88
part	O	89-93
,	O	93-94
by	O	95-97
coordinately	O	98-110
up	O	111-113
-	O	113-114
regulating	O	114-124
ARP5	O	125-129
(	O	130-131
ANGPTL6	O	131-138
)	O	138-139
,	O	139-140
Bmi	O	141-144
-	O	144-145
1	O	145-146
and	O	147-150
E2F	O	151-154
-	O	154-155
3a	O	155-157
,	O	157-158
resulting	O	159-168
in	O	169-171
the	O	172-175
proliferation	O	176-189
of	O	190-192
undifferentiated	O	193-209
GBM	O	210-213
cells	O	214-219
.   	O	219-223

Addition	O	0-8
of	O	9-11
exogenous	O	12-21
miRNA	B	22-27
-	I	27-28
128	I	28-31
to	O	32-34
CRL	O	35-38
-	O	38-39
1690	O	39-43
and	O	44-47
CRL	O	48-51
-	O	51-52
2610	O	52-56
GBM	O	57-60
cell	O	61-65
lines	O	66-71
(	O	72-73
a	O	73-74
)	O	74-75
restored	O	76-84
'	O	85-86
homeostatic	O	86-97
'	O	97-98
ARP5	O	99-103
(	O	104-105
ANGPTL6	O	105-112
)	O	112-113
,	O	113-114
Bmi	O	115-118
-	O	118-119
1	O	119-120
and	O	121-124
E2F	O	125-128
-	O	128-129
3a	O	129-131
expression	O	132-142
,	O	142-143
and	O	144-147
(	O	148-149
b	O	149-150
)	O	150-151
significantly	O	152-165
decreased	O	166-175
the	O	176-179
proliferation	O	180-193
of	O	194-196
CRL	O	197-200
-	O	200-201
1690	O	201-205
and	O	206-209
CRL	O	210-213
-	O	213-214
2610	O	214-218
cell	O	219-223
lines	O	224-229
. 	O	229-231

Three	O	0-5
bioinformatics	O	6-20
-	O	20-21
verified	O	21-29
miRNA	B	30-35
-	I	35-36
128	I	36-39
targets	O	40-47
,	O	47-48
angiopoietin	O	49-61
-	O	61-62
related	O	62-69
growth	O	70-76
factor	O	77-83
protein	O	84-91
5	O	92-93
(	O	94-95
ARP5	O	95-99
;	O	99-100
ANGPTL6	O	101-108
)	O	108-109
,	O	109-110
a	O	111-112
transcription	O	113-126
suppressor	O	127-137
that	O	138-142
promotes	O	143-151
stem	O	152-156
cell	O	157-161
renewal	O	162-169
and	O	170-173
inhibits	O	174-182
the	O	183-186
expression	O	187-197
of	O	198-200
known	O	201-206
tumor	O	207-212
suppressor	O	213-223
genes	O	224-229
involved	O	230-238
in	O	239-241
senescence	O	242-252
and	O	253-256
differentiation	O	257-272
,	O	272-273
Bmi	O	274-277
-	O	277-278
1	O	278-279
,	O	279-280
and	O	281-284
a	O	285-286
transcription	O	287-300
factor	O	301-307
critical	O	308-316
for	O	317-320
the	O	321-324
control	O	325-332
of	O	333-335
cell	O	336-340
-	O	340-341
cycle	O	341-346
progression	O	347-358
,	O	358-359
E2F	O	360-363
-	O	363-364
3a	O	364-366
,	O	366-367
were	O	368-372
found	O	373-378
to	O	379-381
be	O	382-384
up	O	385-387
-	O	387-388
regulated	O	388-397
. 	O	397-399

The	O	0-3
down	O	4-8
-	O	8-9
regulation	O	9-19
of	O	20-22
miRNA	B	23-28
-	I	28-29
128	I	29-32
was	O	33-36
found	O	37-42
to	O	43-45
inversely	O	46-55
correlate	O	56-65
with	O	66-70
WHO	O	71-74
tumor	O	75-80
grade	O	81-86
. 	O	86-88

High	O	0-4
density	O	5-12
micro	O	13-18
-	O	18-19
RNA	O	19-22
(	O	23-24
miRNA	O	24-29
)	O	29-30
arrays	O	31-37
,	O	37-38
fluorescent	O	39-50
-	O	50-51
reporter	O	51-59
miRNA	O	60-65
assay	O	66-71
and	O	72-75
Northern	O	76-84
miRNA	O	85-90
dot	O	91-94
-	O	94-95
blot	O	95-99
analysis	O	100-108
show	O	109-113
that	O	114-118
a	O	119-120
brain	O	121-126
-	O	126-127
enriched	O	127-135
miRNA	B	136-141
-	I	141-142
128	I	142-145
is	O	146-148
significantly	O	149-162
down	O	163-167
-	O	167-168
regulated	O	168-177
in	O	178-180
glioblastoma	O	181-193
multiforme	O	194-204
(	O	205-206
GBM	O	206-209
)	O	209-210
and	O	211-214
in	O	215-217
GBM	O	218-221
cell	O	222-226
lines	O	227-232
when	O	233-237
compared	O	238-246
to	O	247-249
age	O	250-253
-	O	253-254
matched	O	254-261
controls	O	262-270
. 	O	270-272

Micro	B	0-5
-	I	5-6
RNA	I	6-9
-	I	9-10
128	I	10-13
(	O	14-15
miRNA	B	15-20
-	I	20-21
128	I	21-24
)	O	24-25
down	O	26-30
-	O	30-31
regulation	O	31-41
in	O	42-44
glioblastoma	O	45-57
targets	O	58-65
ARP5	O	66-70
(	O	71-72
ANGPTL6	O	72-79
)	O	79-80
,	O	80-81
Bmi	O	82-85
-	O	85-86
1	O	86-87
and	O	88-91
E2F	O	92-95
-	O	95-96
3a	O	96-98
,	O	98-99
key	O	100-103
regulators	O	104-114
of	O	115-117
brain	O	118-123
cell	O	124-128
proliferation	O	129-142
.  	O	142-145

Follow	O	0-6
up	O	7-9
functional	O	10-20
enrichment	O	21-31
analysis	O	32-40
of	O	41-43
these	O	44-49
FFLs	O	50-54
uncovered	O	55-64
some	O	65-69
functions	O	70-79
important	O	80-89
to	O	90-92
carcinogenesis	O	93-107
but	O	108-111
also	O	112-116
some	O	117-121
unique	O	122-128
functions	O	129-138
specific	O	139-147
to	O	148-150
the	O	151-154
FFLs	O	155-159
we	O	160-162
identified	O	163-173
.   	O	173-177

Transcriptional	O	0-15
aberrations	O	16-27
may	O	28-31
play	O	32-36
a	O	37-38
vital	O	39-44
role	O	45-49
in	O	50-52
the	O	53-56
etiology	O	57-65
of	O	66-68
glioblastoma	O	69-81
,	O	81-82
which	O	83-88
might	O	89-94
be	O	95-97
caused	O	98-104
by	O	105-107
both	O	108-112
genomic	O	113-120
alterations	O	121-132
and	O	133-136
other	O	137-142
regulation	O	143-153
molecules	O	154-163
. 	O	163-165

Illustrating	O	0-12
the	O	13-16
functions	O	17-26
being	O	27-32
disturbed	O	33-42
during	O	43-49
carcinogenesis	O	50-64
and	O	65-68
how	O	69-72
they	O	73-77
are	O	78-81
deregulated	O	82-93
is	O	94-96
very	O	97-101
important	O	102-111
for	O	112-115
us	O	116-118
to	O	119-121
understand	O	122-132
its	O	133-136
underlying	O	137-147
mechanism	O	148-157
. 	O	157-159

We	O	0-2
searched	O	3-11
glioblastoma	O	12-24
-	O	24-25
specific	O	25-33
regulatory	O	34-44
networks	O	45-53
by	O	54-56
integrating	O	57-68
glioblastoma	O	69-81
related	O	82-89
miRNAs	O	90-96
,	O	96-97
TFs	O	98-101
and	O	102-105
genes	O	106-111
,	O	111-112
and	O	113-116
identified	O	117-127
54	O	128-130
feed	O	131-135
-	O	135-136
forward	O	136-143
loops	O	144-149
(	O	150-151
FFLs	O	151-155
)	O	155-156
. 	O	156-158

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
investigated	O	18-30
possible	O	31-39
cooperative	O	40-51
deregulation	O	52-64
of	O	65-67
microRNAs	O	68-77
(	O	78-79
miRNAs	O	79-85
)	O	85-86
and	O	87-90
transcription	O	91-104
factors	O	105-112
(	O	113-114
TFs	O	114-117
)	O	117-118
in	O	119-121
glioblastoma	O	122-134
,	O	134-135
under	O	136-141
the	O	142-145
hypothesis	O	146-156
that	O	157-161
miRNAs	O	162-168
and	O	169-172
TFs	O	173-176
might	O	177-182
have	O	183-187
a	O	188-189
combinational	O	190-203
regulatory	O	204-214
effect	O	215-221
on	O	222-224
glioblastoma	O	225-237
genes	O	238-243
. 	O	243-245

Glioblastoma	O	0-12
is	O	13-15
the	O	16-19
most	O	20-24
common	O	25-31
and	O	32-35
most	O	36-40
lethal	O	41-47
brain	O	48-53
tumour	O	54-60
in	O	61-63
humans	O	64-70
. 	O	70-72

Gene	O	0-4
regulation	O	5-15
in	O	16-18
glioblastoma	O	19-31
:	O	31-32
a	O	33-34
combinatorial	O	35-48
analysis	O	49-57
of	O	58-60
microRNAs	O	61-70
and	O	71-74
transcription	O	75-88
factors	O	89-96
.  	O	96-99

Although	O	0-8
microRNAs	O	9-18
are	O	19-22
expressed	O	23-32
extensively	O	33-44
in	O	45-47
the	O	48-51
central	O	52-59
nervous	O	60-67
system	O	68-74
in	O	75-77
physiological	O	78-91
and	O	92-95
pathological	O	96-108
conditions	O	109-119
,	O	119-120
their	O	121-126
expression	O	127-137
in	O	138-140
neurological	O	141-153
disorder	O	154-162
of	O	163-165
epilepsy	O	166-174
has	O	175-178
not	O	179-182
been	O	183-187
well	O	188-192
characterized	O	193-206
. 	O	206-208

Expression	O	0-10
profile	O	11-18
of	O	19-21
microRNAs	O	22-31
in	O	32-34
rat	O	35-38
hippocampus	O	39-50
following	O	51-60
lithium	O	61-68
-	O	68-69
pilocarpine	O	69-80
-	O	80-81
induced	O	81-88
status	O	89-95
epilepticus	O	96-107
.  	O	107-110

Rat	O	0-3
MicroRNA	O	4-12
array	O	13-18
and	O	19-22
differential	O	23-35
analysis	O	36-44
had	O	45-48
detected	O	49-57
19	O	58-60
up	O	61-63
-	O	63-64
regulated	O	64-73
microRNAs	O	74-83
and	O	84-87
7	O	88-89
down	O	90-94
-	O	94-95
regulated	O	95-104
microRNAs	O	105-114
in	O	115-117
rat	O	118-121
hippocampus	O	122-133
,	O	133-134
and	O	135-138
four	O	139-143
randomly	O	144-152
selected	O	153-161
deregulated	O	162-173
microRNAs	O	174-183
(	O	184-185
microRNA	B	185-193
-	I	193-194
34a	I	194-197
,	O	197-198
microRNA	B	199-207
-	I	207-208
22	I	208-210
,	O	210-211
microRNA	B	212-220
-	I	220-221
125a	I	221-225
,	O	225-226
microRNA	B	227-235
-	I	235-236
21	I	236-238
)	O	238-239
were	O	240-244
confirmed	O	245-254
by	O	255-257
qRT	O	258-261
-	O	261-262
PCR	O	262-265
,	O	265-266
then	O	267-271
their	O	272-277
expression	O	278-288
alterations	O	289-300
in	O	301-303
rat	O	304-307
peripheral	O	308-318
blood	O	319-324
were	O	325-329
analyzed	O	330-338
. 	O	338-340

Here	O	0-4
we	O	5-7
investigated	O	8-20
microRNA	O	21-29
expression	O	30-40
pattern	O	41-48
in	O	49-51
post	O	52-56
status	O	57-63
epilepticus	O	64-75
rats	O	76-80
(	O	81-82
24h	O	82-85
after	O	86-91
status	O	92-98
)	O	98-99
. 	O	99-101

Thus	O	0-4
,	O	4-5
our	O	6-9
results	O	10-17
have	O	18-22
not	O	23-26
only	O	27-31
characterized	O	32-45
the	O	46-49
microRNA	O	50-58
expression	O	59-69
profile	O	70-77
in	O	78-80
post	O	81-85
status	O	86-92
epilepticus	O	93-104
rat	O	105-108
hippocampus	O	109-120
but	O	121-124
also	O	125-129
demonstrated	O	130-142
that	O	143-147
some	O	148-152
rat	O	153-156
hippocampal	O	157-168
microRNAs	O	169-178
were	O	179-183
probably	O	184-192
associated	O	193-203
with	O	204-208
rat	O	209-212
peripheral	O	213-223
blood	O	224-229
microRNAs	O	230-239
. 	O	239-241

We	O	0-2
found	O	3-8
that	O	9-13
these	O	14-19
four	O	20-24
deregulated	O	25-36
microRNAs	O	37-46
were	O	47-51
also	O	52-56
differentially	O	57-71
expressed	O	72-81
in	O	82-84
rat	O	85-88
peripheral	O	89-99
blood	O	100-105
,	O	105-106
and	O	107-110
trends	O	111-117
for	O	118-121
their	O	122-127
blood	O	128-133
expression	O	134-144
alterations	O	145-156
were	O	157-161
just	O	162-166
the	O	167-170
same	O	171-175
as	O	176-178
their	O	179-184
counterparts	O	185-197
in	O	198-200
rat	O	201-204
hippocampus	O	205-216
. 	O	216-218

Moreover	O	0-8
,	O	8-9
targets	O	10-17
of	O	18-20
these	O	21-26
deregulated	O	27-38
microRNAs	O	39-48
were	O	49-53
analyzed	O	54-62
using	O	63-68
bioinformatics	O	69-83
and	O	84-87
the	O	88-91
identified	O	92-102
enriched	O	103-111
MAPK	O	112-116
pathway	O	117-124
and	O	125-128
long	O	129-133
-	O	133-134
term	O	134-138
potentiation	O	139-151
pathway	O	152-159
might	O	160-165
have	O	166-170
been	O	171-175
involved	O	176-184
in	O	185-187
molecular	O	188-197
mechanisms	O	198-208
concerning	O	209-219
neuronal	O	220-228
death	O	229-234
,	O	234-235
inflammation	O	236-248
and	O	249-252
epileptogenesis	O	253-268
.   	O	268-272

The	O	0-3
study	O	4-9
of	O	10-12
this	O	13-17
novel	O	18-23
layer	O	24-29
of	O	30-32
gene	O	33-37
regulation	O	38-48
therefore	O	49-58
promises	O	59-67
to	O	68-70
enrich	O	71-77
our	O	78-81
knowledge	O	82-91
of	O	92-94
brain	O	95-100
function	O	101-109
and	O	110-113
pathology	O	114-123
.   	O	123-127

MiRNAs	O	0-6
function	O	7-15
at	O	16-18
all	O	19-22
stages	O	23-29
of	O	30-32
neuronal	O	33-41
development	O	42-53
,	O	53-54
ranging	O	55-62
from	O	63-67
the	O	68-71
initial	O	72-79
specification	O	80-93
of	O	94-96
neuronal	O	97-105
cell	O	106-110
types	O	111-116
to	O	117-119
the	O	120-123
formation	O	124-133
and	O	134-137
plasticity	O	138-148
of	O	149-151
synaptic	O	152-160
connections	O	161-172
between	O	173-180
individual	O	181-191
neurons	O	192-199
. 	O	199-201

Moreover	O	0-8
,	O	8-9
links	O	10-15
between	O	16-23
miRNA	O	24-29
dysfunction	O	30-41
and	O	42-45
neurological	O	46-58
diseases	O	59-67
become	O	68-74
more	O	75-79
and	O	80-83
more	O	84-88
apparent	O	89-97
. 	O	97-99

The	O	0-3
development	O	4-15
and	O	16-19
function	O	20-28
of	O	29-31
the	O	32-35
nervous	O	36-43
system	O	44-50
is	O	51-53
orchestrated	O	54-66
by	O	67-69
a	O	70-71
plethora	O	72-80
of	O	81-83
gene	O	84-88
regulatory	O	89-99
mechanisms	O	100-110
. 	O	110-112

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
,	O	18-19
an	O	20-22
abundant	O	23-31
class	O	32-37
of	O	38-40
small	O	41-46
non	O	47-50
-	O	50-51
coding	O	51-57
RNAs	O	58-62
,	O	62-63
are	O	64-67
emerging	O	68-76
as	O	77-79
important	O	80-89
post	O	90-94
-	O	94-95
transcriptional	O	95-110
regulators	O	111-121
of	O	122-124
gene	O	125-129
expression	O	130-140
in	O	141-143
the	O	144-147
brain	O	148-153
. 	O	153-155

MicroRNA	O	0-8
function	O	9-17
in	O	18-20
neuronal	O	21-29
development	O	30-41
,	O	41-42
plasticity	O	43-53
and	O	54-57
disease	O	58-65
.  	O	65-68

Mice	O	0-4
deficient	O	5-14
in	O	15-17
cystathionine	O	18-31
beta	O	32-36
synthase	O	37-45
display	O	46-53
altered	O	54-61
homocysteine	O	62-74
remethylation	O	75-88
pathway	O	89-96
.  	O	96-99

In	O	0-2
order	O	3-8
to	O	9-11
show	O	12-16
the	O	17-20
effects	O	21-28
of	O	29-31
CBS	O	32-35
deficiency	O	36-46
onto	O	47-51
the	O	52-55
activity	O	56-64
of	O	65-67
the	O	68-71
enzymes	O	72-79
involved	O	80-88
in	O	89-91
the	O	92-95
remethylation	O	96-109
pathway	O	110-117
,	O	117-118
we	O	119-121
used	O	122-126
the	O	127-130
well	O	131-135
characterized	O	136-149
genetic	O	150-157
model	O	158-163
of	O	164-166
severe	O	167-173
hyperhomocysteinemia	O	174-194
in	O	195-197
mice	O	198-202
. 	O	202-204

Cystathionine	O	0-13
beta	O	14-18
synthase	O	19-27
(	O	28-29
CBS	O	29-32
)	O	32-33
deficiency	O	34-44
is	O	45-47
a	O	48-49
metabolic	O	50-59
disorder	O	60-68
that	O	69-73
is	O	74-76
biochemically	O	77-90
characterized	O	91-104
by	O	105-107
severe	O	108-114
hyperhomocysteinemia	O	115-135
. 	O	135-137

We	O	0-2
showed	O	3-9
that	O	10-14
CBS	O	15-18
deficiency	O	19-29
in	O	30-32
mice	O	33-37
reduced	O	38-45
hepatic	O	46-53
methionine	O	54-64
synthase	O	65-73
and	O	74-77
betaine	O	78-85
-	O	85-86
homocysteine	O	86-98
methyltransferase	O	99-116
activities	O	117-127
,	O	127-128
whereas	O	129-136
5	O	137-138
,	O	138-139
10	O	139-141
-	O	141-142
methylene	O	142-151
tetrahydrofolate	O	152-168
reductase	O	169-178
activity	O	179-187
was	O	188-191
increased	O	192-201
.   	O	201-205

Reduction	O	0-9
of	O	10-12
miR	B	13-16
-	I	16-17
21	I	17-19
induces	O	20-27
glioma	O	28-34
cell	O	35-39
apoptosis	O	40-49
via	O	50-53
activating	O	54-64
caspase	O	65-72
9	O	73-74
and	O	75-78
3	O	79-80
.	O	80-81
Extensive	O	83-92
data	O	93-97
indicate	O	98-106
that	O	107-111
miR	B	112-115
-	I	115-116
21	I	116-118
plays	O	119-124
a	O	125-126
critical	O	127-135
role	O	136-140
in	O	141-143
gliomagenesis	O	144-157
,	O	157-158
however	O	159-166
,	O	166-167
knowledge	O	168-177
is	O	178-180
limited	O	181-188
on	O	189-191
the	O	192-195
mechanism	O	196-205
of	O	206-208
action	O	209-215
of	O	216-218
miR	B	219-222
-	I	222-223
21	I	223-225
,	O	225-226
including	O	227-236
cell	O	237-241
proliferation	O	242-255
,	O	255-256
apoptosis	O	257-266
,	O	266-267
and	O	268-271
migration	O	272-281
.  	O	281-283

Moreover	O	0-8
,	O	8-9
reduction	O	10-19
of	O	20-22
miR	B	23-26
-	I	26-27
21	I	27-29
activated	O	30-39
caspase	O	40-47
9	O	48-49
and	O	50-53
3	O	54-55
,	O	55-56
which	O	57-62
may	O	63-66
be	O	67-69
mediated	O	70-78
by	O	79-81
modulating	O	82-92
multiple	O	93-101
potential	O	102-111
target	O	112-118
genes	O	119-124
,	O	124-125
such	O	126-130
as	O	131-133
TIMP3	O	134-139
. 	O	139-141

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
showed	O	18-24
that	O	25-29
down	O	30-34
-	O	34-35
regulation	O	35-45
of	O	46-48
miR	B	49-52
-	I	52-53
21	I	53-55
expression	O	56-66
by	O	67-69
antisense	O	70-79
oligonucleotides	O	80-96
inhibited	O	97-106
glioma	O	107-113
cell	O	114-118
proliferation	O	119-132
and	O	133-136
induced	O	137-144
cell	O	145-149
apoptosis	O	150-159
. 	O	159-161

Together	O	0-8
,	O	8-9
these	O	10-15
findings	O	16-24
indicate	O	25-33
that	O	34-38
miR	B	39-42
-	I	42-43
21	I	43-45
plays	O	46-51
a	O	52-53
key	O	54-57
role	O	58-62
in	O	63-65
regulating	O	66-76
cell	O	77-81
apoptosis	O	82-91
in	O	92-94
gliomas	O	95-102
and	O	103-106
may	O	107-110
serve	O	111-116
as	O	117-119
a	O	120-121
target	O	122-128
for	O	129-132
effective	O	133-142
therapies	O	143-152
.   	O	152-156

The	O	0-3
emerging	O	4-12
therapeutic	O	13-24
role	O	25-29
of	O	30-32
RNA	O	33-36
interference	O	37-49
in	O	50-52
disorders	O	53-62
of	O	63-65
the	O	66-69
central	O	70-77
nervous	O	78-85
system	O	86-92
.     	O	92-98

MicroRNA	B	0-8
-	I	8-9
210	I	9-12
as	O	13-15
a	O	16-17
novel	O	18-23
blood	O	24-29
biomarker	O	30-39
in	O	40-42
acute	O	43-48
cerebral	O	49-57
ischemia	O	58-66
.  	O	66-69

MicroRNA	B	0-8
-	I	8-9
210	I	9-12
(	O	13-14
miR	B	14-17
-	I	17-18
210	I	18-21
)	O	21-22
,	O	22-23
a	O	24-25
master	O	26-32
and	O	33-36
pleiotropic	O	37-48
hypoxia	O	49-56
-	O	56-57
microRNA	O	57-65
,	O	65-66
plays	O	67-72
multiple	O	73-81
roles	O	82-87
in	O	88-90
brain	O	91-96
ischemia	O	97-105
. 	O	105-107

However	O	0-7
,	O	7-8
miR	B	9-12
-	I	12-13
210	I	13-16
expression	O	17-27
and	O	28-31
its	O	32-35
function	O	36-44
in	O	45-47
humans	O	48-54
have	O	55-59
not	O	60-63
been	O	64-68
explored	O	69-77
. 	O	77-79

The	O	0-3
aim	O	4-7
of	O	8-10
our	O	11-14
study	O	15-20
is	O	21-23
to	O	24-26
evaluate	O	27-35
the	O	36-39
correlation	O	40-51
of	O	52-54
blood	O	55-60
miR	B	61-64
-	I	64-65
210	I	65-68
with	O	69-73
clinical	O	74-82
findings	O	83-91
in	O	92-94
acute	O	95-100
ischemic	O	101-109
stroke	O	110-116
. 	O	116-118

Blood	O	0-5
samples	O	6-13
were	O	14-18
obtained	O	19-27
from	O	28-32
stroke	O	33-39
patients	O	40-48
(	O	49-50
n	O	50-51
=	O	51-52
112	O	52-55
)	O	55-56
and	O	57-60
healthy	O	61-68
controls	O	69-77
(	O	78-79
n	O	79-80
=	O	80-81
60	O	82-84
)	O	84-85
. 	O	85-87

MiR	B	0-3
-	I	3-4
210	I	4-7
was	O	8-11
measured	O	12-20
at	O	21-23
within	O	24-30
3	O	31-32
,	O	32-33
7	O	34-35
and	O	36-39
14	O	40-42
days	O	43-47
after	O	48-53
stroke	O	54-60
using	O	61-66
a	O	67-68
quantitative	O	69-81
PCR	O	82-85
technique	O	86-95
. 	O	95-97

Stroke	O	0-6
severity	O	7-15
and	O	16-19
clinical	O	20-28
outcome	O	29-36
were	O	37-41
evaluated	O	42-51
by	O	52-54
NIHSS	O	55-60
and	O	61-64
modified	O	65-73
Rankin	O	74-80
Score	O	81-86
. 	O	86-88

Both	O	0-4
blood	O	5-10
and	O	11-14
brain	O	15-20
miR	B	21-24
-	I	24-25
210	I	25-28
in	O	29-31
ischemic	O	32-40
mice	O	41-45
was	O	46-49
examined	O	50-58
and	O	59-62
the	O	63-66
correlation	O	67-78
was	O	79-82
investigated	O	83-95
. 	O	95-97

Compared	O	0-8
to	O	9-11
healthy	O	12-19
controls	O	20-28
,	O	28-29
blood	O	30-35
miRNA	B	36-41
-	I	41-42
210	I	42-45
was	O	46-49
significantly	O	50-63
decreased	O	64-73
in	O	74-76
stroke	O	77-83
patients	O	84-92
(	O	93-94
0	O	94-95
.	O	95-96
93	O	96-98
vs	O	99-101
.	O	101-102
1	O	103-104
.	O	104-105
36	O	105-107
;	O	107-108
P	O	109-110
=	O	110-111
0	O	111-112
.	O	112-113
001	O	113-116
)	O	116-117
,	O	117-118
especially	O	119-129
at	O	130-132
7	O	133-134
days	O	135-139
(	O	140-141
0	O	141-142
.	O	142-143
56	O	143-145
vs	O	146-148
.	O	148-149
1	O	150-151
.	O	151-152
36	O	152-154
;	O	154-155
P	O	156-157
=	O	157-158
0	O	158-159
.	O	159-160
001	O	160-163
)	O	163-164
and	O	165-168
14	O	169-171
days	O	172-176
of	O	177-179
stroke	O	180-186
onset	O	187-192
(	O	193-194
0	O	194-195
.	O	195-196
50	O	196-198
vs	O	199-201
.	O	201-202
1	O	203-204
.	O	204-205
36	O	205-207
;	O	207-208
P	O	209-210
=	O	210-211
0	O	211-212
.	O	212-213
001	O	213-216
)	O	216-217
. 	O	217-219

The	O	0-3
cut	O	4-7
off	O	8-11
point	O	12-17
of	O	18-20
miR	B	21-24
-	I	24-25
210	I	25-28
in	O	29-31
diagnosis	O	32-41
was	O	42-45
0	O	46-47
.	O	47-48
505	O	48-51
with	O	52-56
88	O	57-59
.	O	59-60
3	O	60-61
per	O	62-65
cent	O	66-70
sensitivity	O	71-82
. 	O	82-84

MiR	B	0-3
-	I	3-4
210	I	4-7
level	O	8-13
in	O	14-16
stroke	O	17-23
patients	O	24-32
with	O	33-37
good	O	38-42
outcome	O	43-50
was	O	51-54
significantly	O	55-68
higher	O	69-75
than	O	76-80
patients	O	81-89
with	O	90-94
poor	O	95-99
outcome	O	100-107
(	O	108-109
1	O	109-110
.	O	110-111
2	O	111-112
vs	O	113-115
.	O	115-116
0	O	117-118
.	O	118-119
44	O	119-121
;	O	121-122
P	O	123-124
=	O	124-125
0	O	125-126
.	O	126-127
012	O	127-130
)	O	130-131
. 	O	131-133

The	O	0-3
correlation	O	4-15
between	O	16-23
blood	O	24-29
and	O	30-33
brain	O	34-39
miR	B	40-43
-	I	43-44
210	I	44-47
in	O	48-50
ischemic	O	51-59
mice	O	60-64
was	O	65-68
positive	O	69-77
(	O	78-79
R2	O	79-81
=	O	81-82
0	O	82-83
.	O	83-84
57	O	84-86
,	O	86-87
P	O	88-89
=	O	89-90
0	O	90-91
.	O	91-92
001	O	92-95
)	O	95-96
. 	O	96-98

Blood	O	0-5
miR	B	6-9
-	I	9-10
210	I	10-13
is	O	14-16
a	O	17-18
novel	O	19-24
sensitive	O	25-34
biomarker	O	35-44
for	O	45-48
clinical	O	49-57
diagnosis	O	58-67
and	O	68-71
prognosis	O	72-81
in	O	82-84
acute	O	85-90
cerebral	O	91-99
ischemia	O	100-108
.   	O	108-112

In	O	0-2
particular	O	3-13
,	O	13-14
SNP	O	15-18
rs12720208	O	19-29
in	O	30-32
the	O	33-36
3	O	37-38
'	O	38-39
untranslated	O	40-52
region	O	53-59
(	O	60-61
3	O	61-62
'	O	62-63
UTR	O	64-67
)	O	67-68
was	O	69-72
linked	O	73-79
to	O	80-82
PD	O	83-85
-	O	85-86
risk	O	86-90
through	O	91-98
a	O	99-100
mechanism	O	101-110
that	O	111-115
would	O	116-121
implicate	O	122-131
a	O	132-133
differential	O	134-146
binding	O	147-154
to	O	155-157
microRNA	B	158-166
-	I	166-167
433	I	167-170
(	O	171-172
miR	B	172-175
-	I	175-176
433	I	176-179
)	O	179-180
. 	O	180-182

The	O	0-3
reduction	O	4-13
of	O	14-16
the	O	17-20
affinity	O	21-29
of	O	30-32
miR	B	33-36
-	I	36-37
433	I	37-40
to	O	41-43
the	O	44-47
3	O	48-49
'	O	49-50
UTR	O	51-54
would	O	55-60
result	O	61-67
in	O	68-70
increased	O	71-80
FGF20	O	81-86
expression	O	87-97
and	O	98-101
upregulation	O	102-114
of	O	115-117
alpha	O	118-123
-	O	123-124
synuclein	O	124-133
,	O	133-134
which	O	135-140
could	O	141-146
in	O	147-149
turn	O	150-154
promote	O	155-162
dopaminergic	O	163-175
neurons	O	176-183
degeneration	O	184-196
. 	O	196-198

FGF20	O	0-5
rs12720208	O	6-16
SNP	O	17-20
and	O	21-24
microRNA	B	25-33
-	I	33-34
433	I	34-37
variation	O	38-47
:	O	47-48
no	O	49-51
association	O	52-63
with	O	64-68
Parkinson	O	69-78
'	O	78-79
s	O	79-80
disease	O	81-88
in	O	89-91
Spanish	O	92-99
patients	O	100-108
.  	O	108-111

DNA	O	0-3
variation	O	4-13
at	O	14-16
the	O	17-20
FGF20	O	21-26
gene	O	27-31
has	O	32-35
been	O	36-40
associated	O	41-51
with	O	52-56
Parkinson	O	57-66
'	O	66-67
s	O	67-68
disease	O	69-76
(	O	77-78
PD	O	78-80
)	O	80-81
. 	O	81-83

In	O	0-2
conclusion	O	3-13
,	O	13-14
our	O	15-18
work	O	19-23
did	O	24-27
not	O	28-31
confirm	O	32-39
the	O	40-43
association	O	44-55
between	O	56-63
rs12720208	O	64-74
and	O	75-78
PD	O	79-81
,	O	81-82
or	O	83-85
an	O	86-88
effect	O	89-95
of	O	96-98
miR	B	99-102
-	I	102-103
433	I	103-106
variants	O	107-115
on	O	116-118
this	O	119-123
disease	O	124-131
.   	O	131-135

None	O	0-4
of	O	5-7
the	O	8-11
patients	O	12-20
had	O	21-24
miR	B	25-28
-	I	28-29
433	I	29-32
variants	O	33-41
. 	O	41-43

We	O	0-2
did	O	3-6
not	O	7-10
find	O	11-15
significant	O	16-27
differences	O	28-39
in	O	40-42
allele	O	43-49
and	O	50-53
genotype	O	54-62
frequencies	O	63-74
between	O	75-82
patients	O	83-91
and	O	92-95
controls	O	96-104
. 	O	104-106

We	O	0-2
genotyped	O	3-12
the	O	13-16
rs12720208	O	17-27
SNP	O	28-31
in	O	32-34
a	O	35-36
total	O	37-42
of	O	43-45
512	O	46-49
PD	O	50-52
patients	O	53-61
and	O	62-65
258	O	66-69
healthy	O	70-77
controls	O	78-86
from	O	87-91
Spain	O	92-97
,	O	97-98
and	O	99-102
searched	O	103-111
for	O	112-115
miR	B	116-119
-	I	119-120
433	I	120-123
variants	O	124-132
in	O	133-135
the	O	136-139
patients	O	140-148
. 	O	148-150

Blood	O	0-5
collection	O	6-16
for	O	17-20
RNA	O	21-24
studies	O	25-32
is	O	33-35
a	O	36-37
new	O	38-41
direction	O	42-51
. 	O	51-53

Genetic	O	0-7
studies	O	8-15
of	O	16-18
longitudinal	O	19-31
phenotypes	O	32-42
hold	O	43-47
promise	O	48-55
for	O	56-59
elucidating	O	60-71
disease	O	72-79
mechanisms	O	80-90
and	O	91-94
risk	O	95-99
,	O	99-100
development	O	101-112
of	O	113-115
therapeutic	O	116-127
strategies	O	128-138
,	O	138-139
and	O	140-143
refining	O	144-152
selection	O	153-162
criteria	O	163-171
for	O	172-175
clinical	O	176-184
trials	O	185-191
.   	O	191-195

Genome	O	0-6
-	O	6-7
wide	O	7-11
array	O	12-17
data	O	18-22
have	O	23-27
been	O	28-32
publicly	O	33-41
released	O	42-50
and	O	51-54
updated	O	55-62
,	O	62-63
and	O	64-67
several	O	68-75
neuroimaging	O	76-88
GWAS	O	89-93
have	O	94-98
recently	O	99-107
been	O	108-112
reported	O	113-121
examining	O	122-131
baseline	O	132-140
magnetic	O	141-149
resonance	O	150-159
imaging	O	160-167
measures	O	168-176
as	O	177-179
quantitative	O	180-192
phenotypes	O	193-203
. 	O	203-205

Other	O	0-5
preliminary	O	6-17
investigations	O	18-32
include	O	33-40
copy	O	41-45
number	O	46-52
variation	O	53-62
in	O	63-65
mild	O	66-70
cognitive	O	71-80
impairment	O	81-91
and	O	92-95
Alzheimer	O	96-105
'	O	105-106
s	O	106-107
disease	O	108-115
and	O	116-119
GWAS	O	120-124
of	O	125-127
baseline	O	128-136
cerebrospinal	O	137-150
fluid	O	151-156
biomarkers	O	157-167
and	O	168-171
longitudinal	O	172-184
changes	O	185-192
on	O	193-195
magnetic	O	196-204
resonance	O	205-214
imaging	O	215-222
. 	O	222-224

The	O	0-3
role	O	4-8
of	O	9-11
the	O	12-15
Alzheimer	O	16-25
'	O	25-26
s	O	26-27
Disease	O	28-35
Neuroimaging	O	36-48
Initiative	O	49-59
Genetics	O	60-68
Core	O	69-73
is	O	74-76
to	O	77-79
facilitate	O	80-90
the	O	91-94
investigation	O	95-108
of	O	109-111
genetic	O	112-119
influences	O	120-130
on	O	131-133
disease	O	134-141
onset	O	142-147
and	O	148-151
trajectory	O	152-162
as	O	163-165
reflected	O	166-175
in	O	176-178
structural	O	179-189
,	O	189-190
functional	O	191-201
,	O	201-202
and	O	203-206
molecular	O	207-216
imaging	O	217-224
changes	O	225-232
;	O	232-233
fluid	O	234-239
biomarkers	O	240-250
;	O	250-251
and	O	252-255
cognitive	O	256-265
status	O	266-272
. 	O	272-274

Major	O	0-5
goals	O	6-11
include	O	12-19
(	O	20-21
1	O	21-22
)	O	22-23
blood	O	24-29
sample	O	30-36
processing	O	37-47
,	O	47-48
genotyping	O	49-59
,	O	59-60
and	O	61-64
dissemination	O	65-78
,	O	78-79
(	O	80-81
2	O	81-82
)	O	82-83
genome	O	84-90
-	O	90-91
wide	O	91-95
association	O	96-107
studies	O	108-115
(	O	116-117
GWAS	O	117-121
)	O	121-122
of	O	123-125
longitudinal	O	126-138
phenotypic	O	139-149
data	O	150-154
,	O	154-155
and	O	156-159
(	O	160-161
3	O	161-162
)	O	162-163
providing	O	164-173
a	O	174-175
central	O	176-183
resource	O	184-192
,	O	192-193
point	O	194-199
of	O	200-202
contact	O	203-210
and	O	211-214
planning	O	215-223
group	O	224-229
for	O	230-233
genetics	O	234-242
within	O	243-249
the	O	250-253
Alzheimer	O	254-263
'	O	263-264
s	O	264-265
Disease	O	266-273
Neuroimaging	O	274-286
Initiative	O	287-297
. 	O	297-299

Alzheimer	O	0-9
'	O	9-10
s	O	10-11
Disease	O	12-19
Neuroimaging	O	20-32
Initiative	O	33-43
biomarkers	O	44-54
as	O	55-57
quantitative	O	58-70
phenotypes	O	71-81
:	O	81-82
Genetics	O	83-91
core	O	92-96
aims	O	97-101
,	O	101-102
progress	O	103-111
,	O	111-112
and	O	113-116
plans	O	117-122
.  	O	122-125

Our	O	0-3
work	O	4-8
places	O	9-15
apl	O	16-19
-	O	19-20
1	O	20-21
in	O	22-24
a	O	25-26
developmental	O	27-40
timing	O	41-47
pathway	O	48-55
and	O	56-59
may	O	60-63
provide	O	64-71
new	O	72-75
insights	O	76-84
into	O	85-89
the	O	90-93
time	O	94-98
-	O	98-99
dependent	O	99-108
progression	O	109-120
of	O	121-123
AD	O	124-126
.   	O	126-130

Moreover	O	0-8
,	O	8-9
the	O	10-13
levels	O	14-20
of	O	21-23
the	O	24-27
apl	O	28-31
-	O	31-32
1	O	32-33
transcription	O	34-47
are	O	48-51
modulated	O	52-61
by	O	62-64
the	O	65-68
activity	O	69-77
of	O	78-80
let	B	81-84
-	I	84-85
7	I	85-86
family	O	87-93
microRNAs	O	94-103
. 	O	103-105

apl	O	0-3
-	O	3-4
1	O	4-5
expression	O	6-16
is	O	17-19
upregulated	O	20-31
during	O	32-38
the	O	39-42
last	O	43-47
larval	O	48-54
stage	O	55-60
in	O	61-63
hypodermal	O	64-74
seam	O	75-79
cells	O	80-85
which	O	86-91
is	O	92-94
transcriptionally	O	95-112
regulated	O	113-122
by	O	123-125
hbl	O	126-129
-	O	129-130
1	O	130-131
,	O	131-132
lin	O	133-136
-	O	136-137
41	O	137-139
and	O	140-143
lin	O	144-147
-	O	147-148
42	O	148-150
. 	O	150-152

On	O	0-2
the	O	3-6
other	O	7-12
hand	O	13-17
,	O	17-18
the	O	19-22
pathogenesis	O	23-35
of	O	36-38
amyloid	O	39-46
plaque	O	47-53
deposition	O	54-64
in	O	65-67
AD	O	68-70
is	O	71-73
thought	O	74-81
to	O	82-84
be	O	85-87
the	O	88-91
result	O	92-98
of	O	99-101
age	O	102-105
-	O	105-106
related	O	106-113
changes	O	114-121
with	O	122-126
unknown	O	127-134
mechanisms	O	135-145
. 	O	145-147

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
the	O	18-21
Caenorhabditis	O	22-36
elegans	O	37-44
homolog	O	45-52
of	O	53-55
APP	O	56-59
,	O	59-60
APP	O	61-64
-	O	64-65
like	O	65-69
-	O	69-70
1	O	70-71
(	O	72-73
apl	O	73-76
-	O	76-77
1	O	77-78
)	O	78-79
,	O	79-80
functions	O	81-90
with	O	91-95
and	O	96-99
is	O	100-102
under	O	103-108
the	O	109-112
control	O	113-120
of	O	121-123
molecules	O	124-133
regulating	O	134-144
developmental	O	145-158
progression	O	159-170
. 	O	170-172

In	O	0-2
C	O	3-4
.	O	4-5
elegans	O	6-13
,	O	13-14
the	O	15-18
timing	O	19-25
of	O	26-28
cell	O	29-33
fate	O	34-38
determination	O	39-52
is	O	53-55
controlled	O	56-66
by	O	67-69
the	O	70-73
heterochronic	O	74-87
genes	O	88-93
,	O	93-94
including	O	95-104
let	B	105-108
-	I	108-109
7	I	109-110
microRNAs	O	111-120
. 	O	120-122

C	O	0-1
.	O	1-2
elegans	O	3-10
apl	O	11-14
-	O	14-15
1	O	15-16
shows	O	17-22
significant	O	23-34
genetic	O	35-42
interactions	O	43-55
with	O	56-60
let	B	61-64
-	I	64-65
7	I	65-66
family	O	67-73
microRNAs	O	74-83
and	O	84-87
let	B	88-91
-	I	91-92
7	I	92-93
-	O	93-94
targeted	O	94-102
heterochronic	O	103-116
genes	O	117-122
,	O	122-123
hbl	O	124-127
-	O	127-128
1	O	128-129
,	O	129-130
lin	O	131-134
-	O	134-135
41	O	135-137
and	O	138-141
lin	O	142-145
-	O	145-146
42	O	146-148
. 	O	148-150

The	O	0-3
expression	O	4-14
of	O	15-17
the	O	18-21
Alzheimer	O	22-31
'	O	31-32
s	O	32-33
amyloid	O	34-41
precursor	O	42-51
protein	O	52-59
-	O	59-60
like	O	60-64
gene	O	65-69
is	O	70-72
regulated	O	73-82
by	O	83-85
developmental	O	86-99
timing	O	100-106
microRNAs	O	107-116
and	O	117-120
their	O	121-126
targets	O	127-134
in	O	135-137
Caenorhabditis	O	138-152
elegans	O	153-160
.  	O	160-163

Alzheimer	O	0-9
'	O	9-10
s	O	10-11
disease	O	12-19
(	O	20-21
AD	O	21-23
)	O	23-24
is	O	25-27
a	O	28-29
neurodegenerative	O	30-47
disorder	O	48-56
characterized	O	57-70
by	O	71-73
the	O	74-77
accumulation	O	78-90
of	O	91-93
dense	O	94-99
plaques	O	100-107
in	O	108-110
the	O	111-114
brain	O	115-120
,	O	120-121
resulting	O	122-131
in	O	132-134
progressive	O	135-146
dementia	O	147-155
. 	O	155-157

A	O	0-1
major	O	2-7
plaque	O	8-14
component	O	15-24
is	O	25-27
the	O	28-31
beta	O	32-36
-	O	36-37
amyloid	O	37-44
peptide	O	45-52
,	O	52-53
which	O	54-59
is	O	60-62
a	O	63-64
cleavage	O	65-73
product	O	74-81
of	O	82-84
the	O	85-88
amyloid	O	89-96
precursor	O	97-106
protein	O	107-114
(	O	115-116
APP	O	116-119
)	O	119-120
. 	O	120-122

Studies	O	0-7
of	O	8-10
dominant	O	11-19
inheritable	O	20-31
familial	O	32-40
AD	O	41-43
support	O	44-51
the	O	52-55
hypothesis	O	56-66
that	O	67-71
APP	O	72-75
is	O	76-78
critical	O	79-87
for	O	88-91
AD	O	92-94
development	O	95-106
. 	O	106-108

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
focus	O	19-24
on	O	25-27
studies	O	28-35
addressing	O	36-46
the	O	47-50
role	O	51-55
of	O	56-58
various	O	59-66
microRNAs	O	67-76
in	O	77-79
heart	O	80-85
,	O	85-86
muscle	O	87-93
,	O	93-94
liver	O	95-100
,	O	100-101
pancreas	O	102-110
,	O	110-111
central	O	112-119
nervous	O	120-127
system	O	128-134
,	O	134-135
and	O	136-139
hematopoiesis	O	140-153
.   	O	153-157

Large	O	0-5
numbers	O	6-13
and	O	14-17
quantities	O	18-28
of	O	29-31
different	O	32-41
,	O	41-42
small	O	43-48
RNA	O	49-52
molecules	O	53-62
are	O	63-66
present	O	67-74
in	O	75-77
the	O	78-81
cytoplasm	O	82-91
of	O	92-94
animal	O	95-101
and	O	102-105
plant	O	106-111
cells	O	112-117
. 	O	117-119

MicroRNAs	O	0-9
in	O	10-12
organogenesis	O	13-26
and	O	27-30
disease	O	31-38
.  	O	38-41

Since	O	0-5
their	O	6-11
discovery	O	12-21
in	O	22-24
the	O	25-28
1990s	O	29-34
a	O	35-36
multitude	O	37-46
of	O	47-49
basic	O	50-55
information	O	56-67
has	O	68-71
accumulated	O	72-83
,	O	83-84
which	O	85-90
has	O	91-94
identified	O	95-105
their	O	106-111
function	O	112-120
in	O	121-123
post	O	124-128
-	O	128-129
transcriptional	O	129-144
control	O	145-152
,	O	152-153
either	O	154-160
via	O	161-164
degradation	O	165-176
or	O	177-179
translational	O	180-193
inhibition	O	194-204
of	O	205-207
target	O	208-214
mRNAs	O	215-220
. 	O	220-222

One	O	0-3
subclass	O	4-12
of	O	13-15
these	O	16-21
molecules	O	22-31
is	O	32-34
represented	O	35-46
by	O	47-49
the	O	50-53
noncoding	O	54-63
microRNAs	O	64-73
. 	O	73-75

MicroRNA	O	0-8
expression	O	9-19
profiles	O	20-28
are	O	29-32
highly	O	33-39
dynamic	O	40-47
during	O	48-54
embryonic	O	55-64
development	O	65-76
and	O	77-80
in	O	81-83
adulthood	O	84-93
. 	O	93-95

This	O	0-4
function	O	5-13
is	O	14-16
in	O	17-19
most	O	20-24
of	O	25-27
the	O	28-31
cases	O	32-37
a	O	38-39
finetuning	O	40-50
of	O	51-53
gene	O	54-58
expression	O	59-69
,	O	69-70
working	O	71-78
in	O	79-81
parallel	O	82-90
with	O	91-95
transcriptional	O	96-111
regulatory	O	112-122
processes	O	123-132
. 	O	132-134

Evidence	O	0-8
from	O	9-13
gain	O	14-18
-	O	18-19
and	O	20-23
loss	O	24-28
-	O	28-29
of	O	29-31
function	O	32-40
studies	O	41-48
indicates	O	49-58
roles	O	59-64
for	O	65-68
microRNAs	O	69-78
in	O	79-81
pathophysiologic	O	82-98
states	O	99-105
including	O	106-115
cardiac	O	116-123
hypertrophy	O	124-135
,	O	135-136
muscle	O	137-143
dystrophy	O	144-153
,	O	153-154
hepatitis	O	155-164
infection	O	165-174
,	O	174-175
diabetes	O	176-184
,	O	184-185
Parkinson	O	186-195
syndrome	O	196-204
,	O	204-205
hematological	O	206-219
malignancies	O	220-232
and	O	233-236
other	O	237-242
types	O	243-248
of	O	249-251
cancer	O	252-258
. 	O	258-260

Misexpression	O	0-13
of	O	14-16
microRNAs	O	17-26
can	O	27-30
perturb	O	31-38
embryogenesis	O	39-52
,	O	52-53
organogenesis	O	54-67
,	O	67-68
tissue	O	69-75
homeostasis	O	76-87
and	O	88-91
the	O	92-95
cell	O	96-100
cycle	O	101-106
. 	O	106-108

The	O	0-3
proliferation	O	4-17
inhibition	O	18-28
and	O	29-32
induced	O	33-40
apoptosis	O	41-50
by	O	51-53
this	O	54-58
recombinant	O	59-70
with	O	71-75
an	O	76-78
apoptosis	O	79-88
ratio	O	89-94
of	O	95-97
21	O	98-100
.	O	100-101
89	O	101-103
%	O	103-104
in	O	105-107
U87	O	108-111
cell	O	112-116
were	O	117-121
also	O	122-126
observed	O	127-135
. 	O	135-137

The	O	0-3
results	O	4-11
of	O	12-14
Western	O	15-22
blot	O	23-27
indicated	O	28-37
the	O	38-41
expression	O	42-52
of	O	53-55
Flag	O	56-60
of	O	61-63
No	O	64-66
1	O	67-68
recombinant	O	69-80
plasmid	O	81-88
group	O	89-94
was	O	95-98
inhibited	O	99-108
heavily	O	109-116
with	O	117-121
a	O	122-123
34	O	124-126
.	O	126-127
3	O	127-128
%	O	128-129
expression	O	130-140
level	O	141-146
by	O	147-149
compared	O	150-158
with	O	159-163
control	O	164-171
group	O	172-177
. 	O	177-179

The	O	0-3
expressed	O	4-13
Flag	O	14-18
protein	O	19-26
was	O	27-30
detected	O	31-39
by	O	40-42
Western	O	43-50
blot	O	51-55
to	O	56-58
evaluate	O	59-67
the	O	68-71
inhibition	O	72-82
effect	O	83-89
of	O	90-92
targeting	O	93-102
sequences	O	103-112
. 	O	112-114

The	O	0-3
confirmed	O	4-13
pGCSIL	O	14-20
-	O	20-21
GFP	O	21-24
recombinants	O	25-37
by	O	38-40
combining	O	41-50
with	O	51-55
pEGFP	O	56-61
-	O	61-62
miR	B	62-65
-	I	65-66
221	I	66-69
were	O	70-74
transfected	O	75-86
into	O	87-91
293T	O	92-96
cells	O	97-102
seperately	O	103-113
. 	O	113-115

RESULTS	O	0-7
:	O	7-8
The	O	9-12
resulting	O	13-22
recombinants	O	23-35
were	O	36-40
confirmed	O	41-50
by	O	51-53
sequencing	O	54-64
which	O	65-70
demonstrated	O	71-83
that	O	84-88
the	O	89-92
recombinant	O	93-104
plasmids	O	105-113
contained	O	114-123
the	O	124-127
correct	O	128-135
sequences	O	136-145
of	O	146-148
designed	O	149-157
transcript	O	158-168
templates	O	169-178
. 	O	178-180

Then	O	0-4
a	O	5-6
recombinant	O	7-18
with	O	19-23
the	O	24-27
highest	O	28-35
anti	O	36-40
-	O	40-41
miR	O	41-44
-	O	44-45
221	O	45-48
effect	O	49-55
was	O	56-59
screened	O	60-68
and	O	69-72
transfected	O	73-84
into	O	85-89
U87	O	90-93
glioma	O	94-100
cell	O	101-105
,	O	105-106
and	O	107-110
its	O	111-114
anti	O	115-119
-	O	119-120
tumor	O	120-125
effect	O	126-132
was	O	133-136
evaluated	O	137-146
by	O	147-149
MTT	O	150-153
and	O	154-157
FCM	O	158-161
. 	O	161-163

[	O	0-1
Construction	O	1-13
and	O	14-17
screening	O	18-27
an	O	28-30
effective	O	31-40
anti	O	41-45
-	O	45-46
miR	O	46-49
-	O	49-50
221	O	50-53
RNAi	O	54-58
vector	O	59-65
in	O	66-68
vitro	O	69-74
]	O	74-75
.  	O	75-78

OBJECTIVE	O	0-9
:	O	9-10
To	O	11-13
construct	O	14-23
and	O	24-27
screen	O	28-34
an	O	35-37
effective	O	38-47
anti	O	48-52
-	O	52-53
miR	O	53-56
-	O	56-57
221	O	57-60
vector	O	61-67
of	O	68-70
siRNA	O	71-76
. 	O	76-78

METHODS	O	0-7
:	O	7-8
Four	O	9-13
hairpin	O	14-21
structure	O	22-31
of	O	32-34
siRNA	O	35-40
transcript	O	41-51
templates	O	52-61
targeting	O	62-71
miR	B	72-75
-	I	75-76
221	I	76-79
and	O	80-83
a	O	84-85
negative	O	86-94
control	O	95-102
were	O	103-107
synthesized	O	108-119
,	O	119-120
then	O	121-125
ligated	O	126-133
with	O	134-138
pGCSIL	O	139-145
-	O	145-146
GFP	O	146-149
vector	O	150-156
and	O	157-160
a	O	161-162
pEGFP	O	163-168
-	O	168-169
miR	B	169-172
-	I	172-173
221	I	173-176
which	O	177-182
express	O	183-190
pre	B	191-194
-	I	194-195
miR	I	195-198
-	I	198-199
221	I	199-202
was	O	203-206
also	O	207-211
constructed	O	212-223
. 	O	223-225

All	O	0-3
the	O	4-7
recombinants	O	8-20
were	O	21-25
sequenced	O	26-35
. 	O	35-37

CONCLUSION	O	0-10
:	O	10-11
The	O	12-15
anti	O	16-20
-	O	20-21
miR	O	21-24
-	O	24-25
221	O	25-28
expression	O	29-39
siRNA	O	40-45
espression	O	46-56
recombinants	O	57-69
were	O	70-74
constructed	O	75-86
successfully	O	87-99
,	O	99-100
and	O	101-104
one	O	105-108
sequence	O	109-117
with	O	118-122
the	O	123-126
highest	O	127-134
inhibition	O	135-145
efficiency	O	146-156
was	O	157-160
screened	O	161-169
out	O	170-173
,	O	173-174
which	O	175-180
could	O	181-186
inhibit	O	187-194
U87	O	195-198
cell	O	199-203
proliferation	O	204-217
and	O	218-221
induce	O	222-228
cell	O	229-233
apoptosis	O	234-243
,	O	243-244
and	O	245-248
could	O	249-254
be	O	255-257
used	O	258-262
to	O	263-265
suppress	O	266-274
target	O	275-281
gene	O	282-286
for	O	287-290
further	O	291-298
study	O	299-304
in	O	305-307
tumor	O	308-313
biology	O	314-321
.   	O	321-325

These	O	0-5
findings	O	6-14
identify	O	15-23
specific	O	24-32
microRNAs	O	33-42
as	O	43-45
attenuators	O	46-57
of	O	58-60
growth	O	61-67
factor	O	68-74
signaling	O	75-84
and	O	85-88
oncogenesis	O	89-100
.   	O	100-104

In	O	0-2
line	O	3-7
with	O	8-12
roles	O	13-18
as	O	19-21
suppressors	O	22-33
of	O	34-36
EGF	O	37-40
receptor	O	41-49
(	O	50-51
EGFR	O	51-55
)	O	55-56
signaling	O	57-66
,	O	66-67
we	O	68-70
report	O	71-77
that	O	78-82
the	O	83-86
abundance	O	87-96
of	O	97-99
this	O	100-104
early	O	105-110
subset	O	111-117
of	O	118-120
microRNAs	O	121-130
is	O	131-133
decreased	O	134-143
in	O	144-146
breast	O	147-153
and	O	154-157
in	O	158-160
brain	O	161-166
tumors	O	167-173
driven	O	174-180
by	O	181-183
the	O	184-187
EGFR	O	188-192
or	O	193-195
the	O	196-199
closely	O	200-207
related	O	208-215
HER2	O	216-220
. 	O	220-222

This	O	0-4
step	O	5-9
permitted	O	10-19
rapid	O	20-25
induction	O	26-35
of	O	36-38
oncogenic	O	39-48
transcription	O	49-62
factors	O	63-70
,	O	70-71
such	O	72-76
as	O	77-79
c	O	80-81
-	O	81-82
FOS	O	82-85
,	O	85-86
encoded	O	87-94
by	O	95-97
immediate	O	98-107
early	O	108-113
genes	O	114-119
. 	O	119-121

EGF	O	0-3
decreases	O	4-13
the	O	14-17
abundance	O	18-27
of	O	28-30
microRNAs	O	31-40
that	O	41-45
restrain	O	46-54
oncogenic	O	55-64
transcription	O	65-78
factors	O	79-86
.  	O	86-89

The	O	0-3
earliest	O	4-12
event	O	13-18
involved	O	19-27
a	O	28-29
decrease	O	30-38
in	O	39-41
the	O	42-45
abundance	O	46-55
of	O	56-58
a	O	59-60
subset	O	61-67
of	O	68-70
23	O	71-73
microRNAs	O	74-83
. 	O	83-85

Using	O	0-5
genome	O	6-12
-	O	12-13
wide	O	13-17
approaches	O	18-28
,	O	28-29
we	O	30-32
showed	O	33-39
that	O	40-44
EGF	O	45-48
stimulation	O	49-60
initiates	O	61-70
a	O	71-72
coordinated	O	73-84
transcriptional	O	85-100
program	O	101-108
of	O	109-111
microRNAs	O	112-121
and	O	122-125
transcription	O	126-139
factors	O	140-147
. 	O	147-149

MicroRNAs	O	0-9
,	O	9-10
which	O	11-16
attenuate	O	17-26
gene	O	27-31
expression	O	32-42
by	O	43-45
binding	O	46-53
complementary	O	54-67
regions	O	68-75
in	O	76-78
messenger	O	79-88
RNAs	O	89-93
,	O	93-94
are	O	95-98
broadly	O	99-106
implicated	O	107-117
in	O	118-120
cancer	O	121-127
. 	O	127-129

Epidermal	O	0-9
growth	O	10-16
factor	O	17-23
(	O	24-25
EGF	O	25-28
)	O	28-29
stimulates	O	30-40
cells	O	41-46
by	O	47-49
launching	O	50-59
gene	O	60-64
expression	O	65-75
programs	O	76-84
that	O	85-89
are	O	90-93
frequently	O	94-104
deregulated	O	105-116
in	O	117-119
cancer	O	120-126
. 	O	126-128

Regeneration	O	0-12
of	O	13-15
neuromuscular	O	16-29
synapses	O	30-38
:	O	38-39
action	O	40-46
of	O	47-49
microRNA	B	50-58
-	I	58-59
206	I	59-62
.     	O	62-68

The	O	0-3
expression	O	4-14
levels	O	15-21
of	O	22-24
most	O	25-29
miRNAs	O	30-36
were	O	37-41
in	O	42-44
accordance	O	45-55
with	O	56-60
previously	O	61-71
published	O	72-81
results	O	82-89
by	O	90-92
microarray	O	93-103
. 	O	103-105

Their	O	0-5
frequency	O	6-15
distribution	O	16-28
was	O	29-32
approximately	O	33-46
a	O	47-48
normal	O	49-55
distribution	O	56-68
. 	O	68-70

However	O	0-7
,	O	7-8
the	O	9-12
positive	O	13-21
rate	O	22-26
was	O	27-30
higher	O	31-37
than	O	38-42
that	O	43-47
detected	O	48-56
by	O	57-59
microarray	O	60-70
. 	O	70-72

[	O	0-1
Profiling	O	1-10
of	O	11-13
microRNAs	O	14-23
in	O	24-26
mouse	O	27-32
brain	O	33-38
with	O	39-43
real	O	44-48
-	O	48-49
time	O	49-53
PCR	O	54-57
array	O	58-63
]	O	63-64
.  	O	64-67

METHODS	O	0-7
:	O	7-8
Low	O	9-12
molecular	O	13-22
weight	O	23-29
RNA	O	30-33
from	O	34-38
cerebrum	O	39-47
of	O	48-50
five	O	51-55
C57BL	O	56-61
/	O	61-62
6J	O	62-64
mice	O	65-69
were	O	70-74
tailed	O	75-81
and	O	82-85
reverse	O	86-93
transcribed	O	94-105
by	O	106-108
extended	O	109-117
RT	O	118-120
-	O	120-121
primer	O	121-127
. 	O	127-129

OBJECTIVE	O	0-9
:	O	9-10
To	O	11-13
examine	O	14-21
global	O	22-28
expression	O	29-39
levels	O	40-46
of	O	47-49
microRNAs	O	50-59
(	O	59-60
miRNAs	O	60-66
)	O	66-67
in	O	68-70
mouse	O	71-76
cerebrum	O	77-85
and	O	86-89
to	O	90-92
provide	O	93-100
an	O	101-103
important	O	104-113
basis	O	114-119
for	O	120-123
detailed	O	124-132
studies	O	133-140
of	O	141-143
individual	O	144-154
miRNAs	O	155-161
,	O	161-162
their	O	163-168
target	O	169-175
genes	O	176-181
,	O	181-182
the	O	183-186
miRNA	O	187-192
-	O	192-193
related	O	193-200
regulatory	O	201-211
networks	O	212-220
in	O	221-223
the	O	224-227
mammalian	O	228-237
central	O	238-245
nervous	O	246-253
system	O	254-260
,	O	260-261
and	O	262-265
their	O	266-271
implications	O	272-284
in	O	285-287
diseases	O	288-296
. 	O	296-298

PCR	O	0-3
was	O	4-7
carried	O	8-15
out	O	16-19
at	O	20-22
different	O	23-32
annealing	O	33-42
temperatures	O	43-55
using	O	56-61
a	O	62-63
gradient	O	64-72
real	O	73-77
-	O	77-78
time	O	78-82
PCR	O	83-86
instrument	O	87-97
. 	O	97-99

miRNA	O	0-5
primers	O	6-13
were	O	14-18
carefully	O	19-28
designed	O	29-37
and	O	38-41
arrayed	O	42-49
on	O	50-52
plates	O	53-59
according	O	60-69
to	O	70-72
the	O	73-76
Tm	O	77-79
of	O	80-82
each	O	83-87
primer	O	88-94
. 	O	94-96

RESULTS	O	0-7
:	O	7-8
Among	O	9-14
the	O	15-18
285	O	19-22
miRNAs	O	23-29
detected	O	30-38
,	O	38-39
260	O	40-43
were	O	44-48
positive	O	49-57
with	O	58-62
varying	O	63-70
abundance	O	71-80
. 	O	80-82

The	O	0-3
relative	O	4-12
expression	O	13-23
level	O	24-29
of	O	30-32
each	O	33-37
miRNA	O	38-43
was	O	44-47
calculated	O	48-58
using	O	59-64
5sRNA	O	65-70
for	O	71-74
normalization	O	75-88
. 	O	88-90

Clusters	O	0-8
of	O	9-11
proximal	O	12-20
miRNAs	O	21-27
were	O	28-32
similar	O	33-40
or	O	41-43
quite	O	44-49
different	O	50-59
in	O	60-62
abundance	O	63-72
. 	O	72-74

miRNAs	O	0-6
originating	O	7-18
from	O	19-23
the	O	24-27
same	O	28-32
hairpin	O	33-40
precursors	O	41-51
expressed	O	52-61
at	O	62-64
similar	O	65-72
or	O	73-75
significantly	O	76-89
different	O	90-99
levels	O	100-106
. 	O	106-108

It	O	0-2
is	O	3-5
suggested	O	6-15
that	O	16-20
the	O	21-24
fate	O	25-29
of	O	30-32
miRNA	O	33-38
after	O	39-44
transcription	O	45-58
determined	O	59-69
their	O	70-75
abundance	O	76-85
. 	O	85-87

CONCLUSION	O	0-10
:	O	10-11
Using	O	12-17
the	O	18-21
RNA	O	22-25
-	O	25-26
tailing	O	26-33
and	O	34-37
primer	O	38-44
-	O	44-45
extension	O	45-54
PCR	O	55-58
array	O	59-64
method	O	65-71
,	O	71-72
we	O	73-75
obtained	O	76-84
expression	O	85-95
profile	O	96-103
of	O	104-106
miRNA	O	107-112
in	O	113-115
mouse	O	116-121
cerebrum	O	122-130
,	O	130-131
especially	O	132-142
the	O	143-146
relative	O	147-155
expression	O	156-166
data	O	167-171
of	O	172-174
many	O	175-179
low	O	180-183
abundant	O	184-192
miRNA	O	193-198
in	O	199-201
mouse	O	202-207
cerebrum	O	208-216
,	O	216-217
which	O	218-223
will	O	224-228
be	O	229-231
of	O	232-234
special	O	235-242
help	O	243-247
for	O	248-251
studying	O	252-260
the	O	261-264
fine	O	265-269
-	O	269-270
tuning	O	270-276
function	O	277-285
of	O	286-288
low	O	289-292
-	O	292-293
level	O	293-298
miRNAs	O	299-305
.   	O	305-309

Vascular	O	0-8
injury	O	9-15
triggers	O	16-24
dedifferentiation	O	25-42
and	O	43-46
cytoskeletal	O	47-59
remodeling	O	60-70
of	O	71-73
smooth	O	74-80
muscle	O	81-87
cells	O	88-93
(	O	94-95
SMCs	O	95-99
)	O	99-100
,	O	100-101
culminating	O	102-113
in	O	114-116
vessel	O	117-123
occlusion	O	124-133
. 	O	133-135

MicroRNAs	O	0-9
miR	B	10-13
-	I	13-14
143	I	14-17
and	O	18-21
miR	B	22-25
-	I	25-26
145	I	26-29
modulate	O	30-38
cytoskeletal	O	39-51
dynamics	O	52-60
and	O	61-64
responsiveness	O	65-79
of	O	80-82
smooth	O	83-89
muscle	O	90-96
cells	O	97-102
to	O	103-105
injury	O	106-112
.  	O	112-115

Serum	O	0-5
response	O	6-14
factor	O	15-21
(	O	22-23
SRF	O	23-26
)	O	26-27
and	O	28-31
its	O	32-35
coactivator	O	36-47
,	O	47-48
myocardin	O	49-58
,	O	58-59
play	O	60-64
a	O	65-66
central	O	67-74
role	O	75-79
in	O	80-82
the	O	83-86
control	O	87-94
of	O	95-97
smooth	O	98-104
muscle	O	105-111
phenotypes	O	112-122
by	O	123-125
regulating	O	126-136
the	O	137-140
expression	O	141-151
of	O	152-154
cytoskeletal	O	155-167
genes	O	168-173
. 	O	173-175

We	O	0-2
show	O	3-7
that	O	8-12
SRF	O	13-16
and	O	17-20
myocardin	O	21-30
regulate	O	31-39
a	O	40-41
cardiovascular	O	42-56
-	O	56-57
specific	O	57-65
microRNA	O	66-74
(	O	75-76
miRNA	O	76-81
)	O	81-82
cluster	O	83-90
encoding	O	91-99
miR	B	100-103
-	I	103-104
143	I	104-107
and	O	108-111
miR	B	112-115
-	I	115-116
145	I	116-119
. 	O	119-121

To	O	0-2
assess	O	3-9
the	O	10-13
functions	O	14-23
of	O	24-26
these	O	27-32
miRNAs	O	33-39
in	O	40-42
vivo	O	43-47
,	O	47-48
we	O	49-51
systematically	O	52-66
deleted	O	67-74
them	O	75-79
singly	O	80-86
and	O	87-90
in	O	91-93
combination	O	94-105
in	O	106-108
mice	O	109-113
. 	O	113-115

Mice	O	0-4
lacking	O	5-12
both	O	13-17
miR	B	18-21
-	I	21-22
143	I	22-25
and	O	26-29
miR	B	30-33
-	I	33-34
145	I	34-37
are	O	38-41
viable	O	42-48
and	O	49-52
do	O	53-55
not	O	56-59
display	O	60-67
overt	O	68-73
abnormalities	O	74-87
in	O	88-90
smooth	O	91-97
muscle	O	98-104
differentiation	O	105-120
,	O	120-121
although	O	122-130
they	O	131-135
show	O	136-140
a	O	141-142
significant	O	143-154
reduction	O	155-164
in	O	165-167
blood	O	168-173
pressure	O	174-182
due	O	183-186
to	O	187-189
reduced	O	190-197
vascular	O	198-206
tone	O	207-211
. 	O	211-213

Remarkably	O	0-10
,	O	10-11
however	O	12-19
,	O	19-20
neointima	O	21-30
formation	O	31-40
in	O	41-43
response	O	44-52
to	O	53-55
vascular	O	56-64
injury	O	65-71
is	O	72-74
profoundly	O	75-85
impeded	O	86-93
in	O	94-96
mice	O	97-101
lacking	O	102-109
these	O	110-115
miRNAs	O	116-122
,	O	122-123
due	O	124-127
to	O	128-130
disarray	O	131-139
of	O	140-142
actin	O	143-148
stress	O	149-155
fibers	O	156-162
and	O	163-166
diminished	O	167-177
migratory	O	178-187
activity	O	188-196
of	O	197-199
SMCs	O	200-204
. 	O	204-206

These	O	0-5
abnormalities	O	6-19
reflect	O	20-27
the	O	28-31
regulation	O	32-42
of	O	43-45
a	O	46-47
cadre	O	48-53
of	O	54-56
modulators	O	57-67
of	O	68-70
SRF	O	71-74
activity	O	75-83
and	O	84-87
actin	O	88-93
dynamics	O	94-102
by	O	103-105
miR	B	106-109
-	I	109-110
143	I	110-113
and	O	114-117
miR	B	118-121
-	I	121-122
145	I	122-125
. 	O	125-127

Thus	O	0-4
,	O	4-5
miR	B	6-9
-	I	9-10
143	I	10-13
and	O	14-17
miR	B	18-21
-	I	21-22
145	I	22-25
act	O	26-29
as	O	30-32
integral	O	33-41
components	O	42-52
of	O	53-55
the	O	56-59
regulatory	O	60-70
network	O	71-78
whereby	O	79-86
SRF	O	87-90
controls	O	91-99
cytoskeletal	O	100-112
remodeling	O	113-123
and	O	124-127
phenotypic	O	128-138
switching	O	139-148
of	O	149-151
SMCs	O	152-156
during	O	157-163
vascular	O	164-172
disease	O	173-180
.   	O	180-184

This	O	0-4
work	O	5-9
represents	O	10-20
the	O	21-24
first	O	25-30
experimental	O	31-43
study	O	44-49
showing	O	50-57
that	O	58-62
an	O	63-65
miR	B	66-69
-	I	69-70
30	I	70-72
-	O	72-73
based	O	73-78
shRNA	O	79-84
construct	O	85-94
prevents	O	95-103
Oas1	O	104-108
pathway	O	109-116
associated	O	117-127
off	O	128-131
-	O	131-132
target	O	132-138
effects	O	139-146
,	O	146-147
which	O	148-153
we	O	154-156
consider	O	157-165
as	O	166-168
an	O	169-171
essential	O	172-181
prerequisite	O	182-194
for	O	195-198
shRNA	O	199-204
use	O	205-208
in	O	209-211
future	O	212-218
gene	O	219-223
therapeutic	O	224-235
approaches	O	236-246
.   	O	246-250

Modification	O	0-12
of	O	13-15
the	O	16-19
shRNA	O	20-25
construct	O	26-35
by	O	36-38
implementing	O	39-51
features	O	52-60
of	O	61-63
the	O	64-67
naturally	O	68-77
occurring	O	78-87
microRNA	B	88-96
-	I	96-97
30	I	97-99
(	O	100-101
miR	B	101-104
-	I	104-105
30	I	105-107
)	O	107-108
precursor	O	109-118
avoided	O	119-126
Oas1	O	127-131
induction	O	132-141
in	O	142-144
transduced	O	145-155
primary	O	156-163
cultures	O	164-172
,	O	172-173
whereby	O	174-181
modification	O	182-194
of	O	195-197
the	O	198-201
passenger	O	202-211
strand	O	212-218
seems	O	219-224
to	O	225-227
be	O	228-230
a	O	231-232
crucial	O	233-240
feature	O	241-248
to	O	249-251
circumvent	O	252-262
interferon	O	263-273
-	O	273-274
stimulated	O	274-284
gene	O	285-289
expression	O	290-300
. 	O	300-302

We	O	0-2
found	O	3-8
that	O	9-13
lentiviral	O	14-24
vector	O	25-31
(	O	32-33
LV	O	33-35
)	O	35-36
-	O	36-37
mediated	O	37-45
expression	O	46-56
of	O	57-59
shRNAs	O	60-66
in	O	67-69
primary	O	70-77
cortical	O	78-86
cultures	O	87-95
resulted	O	96-104
in	O	105-107
strong	O	108-114
expression	O	115-125
of	O	126-128
the	O	129-132
interferon	O	133-143
-	O	143-144
stimulated	O	144-154
gene	O	155-159
oligoadenylate	O	160-174
synthetase	O	175-185
1	O	186-187
(	O	188-189
Oas1	O	189-193
)	O	193-194
,	O	194-195
which	O	196-201
was	O	202-205
accompanied	O	206-217
by	O	218-220
accelerated	O	221-232
apoptosis	O	233-242
and	O	243-246
substantial	O	247-258
net	O	259-262
neuron	O	263-269
loss	O	270-274
. 	O	274-276

Prevention	O	0-10
of	O	11-13
interferon	O	14-24
-	O	24-25
stimulated	O	25-35
gene	O	36-40
expression	O	41-51
using	O	52-57
microRNA	O	58-66
-	O	66-67
designed	O	67-75
hairpins	O	76-84
.  	O	84-87

However	O	0-7
,	O	7-8
growing	O	9-16
evidence	O	17-25
exists	O	26-32
that	O	33-37
the	O	38-41
expression	O	42-52
of	O	53-55
short	O	56-61
hairpin	O	62-69
RNAs	O	70-74
(	O	75-76
shRNAs	O	76-82
)	O	82-83
can	O	84-87
trigger	O	88-95
cellular	O	96-104
immune	O	105-111
response	O	112-120
resulting	O	121-130
in	O	131-133
unspecific	O	134-144
cellular	O	145-153
phenotypes	O	154-164
and	O	165-168
severe	O	169-175
side	O	176-180
effects	O	181-188
. 	O	188-190

RNA	O	0-3
interference	O	4-16
allows	O	17-23
selective	O	24-33
gene	O	34-38
silencing	O	39-48
,	O	48-49
and	O	50-53
is	O	54-56
widely	O	57-63
used	O	64-68
for	O	69-72
functional	O	73-83
analysis	O	84-92
of	O	93-95
individual	O	96-106
genes	O	107-112
in	O	113-115
vertebrate	O	116-126
cells	O	127-132
and	O	133-136
represents	O	137-147
an	O	148-150
attractive	O	151-161
therapeutic	O	162-173
option	O	174-180
for	O	181-184
treating	O	185-193
central	O	194-201
nervous	O	202-209
system	O	210-216
diseases	O	217-225
. 	O	225-227

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
,	O	28-29
noncoding	O	30-39
RNAs	O	40-44
that	O	45-49
play	O	50-54
a	O	55-56
critical	O	57-65
role	O	66-70
in	O	71-73
developmental	O	74-87
and	O	88-91
physiological	O	92-105
processes	O	106-115
and	O	116-119
are	O	120-123
implicated	O	124-134
in	O	135-137
the	O	138-141
pathogenesis	O	142-154
of	O	155-157
several	O	158-165
human	O	166-171
diseases	O	172-180
,	O	180-181
including	O	182-191
cancer	O	192-198
. 	O	198-200

Downregulation	O	0-14
of	O	15-17
Pdcd4	O	18-23
by	O	24-26
mir	B	27-30
-	I	30-31
21	I	31-33
facilitates	O	34-45
glioblastoma	O	46-58
proliferation	O	59-72
in	O	73-75
vivo	O	76-80
.  	O	80-83

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
examined	O	18-26
the	O	27-30
role	O	31-35
of	O	36-38
oncogenic	O	39-48
mir	B	49-52
-	I	52-53
21	I	53-55
in	O	56-58
the	O	59-62
pathogenesis	O	63-75
of	O	76-78
glioblastoma	O	79-91
,	O	91-92
the	O	93-96
most	O	97-101
aggressive	O	102-112
form	O	113-117
of	O	118-120
primary	O	121-128
brain	O	129-134
tumor	O	135-140
. 	O	140-142

They	O	0-4
function	O	5-13
by	O	14-16
regulating	O	17-27
target	O	28-34
gene	O	35-39
expression	O	40-50
post	O	51-55
-	O	55-56
transcriptionally	O	56-73
. 	O	73-75

We	O	0-2
demonstrate	O	3-14
that	O	15-19
downregulation	O	20-34
of	O	35-37
mir	B	38-41
-	I	41-42
21	I	42-44
in	O	45-47
glioblastoma	O	48-60
-	O	60-61
derived	O	61-68
cell	O	69-73
lines	O	74-79
results	O	80-87
in	O	88-90
increased	O	91-100
expression	O	101-111
of	O	112-114
its	O	115-118
target	O	119-125
,	O	125-126
programmed	O	127-137
cell	O	138-142
death	O	143-148
4	O	149-150
(	O	151-152
Pdcd4	O	152-157
)	O	157-158
,	O	158-159
a	O	160-161
known	O	162-167
tumor	O	168-173
-	O	173-174
suppressor	O	174-184
gene	O	185-189
. 	O	189-191

We	O	0-2
have	O	3-7
previously	O	8-18
reported	O	19-27
that	O	28-32
mir	B	33-36
-	I	36-37
21	I	37-39
is	O	40-42
expressed	O	43-52
at	O	53-55
higher	O	56-62
levels	O	63-69
in	O	70-72
primary	O	73-80
glioblastoma	O	81-93
-	O	93-94
tissue	O	94-100
and	O	101-104
glioblastoma	O	105-117
-	O	117-118
derived	O	118-125
cell	O	126-130
lines	O	131-136
than	O	137-141
in	O	142-144
normal	O	145-151
brain	O	152-157
tissue	O	158-164
. 	O	164-166

Using	O	0-5
a	O	6-7
glioblastoma	O	8-20
xenograft	O	21-30
model	O	31-36
in	O	37-39
immune	O	40-46
-	O	46-47
deficient	O	47-56
nude	O	57-61
mice	O	62-66
,	O	66-67
we	O	68-70
observe	O	71-78
that	O	79-83
glioblastoma	O	84-96
-	O	96-97
derived	O	97-104
cell	O	105-109
lines	O	110-115
in	O	116-118
which	O	119-124
mir	B	125-128
-	I	128-129
21	I	129-131
levels	O	132-138
are	O	139-142
downregulated	O	143-156
or	O	157-159
Pdcd4	O	160-165
is	O	166-168
over	O	169-173
-	O	173-174
expressed	O	174-183
exhibit	O	184-191
decreased	O	192-201
tumor	O	202-207
formation	O	208-217
and	O	218-221
growth	O	222-228
. 	O	228-230

In	O	0-2
addition	O	3-11
,	O	11-12
our	O	13-16
data	O	17-21
indicate	O	22-30
that	O	31-35
either	O	36-42
downregulation	O	43-57
of	O	58-60
mir	B	61-64
-	I	64-65
21	I	65-67
or	O	68-70
overexpression	O	71-85
of	O	86-88
its	O	89-92
target	O	93-99
,	O	99-100
Pdcd4	O	101-106
,	O	106-107
in	O	108-110
glioblastoma	O	111-123
-	O	123-124
derived	O	124-131
cell	O	132-136
lines	O	137-142
leads	O	143-148
to	O	149-151
decreased	O	152-161
proliferation	O	162-175
,	O	175-176
increased	O	177-186
apoptosis	O	187-196
,	O	196-197
and	O	198-201
decreased	O	202-211
colony	O	212-218
formation	O	219-228
in	O	229-231
soft	O	232-236
agar	O	237-241
. 	O	241-243

Significantly	O	0-13
,	O	13-14
tumors	O	15-21
grow	O	22-26
when	O	27-31
the	O	32-35
glioblastoma	O	36-48
-	O	48-49
derived	O	49-56
cell	O	57-61
lines	O	62-67
are	O	68-71
transfected	O	72-83
with	O	84-88
anti	O	89-93
-	O	93-94
mir	O	94-97
-	O	97-98
21	O	98-100
and	O	101-104
siRNA	O	105-110
to	O	111-113
Pdcd4	O	114-119
,	O	119-120
confirming	O	121-131
that	O	132-136
the	O	137-140
tumor	O	141-146
growth	O	147-153
is	O	154-156
specifically	O	157-169
regulated	O	170-179
by	O	180-182
Pdcd4	O	183-188
. 	O	188-190

These	O	0-5
critical	O	6-14
in	O	15-17
vivo	O	18-22
findings	O	23-31
demonstrate	O	32-43
an	O	44-46
important	O	47-56
functional	O	57-67
linkage	O	68-75
between	O	76-83
mir	B	84-87
-	I	87-88
21	I	88-90
and	O	91-94
Pdcd4	O	95-100
and	O	101-104
further	O	105-112
elucidate	O	113-122
the	O	123-126
molecular	O	127-136
mechanisms	O	137-147
by	O	148-150
which	O	151-156
the	O	157-160
known	O	161-166
high	O	167-171
level	O	172-177
of	O	178-180
mir	B	181-184
-	I	184-185
21	I	185-187
expression	O	188-198
in	O	199-201
glioblastoma	O	202-214
can	O	215-218
attribute	O	219-228
to	O	229-231
tumorigenesis	O	232-245
-	O	245-246
-	O	246-247
namely	O	247-253
,	O	253-254
inhibition	O	255-265
of	O	266-268
Pdcd4	O	269-274
and	O	275-278
its	O	279-282
tumor	O	283-288
-	O	288-289
suppressive	O	289-300
functions	O	301-310
.   	O	310-314

New	O	0-3
insights	O	4-12
into	O	13-17
non	O	18-21
-	O	21-22
coding	O	22-28
RNA	O	29-32
networks	O	33-41
in	O	42-44
Huntington	O	45-55
'	O	55-56
s	O	56-57
disease	O	58-65
.     	O	65-71

Plasma	O	0-6
miRNAs	O	7-13
should	O	14-20
be	O	21-23
investigated	O	24-36
further	O	37-44
as	O	45-47
leading	O	48-55
indicators	O	56-66
of	O	67-69
HIV	O	70-73
diseases	O	74-82
as	O	83-85
early	O	86-91
as	O	92-94
acute	O	95-100
infection	O	101-110
.   	O	110-114

CONCLUSION	O	0-10
:	O	10-11
:	O	12-13
Acute	O	14-19
-	O	19-20
phase	O	20-25
differential	O	26-38
expression	O	39-49
of	O	50-52
plasma	O	53-59
miRNAs	O	60-66
predicts	O	67-75
CNS	O	76-79
disease	O	80-87
and	O	88-91
suggests	O	92-100
that	O	101-105
CNS	O	106-109
damage	O	110-116
or	O	117-119
predisposition	O	120-134
to	O	135-137
disease	O	138-145
progression	O	146-157
begins	O	158-164
in	O	165-167
the	O	168-171
earliest	O	172-180
phase	O	181-186
of	O	187-189
infection	O	190-199
. 	O	199-201

At	O	0-2
least	O	3-8
six	O	9-12
miRNAs	O	13-19
were	O	20-24
significantly	O	25-38
differentially	O	39-53
expressed	O	54-63
in	O	64-66
individuals	O	67-78
with	O	79-83
severe	O	84-90
versus	O	91-97
no	O	98-100
CNS	O	101-104
disease	O	105-112
;	O	112-113
in	O	114-116
an	O	117-119
unweighted	O	120-130
expression	O	131-141
test	O	142-146
,	O	146-147
they	O	148-152
predicted	O	153-162
CNS	O	163-166
disease	O	167-174
. 	O	174-176

miRNAs	O	0-6
tracked	O	7-14
with	O	15-19
viral	O	20-25
load	O	26-30
and	O	31-34
platelet	O	35-43
count	O	44-49
were	O	50-54
also	O	55-59
predictors	O	60-70
of	O	71-73
CNS	O	74-77
disease	O	78-85
. 	O	85-87

OBJECTIVE	O	0-9
:	O	9-10
:	O	11-12
Plasma	O	13-19
microRNAs	O	20-29
(	O	30-31
miRNAs	O	31-37
)	O	37-38
are	O	39-42
modulated	O	43-52
during	O	53-59
disease	O	60-67
and	O	68-71
are	O	72-75
emerging	O	76-84
biomarkers	O	85-95
;	O	95-96
they	O	97-101
have	O	102-106
not	O	107-110
been	O	111-115
characterized	O	116-129
in	O	130-132
HIV	O	133-136
infection	O	137-146
. 	O	146-148

A	O	0-1
plasma	O	2-8
microRNA	O	9-17
signature	O	18-27
of	O	28-30
acute	O	31-36
lentiviral	O	37-47
infection	O	48-57
:	O	57-58
biomarkers	O	60-70
of	O	71-73
central	O	74-81
nervous	O	82-89
system	O	90-96
disease	O	97-104
.   	O	104-107

miRNA	O	0-5
expression	O	6-16
was	O	17-20
compared	O	21-29
with	O	30-34
levels	O	35-41
of	O	42-44
cytokines	O	45-54
,	O	54-55
virus	O	56-61
,	O	61-62
and	O	63-66
plasma	O	67-73
platelet	O	74-82
count	O	83-88
. 	O	88-90

METHODS	O	0-7
:	O	7-8
:	O	9-10
Plasma	O	11-17
miRNA	O	18-23
expression	O	24-34
profiles	O	35-43
were	O	44-48
determined	O	49-59
by	O	60-62
TaqMan	O	63-69
low	O	70-73
-	O	73-74
density	O	74-81
array	O	82-87
for	O	88-91
six	O	92-95
individuals	O	96-107
. 	O	107-109

DESIGN	O	0-6
:	O	6-7
:	O	8-9
Plasma	O	10-16
samples	O	17-24
were	O	25-29
obtained	O	30-38
before	O	39-45
inoculation	O	46-57
and	O	58-61
10	O	62-64
days	O	65-69
after	O	70-75
inoculation	O	76-87
from	O	88-92
SIV	O	93-96
-	O	96-97
infected	O	97-105
macaques	O	106-114
. 	O	114-116

Using	O	0-5
our	O	6-9
macaque	O	10-17
/	O	17-18
simian	O	18-24
immunodeficiency	O	25-41
virus	O	42-47
(	O	48-49
SIV	O	49-52
)	O	52-53
model	O	54-59
of	O	60-62
HIV	O	63-66
,	O	66-67
we	O	68-70
sought	O	71-77
to	O	78-80
identify	O	81-89
a	O	90-91
plasma	O	92-98
miRNA	O	99-104
profile	O	105-112
of	O	113-115
acute	O	116-121
lentiviral	O	122-132
infection	O	133-142
,	O	142-143
evaluate	O	144-152
its	O	153-156
relationship	O	157-169
with	O	170-174
known	O	175-180
cellular	O	181-189
and	O	190-193
viral	O	194-199
determinants	O	200-212
of	O	213-215
lentivirus	O	216-226
-	O	226-227
associated	O	227-237
central	O	238-245
nervous	O	246-253
system	O	254-260
(	O	261-262
CNS	O	262-265
)	O	265-266
disease	O	267-274
,	O	274-275
and	O	276-279
explore	O	280-287
the	O	288-291
potential	O	292-301
of	O	302-304
miRNAs	O	305-311
to	O	312-314
predict	O	315-322
CNS	O	323-326
disease	O	327-334
. 	O	334-336

Several	O	0-7
differentially	O	8-22
expressed	O	23-32
miRNAs	O	33-39
correlated	O	40-50
with	O	51-55
CNS	O	56-59
disease	O	60-67
-	O	67-68
associated	O	68-78
cytokines	O	79-88
interleukin	O	89-100
-	O	100-101
6	O	101-102
and	O	103-106
CCL2	O	107-111
and	O	112-115
included	O	116-124
predicted	O	125-134
and	O	135-138
/	O	138-139
or	O	139-141
validated	O	142-151
regulators	O	152-162
of	O	163-165
the	O	166-169
corresponding	O	170-183
mRNAs	O	184-189
. 	O	189-191

RESULTS	O	0-7
:	O	7-8
:	O	9-10
A	O	11-12
45	O	13-15
-	O	15-16
miRNA	O	16-21
signature	O	22-31
of	O	32-34
acute	O	35-40
infection	O	41-50
(	O	51-52
differential	O	52-64
expression	O	65-75
with	O	76-80
P 	O	81-85
<	O	85-86
 0	O	86-90
.	O	90-91
05	O	91-93
after	O	94-99
multiple	O	100-108
comparison	O	109-119
correction	O	120-130
)	O	130-131
classified	O	132-142
plasma	O	143-149
as	O	150-152
infected	O	153-161
or	O	162-164
not	O	165-168
. 	O	168-170

Nineteen	O	0-8
individuals	O	9-20
were	O	21-25
used	O	26-30
to	O	31-33
validate	O	34-42
a	O	43-44
disease	O	45-52
prediction	O	53-63
test	O	64-68
. 	O	68-70

miRNA	O	0-5
results	O	6-13
were	O	14-18
confirmed	O	19-28
by	O	29-31
single	O	32-38
miRNA	O	39-44
-	O	44-45
specific	O	45-53
assays	O	54-60
for	O	61-64
10	O	65-67
macaques	O	68-76
. 	O	76-78

Regulation	O	0-10
of	O	11-13
oligodendrocyte	O	14-29
differentiation	O	30-45
and	O	46-49
myelination	O	50-61
.  	O	61-64

These	O	0-5
recent	O	6-12
advances	O	13-21
provide	O	22-29
new	O	30-33
insight	O	34-41
into	O	42-46
how	O	47-50
remyelination	O	51-64
may	O	65-68
be	O	69-71
stimulated	O	72-82
in	O	83-85
demyelinating	O	86-99
disorders	O	100-109
such	O	110-114
as	O	115-117
multiple	O	118-126
sclerosis	O	127-136
.   	O	136-140

Studies	O	0-7
have	O	8-12
also	O	13-17
demonstrated	O	18-30
an	O	31-33
unexpected	O	34-44
level	O	45-50
of	O	51-53
plasticity	O	54-64
of	O	65-67
myelin	O	68-74
in	O	75-77
the	O	78-81
adult	O	82-87
CNS	O	88-91
. 	O	91-93

Recent	O	0-6
results	O	7-14
have	O	15-19
greatly	O	20-27
advanced	O	28-36
this	O	37-41
understanding	O	42-55
,	O	55-56
identifying	O	57-68
new	O	69-72
transcriptional	O	73-88
regulators	O	89-99
of	O	100-102
myelin	O	103-109
gene	O	110-114
expression	O	115-125
,	O	125-126
elucidating	O	127-138
vital	O	139-144
roles	O	145-150
for	O	151-154
microRNAs	O	155-164
in	O	165-167
controlling	O	168-179
myelination	O	180-191
,	O	191-192
and	O	193-196
clarifying	O	197-207
the	O	208-211
extracellular	O	212-225
signaling	O	226-235
mechanisms	O	236-246
that	O	247-251
orchestrate	O	252-263
the	O	264-267
development	O	268-279
of	O	280-282
myelin	O	283-289
. 	O	289-291

Despite	O	0-7
the	O	8-11
importance	O	12-22
of	O	23-25
myelin	O	26-32
for	O	33-36
the	O	37-40
rapid	O	41-46
conduction	O	47-57
of	O	58-60
action	O	61-67
potentials	O	68-78
,	O	78-79
the	O	80-83
molecular	O	84-93
bases	O	94-99
of	O	100-102
oligodendrocyte	O	103-118
differentiation	O	119-134
and	O	135-138
central	O	139-146
nervous	O	147-154
system	O	155-161
(	O	162-163
CNS	O	163-166
)	O	166-167
myelination	O	168-179
are	O	180-183
still	O	184-189
incompletely	O	190-202
understood	O	203-213
. 	O	213-215

miR	B	0-3
-	I	3-4
182	I	4-7
as	O	8-10
a	O	11-12
prognostic	O	13-23
marker	O	24-30
for	O	31-34
glioma	O	35-41
progression	O	42-53
and	O	54-57
patient	O	58-65
survival	O	66-74
.  	O	74-77

Taken	O	0-5
together	O	6-14
,	O	14-15
our	O	16-19
results	O	20-27
suggest	O	28-35
that	O	36-40
miR	B	41-44
-	I	44-45
182	I	45-48
could	O	49-54
be	O	55-57
a	O	58-59
valuable	O	60-68
marker	O	69-75
of	O	76-78
glioma	O	79-85
progression	O	86-97
and	O	98-101
that	O	102-106
high	O	107-111
miR	B	112-115
-	I	115-116
182	I	116-119
expression	O	120-130
is	O	131-133
associated	O	134-144
with	O	145-149
poor	O	150-154
overall	O	155-162
survival	O	163-171
in	O	172-174
patients	O	175-183
with	O	184-188
malignant	O	189-198
glioma	O	199-205
.   	O	205-209

Moreover	O	0-8
,	O	8-9
the	O	10-13
correlations	O	14-26
of	O	27-29
miR	B	30-33
-	I	33-34
182	I	34-37
level	O	38-43
with	O	44-48
the	O	49-52
clinical	O	53-61
features	O	62-70
of	O	71-73
glioma	O	74-80
suggested	O	81-90
in	O	91-93
the	O	94-97
in	O	98-100
situ	O	101-105
hybridization	O	106-119
analysis	O	120-128
were	O	129-133
further	O	134-141
verified	O	142-150
by	O	151-153
the	O	154-157
real	O	158-162
-	O	162-163
time	O	163-167
RT	O	168-170
-	O	170-171
PCR	O	171-174
analysis	O	175-183
. 	O	183-185

The	O	0-3
cumulative	O	4-14
5	O	15-16
-	O	16-17
year	O	17-21
survival	O	22-30
rate	O	31-35
of	O	36-38
glioma	O	39-45
patients	O	46-54
was	O	55-58
51	O	59-61
.	O	61-62
54	O	62-64
%	O	64-65
(	O	66-67
95	O	67-69
%	O	69-70
confidence	O	71-81
interval	O	82-90
,	O	90-91
0	O	92-93
.	O	93-94
435	O	94-97
to	O	98-100
0	O	101-102
.	O	102-103
596	O	103-106
)	O	106-107
in	O	108-110
the	O	111-114
low	O	115-118
miR	B	119-122
-	I	122-123
182	I	123-126
-	O	126-127
expression	O	127-137
group	O	138-143
,	O	143-144
whereas	O	145-152
it	O	153-155
was	O	156-159
only	O	160-164
7	O	165-166
.	O	166-167
23	O	167-169
%	O	169-170
(	O	171-172
95	O	172-174
%	O	174-175
confidence	O	176-186
interval	O	187-195
,	O	195-196
0	O	197-198
.	O	198-199
027	O	199-202
to	O	203-205
0	O	206-207
.	O	207-208
118	O	208-211
)	O	211-212
in	O	213-215
the	O	216-219
high	O	220-224
miR	B	225-228
-	I	228-229
182	I	229-232
-	O	232-233
expression	O	233-243
group	O	244-249
(	O	250-251
P	O	251-252
=	O	253-254
0	O	255-256
.	O	256-257
001	O	257-260
)	O	260-261
,	O	261-262
and	O	263-266
multivariate	O	267-279
Cox	O	280-283
regression	O	284-294
analysis	O	295-303
indicated	O	304-313
that	O	314-318
miR	B	319-322
-	I	322-323
182	I	323-326
expression	O	327-337
was	O	338-341
an	O	342-344
independent	O	345-356
prognostic	O	357-367
indicator	O	368-377
for	O	378-381
the	O	382-385
survival	O	386-394
of	O	395-397
glioma	O	398-404
patients	O	405-413
. 	O	413-415

Statistical	O	0-11
analysis	O	12-20
revealed	O	21-29
a	O	30-31
significant	O	32-43
correlation	O	44-55
between	O	56-63
miR	B	64-67
-	I	67-68
182	I	68-71
expression	O	72-82
and	O	83-86
World	O	87-92
Health	O	93-99
Organization	O	100-112
glioma	O	113-119
grading	O	120-127
(	O	128-129
P	O	129-130
<	O	131-132
0	O	133-134
.	O	134-135
001	O	135-138
)	O	138-139
. 	O	139-141

Elevated	O	0-8
expression	O	9-19
of	O	20-22
miR	B	23-26
-	I	26-27
182	I	27-30
was	O	31-34
further	O	35-42
identified	O	43-53
by	O	54-56
in	O	57-59
situ	O	60-64
hybridization	O	65-78
in	O	79-81
248	O	82-85
of	O	86-88
253	O	89-92
(	O	93-94
98	O	94-96
%	O	96-97
)	O	97-98
archived	O	99-107
human	O	108-113
glioma	O	114-120
biopsies	O	121-129
tested	O	130-136
. 	O	136-138

Quantitative	O	0-12
PCR	O	13-16
analysis	O	17-25
showed	O	26-32
that	O	33-37
miR	B	38-41
-	I	41-42
182	I	42-45
was	O	46-49
significantly	O	50-63
increased	O	64-73
by	O	74-76
up	O	77-79
to	O	80-82
32	O	83-85
-	O	85-86
fold	O	86-90
in	O	91-93
glioma	O	94-100
tumors	O	101-107
compared	O	108-116
with	O	117-121
the	O	122-125
adjacent	O	126-134
nontumor	O	135-143
brain	O	144-149
tissues	O	150-157
obtained	O	158-166
from	O	167-171
the	O	172-175
same	O	176-180
patient	O	181-188
. 	O	188-190

We	O	0-2
report	O	3-9
that	O	10-14
the	O	15-18
expression	O	19-29
level	O	30-35
of	O	36-38
miR	B	39-42
-	I	42-43
182	I	43-46
was	O	47-50
markedly	O	51-59
up	O	60-62
-	O	62-63
regulated	O	63-72
in	O	73-75
glioma	O	76-82
cell	O	83-87
lines	O	88-93
and	O	94-97
in	O	98-100
human	O	101-106
primary	O	107-114
glioma	O	115-121
specimens	O	122-131
. 	O	131-133

Accumulating	O	0-12
evidence	O	13-21
indicates	O	22-31
that	O	32-36
miRNA	O	37-42
expression	O	43-53
can	O	54-57
be	O	58-60
used	O	61-65
as	O	66-68
a	O	69-70
diagnostic	O	71-81
and	O	82-85
prognostic	O	86-96
marker	O	97-103
for	O	104-107
human	O	108-113
cancers	O	114-121
. 	O	121-123

Leukodystrophy	O	0-14
and	O	15-18
gene	O	19-23
therapy	O	24-31
with	O	32-36
a	O	37-38
dimmer	O	39-45
switch	O	46-52
.     	O	52-58

Recently	O	0-8
,	O	8-9
we	O	10-12
have	O	13-17
found	O	18-23
that	O	24-28
microRNA	O	29-37
(	O	38-39
miRNA	O	39-44
)	O	44-45
miR	B	46-49
-	I	49-50
145	I	50-53
is	O	54-56
the	O	57-60
most	O	61-65
abundant	O	66-74
miRNA	O	75-80
in	O	81-83
normal	O	84-90
vascular	O	91-99
walls	O	100-105
and	O	106-109
in	O	110-112
freshly	O	113-120
isolated	O	121-129
VSMCs	O	130-135
;	O	135-136
however	O	137-144
,	O	144-145
the	O	146-149
role	O	150-154
of	O	155-157
miR	B	158-161
-	I	161-162
145	I	162-165
in	O	166-168
VSMC	O	169-173
phenotypic	O	174-184
modulation	O	185-195
and	O	196-199
vascular	O	200-208
diseases	O	209-217
is	O	218-220
currently	O	221-230
unknown	O	231-238
. 	O	238-240

Phenotypic	O	0-10
modulation	O	11-21
of	O	22-24
vascular	O	25-33
smooth	O	34-40
muscle	O	41-47
cells	O	48-53
(	O	54-55
VSMCs	O	55-60
)	O	60-61
plays	O	62-67
a	O	68-69
critical	O	70-78
role	O	79-83
in	O	84-86
the	O	87-90
pathogenesis	O	91-103
of	O	104-106
a	O	107-108
variety	O	109-116
of	O	117-119
proliferative	O	120-133
vascular	O	134-142
diseases	O	143-151
. 	O	151-153

More	O	0-4
importantly	O	5-16
,	O	16-17
both	O	18-22
in	O	23-25
cultured	O	26-34
rat	O	35-38
VSMCs	O	39-44
in	O	45-47
vitro	O	48-53
and	O	54-57
in	O	58-60
balloon	O	61-68
-	O	68-69
injured	O	69-76
rat	O	77-80
carotid	O	81-88
arteries	O	89-97
in	O	98-100
vivo	O	101-105
,	O	105-106
we	O	107-109
demonstrate	O	110-121
that	O	122-126
the	O	127-130
noncoding	O	131-140
RNA	O	141-144
miR	B	145-148
-	I	148-149
145	I	149-152
is	O	153-155
a	O	156-157
novel	O	158-163
phenotypic	O	164-174
marker	O	175-181
and	O	182-185
a	O	186-187
novel	O	188-193
phenotypic	O	194-204
modulator	O	205-214
of	O	215-217
VSMCs	O	218-223
. 	O	223-225

Here	O	0-4
we	O	5-7
find	O	8-12
that	O	13-17
miR	B	18-21
-	I	21-22
145	I	22-25
is	O	26-28
selectively	O	29-40
expressed	O	41-50
in	O	51-53
VSMCs	O	54-59
of	O	60-62
the	O	63-66
vascular	O	67-75
wall	O	76-80
and	O	81-84
its	O	85-88
expression	O	89-99
is	O	100-102
significantly	O	103-116
downregulated	O	117-130
in	O	131-133
the	O	134-137
vascular	O	138-146
walls	O	147-152
with	O	153-157
neointimal	O	158-168
lesion	O	169-175
formation	O	176-185
and	O	186-189
in	O	190-192
cultured	O	193-201
dedifferentiated	O	202-218
VSMCs	O	219-224
. 	O	224-226

MicroRNA	B	0-8
-	I	8-9
145	I	9-12
,	O	12-13
a	O	14-15
novel	O	16-21
smooth	O	22-28
muscle	O	29-35
cell	O	36-40
phenotypic	O	41-51
marker	O	52-58
and	O	59-62
modulator	O	63-72
,	O	72-73
controls	O	74-82
vascular	O	83-91
neointimal	O	92-102
lesion	O	103-109
formation	O	110-119
.  	O	119-122

These	O	0-5
novel	O	6-11
findings	O	12-20
may	O	21-24
have	O	25-29
extensive	O	30-39
implications	O	40-52
for	O	53-56
the	O	57-60
diagnosis	O	61-70
and	O	71-74
therapy	O	75-82
of	O	83-85
a	O	86-87
variety	O	88-95
of	O	96-98
proliferative	O	99-112
vascular	O	113-121
diseases	O	122-130
.   	O	130-134

We	O	0-2
have	O	3-7
further	O	8-15
identified	O	16-26
that	O	27-31
miR	B	32-35
-	I	35-36
145	I	36-39
-	O	39-40
mediated	O	40-48
phenotypic	O	49-59
modulation	O	60-70
of	O	71-73
VSMCs	O	74-79
is	O	80-82
through	O	83-90
its	O	91-94
target	O	95-101
gene	O	102-106
KLF5	O	107-111
and	O	112-115
its	O	116-119
downstream	O	120-130
signaling	O	131-140
molecule	O	141-149
,	O	149-150
myocardin	O	151-160
. 	O	160-162

VSMC	O	0-4
differentiation	O	5-20
marker	O	21-27
genes	O	28-33
such	O	34-38
as	O	39-41
SM	O	42-44
alpha	O	45-50
-	O	50-51
actin	O	51-56
,	O	56-57
calponin	O	58-66
,	O	66-67
and	O	68-71
SM	O	72-74
-	O	74-75
MHC	O	75-78
are	O	79-82
upregulated	O	83-94
by	O	95-97
premiR	B	98-104
-	I	104-105
145	I	105-108
or	O	109-111
adenovirus	O	112-122
expressing	O	123-133
miR	B	134-137
-	I	137-138
145	I	138-141
(	O	142-143
Ad	O	143-145
-	O	145-146
miR	B	146-149
-	I	149-150
145	I	150-153
)	O	153-154
but	O	155-158
are	O	159-162
downregulated	O	163-176
by	O	177-179
the	O	180-183
miR	O	184-187
-	O	187-188
145	O	188-191
inhibitor	O	192-201
2	O	202-203
'	O	203-204
OMe	O	204-207
-	O	207-208
miR	O	208-211
-	O	211-212
145	O	212-215
. 	O	215-217

We	O	0-2
conclude	O	3-11
that	O	12-16
miR	B	17-20
-	I	20-21
145	I	21-24
is	O	25-27
a	O	28-29
novel	O	30-35
VSMC	O	36-40
phenotypic	O	41-51
marker	O	52-58
and	O	59-62
modulator	O	63-72
that	O	73-77
is	O	78-80
able	O	81-85
of	O	86-88
controlling	O	89-100
vascular	O	101-109
neointimal	O	110-120
lesion	O	121-127
formation	O	128-137
. 	O	137-139

Finally	O	0-7
,	O	7-8
restoration	O	9-20
of	O	21-23
miR	B	24-27
-	I	27-28
145	I	28-31
in	O	32-34
balloon	O	35-42
-	O	42-43
injured	O	43-50
arteries	O	51-59
via	O	60-63
Ad	O	64-66
-	O	66-67
miR	B	67-70
-	I	70-71
145	I	71-74
inhibits	O	75-83
neointimal	O	84-94
growth	O	95-101
. 	O	101-103

MicroRNAs	O	0-9
and	O	10-13
regenerative	O	14-26
medicine	O	27-35
.  	O	35-38

Recently	O	0-8
,	O	8-9
researchers	O	10-21
have	O	22-26
demonstrated	O	27-39
the	O	40-43
crucial	O	44-51
roles	O	52-57
of	O	58-60
microRNAs	O	61-70
,	O	70-71
not	O	72-75
only	O	76-80
in	O	81-83
the	O	84-87
differentiation	O	88-103
and	O	104-107
proliferation	O	108-121
of	O	122-124
stem	O	125-129
cells	O	130-135
,	O	135-136
which	O	137-142
have	O	143-147
a	O	148-149
key	O	150-153
function	O	154-162
in	O	163-165
the	O	166-169
regeneration	O	170-182
and	O	183-186
transplantation	O	187-202
of	O	203-205
organs	O	206-212
,	O	212-213
but	O	214-217
also	O	218-222
in	O	223-225
oncogenesis	O	226-237
. 	O	237-239

In	O	0-2
this	O	3-7
paper	O	8-13
,	O	13-14
we	O	15-17
review	O	18-24
the	O	25-28
prospects	O	29-38
of	O	39-41
microRNAs	O	42-51
as	O	52-54
future	O	55-61
therapies	O	62-71
in	O	72-74
regenerative	O	75-87
medicine	O	88-96
. 	O	96-98

The	O	0-3
combination	O	4-15
of	O	16-18
microRNAs	O	19-28
and	O	29-32
regenerative	O	33-45
medicine	O	46-54
is	O	55-57
an	O	58-60
emerging	O	61-69
interdisciplinary	O	70-87
medical	O	88-95
field	O	96-101
that	O	102-106
can	O	107-110
yield	O	111-116
exciting	O	117-125
new	O	126-129
possibilities	O	130-143
for	O	144-147
clinical	O	148-156
medicine	O	157-165
. 	O	165-167

MicroRNAs	O	0-9
,	O	9-10
identified	O	11-21
only	O	22-26
relatively	O	27-37
recently	O	38-46
,	O	46-47
are	O	48-51
regulators	O	52-62
of	O	63-65
gene	O	66-70
expression	O	71-81
with	O	82-86
potential	O	87-96
medical	O	97-104
benefits	O	105-113
. 	O	113-115

Further	O	0-7
,	O	7-8
microRNAs	O	9-18
have	O	19-23
been	O	24-28
indicated	O	29-38
to	O	39-41
be	O	42-44
involved	O	45-53
in	O	54-56
diverse	O	57-64
biological	O	65-75
processes	O	76-85
,	O	85-86
suggesting	O	87-97
the	O	98-101
potential	O	102-111
role	O	112-116
of	O	117-119
these	O	120-125
molecules	O	126-135
in	O	136-138
the	O	139-142
treatment	O	143-152
of	O	153-155
diseases	O	156-164
.   	O	164-168

Several	O	0-7
lines	O	8-13
of	O	14-16
indirect	O	17-25
evidence	O	26-34
show	O	35-39
that	O	40-44
the	O	45-48
initiation	O	49-59
and	O	60-63
maintenance	O	64-75
of	O	76-78
cancer	O	79-85
stem	O	86-90
cells	O	91-96
might	O	97-102
also	O	103-107
be	O	108-110
under	O	111-116
the	O	117-120
control	O	121-128
of	O	129-131
microRNAs	O	132-141
. 	O	141-143

MicroRNAs	O	0-9
in	O	10-12
CNS	O	13-16
injury	O	17-23
:	O	23-24
potential	O	25-34
roles	O	35-40
and	O	41-44
therapeutic	O	45-56
implications	O	57-69
.     	O	69-75

Ameliorating	O	0-12
amyotrophic	O	13-24
lateral	O	25-32
sclerosis	O	33-42
.     	O	42-48

Pathway	O	0-7
analyses	O	8-16
showed	O	17-23
that	O	24-28
majority	O	29-37
of	O	38-40
these	O	41-46
miRNAs	O	47-53
are	O	54-57
involved	O	58-66
in	O	67-69
the	O	70-73
neuronal	O	74-82
development	O	83-94
and	O	95-98
function	O	99-107
. 	O	107-109

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
report	O	18-24
for	O	25-28
the	O	29-32
first	O	33-38
time	O	39-43
that	O	44-48
VEEV	O	49-53
infection	O	54-63
in	O	64-66
mice	O	67-71
brain	O	72-77
causes	O	78-84
modulation	O	85-95
of	O	96-98
miRNA	O	99-104
expression	O	105-115
. 	O	115-117

Target	O	0-6
gene	O	7-11
prediction	O	12-22
of	O	23-25
the	O	26-29
modulated	O	30-39
miRNAs	O	40-46
correlates	O	47-57
with	O	58-62
our	O	63-66
recently	O	67-75
reported	O	76-84
mRNA	O	85-89
expression	O	90-100
in	O	101-103
VEEV	O	104-108
infected	O	109-117
mice	O	118-122
brain	O	123-128
.   	O	128-132

Recent	O	0-6
studies	O	7-14
have	O	15-19
shown	O	20-25
that	O	26-30
cellular	O	31-39
miRNA	O	40-45
plays	O	46-51
a	O	52-53
very	O	54-58
important	O	59-68
role	O	69-73
in	O	74-76
the	O	77-80
pathogenesis	O	81-93
of	O	94-96
viral	O	97-102
infection	O	103-112
. 	O	112-114

MicroRNAs	O	0-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
are	O	18-21
small	O	22-27
RNA	O	28-31
(	O	32-33
approximately	O	33-46
22nts	O	47-52
)	O	52-53
molecules	O	54-63
that	O	64-68
are	O	69-72
expressed	O	73-82
endogenously	O	83-95
in	O	96-98
cells	O	99-104
and	O	105-108
play	O	109-113
an	O	114-116
important	O	117-126
role	O	127-131
in	O	132-134
regulating	O	135-145
gene	O	146-150
expression	O	151-161
. 	O	161-163

VEEV	O	0-4
is	O	5-7
infectious	O	8-18
in	O	19-21
aerosol	O	22-29
form	O	30-34
and	O	35-38
is	O	39-41
a	O	42-43
potential	O	44-53
biothreat	O	54-63
agent	O	64-69
. 	O	69-71

Venezuelan	O	0-10
equine	O	11-17
encephalitis	O	18-30
virus	O	31-36
(	O	37-38
VEEV	O	38-42
)	O	42-43
is	O	44-46
an	O	47-49
RNA	O	50-53
virus	O	54-59
and	O	60-63
is	O	64-66
a	O	67-68
member	O	69-75
of	O	76-78
the	O	79-82
genus	O	83-88
Alphavirus	O	89-99
in	O	100-102
the	O	103-106
family	O	107-113
Togaviridae	O	114-125
. 	O	125-127

Analysis	O	0-8
of	O	9-11
microRNAs	O	12-21
induced	O	22-29
by	O	30-32
Venezuelan	O	33-43
equine	O	44-50
encephalitis	O	51-63
virus	O	64-69
infection	O	70-79
in	O	80-82
mouse	O	83-88
brain	O	89-94
.  	O	94-97

The	O	0-3
accurate	O	4-12
diagnosis	O	13-22
of	O	23-25
brain	O	26-31
malignancies	O	32-44
is	O	45-47
essential	O	48-57
for	O	58-61
selection	O	62-71
of	O	72-74
proper	O	75-81
treatment	O	82-91
. 	O	91-93

A	O	0-1
recurring	O	2-11
challenge	O	12-21
for	O	22-25
brain	O	26-31
pathologists	O	32-44
is	O	45-47
to	O	48-50
diagnose	O	51-59
whether	O	60-67
a	O	68-69
brain	O	70-75
malignancy	O	76-86
is	O	87-89
a	O	90-91
primary	O	92-99
tumor	O	100-105
or	O	106-108
a	O	109-110
metastasis	O	111-121
from	O	122-126
some	O	127-131
other	O	132-137
tissue	O	138-144
. 	O	144-146

MiR	B	0-3
-	I	3-4
92b	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
9	I	16-17
/	I	17-18
9	I	18-19
*	O	19-20
are	O	21-24
specifically	O	25-37
expressed	O	38-47
in	O	48-50
brain	O	51-56
primary	O	57-64
tumors	O	65-71
and	O	72-75
can	O	76-79
be	O	80-82
used	O	83-87
to	O	88-90
differentiate	O	91-104
primary	O	105-112
from	O	113-117
metastatic	O	118-128
brain	O	129-134
tumors	O	135-141
.  	O	141-144

These	O	0-5
microRNAs	O	6-15
thus	O	16-20
represent	O	21-30
excellent	O	31-40
biomarkers	O	41-51
for	O	52-55
brain	O	56-61
primary	O	62-69
tumors	O	70-76
. 	O	76-78

By	O	0-2
considering	O	3-14
the	O	15-18
expression	O	19-29
of	O	30-32
only	O	33-37
these	O	38-43
two	O	44-47
microRNAs	O	48-57
,	O	57-58
it	O	59-61
is	O	62-64
possible	O	65-73
to	O	74-76
distinguish	O	77-88
between	O	89-96
primary	O	97-104
and	O	105-108
metastatic	O	109-119
brain	O	120-125
tumors	O	126-132
with	O	133-137
very	O	138-142
high	O	143-147
accuracy	O	148-156
. 	O	156-158

Using	O	0-5
microRNA	O	6-14
expression	O	15-25
profiling	O	26-35
,	O	35-36
we	O	37-39
found	O	40-45
that	O	46-50
hsa	B	51-54
-	I	54-55
miR	I	55-58
-	I	58-59
92b	I	59-62
and	O	63-66
hsa	B	67-70
-	I	70-71
miR	I	71-74
-	I	74-75
9	I	75-76
/	I	76-77
hsa	I	77-80
-	I	80-81
miR	I	81-84
-	I	84-85
9	I	85-86
*	O	86-87
are	O	88-91
over	O	92-96
-	O	96-97
expressed	O	97-106
,	O	106-107
specifically	O	108-120
in	O	121-123
brain	O	124-129
primary	O	130-137
tumors	O	138-144
,	O	144-145
as	O	146-148
compared	O	149-157
to	O	158-160
primary	O	161-168
tumors	O	169-175
from	O	176-180
other	O	181-186
tissues	O	187-194
and	O	195-198
their	O	199-204
metastases	O	205-215
to	O	216-218
the	O	219-222
brain	O	223-228
. 	O	228-230

MicroRNAs	O	0-9
are	O	10-13
a	O	14-15
class	O	16-21
of	O	22-24
small	O	25-30
non	O	31-34
-	O	34-35
coding	O	35-41
RNA	O	42-45
species	O	46-53
that	O	54-58
regulate	O	59-67
gene	O	68-72
expression	O	73-83
;	O	83-84
many	O	85-89
exhibit	O	90-97
tissue	O	98-104
-	O	104-105
specific	O	105-113
expression	O	114-124
and	O	125-128
are	O	129-132
misregulated	O	133-145
in	O	146-148
cancer	O	149-155
. 	O	155-157

Previous	O	0-8
reports	O	9-16
have	O	17-21
found	O	22-27
that	O	28-32
hsa	B	33-36
-	I	36-37
miR	I	37-40
-	I	40-41
92b	I	41-44
and	O	45-48
hsa	B	49-52
-	I	52-53
miR	I	53-56
-	I	56-57
9	I	57-58
/	I	58-59
hsa	I	59-62
-	I	62-63
miR	I	63-66
-	I	66-67
9	I	67-68
*	O	68-69
are	O	70-73
expressed	O	74-83
more	O	84-88
strongly	O	89-97
in	O	98-100
developing	O	101-111
neurons	O	112-119
and	O	120-123
brain	O	124-129
than	O	130-134
in	O	135-137
adult	O	138-143
brain	O	144-149
. 	O	149-151

Thus	O	0-4
,	O	4-5
their	O	6-11
specific	O	12-20
over	O	21-25
-	O	25-26
expression	O	26-36
in	O	37-39
brain	O	40-45
primary	O	46-53
tumors	O	54-60
supports	O	61-69
a	O	70-71
functional	O	72-82
role	O	83-87
for	O	88-91
these	O	92-97
microRNAs	O	98-107
or	O	108-110
a	O	111-112
link	O	113-117
between	O	118-125
neuronal	O	126-134
stem	O	135-139
cells	O	140-145
and	O	146-149
brain	O	150-155
tumorigenesis	O	156-169
.   	O	169-173

These	O	0-5
findings	O	6-14
call	O	15-19
attention	O	20-29
to	O	30-32
the	O	33-36
potential	O	37-46
of	O	47-49
microRNAs	O	50-59
to	O	60-62
provide	O	63-70
etiologic	O	71-80
insights	O	81-89
as	O	90-92
well	O	93-97
as	O	98-100
to	O	101-103
serve	O	104-109
as	O	110-112
both	O	113-117
diagnostic	O	118-128
markers	O	129-136
and	O	137-140
therapeutic	O	141-152
targets	O	153-160
for	O	161-164
many	O	165-169
different	O	170-179
tumor	O	180-185
types	O	186-191
.   	O	191-195

Our	O	0-3
results	O	4-11
provide	O	12-19
evidence	O	20-28
that	O	29-33
microRNA	O	34-42
expression	O	43-53
patterns	O	54-62
may	O	63-66
mark	O	67-71
specific	O	72-80
biological	O	81-91
characteristics	O	92-107
of	O	108-110
tumors	O	111-117
and	O	118-121
/	O	121-122
or	O	122-124
mediate	O	125-132
biological	O	133-143
activities	O	144-154
important	O	155-164
for	O	165-168
the	O	169-172
pathobiology	O	173-185
of	O	186-188
malignant	O	189-198
tumors	O	199-205
. 	O	205-207

Agglomerative	O	0-13
hierarchical	O	14-26
clustering	O	27-37
analysis	O	38-46
of	O	47-49
microRNA	O	50-58
expression	O	59-69
revealed	O	70-78
four	O	79-83
groups	O	84-90
among	O	91-96
the	O	97-100
NCI	O	101-104
-	O	104-105
60	O	105-107
cell	O	108-112
lines	O	113-118
consisting	O	119-129
of	O	130-132
hematologic	O	133-144
,	O	144-145
colon	O	146-151
,	O	151-152
central	O	153-160
nervous	O	161-168
system	O	169-175
,	O	175-176
and	O	177-180
melanoma	O	181-189
tumor	O	190-195
-	O	195-196
derived	O	196-203
cell	O	204-208
lines	O	209-214
clustered	O	215-224
in	O	225-227
a	O	228-229
manner	O	230-236
that	O	237-241
reflected	O	242-251
their	O	252-257
tissue	O	258-264
of	O	265-267
origin	O	268-274
. 	O	274-276

Most	O	0-4
microRNAs	O	5-14
were	O	15-19
expressed	O	20-29
at	O	30-32
lower	O	33-38
levels	O	39-45
in	O	46-48
tumor	O	49-54
-	O	54-55
derived	O	55-62
cell	O	63-67
lines	O	68-73
compared	O	74-82
with	O	83-87
the	O	88-91
corresponding	O	92-105
normal	O	106-112
tissue	O	113-119
. 	O	119-121

We	O	0-2
also	O	3-7
identified	O	8-18
specific	O	19-27
microRNA	O	28-36
expression	O	37-47
patterns	O	48-56
that	O	57-61
correlated	O	62-72
with	O	73-77
the	O	78-81
proliferation	O	82-95
indices	O	96-103
of	O	104-106
the	O	107-110
NCI	O	111-114
-	O	114-115
60	O	115-117
cell	O	118-122
lines	O	123-128
,	O	128-129
and	O	130-133
we	O	134-136
developed	O	137-146
evidence	O	147-155
for	O	156-159
the	O	160-163
identification	O	164-178
of	O	179-181
specific	O	182-190
microRNAs	O	191-200
as	O	201-203
candidate	O	204-213
oncogenes	O	214-223
and	O	224-227
tumor	O	228-233
suppressor	O	234-244
genes	O	245-250
in	O	251-253
different	O	254-263
tumor	O	264-269
types	O	270-275
. 	O	275-277

We	O	0-2
identified	O	3-13
specific	O	14-22
subsets	O	23-30
of	O	31-33
microRNAs	O	34-43
that	O	44-48
provide	O	49-56
candidate	O	57-66
molecular	O	67-76
signatures	O	77-87
characteristic	O	88-102
of	O	103-105
the	O	106-109
tumor	O	110-115
-	O	115-116
derived	O	116-123
cell	O	124-128
lines	O	129-134
belonging	O	135-144
to	O	145-147
these	O	148-153
four	O	154-158
clusters	O	159-167
. 	O	167-169

They	O	0-4
play	O	5-9
a	O	10-11
critical	O	12-20
role	O	21-25
in	O	26-28
developmental	O	29-42
and	O	43-46
physiologic	O	47-58
processes	O	59-68
and	O	69-72
are	O	73-76
implicated	O	77-87
in	O	88-90
the	O	91-94
pathogenesis	O	95-107
of	O	108-110
several	O	111-118
human	O	119-124
diseases	O	125-133
including	O	134-143
cancer	O	144-150
. 	O	150-152

MicroRNAs	O	0-9
are	O	10-13
small	O	14-19
noncoding	O	20-29
RNAs	O	30-34
that	O	35-39
function	O	40-48
by	O	49-51
regulating	O	52-62
target	O	63-69
gene	O	70-74
expression	O	75-85
posttranscriptionally	O	86-107
. 	O	107-109

To	O	0-2
quantify	O	3-11
microRNA	O	12-20
expression	O	21-31
,	O	31-32
we	O	33-35
employed	O	36-44
a	O	45-46
highly	O	47-53
sensitive	O	54-63
technique	O	64-73
that	O	74-78
uses	O	79-83
stem	O	84-88
-	O	88-89
loop	O	89-93
primers	O	94-101
for	O	102-105
reverse	O	106-113
transcription	O	114-127
followed	O	128-136
by	O	137-139
real	O	140-144
-	O	144-145
time	O	145-149
PCR	O	150-153
. 	O	153-155

We	O	0-2
examined	O	3-11
the	O	12-15
expression	O	16-26
profiles	O	27-35
of	O	36-38
241	O	39-42
human	O	43-48
microRNAs	O	49-58
in	O	59-61
normal	O	62-68
tissues	O	69-76
and	O	77-80
the	O	81-84
NCI	O	85-88
-	O	88-89
60	O	89-91
panel	O	92-97
of	O	98-100
human	O	101-106
tumor	O	107-112
-	O	112-113
derived	O	113-120
cell	O	121-125
lines	O	126-131
. 	O	131-133

Characterization	O	0-16
of	O	17-19
microRNA	O	20-28
expression	O	29-39
levels	O	40-46
and	O	47-50
their	O	51-56
biological	O	57-67
correlates	O	68-78
in	O	79-81
human	O	82-87
cancer	O	88-94
cell	O	95-99
lines	O	100-105
.  	O	105-108

Recent	O	0-6
evidence	O	7-15
suggests	O	16-24
that	O	25-29
both	O	30-34
development	O	35-46
and	O	47-50
proper	O	51-57
function	O	58-66
of	O	67-69
central	O	70-77
nervous	O	78-85
system	O	86-92
require	O	93-100
intricate	O	101-110
spatiotemporal	O	111-125
expression	O	126-136
of	O	137-139
a	O	140-141
wide	O	142-146
repertoire	O	147-157
of	O	158-160
small	O	161-166
regulatory	O	167-177
RNAs	O	178-182
. 	O	182-184

Increasingly	O	0-12
complex	O	13-20
networks	O	21-29
of	O	30-32
small	O	33-38
RNAs	O	39-43
act	O	44-47
through	O	48-55
RNA	O	56-59
interference	O	60-72
pathway	O	73-80
to	O	81-83
regulate	O	84-92
gene	O	93-97
expression	O	98-108
. 	O	108-110

Small	O	0-5
regulatory	O	6-16
RNAs	O	17-21
in	O	22-24
neurodevelopmental	O	25-43
disorders	O	44-53
.  	O	53-56

Here	O	0-4
,	O	4-5
we	O	6-8
will	O	9-13
review	O	14-20
recent	O	21-27
progress	O	28-36
made	O	37-41
toward	O	42-48
understanding	O	49-62
roles	O	63-68
of	O	69-71
small	O	72-77
regulatory	O	78-88
RNAs	O	89-93
in	O	94-96
neurodevelopmental	O	97-115
disorders	O	116-125
and	O	126-129
discuss	O	130-137
the	O	138-141
potential	O	142-151
involvement	O	152-163
of	O	164-166
newly	O	167-172
discovered	O	173-183
classes	O	184-191
of	O	192-194
small	O	195-200
RNAs	O	201-205
in	O	206-208
these	O	209-214
disorders	O	215-224
.   	O	224-228

Misregulation	O	0-13
of	O	14-16
these	O	17-22
small	O	23-28
regulatory	O	29-39
RNAs	O	40-44
could	O	45-50
contribute	O	51-61
to	O	62-64
the	O	65-68
abnormalities	O	69-82
in	O	83-85
brain	O	86-91
development	O	92-103
that	O	104-108
are	O	109-112
associated	O	113-123
with	O	124-128
neurodevelopmental	O	129-147
disorders	O	148-157
. 	O	157-159

MicroRNA	O	0-8
expression	O	9-19
profiling	O	20-29
for	O	30-33
molecular	O	34-43
classification	O	44-58
of	O	59-61
pediatric	O	62-71
brain	O	72-77
tumors	O	78-84
.     	O	84-90

These	O	0-5
concepts	O	6-14
will	O	15-19
be	O	20-22
explored	O	23-31
in	O	32-34
this	O	35-39
article	O	40-47
.   	O	47-51

This	O	0-4
encourages	O	5-15
the	O	16-19
idea	O	20-24
that	O	25-29
certain	O	30-37
miRs	O	38-42
allow	O	43-48
continued	O	49-58
tumor	O	59-64
growth	O	65-71
through	O	72-79
the	O	80-83
suppression	O	84-95
of	O	96-98
differentiation	O	99-114
and	O	115-118
the	O	119-122
maintenance	O	123-134
of	O	135-137
the	O	138-141
stem	O	142-146
cell	O	147-151
-	O	151-152
like	O	152-156
properties	O	157-167
of	O	168-170
tumor	O	171-176
cells	O	177-182
. 	O	182-184

At	O	0-2
the	O	3-6
same	O	7-11
time	O	12-16
,	O	16-17
it	O	18-20
has	O	21-24
become	O	25-31
clear	O	32-37
that	O	38-42
one	O	43-46
of	O	47-49
the	O	50-53
major	O	54-59
roles	O	60-65
that	O	66-70
microRNAs	O	71-80
play	O	81-85
is	O	86-88
in	O	89-91
the	O	92-95
regulation	O	96-106
of	O	107-109
stem	O	110-114
cell	O	115-119
biology	O	120-127
,	O	127-128
differentiation	O	129-144
,	O	144-145
and	O	146-149
cell	O	150-154
'	O	155-156
identity	O	156-164
'	O	164-165
. 	O	165-167

Recent	O	0-6
data	O	7-11
draw	O	12-16
close	O	17-22
parallels	O	23-32
between	O	33-40
cancer	O	41-47
,	O	47-48
including	O	49-58
glial	O	59-64
brain	O	65-70
tumors	O	71-77
,	O	77-78
and	O	79-82
the	O	83-86
biology	O	87-94
of	O	95-97
stem	O	98-102
and	O	103-106
progenitor	O	107-117
cells	O	118-123
. 	O	123-125

Interestingly	O	0-13
,	O	13-14
initial	O	15-22
studies	O	23-30
in	O	31-33
the	O	34-37
incurable	O	38-47
brain	O	48-53
tumor	O	54-59
glioblastoma	O	60-72
multiforme	O	73-83
strongly	O	84-92
suggest	O	93-100
that	O	101-105
microRNAs	O	106-115
involved	O	116-124
in	O	125-127
neural	O	128-134
development	O	135-146
play	O	147-151
a	O	152-153
role	O	154-158
in	O	159-161
this	O	162-166
disease	O	167-174
. 	O	174-176

For	O	0-3
example	O	4-11
,	O	11-12
microRNAs	O	13-22
have	O	23-27
been	O	28-32
increasingly	O	33-45
implicated	O	46-56
in	O	57-59
the	O	60-63
regulation	O	64-74
of	O	75-77
neural	O	78-84
differentiation	O	85-100
. 	O	100-102

MicroRNAs	O	0-9
and	O	10-13
glioblastoma	O	14-26
;	O	26-27
the	O	28-31
stem	O	32-36
cell	O	37-41
connection	O	42-52
.  	O	52-55

MicroRNA	B	0-8
-	I	8-9
223	I	9-12
expression	O	13-23
in	O	24-26
neutrophils	O	27-38
in	O	39-41
the	O	42-45
early	O	46-51
phase	O	52-57
of	O	58-60
secondary	O	61-70
damage	O	71-77
after	O	78-83
spinal	O	84-90
cord	O	91-95
injury	O	96-102
.  	O	102-105

MicroRNA	O	0-8
(	O	9-10
miR	O	10-13
)	O	13-14
s	O	14-15
are	O	16-19
short	O	20-25
non	O	26-29
-	O	29-30
coding	O	30-36
RNAs	O	37-41
that	O	42-46
suppress	O	47-55
the	O	56-59
translation	O	60-71
of	O	72-74
target	O	75-81
genes	O	82-87
,	O	87-88
and	O	89-92
play	O	93-97
an	O	98-100
important	O	101-110
role	O	111-115
in	O	116-118
gene	O	119-123
regulation	O	124-134
. 	O	134-136

Despite	O	0-7
this	O	8-12
prominence	O	13-23
,	O	23-24
there	O	25-30
are	O	31-34
few	O	35-38
reports	O	39-46
that	O	47-51
refer	O	52-57
to	O	58-60
the	O	61-64
expression	O	65-75
of	O	76-78
miRs	O	79-83
after	O	84-89
spinal	O	90-96
cord	O	97-101
injury	O	102-108
(	O	109-110
SCI	O	110-113
)	O	113-114
. 	O	114-116

Previously	O	0-10
,	O	10-11
we	O	12-14
reported	O	15-23
on	O	24-26
miR	B	27-30
-	I	30-31
223	I	31-34
expression	O	35-45
after	O	46-51
SCI	O	52-55
in	O	56-58
mice	O	59-63
. 	O	63-65

The	O	0-3
purpose	O	4-11
of	O	12-14
this	O	15-19
study	O	20-25
is	O	26-28
to	O	29-31
reveal	O	32-38
the	O	39-42
distribution	O	43-55
of	O	56-58
miR	B	59-62
-	I	62-63
223	I	63-66
and	O	67-70
identify	O	71-79
the	O	80-83
cells	O	84-89
that	O	90-94
express	O	95-102
miR	B	103-106
-	I	106-107
223	I	107-110
in	O	111-113
the	O	114-117
injured	O	118-125
spinal	O	126-132
cord	O	133-137
. 	O	137-139

Quantitative	O	0-12
polymerase	O	13-23
chain	O	24-29
reaction	O	30-38
analysis	O	39-47
revealed	O	48-56
high	O	57-61
expression	O	62-72
of	O	73-75
miR	B	76-79
-	I	79-80
223	I	80-83
at	O	84-86
12h	O	87-90
after	O	91-96
SCI	O	97-100
.	O	100-101
Double	O	102-108
staining	O	109-117
of	O	118-120
in	O	121-123
situ	O	124-128
hybridization	O	129-142
and	O	143-146
immunohistochemistry	O	147-167
showed	O	168-174
that	O	175-179
the	O	180-183
signals	O	184-191
of	O	192-194
miR	B	195-198
-	I	198-199
223	I	199-202
merged	O	203-209
with	O	210-214
Gr	O	215-217
-	O	217-218
1	O	218-219
positive	O	220-228
neutrophils	O	229-240
. 	O	240-242

Our	O	0-3
data	O	4-8
indicate	O	9-17
that	O	18-22
miR	B	23-26
-	I	26-27
223	I	27-30
might	O	31-36
regulate	O	37-45
neutrophils	O	46-57
in	O	58-60
the	O	61-64
early	O	65-70
phase	O	71-76
after	O	77-82
SCI	O	83-86
.   	O	86-90

Our	O	0-3
results	O	4-11
suggest	O	12-19
that	O	20-24
miR	B	25-28
-	I	28-29
124a	I	29-33
may	O	34-37
play	O	38-42
a	O	43-44
role	O	45-49
in	O	50-52
GBM	O	53-56
migration	O	57-66
,	O	66-67
and	O	68-71
that	O	72-76
targeted	O	77-85
delivery	O	86-94
of	O	95-97
miR	B	98-101
-	I	101-102
124a	I	102-106
may	O	107-110
be	O	111-113
a	O	114-115
novel	O	116-121
inhibitor	O	122-131
of	O	132-134
GBM	O	135-138
invasion	O	139-147
.   	O	147-151

Glioblastoma	O	0-12
(	O	13-14
GBM	O	14-17
)	O	17-18
represents	O	19-29
a	O	30-31
formidable	O	32-42
clinical	O	43-51
challenge	O	52-61
for	O	62-65
both	O	66-70
patients	O	71-79
and	O	80-83
treating	O	84-92
physicians	O	93-103
. 	O	103-105

Due	O	0-3
to	O	4-6
better	O	7-13
local	O	14-19
treatments	O	20-30
and	O	31-34
prolonged	O	35-44
patient	O	45-52
survival	O	53-61
,	O	61-62
remote	O	63-69
recurrences	O	70-81
are	O	82-85
increasingly	O	86-98
observed	O	99-107
,	O	107-108
underpinning	O	109-121
the	O	122-125
importance	O	126-136
of	O	137-139
targeting	O	140-149
tumour	O	150-156
migration	O	157-166
and	O	167-170
attachment	O	171-181
. 	O	181-183

Aberrant	O	0-8
expression	O	9-19
of	O	20-22
microRNA	O	23-31
(	O	32-33
miRNA	O	33-38
)	O	38-39
is	O	40-42
commonly	O	43-51
associated	O	52-62
with	O	63-67
cancer	O	68-74
and	O	75-78
loss	O	79-83
of	O	84-86
miR	B	87-90
-	I	90-91
124a	I	91-95
has	O	96-99
previously	O	100-110
been	O	111-115
implicated	O	116-126
to	O	127-129
function	O	130-138
as	O	139-141
a	O	142-143
tumour	O	144-150
suppressor	O	151-161
. 	O	161-163

The	O	0-3
assessment	O	4-14
of	O	15-17
miR	B	18-21
-	I	21-22
124a	I	22-26
in	O	27-29
clinical	O	30-38
specimens	O	39-48
has	O	49-52
been	O	53-57
limited	O	58-65
and	O	66-69
a	O	70-71
potential	O	72-81
role	O	82-86
in	O	87-89
migration	O	90-99
and	O	100-103
invasion	O	104-112
has	O	113-116
been	O	117-121
unexplored	O	122-132
until	O	133-138
now	O	139-142
. 	O	142-144

We	O	0-2
measured	O	3-11
the	O	12-15
expression	O	16-26
levels	O	27-33
of	O	34-36
mature	O	37-43
miR	B	44-47
-	I	47-48
124a	I	48-52
in	O	53-55
a	O	56-57
retrospective	O	58-71
series	O	72-78
of	O	79-81
119	O	82-85
cases	O	86-91
of	O	92-94
histologically	O	95-109
confirmed	O	110-119
GBM	O	120-123
and	O	124-127
found	O	128-133
its	O	134-137
expression	O	138-148
was	O	149-152
markedly	O	153-161
lower	O	162-167
in	O	168-170
over	O	171-175
80	O	176-178
%	O	178-179
of	O	180-182
the	O	183-186
GBM	O	187-190
clinical	O	191-199
specimens	O	200-209
compared	O	210-218
to	O	219-221
normal	O	222-228
brain	O	229-234
tissue	O	235-241
. 	O	241-243

The	O	0-3
level	O	4-9
of	O	10-12
reduction	O	13-22
in	O	23-25
the	O	26-29
clinical	O	30-38
cohort	O	39-45
varied	O	46-52
significantly	O	53-66
and	O	67-70
patients	O	71-79
with	O	80-84
lower	O	85-90
than	O	91-95
the	O	96-99
average	O	100-107
miR	B	108-111
-	I	111-112
124a	I	112-116
expression	O	117-127
levels	O	128-134
displayed	O	135-144
shorter	O	145-152
survival	O	153-161
times	O	162-167
. 	O	167-169

Endogenous	O	0-10
miR	B	11-14
-	I	14-15
124a	I	15-19
expression	O	20-30
and	O	31-34
the	O	35-38
protein	O	39-46
expression	O	47-57
of	O	58-60
three	O	61-66
of	O	67-69
its	O	70-73
targets	O	74-81
;	O	81-82
IQ	O	83-85
motif	O	86-91
containing	O	92-102
GTPase	O	103-109
activating	O	110-120
protein	O	121-128
1	O	129-130
(	O	131-132
IQGAP1	O	132-138
)	O	138-139
,	O	139-140
laminin	O	141-148
γ1	O	149-152
(	O	153-154
LAMC1	O	154-159
)	O	159-160
and	O	161-164
integrin	O	165-173
β1	O	174-177
(	O	178-179
ITGB1	O	179-184
)	O	184-185
were	O	186-190
significantly	O	191-204
reciprocally	O	205-217
associated	O	218-228
in	O	229-231
the	O	232-235
majority	O	236-244
of	O	245-247
the	O	248-251
clinical	O	252-260
cases	O	261-266
. 	O	266-268

We	O	0-2
confirmed	O	3-12
this	O	13-17
association	O	18-29
in	O	30-32
our	O	33-36
in	O	37-39
vitro	O	40-45
model	O	46-51
. 	O	51-53

miR	B	0-3
-	I	3-4
124a	I	4-8
is	O	9-11
frequently	O	12-22
down	O	23-27
-	O	27-28
regulated	O	28-37
in	O	38-40
glioblastoma	O	41-53
and	O	54-57
is	O	58-60
involved	O	61-69
in	O	70-72
migration	O	73-82
and	O	83-86
invasion	O	87-95
.  	O	95-98

Functionally	O	0-12
,	O	12-13
the	O	14-17
ectopic	O	18-25
expression	O	26-36
of	O	37-39
mature	O	40-46
miR	B	47-50
-	I	50-51
124a	I	51-55
in	O	56-58
a	O	59-60
GBM	O	61-64
cell	O	65-69
line	O	70-74
resulted	O	75-83
in	O	84-86
significant	O	87-98
inhibition	O	99-109
of	O	110-112
migration	O	113-122
and	O	123-126
invasion	O	127-135
,	O	135-136
demonstrating	O	137-150
a	O	151-152
role	O	153-157
for	O	158-161
miR	B	162-165
-	I	165-166
124a	I	166-170
in	O	171-173
promoting	O	174-183
tumour	O	184-190
invasiveness	O	191-203
. 	O	203-205

Specificity	O	0-11
,	O	11-12
duplex	O	13-19
degradation	O	20-31
and	O	32-35
subcellular	O	36-47
localization	O	48-60
of	O	61-63
antagomirs	O	64-74
.  	O	74-77

Finally	O	0-7
,	O	7-8
we	O	9-11
show	O	12-16
that	O	17-21
antagomirs	O	22-32
,	O	32-33
although	O	34-42
incapable	O	43-52
of	O	53-55
silencing	O	56-65
miRNAs	O	66-72
in	O	73-75
the	O	76-79
central	O	80-87
nervous	O	88-95
system	O	96-102
(	O	103-104
CNS	O	104-107
)	O	107-108
when	O	109-113
injected	O	114-122
systemically	O	123-135
,	O	135-136
efficiently	O	137-148
target	O	149-155
miRNAs	O	156-162
when	O	163-167
injected	O	168-176
locally	O	177-184
into	O	185-189
the	O	190-193
mouse	O	194-199
cortex	O	200-206
. 	O	206-208

Our	O	0-3
data	O	4-8
further	O	9-16
validate	O	17-25
the	O	26-29
effectiveness	O	30-43
of	O	44-46
antagomirs	O	47-57
in	O	58-60
vivo	O	61-65
and	O	66-69
should	O	70-76
facilitate	O	77-87
future	O	88-94
studies	O	95-102
to	O	103-105
silence	O	106-113
miRNAs	O	114-120
for	O	121-124
functional	O	125-135
analysis	O	136-144
and	O	145-148
in	O	149-151
clinically	O	152-162
relevant	O	163-171
settings	O	172-180
.   	O	180-184

We	O	0-2
demonstrate	O	3-14
that	O	15-19
antagomirs	O	20-30
harbor	O	31-37
optimized	O	38-47
phosphorothioate	O	48-64
modifications	O	65-78
,	O	78-79
require	O	80-87
>	O	88-89
19	O	89-91
-	O	91-92
nt	O	92-94
length	O	95-101
for	O	102-105
highest	O	106-113
efficiency	O	114-124
and	O	125-128
can	O	129-132
discriminate	O	133-145
between	O	146-153
single	O	154-160
nucleotide	O	161-171
mismatches	O	172-182
of	O	183-185
the	O	186-189
targeted	O	190-198
miRNA	O	199-204
. 	O	204-206

Degradation	O	0-11
of	O	12-14
different	O	15-24
chemically	O	25-35
protected	O	36-45
miRNA	O	46-51
/	O	51-52
antagomir	O	52-61
duplexes	O	62-70
in	O	71-73
mouse	O	74-79
livers	O	80-86
and	O	87-90
localization	O	91-103
of	O	104-106
antagomirs	O	107-117
in	O	118-120
a	O	121-122
cytosolic	O	123-132
compartment	O	133-144
that	O	145-149
is	O	150-152
distinct	O	153-161
from	O	162-166
processing	O	167-177
(	O	178-179
P	O	179-180
)	O	180-181
-	O	181-182
bodies	O	182-188
indicates	O	189-198
a	O	199-200
degradation	O	201-212
mechanism	O	213-222
independent	O	223-234
of	O	235-237
the	O	238-241
RNA	O	242-245
interference	O	246-258
(	O	259-260
RNAi	O	260-264
)	O	264-265
pathway	O	266-273
. 	O	273-275

We	O	0-2
recently	O	3-11
demonstrated	O	12-24
silencing	O	25-34
miRNA	O	35-40
function	O	41-49
in	O	50-52
mice	O	53-57
using	O	58-63
chemically	O	64-74
modified	O	75-83
and	O	84-87
cholesterol	O	88-99
-	O	99-100
conjugated	O	100-110
RNAs	O	111-115
termed	O	116-122
'	O	123-124
antagomirs	O	124-134
'	O	134-135
. 	O	135-137

Here	O	0-4
,	O	4-5
we	O	6-8
further	O	9-16
characterize	O	17-29
the	O	30-33
properties	O	34-44
and	O	45-48
function	O	49-57
of	O	58-60
antagomirs	O	61-71
in	O	72-74
mice	O	75-79
. 	O	79-81

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
an	O	23-25
abundant	O	26-34
class	O	35-40
of	O	41-43
20	O	44-46
-	O	46-47
23	O	47-49
-	O	49-50
nt	O	50-52
long	O	53-57
regulators	O	58-68
of	O	69-71
gene	O	72-76
expression	O	77-87
. 	O	87-89

The	O	0-3
study	O	4-9
of	O	10-12
miRNA	O	13-18
function	O	19-27
in	O	28-30
mice	O	31-35
and	O	36-39
potential	O	40-49
therapeutic	O	50-61
approaches	O	62-72
largely	O	73-80
depend	O	81-87
on	O	88-90
modified	O	91-99
oligonucleotides	O	100-116
. 	O	116-118

Many	O	0-4
of	O	5-7
these	O	8-13
pathways	O	14-22
were	O	23-27
first	O	28-33
identified	O	34-44
in	O	45-47
genetic	O	48-55
screens	O	56-63
in	O	64-66
Drosophila	O	67-77
and	O	78-81
other	O	82-87
lower	O	88-93
organisms	O	94-103
. 	O	103-105

In	O	0-2
the	O	3-6
last	O	7-11
20	O	12-14
years	O	15-20
,	O	20-21
it	O	22-24
has	O	25-28
become	O	29-35
clear	O	36-41
that	O	42-46
developmental	O	47-60
genes	O	61-66
and	O	67-70
their	O	71-76
regulators	O	77-87
,	O	87-88
noncoding	O	89-98
RNAs	O	99-103
including	O	104-113
microRNAs	O	114-123
and	O	124-127
long	O	128-132
-	O	132-133
noncoding	O	133-142
RNAs	O	143-147
,	O	147-148
within	O	149-155
signaling	O	156-165
pathways	O	166-174
play	O	175-179
a	O	180-181
critical	O	182-190
role	O	191-195
in	O	196-198
the	O	199-202
pathogenesis	O	203-215
of	O	216-218
cancer	O	219-225
. 	O	225-227

Genes	O	0-5
and	O	6-9
pathways	O	10-18
expressed	O	19-28
during	O	29-35
embryonic	O	36-45
development	O	46-57
,	O	57-58
including	O	59-68
the	O	69-72
Notch	O	73-78
,	O	78-79
Wnt	O	80-83
/	O	83-84
β	O	84-86
-	O	86-87
Catenin	O	87-94
,	O	94-95
TGF	O	96-99
-	O	99-100
β	O	100-102
/	O	102-103
BMP	O	103-106
,	O	106-107
Shh	O	108-111
/	O	111-112
Patched	O	112-119
,	O	119-120
and	O	121-124
Hippo	O	125-130
pathways	O	131-139
are	O	140-143
mutated	O	144-151
,	O	151-152
lost	O	153-157
,	O	157-158
or	O	159-161
aberrantly	O	162-172
regulated	O	173-182
in	O	183-185
a	O	186-187
wide	O	188-192
variety	O	193-200
of	O	201-203
human	O	204-209
cancers	O	210-217
,	O	217-218
including	O	219-228
skin	O	229-233
,	O	233-234
breast	O	235-241
,	O	241-242
blood	O	243-248
,	O	248-249
and	O	250-253
brain	O	254-259
cancers	O	260-267
,	O	267-268
including	O	269-278
medulloblastoma	O	279-294
. 	O	294-296

Mammalian	O	0-9
orthologs	O	10-19
were	O	20-24
subsequently	O	25-37
identified	O	38-48
and	O	49-52
genes	O	53-58
within	O	59-65
the	O	66-69
pathways	O	70-78
cloned	O	79-85
and	O	86-89
found	O	90-95
to	O	96-98
regulate	O	99-107
cell	O	108-112
growth	O	113-119
. 	O	119-121

Cerebellum	O	0-10
development	O	11-22
and	O	23-26
medulloblastoma	O	27-42
.  	O	42-45

Medulloblastoma	O	0-15
,	O	15-16
the	O	17-20
most	O	21-25
common	O	26-32
malignant	O	33-42
nervous	O	43-50
system	O	51-57
tumor	O	58-63
in	O	64-66
childhood	O	67-76
,	O	76-77
are	O	78-81
thought	O	82-89
to	O	90-92
arise	O	93-98
from	O	99-103
disruptions	O	104-115
in	O	116-118
cerebellar	O	119-129
development	O	130-141
[	O	142-143
reviewed	O	143-151
by	O	152-154
Marino	O	155-161
,	O	161-162
S	O	163-164
.	O	164-165
(	O	166-167
2005	O	167-171
)	O	171-172
]	O	172-173
. 	O	173-175

These	O	0-5
biochemical	O	6-17
pathways	O	18-26
affect	O	27-33
cell	O	34-38
fate	O	39-43
determination	O	44-57
,	O	57-58
axis	O	59-63
formation	O	64-73
,	O	73-74
and	O	75-78
patterning	O	79-89
during	O	90-96
development	O	97-108
and	O	109-112
regulate	O	113-121
tissue	O	122-128
homeostasis	O	129-140
and	O	141-144
regeneration	O	145-157
in	O	158-160
adults	O	161-167
. 	O	167-169

In	O	0-2
this	O	3-7
chapter	O	8-15
,	O	15-16
we	O	17-19
will	O	20-24
review	O	25-31
the	O	32-35
development	O	36-47
of	O	48-50
the	O	51-54
cerebellar	O	55-65
cortex	O	66-72
,	O	72-73
highlighting	O	74-86
signaling	O	87-96
pathways	O	97-105
of	O	106-108
potential	O	109-118
relevance	O	119-128
to	O	129-131
tumorigenesis	O	132-145
.   	O	145-149

Defining	O	0-8
the	O	9-12
extracellular	O	13-26
cues	O	27-31
and	O	32-35
intracellular	O	36-49
signaling	O	50-59
pathways	O	60-68
that	O	69-73
control	O	74-81
cerebellar	O	82-92
neurogenesis	O	93-105
,	O	105-106
especially	O	107-117
granule	O	118-125
cell	O	126-130
progenitor	O	131-141
(	O	142-143
GCP	O	143-146
)	O	146-147
proliferation	O	148-161
and	O	162-165
differentiation	O	166-181
has	O	182-185
been	O	186-190
useful	O	191-197
for	O	198-201
developing	O	202-212
models	O	213-219
to	O	220-222
unravel	O	223-230
the	O	231-234
mechanisms	O	235-245
underlying	O	246-256
medulloblastoma	O	257-272
formation	O	273-282
and	O	283-286
growth	O	287-293
. 	O	293-295

A	O	0-1
specific	O	2-10
miRNA	O	11-16
signature	O	17-26
in	O	27-29
the	O	30-33
peripheral	O	34-44
blood	O	45-50
of	O	51-53
glioblastoma	O	54-66
patients	O	67-75
.  	O	75-78

Biomarkers	O	0-10
for	O	11-14
the	O	15-18
disease	O	19-26
would	O	27-32
be	O	33-35
desirable	O	36-45
in	O	46-48
order	O	49-54
to	O	55-57
allow	O	58-63
for	O	64-67
an	O	68-70
early	O	71-76
detection	O	77-86
of	O	87-89
tumor	O	90-95
progression	O	96-107
or	O	108-110
to	O	111-113
indicate	O	114-122
rapidly	O	123-130
growing	O	131-138
tumor	O	139-144
subtypes	O	145-153
requiring	O	154-163
more	O	164-168
intensive	O	169-178
therapy	O	179-186
. 	O	186-188

The	O	0-3
prognosis	O	4-13
of	O	14-16
patients	O	17-25
afflicted	O	26-35
by	O	36-38
glioblastoma	O	39-51
remains	O	52-59
poor	O	60-64
. 	O	64-66

To	O	0-2
this	O	3-7
end	O	8-11
,	O	11-12
miRNA	O	13-18
profiles	O	19-27
from	O	28-32
the	O	33-36
blood	O	37-42
of	O	43-45
20	O	46-48
patients	O	49-57
with	O	58-62
glioblastoma	O	63-75
and	O	76-79
20	O	80-82
age	O	83-86
-	O	86-87
and	O	88-91
sex	O	92-95
-	O	95-96
matched	O	96-103
healthy	O	104-111
controls	O	112-120
were	O	121-125
compared	O	126-134
. 	O	134-136

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
investigated	O	18-30
whether	O	31-38
a	O	39-40
blood	O	41-46
-	O	46-47
derived	O	47-54
specific	O	55-63
miRNA	O	64-69
fingerprint	O	70-81
can	O	82-85
be	O	86-88
defined	O	89-96
in	O	97-99
patients	O	100-108
with	O	109-113
glioblastoma	O	114-126
. 	O	126-128

Of	O	0-2
these	O	3-8
,	O	8-9
two	O	10-13
candidates	O	14-24
,	O	24-25
miR	B	26-29
-	I	29-30
128	I	30-33
(	O	34-35
up	O	35-37
-	O	37-38
regulated	O	38-47
)	O	47-48
and	O	49-52
miR	B	53-56
-	I	56-57
342	I	57-60
-	I	60-61
3p	I	61-63
(	O	64-65
down	O	65-69
-	O	69-70
regulated	O	70-79
)	O	79-80
,	O	80-81
remained	O	82-90
significant	O	91-102
after	O	103-108
correcting	O	109-119
for	O	120-123
multiple	O	124-132
testing	O	133-140
by	O	141-143
Benjamini	O	144-153
-	O	153-154
Hochberg	O	154-162
adjustment	O	163-173
with	O	174-178
a	O	179-180
p	O	181-182
-	O	182-183
value	O	183-188
of	O	189-191
0	O	192-193
.	O	193-194
025	O	194-197
. 	O	197-199

Of	O	0-2
1158	O	3-7
tested	O	8-14
miRNAs	O	15-21
,	O	21-22
52	O	23-25
were	O	26-30
significantly	O	31-44
deregulated	O	45-56
,	O	56-57
as	O	58-60
assessed	O	61-69
by	O	70-72
unadjusted	O	73-83
Student	O	84-91
'	O	91-92
s	O	92-93
t	O	94-95
-	O	95-96
test	O	96-100
at	O	101-103
an	O	104-106
alpha	O	107-112
level	O	113-118
of	O	119-121
0	O	122-123
.	O	123-124
05	O	124-126
. 	O	126-128

The	O	0-3
altered	O	4-11
expression	O	12-22
of	O	23-25
these	O	26-31
two	O	32-35
biomarkers	O	36-46
was	O	47-50
confirmed	O	51-60
in	O	61-63
a	O	64-65
second	O	66-72
cohort	O	73-79
of	O	80-82
glioblastoma	O	83-95
patients	O	96-104
and	O	105-108
healthy	O	109-116
controls	O	117-125
by	O	126-128
real	O	129-133
-	O	133-134
time	O	134-138
PCR	O	139-142
and	O	143-146
validated	O	147-156
for	O	157-160
patients	O	161-169
who	O	170-173
had	O	174-177
received	O	178-186
neither	O	187-194
radio	O	195-200
-	O	200-201
nor	O	202-205
chemotherapy	O	206-218
and	O	219-222
for	O	223-226
patients	O	227-235
who	O	236-239
had	O	240-243
their	O	244-249
glioblastomas	O	250-263
resected	O	264-272
more	O	273-277
than	O	278-282
6	O	283-284
months	O	285-291
ago	O	292-295
. 	O	295-297

Moreover	O	0-8
,	O	8-9
using	O	10-15
machine	O	16-23
learning	O	24-32
,	O	32-33
a	O	34-35
comprehensive	O	36-49
miRNA	O	50-55
signature	O	56-65
was	O	66-69
obtained	O	70-78
that	O	79-83
allowed	O	84-91
for	O	92-95
the	O	96-99
discrimination	O	100-114
between	O	115-122
blood	O	123-128
samples	O	129-136
of	O	137-139
glioblastoma	O	140-152
patients	O	153-161
and	O	162-165
healthy	O	166-173
controls	O	174-182
with	O	183-187
an	O	188-190
accuracy	O	191-199
of	O	200-202
81	O	203-205
%	O	205-206
[	O	207-208
95	O	208-210
%	O	210-211
confidence	O	212-222
interval	O	223-231
(	O	232-233
CI	O	233-235
)	O	235-236
78	O	237-239
-	O	239-240
84	O	240-242
%	O	242-243
]	O	243-244
,	O	244-245
specificity	O	246-257
of	O	258-260
79	O	261-263
%	O	263-264
(	O	265-266
95	O	266-268
%	O	268-269
CI	O	270-272
75	O	273-275
-	O	275-276
83	O	276-278
%	O	278-279
)	O	279-280
and	O	281-284
sensitivity	O	285-296
of	O	297-299
83	O	300-302
%	O	302-303
(	O	304-305
95	O	305-307
%	O	307-308
CI	O	309-311
71	O	312-314
-	O	314-315
85	O	315-317
%	O	317-318
)	O	318-319
. 	O	319-321

In	O	0-2
summary	O	3-10
,	O	10-11
our	O	12-15
proof	O	16-21
-	O	21-22
of	O	22-24
-	O	24-25
concept	O	25-32
study	O	33-38
demonstrates	O	39-51
that	O	52-56
blood	O	57-62
-	O	62-63
derived	O	63-70
glioblastoma	O	71-83
-	O	83-84
associated	O	84-94
characteristic	O	95-109
miRNA	O	110-115
fingerprints	O	116-128
may	O	129-132
be	O	133-135
suitable	O	136-144
biomarkers	O	145-155
and	O	156-159
warrant	O	160-167
further	O	168-175
exploration	O	176-187
.   	O	187-191

The	O	0-3
clinical	O	4-12
relevance	O	13-22
of	O	23-25
our	O	26-29
findings	O	30-38
was	O	39-42
evaluated	O	43-52
in	O	53-55
HIV	O	56-59
-	O	59-60
encephalitis	O	60-72
(	O	73-74
HIVE	O	74-78
)	O	78-79
brain	O	80-85
samples	O	86-93
in	O	94-96
which	O	97-102
decreased	O	103-112
levels	O	113-119
of	O	120-122
MCP	O	123-126
-	O	126-127
2	O	127-128
and	O	129-132
increased	O	133-142
levels	O	143-149
of	O	150-152
mir	B	153-156
-	I	156-157
146a	I	157-161
were	O	162-166
observed	O	167-175
,	O	175-176
suggesting	O	177-187
a	O	188-189
role	O	190-194
for	O	195-198
mir	B	199-202
-	I	202-203
146a	I	203-207
in	O	208-210
the	O	211-214
maintenance	O	215-226
of	O	227-229
HIV	O	230-233
-	O	233-234
mediated	O	234-242
chronic	O	243-250
inflammation	O	251-263
of	O	264-266
the	O	267-270
brain	O	271-276
.   	O	276-280

We	O	0-2
further	O	3-10
show	O	11-15
that	O	16-20
CCL8	O	21-25
/	O	25-26
MCP	O	26-29
-	O	29-30
2	O	30-31
is	O	32-34
a	O	35-36
target	O	37-43
for	O	44-47
mir	B	48-51
-	I	51-52
146a	I	52-56
in	O	57-59
HIV	O	60-63
-	O	63-64
1	O	64-65
infected	O	66-74
microglia	O	75-84
,	O	84-85
as	O	86-88
overexpression	O	89-103
of	O	104-106
mir	B	107-110
-	I	110-111
146a	I	111-115
prevented	O	116-125
HIV	O	126-129
-	O	129-130
induced	O	130-137
secretion	O	138-147
of	O	148-150
MCP	O	151-154
-	O	154-155
2	O	155-156
chemokine	O	157-166
. 	O	166-168

In	O	0-2
the	O	3-6
present	O	7-14
study	O	15-20
,	O	20-21
we	O	22-24
have	O	25-29
analyzed	O	30-38
changes	O	39-46
in	O	47-49
the	O	50-53
expression	O	54-64
of	O	65-67
mir	B	68-71
-	I	71-72
146a	I	72-76
in	O	77-79
primary	O	80-87
human	O	88-93
fetal	O	94-99
microglial	O	100-110
cells	O	111-116
upon	O	117-121
infection	O	122-131
with	O	132-136
HIV	O	137-140
-	O	140-141
1	O	141-142
and	O	143-146
found	O	147-152
increased	O	153-162
expression	O	163-173
of	O	174-176
mir	B	177-180
-	I	180-181
146a	I	181-185
. 	O	185-187

MicroRNA	O	0-8
-	O	8-9
mediated	O	9-17
regulation	O	18-28
of	O	29-31
gene	O	32-36
expression	O	37-47
appears	O	48-55
to	O	56-58
be	O	59-61
involved	O	62-70
in	O	71-73
a	O	74-75
variety	O	76-83
of	O	84-86
cellular	O	87-95
processes	O	96-105
,	O	105-106
including	O	107-116
development	O	117-128
,	O	128-129
differentiation	O	130-145
,	O	145-146
proliferation	O	147-160
,	O	160-161
and	O	162-165
apoptosis	O	166-175
. 	O	175-177

CCL8	O	0-4
/	O	4-5
MCP	O	5-8
-	O	8-9
2	O	9-10
is	O	11-13
a	O	14-15
target	O	16-22
for	O	23-26
mir	B	27-30
-	I	30-31
146a	I	31-35
in	O	36-38
HIV	O	39-42
-	O	42-43
1	O	43-44
-	O	44-45
infected	O	45-53
human	O	54-59
microglial	O	60-70
cells	O	71-76
.  	O	76-79

Among	O	0-5
the	O	6-9
predicted	O	10-19
gene	O	20-24
targets	O	25-32
for	O	33-36
mir	B	37-40
-	I	40-41
146a	I	41-45
,	O	45-46
the	O	47-50
chemokine	O	51-60
CCL8	O	61-65
/	O	65-66
MCP	O	66-69
-	O	69-70
2	O	70-71
is	O	72-74
a	O	75-76
ligand	O	77-83
for	O	84-87
the	O	88-91
CCR5	O	92-96
chemokine	O	97-106
receptor	O	107-115
and	O	116-119
a	O	120-121
potent	O	122-128
inhibitor	O	129-138
of	O	139-141
CD4	O	142-145
/	O	145-146
CCR5	O	146-150
-	O	150-151
mediated	O	151-159
HIV	O	160-163
-	O	163-164
1	O	164-165
entry	O	166-171
and	O	172-175
replication	O	176-187
. 	O	187-189

Mir	B	0-3
-	I	3-4
146a	I	4-8
is	O	9-11
thought	O	12-19
to	O	20-22
be	O	23-25
involved	O	26-34
in	O	35-37
the	O	38-41
regulation	O	42-52
of	O	53-55
the	O	56-59
innate	O	60-66
immune	O	67-73
response	O	74-82
,	O	82-83
and	O	84-87
its	O	88-91
expression	O	92-102
is	O	103-105
increased	O	106-115
in	O	116-118
tissues	O	119-126
associated	O	127-137
with	O	138-142
chronic	O	143-150
inflammation	O	151-163
. 	O	163-165

We	O	0-2
explored	O	3-11
the	O	12-15
role	O	16-20
of	O	21-23
microRNAs	O	24-33
(	O	34-35
miRNAs	O	35-41
)	O	41-42
in	O	43-45
glioma	O	46-52
progression	O	53-64
by	O	65-67
investigating	O	68-81
the	O	82-85
expression	O	86-96
profiles	O	97-105
of	O	106-108
157	O	109-112
miRNAs	O	113-119
in	O	120-122
four	O	123-127
patients	O	128-136
with	O	137-141
primary	O	142-149
WHO	O	150-153
grade	O	154-159
II	O	160-162
gliomas	O	163-170
that	O	171-175
spontaneously	O	176-189
progressed	O	190-200
to	O	201-203
WHO	O	204-207
grade	O	208-213
IV	O	214-216
secondary	O	217-226
glioblastomas	O	227-240
. 	O	240-242

Thereby	O	0-7
,	O	7-8
we	O	9-11
identified	O	12-22
12	O	23-25
miRNAs	O	26-32
(	O	33-34
miR	B	34-37
-	I	37-38
9	I	38-39
,	O	39-40
miR	B	41-44
-	I	44-45
15a	I	45-48
,	O	48-49
miR	B	50-53
-	I	53-54
16	I	54-56
,	O	56-57
miR	B	58-61
-	I	61-62
17	I	62-64
,	O	64-65
miR	B	66-69
-	I	69-70
19a	I	70-73
,	O	73-74
miR	B	75-78
-	I	78-79
20a	I	79-82
,	O	82-83
miR	B	84-87
-	I	87-88
21	I	88-90
,	O	90-91
miR	B	92-95
-	I	95-96
25	I	96-98
,	O	98-99
miR	B	100-103
-	I	103-104
28	I	104-106
,	O	106-107
miR	B	108-111
-	I	111-112
130b	I	112-116
,	O	116-117
miR	B	118-121
-	I	121-122
140	I	122-125
and	O	126-129
miR	B	130-133
-	I	133-134
210	I	134-137
)	O	137-138
showing	O	139-146
increased	O	147-156
expression	O	157-167
,	O	167-168
and	O	169-172
two	O	173-176
miRNAs	O	177-183
(	O	184-185
miR	B	185-188
-	I	188-189
184	I	189-192
and	O	193-196
miR	B	197-200
-	I	200-201
328	I	201-204
)	O	204-205
showing	O	206-213
reduced	O	214-221
expression	O	222-232
upon	O	233-237
progression	O	238-249
. 	O	249-251

Identification	O	0-14
and	O	15-18
functional	O	19-29
characterization	O	30-46
of	O	47-49
microRNAs	O	50-59
involved	O	60-68
in	O	69-71
the	O	72-75
malignant	O	76-85
progression	O	86-97
of	O	98-100
gliomas	O	101-108
.  	O	108-111

Diffuse	O	0-7
astrocytoma	O	8-19
of	O	20-22
World	O	23-28
Health	O	29-35
Organization	O	36-48
(	O	49-50
WHO	O	50-53
)	O	53-54
grade	O	55-60
II	O	61-63
has	O	64-67
an	O	68-70
inherent	O	71-79
tendency	O	80-88
to	O	89-91
spontaneously	O	92-105
progress	O	106-114
to	O	115-117
anaplastic	O	118-128
astrocytoma	O	129-140
WHO	O	141-144
grade	O	145-150
III	O	151-154
or	O	155-157
secondary	O	158-167
glioblastoma	O	168-180
WHO	O	181-184
grade	O	185-190
IV	O	191-193
. 	O	193-195

Taken	O	0-5
together	O	6-14
,	O	14-15
our	O	16-19
results	O	20-27
support	O	28-35
an	O	36-38
important	O	39-48
role	O	49-53
of	O	54-56
altered	O	57-64
miRNA	O	65-70
expression	O	71-81
in	O	82-84
gliomas	O	85-92
,	O	92-93
and	O	94-97
suggest	O	98-105
miR	B	106-109
-	I	109-110
17	I	110-112
and	O	113-116
miR	B	117-120
-	I	120-121
184	I	121-124
as	O	125-127
interesting	O	128-139
candidates	O	140-150
contributing	O	151-163
to	O	164-166
glioma	O	167-173
progression	O	174-185
.   	O	185-189

Using	O	0-5
mRNA	O	6-10
and	O	11-14
protein	O	15-22
expression	O	23-33
profiling	O	34-43
,	O	43-44
we	O	45-47
identified	O	48-58
distinct	O	59-67
sets	O	68-72
of	O	73-75
transcripts	O	76-87
and	O	88-91
proteins	O	92-100
that	O	101-105
were	O	106-110
differentially	O	111-125
expressed	O	126-135
after	O	136-141
inhibition	O	142-152
of	O	153-155
miR	B	156-159
-	I	159-160
17	I	160-162
or	O	163-165
overexpression	O	166-180
of	O	181-183
miR	B	184-187
-	I	187-188
184	I	188-191
in	O	192-194
glioma	O	195-201
cells	O	202-207
. 	O	207-209

These	O	0-5
studies	O	6-13
revealed	O	14-22
miRNA	O	23-28
-	O	28-29
specific	O	29-37
influences	O	38-48
on	O	49-51
the	O	52-55
viability	O	56-65
,	O	65-66
proliferation	O	67-80
,	O	80-81
apoptosis	O	82-91
and	O	92-95
invasive	O	96-104
growth	O	105-111
properties	O	112-122
of	O	123-125
A172	O	126-130
and	O	131-134
T98G	O	135-139
glioma	O	140-146
cells	O	147-152
in	O	153-155
vitro	O	156-161
. 	O	161-163

Validation	O	0-10
experiments	O	11-22
on	O	23-25
independent	O	26-37
series	O	38-44
of	O	45-47
primary	O	48-55
low	O	56-59
-	O	59-60
grade	O	60-65
and	O	66-69
secondary	O	70-79
high	O	80-84
-	O	84-85
grade	O	85-90
astrocytomas	O	91-103
confirmed	O	104-113
miR	B	114-117
-	I	117-118
17	I	118-120
and	O	121-124
miR	B	125-128
-	I	128-129
184	I	129-132
as	O	133-135
promising	O	136-145
candidates	O	146-156
,	O	156-157
which	O	158-163
were	O	164-168
selected	O	169-177
for	O	178-181
functional	O	182-192
analyses	O	193-201
. 	O	201-203

MicroRNA	B	0-8
-	I	8-9
328	I	9-12
(	O	13-14
miR	B	14-17
-	I	17-18
328	I	18-21
)	O	21-22
is	O	23-25
underexpressed	O	26-40
in	O	41-43
many	O	44-48
cancers	O	49-56
including	O	57-66
glioblastoma	O	67-79
multiforme	O	80-90
and	O	91-94
contributes	O	95-106
to	O	107-109
tumor	O	110-115
resistance	O	116-126
to	O	127-129
chemotherapy	O	130-142
. 	O	142-144

MicroRNAs	O	0-9
control	O	10-17
a	O	18-19
wide	O	20-24
array	O	25-30
of	O	31-33
biological	O	34-44
processes	O	45-54
(	O	55-56
e	O	56-57
.	O	57-58
g	O	58-59
.	O	59-60
,	O	60-61
cell	O	62-66
differentiation	O	67-82
,	O	82-83
proliferation	O	84-97
and	O	98-101
apoptosis	O	102-111
)	O	111-112
whose	O	113-118
dysregulation	O	119-132
is	O	133-135
a	O	136-137
hallmark	O	138-146
of	O	147-149
cancer	O	150-156
. 	O	156-158

ABCG2	O	0-5
,	O	5-6
which	O	7-12
encodes	O	13-20
an	O	21-23
ATP	O	24-27
-	O	27-28
binding	O	28-35
cassette	O	36-44
transporter	O	45-56
protein	O	57-64
,	O	64-65
is	O	66-68
associated	O	69-79
with	O	80-84
the	O	85-88
phenotype	O	89-98
of	O	99-101
cancer	O	102-108
stem	O	109-113
cells	O	114-119
and	O	120-123
is	O	124-126
used	O	127-131
to	O	132-134
define	O	135-141
the	O	142-145
pluripotential	O	146-160
side	O	161-165
population	O	166-176
cells	O	177-182
by	O	183-185
flow	O	186-190
cytometry	O	191-200
and	O	201-204
slide	O	205-210
-	O	210-211
cytometry	O	211-220
. 	O	220-222

Downregulation	O	0-14
of	O	15-17
ABCG2	O	18-23
expression	O	24-34
in	O	35-37
glioblastoma	O	38-50
cancer	O	51-57
stem	O	58-62
cells	O	63-68
with	O	69-73
miRNA	B	74-79
-	I	79-80
328	I	80-83
may	O	84-87
decrease	O	88-96
their	O	97-102
chemoresistance	O	103-118
.  	O	118-121

Thus	O	0-4
,	O	4-5
we	O	6-8
hypothesize	O	9-20
that	O	21-25
modulating	O	26-36
ABCG2	O	37-42
expression	O	43-53
by	O	54-56
targeting	O	57-66
miRNA	B	67-72
-	I	72-73
328	I	73-76
in	O	77-79
glioblastoma	O	80-92
cancer	O	93-99
stem	O	100-104
cells	O	105-110
could	O	111-116
represent	O	117-126
a	O	127-128
promising	O	129-138
strategy	O	139-147
for	O	148-151
therapeutic	O	152-163
manipulation	O	164-176
to	O	177-179
increase	O	180-188
the	O	189-192
efficacy	O	193-201
of	O	202-204
chemotherapeutic	O	205-221
agents	O	222-228
for	O	229-232
glioblastoma	O	233-245
,	O	245-246
a	O	247-248
highly	O	249-255
lethal	O	256-262
type	O	263-267
of	O	268-270
cancer	O	271-277
.   	O	277-281

ABCG2	O	0-5
is	O	6-8
associated	O	9-19
with	O	20-24
multi	O	25-30
-	O	30-31
drug	O	31-35
resistance	O	36-46
and	O	47-50
is	O	51-53
also	O	54-58
highly	O	59-65
expressed	O	66-75
in	O	76-78
glioblastoma	O	79-91
. 	O	91-93

Some	O	0-4
preliminary	O	5-16
studies	O	17-24
have	O	25-29
shown	O	30-35
that	O	36-40
ABCG2	O	41-46
is	O	47-49
the	O	50-53
target	O	54-60
gene	O	61-65
for	O	66-69
miRNA	B	70-75
-	I	75-76
328	I	76-79
. 	O	79-81

This	O	0-4
is	O	5-7
the	O	8-11
first	O	12-17
study	O	18-23
suggesting	O	24-34
that	O	35-39
plasma	O	40-46
miRs	O	47-51
might	O	52-57
be	O	58-60
used	O	61-65
as	O	66-68
biomarkers	O	69-79
for	O	80-83
HD	O	84-86
.   	O	86-90

Huntington	O	0-10
'	O	10-11
s	O	11-12
disease	O	13-20
(	O	21-22
HD	O	22-24
)	O	24-25
is	O	26-28
a	O	29-30
devastating	O	31-42
,	O	42-43
neurodegenerative	O	44-61
condition	O	62-71
,	O	71-72
which	O	73-78
lacks	O	79-84
effective	O	85-94
treatment	O	95-104
. 	O	104-106

Hsa	B	0-3
-	I	3-4
miR	I	4-7
-	I	7-8
34b	I	8-11
is	O	12-14
a	O	15-16
plasma	O	17-23
-	O	23-24
stable	O	24-30
microRNA	O	31-39
that	O	40-44
is	O	45-47
elevated	O	48-56
in	O	57-59
pre	O	60-63
-	O	63-64
manifest	O	64-72
Huntington	O	73-83
'	O	83-84
s	O	84-85
disease	O	86-93
.  	O	93-96

Importantly	O	0-11
,	O	11-12
miRs	O	13-17
are	O	18-21
present	O	22-29
in	O	30-32
a	O	33-34
bio	O	35-38
-	O	38-39
stable	O	39-45
form	O	46-50
in	O	51-53
human	O	54-59
peripheral	O	60-70
blood	O	71-76
plasma	O	77-83
and	O	84-87
have	O	88-92
recently	O	93-101
been	O	102-106
shown	O	107-112
to	O	113-115
be	O	116-118
useful	O	119-125
biomarkers	O	126-136
in	O	137-139
other	O	140-145
diseases	O	146-154
. 	O	154-156

Normal	O	0-6
Huntingtin	O	7-17
(	O	18-19
HTT	O	19-22
)	O	22-23
and	O	24-27
mutant	O	28-34
Huntingtin	O	35-45
(	O	46-47
mHTT	O	47-51
)	O	51-52
are	O	53-56
expressed	O	57-66
in	O	67-69
multiple	O	70-78
tissues	O	79-86
and	O	87-90
can	O	91-94
alter	O	95-100
transcription	O	101-114
of	O	115-117
microRNAs	O	118-127
(	O	128-129
miRs	O	129-133
)	O	133-134
. 	O	134-136

In	O	0-2
a	O	3-4
cell	O	5-9
line	O	10-14
over	O	15-19
-	O	19-20
expressing	O	20-30
mHTT	O	31-35
-	O	35-36
Exon	O	36-40
-	O	40-41
1	O	41-42
,	O	42-43
miR	O	44-47
microarray	O	48-58
analysis	O	59-67
was	O	68-71
used	O	72-76
to	O	77-79
identify	O	80-88
candidate	O	89-98
miRs	O	99-103
. 	O	103-105

We	O	0-2
therefore	O	3-12
sought	O	13-19
to	O	20-22
identify	O	23-31
potential	O	32-41
miR	O	42-45
biomarkers	O	46-56
of	O	57-59
HD	O	60-62
that	O	63-67
are	O	68-71
present	O	72-79
in	O	80-82
,	O	82-83
and	O	84-87
have	O	88-92
functional	O	93-103
consequences	O	104-116
for	O	117-120
,	O	120-121
neuronal	O	122-130
and	O	131-134
non	O	135-138
-	O	138-139
neuronal	O	139-147
tissues	O	148-155
. 	O	155-157

We	O	0-2
found	O	3-8
that	O	9-13
miR	B	14-17
-	I	17-18
34b	I	18-21
is	O	22-24
significantly	O	25-38
elevated	O	39-47
in	O	48-50
response	O	51-59
to	O	60-62
mHTT	O	63-67
-	O	67-68
Exon	O	68-72
-	O	72-73
1	O	73-74
,	O	74-75
and	O	76-79
its	O	80-83
blockade	O	84-92
alters	O	93-99
the	O	100-103
toxicity	O	104-112
of	O	113-115
mHTT	O	116-120
-	O	120-121
Exon	O	121-125
-	O	125-126
1	O	126-127
in	O	128-130
vitro	O	131-136
. 	O	136-138

We	O	0-2
then	O	3-7
examined	O	8-16
their	O	17-22
presence	O	23-31
and	O	32-35
bio	O	36-39
-	O	39-40
stability	O	40-49
in	O	50-52
control	O	53-60
and	O	61-64
HD	O	65-67
plasma	O	68-74
. 	O	74-76

We	O	0-2
also	O	3-7
show	O	8-12
that	O	13-17
miR	B	18-21
-	I	21-22
34b	I	22-25
is	O	26-28
detectable	O	29-39
in	O	40-42
plasma	O	43-49
from	O	50-54
small	O	55-60
input	O	61-66
volumes	O	67-74
and	O	75-78
is	O	79-81
insensitive	O	82-93
to	O	94-96
freeze	O	97-103
-	O	103-104
thaw	O	104-108
-	O	108-109
induced	O	109-116
RNA	O	117-120
degradation	O	121-132
. 	O	132-134

Interestingly	O	0-13
,	O	13-14
miR	B	15-18
-	I	18-19
34b	I	19-22
is	O	23-25
significantly	O	26-39
elevated	O	40-48
in	O	49-51
plasma	O	52-58
from	O	59-63
HD	O	64-66
gene	O	67-71
carriers	O	72-80
prior	O	81-86
to	O	87-89
symptom	O	90-97
onset	O	98-103
. 	O	103-105

Additionally	O	0-12
,	O	12-13
gene	O	14-18
ontology	O	19-27
analyses	O	28-36
of	O	37-39
the	O	40-43
target	O	44-50
genes	O	51-56
suggested	O	57-66
a	O	67-68
distinct	O	69-77
role	O	78-82
for	O	83-86
each	O	87-91
miRNA	O	92-97
. 	O	97-99

Our	O	0-3
results	O	4-11
show	O	12-16
that	O	17-21
NPC	O	22-25
fibroblasts	O	26-37
have	O	38-42
an	O	43-45
altered	O	46-53
miRNA	O	54-59
expression	O	60-70
profile	O	71-78
and	O	79-82
certain	O	83-90
miRNAs	O	91-97
have	O	98-102
importance	O	103-113
in	O	114-116
disease	O	117-124
pathogenesis	O	125-137
as	O	138-140
well	O	141-145
as	O	146-148
the	O	149-152
therapeutic	O	153-164
capacity	O	165-173
to	O	174-176
correct	O	177-184
lipid	O	185-190
related	O	191-198
pathophysiologies	O	199-216
in	O	217-219
the	O	220-223
NPC	O	224-227
cells	O	228-233
.   	O	233-237

Expression	O	0-10
differences	O	11-22
between	O	23-30
the	O	31-34
healthy	O	35-42
and	O	43-46
NPC	O	47-50
cells	O	51-56
were	O	57-61
detected	O	62-70
according	O	71-80
to	O	81-83
the	O	84-87
relative	O	88-96
quantification	O	97-111
values	O	112-118
. 	O	118-120

Target	O	0-6
genes	O	7-12
were	O	13-17
predicted	O	18-27
by	O	28-30
using	O	31-36
three	O	37-42
different	O	43-52
algorithms	O	53-63
and	O	64-67
classified	O	68-78
regarding	O	79-88
NPC	O	89-92
related	O	93-100
biological	O	101-111
processes	O	112-121
and	O	122-125
cellular	O	126-134
components	O	135-145
. 	O	145-147

We	O	0-2
found	O	3-8
that	O	9-13
three	O	14-19
miRNAs	O	20-26
,	O	26-27
miR	B	28-31
-	I	31-32
196a	I	32-36
,	O	36-37
miR	B	38-41
-	I	41-42
196b	I	42-46
and	O	47-50
miR	B	51-54
-	I	54-55
296	I	55-58
were	O	59-63
up	O	64-66
-	O	66-67
regulated	O	67-76
(	O	77-78
>	O	78-79
3	O	79-80
.	O	80-81
5	O	81-82
-	O	82-83
fold	O	83-87
increase	O	88-96
,	O	96-97
p	O	98-99
<	O	99-100
0	O	100-101
.	O	101-102
05	O	102-104
)	O	104-105
whereas	O	106-113
38	O	114-116
miRNAs	O	117-123
were	O	124-128
significantly	O	129-142
down	O	143-147
-	O	147-148
regulated	O	148-157
in	O	158-160
NPC	O	161-164
cells	O	165-170
(	O	171-172
>	O	172-173
3	O	173-174
.	O	174-175
5	O	175-176
-	O	176-177
fold	O	177-181
decrease	O	182-190
,	O	190-191
p	O	192-193
<	O	193-194
0	O	194-195
.	O	195-196
05	O	196-198
)	O	198-199
. 	O	199-201

Among	O	0-5
these	O	6-11
non	O	12-15
-	O	15-16
coding	O	16-22
RNAs	O	23-27
,	O	27-28
miR	B	29-32
-	I	32-33
98	I	33-35
was	O	36-39
the	O	40-43
most	O	44-48
down	O	49-53
-	O	53-54
regulated	O	54-63
(	O	64-65
-	O	65-66
33	O	66-68
.	O	68-69
3	O	69-70
-	O	70-71
fold	O	71-75
)	O	75-76
miRNA	O	77-82
and	O	83-86
miR	B	87-90
-	I	90-91
143	I	91-94
,	O	94-95
the	O	96-99
lipid	O	100-105
biosynthesis	O	106-118
associated	O	119-129
miRNA	O	130-135
,	O	135-136
had	O	137-140
a	O	141-142
20	O	143-145
-	O	145-146
fold	O	146-150
decreased	O	151-160
expression	O	161-171
in	O	172-174
the	O	175-178
NPC	O	179-182
cells	O	183-188
. 	O	188-190

Dysregulation	O	0-13
of	O	14-16
miRNA	O	17-22
expression	O	23-33
may	O	34-37
lead	O	38-42
to	O	43-45
severe	O	46-52
pathophysiologies	O	53-70
in	O	71-73
human	O	74-79
cells	O	80-85
. 	O	85-87

Niemann	O	0-7
-	O	7-8
Pick	O	8-12
type	O	13-17
C	O	18-19
(	O	20-21
NPC	O	21-24
)	O	24-25
disease	O	26-33
is	O	34-36
a	O	37-38
complex	O	39-46
lipid	O	47-52
storage	O	53-60
disease	O	61-68
characterized	O	69-82
by	O	83-85
late	O	86-90
endosomal	O	91-100
-	O	100-101
lysosomal	O	101-110
accumulation	O	111-123
of	O	124-126
multiple	O	127-135
lipid	O	136-141
molecules	O	142-151
. 	O	151-153

Our	O	0-3
aim	O	4-7
was	O	8-11
to	O	12-14
characterize	O	15-27
the	O	28-31
miRNA	O	32-37
profile	O	38-45
in	O	46-48
NPC	O	49-52
fibroblasts	O	53-64
as	O	65-67
they	O	68-72
may	O	73-76
play	O	77-81
an	O	82-84
active	O	85-91
role	O	92-96
in	O	97-99
the	O	100-103
NPC	O	104-107
disease	O	108-115
associated	O	116-126
changes	O	127-134
in	O	135-137
the	O	138-141
cellular	O	142-150
physiology	O	151-161
. 	O	161-163

To	O	0-2
investigate	O	3-14
the	O	15-18
miRNA	O	19-24
expression	O	25-35
,	O	35-36
total	O	37-42
RNAs	O	43-47
were	O	48-52
isolated	O	53-61
from	O	62-66
cultured	O	67-75
human	O	76-81
NPC	O	82-85
fibroblasts	O	86-97
and	O	98-101
healthy	O	102-109
fibroblasts	O	110-121
and	O	122-125
then	O	126-130
,	O	130-131
TaqMan	O	132-138
Low	O	139-142
-	O	142-143
Density	O	143-150
Array	O	151-156
system	O	157-163
containing	O	164-174
365	O	175-178
mature	O	179-185
human	O	186-191
miRNAs	O	192-198
was	O	199-202
used	O	203-207
. 	O	207-209

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
non	O	23-26
-	O	26-27
coding	O	27-33
RNAs	O	34-38
that	O	39-43
regulate	O	44-52
gene	O	53-57
expression	O	58-68
at	O	69-71
post	O	72-76
-	O	76-77
transcriptional	O	77-92
level	O	93-98
. 	O	98-100

Niemann	O	0-7
-	O	7-8
Pick	O	8-12
type	O	13-17
C	O	18-19
fibroblasts	O	20-31
have	O	32-36
a	O	37-38
distinct	O	39-47
microRNA	O	48-56
profile	O	57-64
related	O	65-72
to	O	73-75
lipid	O	76-81
metabolism	O	82-92
and	O	93-96
certain	O	97-104
cellular	O	105-113
components	O	114-124
.  	O	124-127

Frequent	O	0-8
amplification	O	9-22
of	O	23-25
a	O	26-27
chr19q13	O	28-36
.	O	36-37
41	O	37-39
microRNA	O	40-48
polycistron	O	49-60
in	O	61-63
aggressive	O	64-74
primitive	O	75-84
neuroectodermal	O	85-100
brain	O	101-106
tumors	O	107-113
.  	O	113-116

microRNA	O	0-8
(	O	9-10
miRNA	O	10-15
)	O	15-16
cluster	O	17-24
(	O	25-26
C19MC	O	26-31
)	O	31-32
in	O	33-35
11	O	36-38
/	O	38-39
45	O	39-41
(	O	42-43
approximately	O	44-57
25	O	58-60
%	O	60-61
)	O	61-62
primary	O	63-70
CNS	O	71-74
-	O	74-75
PNET	O	75-79
,	O	79-80
which	O	81-86
results	O	87-94
in	O	95-97
striking	O	98-106
overexpression	O	107-121
of	O	122-124
miR	B	125-128
-	I	128-129
517c	I	129-133
and	I	134-137
520g	I	138-142
. 	O	142-144

We	O	0-2
discovered	O	3-13
a	O	14-15
high	O	16-20
-	O	20-21
level	O	21-26
amplicon	O	27-35
involving	O	36-45
the	O	46-49
chr19q13	O	50-58
.	O	58-59
41 	O	59-62

Remarkably	O	0-10
,	O	10-11
the	O	12-15
C19MC	O	16-21
amplicon	O	22-30
,	O	30-31
which	O	32-37
is	O	38-40
very	O	41-45
rare	O	46-50
in	O	51-53
other	O	54-59
brain	O	60-65
tumors	O	66-72
(	O	73-74
1	O	74-75
/	O	75-76
263	O	76-79
)	O	79-80
,	O	80-81
identifies	O	82-92
an	O	93-95
aggressive	O	96-106
subgroup	O	107-115
of	O	116-118
CNS	O	119-122
-	O	122-123
PNET	O	123-127
with	O	128-132
distinct	O	133-141
gene	O	142-146
-	O	146-147
expression	O	147-157
profiles	O	158-166
,	O	166-167
characteristic	O	168-182
histology	O	183-192
,	O	192-193
and	O	194-197
dismal	O	198-204
survival	O	205-213
. 	O	213-215

Constitutive	O	0-12
expression	O	13-23
of	O	24-26
miR	B	27-30
-	I	30-31
517c	I	31-35
or	O	36-38
520g	O	39-43
promotes	O	44-52
in	O	53-55
vitro	O	56-61
and	O	62-65
in	O	66-68
vivo	O	69-73
oncogenicity	O	74-86
,	O	86-87
modulates	O	88-97
cell	O	98-102
survival	O	103-111
,	O	111-112
and	O	113-116
robustly	O	117-125
enhances	O	126-134
growth	O	135-141
of	O	142-144
untransformed	O	145-158
human	O	159-164
neural	O	165-171
stem	O	172-176
cells	O	177-182
(	O	183-184
hNSCs	O	184-189
)	O	189-190
in	O	191-193
part	O	194-198
by	O	199-201
upregulating	O	202-214
WNT	O	215-218
pathway	O	219-226
signaling	O	227-236
and	O	237-240
restricting	O	241-252
differentiation	O	253-268
of	O	269-271
hNSCs	O	272-277
. 	O	277-279

Our	O	0-3
data	O	4-8
implicate	O	9-18
miR	B	19-22
-	I	22-23
517c	I	23-27
and	O	28-31
520g	O	32-36
as	O	37-39
oncogenes	O	40-49
and	O	50-53
promising	O	54-63
biological	O	64-74
markers	O	75-82
for	O	83-86
CNS	O	87-90
-	O	90-91
PNET	O	91-95
and	O	96-99
provide	O	100-107
important	O	108-117
insights	O	118-126
into	O	127-131
oncogenic	O	132-141
properties	O	142-152
of	O	153-155
the	O	156-159
C19MC	O	160-165
locus	O	166-171
.   	O	171-175

Our	O	0-3
findings	O	4-12
suggest	O	13-20
that	O	21-25
microRNAs	O	26-35
are	O	36-39
important	O	40-49
determinants	O	50-62
of	O	63-65
glioblastoma	O	66-78
subclasses	O	79-89
through	O	90-97
their	O	98-103
ability	O	104-111
to	O	112-114
regulate	O	115-123
developmental	O	124-137
growth	O	138-144
and	O	145-148
differentiation	O	149-164
programs	O	165-173
in	O	174-176
several	O	177-184
transformed	O	185-196
neural	O	197-203
precursor	O	204-213
cell	O	214-218
types	O	219-224
. 	O	224-226

Foremost	O	0-8
among	O	9-14
these	O	15-20
is	O	21-23
miR	B	24-27
-	I	27-28
9	I	28-29
,	O	29-30
which	O	31-36
suppresses	O	37-47
mesenchymal	O	48-59
differentiation	O	60-75
in	O	76-78
glioblastoma	O	79-91
by	O	92-94
downregulating	O	95-109
expression	O	110-120
of	O	121-123
JAK	O	124-127
kinases	O	128-135
and	O	136-139
inhibiting	O	140-150
activation	O	151-161
of	O	162-164
STAT3	O	165-170
. 	O	170-172

Taken	O	0-5
together	O	6-14
,	O	14-15
our	O	16-19
results	O	20-27
define	O	28-34
developmental	O	35-48
microRNA	O	49-57
expression	O	58-68
signatures	O	69-79
that	O	80-84
both	O	85-89
characterize	O	90-102
and	O	103-106
contribute	O	107-117
to	O	118-120
the	O	121-124
phenotypic	O	125-135
diversity	O	136-145
of	O	146-148
glioblastoma	O	149-161
subclasses	O	162-172
,	O	172-173
thereby	O	174-181
providing	O	182-191
an	O	192-194
expanded	O	195-203
framework	O	204-213
for	O	214-217
understanding	O	218-231
the	O	232-235
pathogenesis	O	236-248
of	O	249-251
glioblastoma	O	252-264
in	O	265-267
a	O	268-269
human	O	270-275
neurodevelopmental	O	276-294
context	O	295-302
.   	O	302-306

These	O	0-5
microRNA	O	6-14
-	O	14-15
based	O	15-20
glioblastoma	O	21-33
subclasses	O	34-44
displayed	O	45-54
microRNA	O	55-63
and	O	64-67
mRNA	O	68-72
expression	O	73-83
signatures	O	84-94
resembling	O	95-105
those	O	106-111
of	O	112-114
radial	O	115-121
glia	O	122-126
,	O	126-127
oligoneuronal	O	128-141
precursors	O	142-152
,	O	152-153
neuronal	O	154-162
precursors	O	163-173
,	O	173-174
neuroepithelial	O	175-190
/	O	190-191
neural	O	191-197
crest	O	198-203
precursors	O	204-214
,	O	214-215
or	O	216-218
astrocyte	O	219-228
precursors	O	229-239
. 	O	239-241

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
analyzed	O	18-26
261	O	27-30
microRNA	O	31-39
expression	O	40-50
profiles	O	51-59
from	O	60-64
The	O	65-68
Cancer	O	69-75
Genome	O	76-82
Atlas	O	83-88
(	O	89-90
TCGA	O	90-94
)	O	94-95
,	O	95-96
identifying	O	97-108
five	O	109-113
clinically	O	114-124
and	O	125-128
genetically	O	129-140
distinct	O	141-149
subclasses	O	150-160
of	O	161-163
glioblastoma	O	164-176
that	O	177-181
each	O	182-186
related	O	187-194
to	O	195-197
a	O	198-199
different	O	200-209
neural	O	210-216
precursor	O	217-226
cell	O	227-231
type	O	232-236
. 	O	236-238

We	O	0-2
also	O	3-7
identified	O	8-18
several	O	19-26
microRNAs	O	27-36
as	O	37-39
potent	O	40-46
regulators	O	47-57
of	O	58-60
subclass	O	61-69
-	O	69-70
specific	O	70-78
gene	O	79-83
expression	O	84-94
networks	O	95-103
in	O	104-106
glioblastoma	O	107-119
. 	O	119-121

Each	O	0-4
subclass	O	5-13
was	O	14-17
determined	O	18-28
to	O	29-31
be	O	32-34
genetically	O	35-46
distinct	O	47-55
,	O	55-56
based	O	57-62
on	O	63-65
the	O	66-69
significant	O	70-81
differences	O	82-93
they	O	94-98
displayed	O	99-108
in	O	109-111
terms	O	112-117
of	O	118-120
patient	O	121-128
race	O	129-133
,	O	133-134
age	O	135-138
,	O	138-139
treatment	O	140-149
response	O	150-158
,	O	158-159
and	O	160-163
survival	O	164-172
. 	O	172-174

mRNA	O	0-4
expression	O	5-15
profiling	O	16-25
has	O	26-29
suggested	O	30-39
the	O	40-43
existence	O	44-53
of	O	54-56
multiple	O	57-65
glioblastoma	O	66-78
subclasses	O	79-89
,	O	89-90
but	O	91-94
their	O	95-100
number	O	101-107
and	O	108-111
characteristics	O	112-127
vary	O	128-132
among	O	133-138
studies	O	139-146
and	O	147-150
the	O	151-154
etiology	O	155-163
underlying	O	164-174
their	O	175-180
development	O	181-192
is	O	193-195
unclear	O	196-203
. 	O	203-205

A	O	0-1
developmental	O	2-15
taxonomy	O	16-24
of	O	25-27
glioblastoma	O	28-40
defined	O	41-48
and	O	49-52
maintained	O	53-63
by	O	64-66
MicroRNAs	O	67-76
.  	O	76-79

miRNAs	O	0-6
are	O	7-10
small	O	11-16
,	O	16-17
endogenously	O	18-30
expressed	O	31-40
noncoding	O	41-50
RNAs	O	51-55
that	O	56-60
regulate	O	61-69
gene	O	70-74
expression	O	75-85
,	O	85-86
mainly	O	87-93
at	O	94-96
the	O	97-100
post	O	101-105
-	O	105-106
transcriptional	O	106-121
level	O	122-127
,	O	127-128
via	O	129-132
degradation	O	133-144
or	O	145-147
translational	O	148-161
inhibition	O	162-172
of	O	173-175
their	O	176-181
target	O	182-188
mRNAs	O	189-194
. 	O	194-196

Functionally	O	0-12
,	O	12-13
an	O	14-16
individual	O	17-27
miRNA	O	28-33
can	O	34-37
regulate	O	38-46
the	O	47-50
expression	O	51-61
of	O	62-64
multiple	O	65-73
target	O	74-80
genes	O	81-86
. 	O	86-88

miRNAs	O	0-6
:	O	6-7
roles	O	8-13
and	O	14-17
clinical	O	18-26
applications	O	27-39
in	O	40-42
vascular	O	43-51
disease	O	52-59
.  	O	59-62

The	O	0-3
study	O	4-9
of	O	10-12
miRNAs	O	13-19
is	O	20-22
rapidly	O	23-30
growing	O	31-38
and	O	39-42
recent	O	43-49
studies	O	50-57
have	O	58-62
revealed	O	63-71
a	O	72-73
significant	O	74-85
role	O	86-90
of	O	91-93
miRNAs	O	94-100
in	O	101-103
vascular	O	104-112
biology	O	113-120
and	O	121-124
disease	O	125-132
. 	O	132-134

Many	O	0-4
miRNAs	O	5-11
are	O	12-15
highly	O	16-22
expressed	O	23-32
in	O	33-35
the	O	36-39
vasculature	O	40-51
,	O	51-52
and	O	53-56
their	O	57-62
expression	O	63-73
is	O	74-76
dysregulated	O	77-89
in	O	90-92
diseased	O	93-101
vessels	O	102-109
. 	O	109-111

Several	O	0-7
miRNAs	O	8-14
have	O	15-19
been	O	20-24
found	O	25-30
to	O	31-33
be	O	34-36
critical	O	37-45
modulators	O	46-56
of	O	57-59
vascular	O	60-68
pathologies	O	69-80
,	O	80-81
such	O	82-86
as	O	87-89
atherosclerosis	O	90-105
,	O	105-106
lipoprotein	O	107-118
metabolism	O	119-129
,	O	129-130
inflammation	O	131-143
,	O	143-144
arterial	O	145-153
remodeling	O	154-164
,	O	164-165
angiogenesis	O	166-178
,	O	178-179
smooth	O	180-186
muscle	O	187-193
cell	O	194-198
regeneration	O	199-211
,	O	211-212
hypertension	O	213-225
,	O	225-226
apoptosis	O	227-236
,	O	236-237
neointimal	O	238-248
hyperplasia	O	249-260
and	O	261-264
signal	O	265-271
transduction	O	272-284
pathways	O	285-293
. 	O	293-295

Thus	O	0-4
,	O	4-5
miRNAs	O	6-12
may	O	13-16
serve	O	17-22
as	O	23-25
novel	O	26-31
biomarkers	O	32-42
and	O	43-46
/	O	46-47
or	O	47-49
therapeutic	O	50-61
targets	O	62-69
for	O	70-73
vascular	O	74-82
disease	O	83-90
. 	O	90-92

This	O	0-4
article	O	5-12
summarizes	O	13-23
the	O	24-27
current	O	28-35
studies	O	36-43
related	O	44-51
to	O	52-54
the	O	55-58
disease	O	59-66
correlations	O	67-79
and	O	80-83
functional	O	84-94
roles	O	95-100
of	O	101-103
miRNAs	O	104-110
in	O	111-113
the	O	114-117
vascular	O	118-126
system	O	127-133
and	O	134-137
discusses	O	138-147
the	O	148-151
potential	O	152-161
applications	O	162-174
of	O	175-177
miRNAs	O	178-184
in	O	185-187
vascular	O	188-196
disease	O	197-204
.   	O	204-208

Co	O	0-2
-	O	2-3
suppression	O	3-14
of	O	15-17
miR	B	18-21
-	I	21-22
221	I	22-25
/	I	25-26
222	I	26-29
directly	O	30-38
resulted	O	39-47
in	O	48-50
the	O	51-54
up	O	55-57
-	O	57-58
regulation	O	58-68
of	O	69-71
p27Kip1	O	72-79
in	O	80-82
the	O	83-86
tested	O	87-93
cells	O	94-99
,	O	99-100
consequently	O	101-113
,	O	113-114
affects	O	115-122
their	O	123-128
growth	O	129-135
potential	O	136-145
by	O	146-148
reducing	O	149-157
a	O	158-159
G1	O	160-162
to	O	163-165
S	O	166-167
shift	O	168-173
in	O	174-176
the	O	177-180
cell	O	181-185
cycle	O	186-191
. 	O	191-193

Consistently	O	0-12
,	O	12-13
miR	B	14-17
-	I	17-18
221	I	18-21
/	I	21-22
222	I	22-25
knocked	O	26-33
-	O	33-34
down	O	34-38
through	O	39-46
antisense	O	47-56
2	O	57-58
'	O	58-59
-	O	59-60
OME	O	60-63
-	O	63-64
oligonucleotides	O	64-80
increased	O	81-90
p27Kip1	O	91-98
in	O	99-101
U251	O	102-106
glioma	O	107-113
subcutaneous	O	114-126
mice	O	127-131
and	O	132-135
strongly	O	136-144
reduced	O	145-152
tumor	O	153-158
growth	O	159-165
in	O	166-168
vivo	O	169-173
through	O	174-181
up	O	182-184
regulation	O	185-195
of	O	196-198
p27Kip1	O	199-206
. 	O	206-208

Our	O	0-3
results	O	4-11
suggest	O	12-19
that	O	20-24
miR	B	25-28
-	I	28-29
221	I	29-32
/	I	32-33
222	I	33-36
is	O	37-39
a	O	40-41
regulator	O	42-51
of	O	52-54
the	O	55-58
tumor	O	59-64
suppressor	O	65-75
gene	O	76-80
p27Kip1	O	81-88
,	O	88-89
and	O	90-93
co	O	94-96
-	O	96-97
suppression	O	97-108
of	O	109-111
miR	B	112-115
-	I	115-116
221	I	116-119
/	I	119-120
222	I	120-123
expression	O	124-134
in	O	135-137
advanced	O	138-146
gliomas	O	147-154
may	O	155-158
inhibit	O	159-166
glioma	O	167-173
cell	O	174-178
proliferation	O	179-192
by	O	193-195
a	O	196-197
mechanism	O	198-207
involving	O	208-217
the	O	218-221
up	O	222-224
-	O	224-225
regulation	O	225-235
of	O	236-238
p27Kip1	O	239-246
in	O	247-249
vitro	O	250-255
and	O	256-259
in	O	260-262
vivo	O	263-267
.   	O	267-271

Co	O	0-2
-	O	2-3
suppression	O	3-14
of	O	15-17
miR	B	18-21
-	I	21-22
221	I	22-25
/	I	25-26
222	I	26-29
cluster	O	30-37
suppresses	O	38-48
human	O	49-54
glioma	O	55-61
cell	O	62-66
growth	O	67-73
by	O	74-76
targeting	O	77-86
p27kip1	O	87-94
in	O	95-97
vitro	O	98-103
and	O	104-107
in	O	108-110
vivo	O	111-115
.  	O	115-118

MicroRNAs	O	0-9
are	O	10-13
short	O	14-19
regulatory	O	20-30
RNAs	O	31-35
that	O	36-40
negatively	O	41-51
modulate	O	52-60
protein	O	61-68
expression	O	69-79
at	O	80-82
a	O	83-84
post	O	85-89
-	O	89-90
transcriptional	O	90-105
level	O	106-111
. 	O	111-113

Emerging	O	0-8
evidence	O	9-17
suggests	O	18-26
that	O	27-31
altered	O	32-39
regulation	O	40-50
of	O	51-53
miRNA	O	54-59
may	O	60-63
be	O	64-66
involved	O	67-75
in	O	76-78
the	O	79-82
pathogenesis	O	83-95
of	O	96-98
several	O	99-106
types	O	107-112
of	O	113-115
cancers	O	116-123
. 	O	123-125

In	O	0-2
the	O	3-6
current	O	7-14
study	O	15-20
,	O	20-21
an	O	22-24
inverse	O	25-32
relationship	O	33-45
between	O	46-53
the	O	54-57
expression	O	58-68
of	O	69-71
miR	B	72-75
-	I	75-76
221	I	76-79
/	O	79-80
miR	B	80-83
-	I	83-84
222	I	84-87
and	O	88-91
the	O	92-95
cell	O	96-100
cycle	O	101-106
inhibitor	O	107-116
p27Kip1	O	117-124
was	O	125-128
identified	O	129-139
in	O	140-142
U251	O	143-147
glioma	O	148-154
cells	O	155-160
. 	O	160-162

The	O	0-3
therapy	O	4-11
employed	O	12-20
,	O	20-21
in	O	22-24
a	O	25-26
single	O	27-33
baculoviral	O	34-45
vector	O	46-52
,	O	52-53
a	O	54-55
glial	O	56-61
fibrillary	O	62-72
acidic	O	73-79
protein	O	80-87
(	O	88-89
GFAP	O	89-93
)	O	93-94
gene	O	95-99
promoter	O	100-108
and	O	109-112
the	O	113-116
repeated	O	117-125
target	O	126-132
sequences	O	133-142
of	O	143-145
three	O	146-151
miRNAs	O	152-158
that	O	159-163
are	O	164-167
enriched	O	168-176
in	O	177-179
astrocytes	O	180-190
but	O	191-194
downregulated	O	195-208
in	O	209-211
glioblastoma	O	212-224
cells	O	225-230
to	O	231-233
control	O	234-241
the	O	242-245
expression	O	246-256
of	O	257-259
the	O	260-263
herpes	O	264-270
simplex	O	271-278
virus	O	279-284
thymidine	O	285-294
kinase	O	295-301
(	O	302-303
HSVtk	O	303-308
)	O	308-309
gene	O	310-314
. 	O	314-316

This	O	0-4
resulted	O	5-13
in	O	14-16
significantly	O	17-30
improved	O	31-39
in	O	40-42
vivo	O	43-47
selectivity	O	48-59
over	O	60-64
the	O	65-68
use	O	69-72
of	O	73-75
a	O	76-77
control	O	78-85
vector	O	86-92
without	O	93-100
miRNA	O	101-106
regulation	O	107-117
,	O	117-118
enabling	O	119-127
effective	O	128-137
elimination	O	138-149
of	O	150-152
human	O	153-158
glioma	O	159-165
xenografts	O	166-176
while	O	177-182
producing	O	183-192
negligible	O	193-203
toxic	O	204-209
effects	O	210-217
on	O	218-220
normal	O	221-227
astrocytes	O	228-238
. 	O	238-240

In	O	0-2
the	O	3-6
context	O	7-14
of	O	15-17
cancer	O	18-24
suicide	O	25-32
gene	O	33-37
therapy	O	38-45
,	O	45-46
this	O	47-51
approach	O	52-60
may	O	61-64
lead	O	65-69
to	O	70-72
cytotoxic	O	73-82
effects	O	83-90
in	O	91-93
both	O	94-98
cancer	O	99-105
and	O	106-109
nontarget	O	110-119
normal	O	120-126
cells	O	127-132
. 	O	132-134

Considering	O	0-11
microRNA	O	12-20
(	O	21-22
miRNA	O	22-27
)	O	27-28
function	O	29-37
in	O	38-40
post	O	41-45
-	O	45-46
transcriptional	O	46-61
regulation	O	62-72
of	O	73-75
gene	O	76-80
expression	O	81-91
,	O	91-92
we	O	93-95
have	O	96-100
developed	O	101-110
a	O	111-112
viral	O	113-118
vector	O	119-125
platform	O	126-134
combining	O	135-144
cellular	O	145-153
promoter	O	154-162
-	O	162-163
based	O	163-168
transcriptional	O	169-184
targeting	O	185-194
with	O	195-199
miRNA	O	200-205
regulation	O	206-216
for	O	217-220
a	O	221-222
glioma	O	223-229
suicide	O	230-237
gene	O	238-242
therapy	O	243-250
in	O	251-253
the	O	254-257
mouse	O	258-263
brain	O	264-269
. 	O	269-271

Thus	O	0-4
,	O	4-5
incorporating	O	6-19
miRNA	O	20-25
regulation	O	26-36
into	O	37-41
a	O	42-43
transcriptional	O	44-59
targeting	O	60-69
vector	O	70-76
adds	O	77-81
an	O	82-84
extra	O	85-90
layer	O	91-96
of	O	97-99
security	O	100-108
to	O	109-111
prevent	O	112-119
off	O	120-123
-	O	123-124
target	O	124-130
transgene	O	131-140
expression	O	141-151
and	O	152-155
should	O	156-162
be	O	163-165
useful	O	166-172
for	O	173-176
the	O	177-180
development	O	181-192
of	O	193-195
gene	O	196-200
delivery	O	201-209
vectors	O	210-217
with	O	218-222
high	O	223-227
targeting	O	228-237
specificity	O	238-249
for	O	250-253
cancer	O	254-260
therapy	O	261-268
.   	O	268-272

Transcriptional	O	0-15
targeting	O	16-25
using	O	26-31
a	O	32-33
tissue	O	34-40
-	O	40-41
specific	O	41-49
cellular	O	50-58
promoter	O	59-67
is	O	68-70
proving	O	71-78
to	O	79-81
be	O	82-84
a	O	85-86
powerful	O	87-95
means	O	96-101
for	O	102-105
restricting	O	106-117
transgene	O	118-127
expression	O	128-138
in	O	139-141
targeted	O	142-150
tissues	O	151-158
. 	O	158-160

Combinatorial	O	0-13
control	O	14-21
of	O	22-24
suicide	O	25-32
gene	O	33-37
expression	O	38-48
by	O	49-51
tissue	O	52-58
-	O	58-59
specific	O	59-67
promoter	O	68-76
and	O	77-80
microRNA	O	81-89
regulation	O	90-100
for	O	101-104
cancer	O	105-111
therapy	O	112-119
.  	O	119-122

[	O	0-1
AD	O	1-3
-	O	3-4
FTLD	O	4-8
spectrum	O	9-17
-	O	17-18
-	O	18-19
new	O	19-22
findings	O	23-31
on	O	32-34
risk	O	35-39
genes	O	40-45
in	O	46-48
neurodegenerative	O	49-66
diseases	O	67-75
]	O	75-76
.     	O	76-82

Interestingly	O	0-13
,	O	13-14
the	O	15-18
above	O	19-24
data	O	25-29
suggested	O	30-39
that	O	40-44
in	O	45-47
both	O	48-52
the	O	53-56
PTEN	O	57-61
mutant	O	62-68
and	O	69-72
the	O	73-76
wild	O	77-81
-	O	81-82
type	O	82-86
GBM	O	87-90
cells	O	91-96
,	O	96-97
miR	B	98-101
-	I	101-102
21	I	102-104
blockage	O	105-113
increased	O	114-123
the	O	124-127
chemosensitivity	O	128-144
to	O	145-147
taxol	O	148-153
. 	O	153-155

It	O	0-2
is	O	3-5
worth	O	6-11
noting	O	12-18
that	O	19-23
the	O	24-27
miR	O	28-31
-	O	31-32
21	O	32-34
inhibitor	O	35-44
additively	O	45-55
interacted	O	56-66
with	O	67-71
taxol	O	72-77
on	O	78-80
U251cells	O	81-90
and	O	91-94
synergistically	O	95-110
on	O	111-113
LN229	O	114-119
cells	O	120-125
. 	O	125-127

Furthermore	O	0-11
,	O	11-12
the	O	13-16
miR	O	17-20
-	O	20-21
21	O	21-23
inhibitor	O	24-33
significantly	O	34-47
enhanced	O	48-56
apoptosis	O	57-66
in	O	67-69
both	O	70-74
U251	O	75-79
cells	O	80-85
and	O	86-89
LN229	O	90-95
cells	O	96-101
,	O	101-102
and	O	103-106
cell	O	107-111
invasiveness	O	112-124
was	O	125-128
obviously	O	129-138
weakened	O	139-147
. 	O	147-149

The	O	0-3
data	O	4-8
strongly	O	9-17
suggested	O	18-27
that	O	28-32
a	O	33-34
regulatory	O	35-45
loop	O	46-50
between	O	51-58
miR	B	59-62
-	I	62-63
21	I	63-65
and	O	66-69
STAT3	O	70-75
might	O	76-81
provide	O	82-89
an	O	90-92
insight	O	93-100
into	O	101-105
the	O	106-109
mechanism	O	110-119
of	O	120-122
modulating	O	123-133
EGFR	O	134-138
/	O	138-139
STAT3	O	139-144
signaling	O	145-154
. 	O	154-156

CONCLUSIONS	O	0-11
:	O	11-12
Taken	O	13-18
together	O	19-27
,	O	27-28
the	O	29-32
miR	O	33-36
-	O	36-37
21	O	37-39
inhibitor	O	40-49
could	O	50-55
enhance	O	56-63
the	O	64-67
chemo	O	68-73
-	O	73-74
sensitivity	O	74-85
of	O	86-88
human	O	89-94
glioblastoma	O	95-107
cells	O	108-113
to	O	114-116
taxol	O	117-122
. 	O	122-124

Thus	O	0-4
,	O	4-5
the	O	6-9
miR	O	10-13
-	O	13-14
21	O	14-16
inhibitor	O	17-26
might	O	27-32
interrupt	O	33-42
the	O	43-46
activity	O	47-55
of	O	56-58
EGFR	O	59-63
pathways	O	64-72
,	O	72-73
independently	O	74-87
of	O	88-90
PTEN	O	91-95
status	O	96-102
. 	O	102-104

Meanwhile	O	0-9
,	O	9-10
the	O	11-14
expression	O	15-25
of	O	26-28
STAT3	O	29-34
and	O	35-38
p	O	39-40
-	O	40-41
STAT3	O	41-46
decreased	O	47-56
to	O	57-59
relatively	O	60-70
low	O	71-74
levels	O	75-81
after	O	82-87
miR	O	88-91
-	O	91-92
21	O	92-94
inhibitor	O	95-104
and	O	105-108
taxol	O	109-114
treatment	O	115-124
. 	O	124-126

A	O	0-1
combination	O	2-13
of	O	14-16
miR	O	17-20
-	O	20-21
21	O	21-23
inhibitor	O	24-33
and	O	34-37
taxol	O	38-43
could	O	44-49
be	O	50-52
an	O	53-55
effective	O	56-65
therapeutic	O	66-77
strategy	O	78-86
for	O	87-90
controlling	O	91-102
the	O	103-106
growth	O	107-113
of	O	114-116
GBM	O	117-120
by	O	121-123
inhibiting	O	124-134
STAT3	O	135-140
expression	O	141-151
and	O	152-155
phosphorylation	O	156-171
.   	O	171-175

Expression	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
21	I	18-20
was	O	21-24
investigated	O	25-37
by	O	38-40
RT	O	41-43
-	O	43-44
PCR	O	44-47
,	O	47-48
and	O	49-52
western	O	53-60
blotting	O	61-69
was	O	70-73
performed	O	74-83
to	O	84-86
evaluate	O	87-95
malignancy	O	96-106
related	O	107-114
protein	O	115-122
alteration	O	123-133
. 	O	133-135

RESULTS	O	0-7
:	O	7-8
IC	O	9-11
(	O	11-12
50	O	12-14
)	O	14-15
values	O	16-22
were	O	23-27
dramatically	O	28-40
decreased	O	41-50
in	O	51-53
cells	O	54-59
treated	O	60-67
with	O	68-72
miR	O	73-76
-	O	76-77
21	O	77-79
inhibitor	O	80-89
combine	O	90-97
with	O	98-102
taxol	O	103-108
,	O	108-109
to	O	110-112
a	O	113-114
greater	O	115-122
extent	O	123-129
than	O	130-134
those	O	135-140
treated	O	141-148
with	O	149-153
taxol	O	154-159
alone	O	160-165
. 	O	165-167

The	O	0-3
mechanism	O	4-13
between	O	14-21
the	O	22-25
miR	O	26-29
-	O	29-30
21	O	30-32
inhibitor	O	33-42
and	O	43-46
the	O	47-50
anticancer	O	51-61
drug	O	62-66
taxol	O	67-72
was	O	73-76
analyzed	O	77-85
using	O	86-91
the	O	92-95
Zheng	O	96-101
-	O	101-102
Jun	O	102-105
Jin	O	106-109
method	O	110-116
. 	O	116-118

Annexin	O	0-7
V	O	8-9
/	O	9-10
PI	O	10-12
staining	O	13-21
was	O	22-25
performed	O	26-35
,	O	35-36
and	O	37-40
apoptosis	O	41-50
and	O	51-54
the	O	55-58
cell	O	59-63
cycle	O	64-69
were	O	70-74
evaluated	O	75-84
by	O	85-87
flow	O	88-92
cytometry	O	93-102
analysis	O	103-111
. 	O	111-113

BACKGROUND	O	0-10
:	O	10-11
Substantial	O	12-23
data	O	24-28
indicate	O	29-37
that	O	38-42
the	O	43-46
oncogene	O	47-55
microRNA	B	56-64
21	I	65-67
(	O	68-69
miR	B	69-72
-	I	72-73
21	I	73-75
)	O	75-76
is	O	77-79
significantly	O	80-93
elevated	O	94-102
in	O	103-105
glioblastoma	O	106-118
multiforme	O	119-129
(	O	130-131
GBM	O	131-134
)	O	134-135
and	O	136-139
regulates	O	140-149
multiple	O	150-158
genes	O	159-164
associated	O	165-175
with	O	176-180
cancer	O	181-187
cell	O	188-192
proliferation	O	193-206
,	O	206-207
apoptosis	O	208-217
,	O	217-218
and	O	219-222
invasiveness	O	223-235
. 	O	235-237

MicroRNA	O	0-8
-	O	8-9
21	O	9-11
inhibitor	O	12-21
sensitizes	O	22-32
human	O	33-38
glioblastoma	O	39-51
cells	O	52-57
U251	O	58-62
(	O	63-64
PTEN	O	64-68
-	O	68-69
mutant	O	69-75
)	O	75-76
and	O	77-80
LN229	O	81-86
(	O	87-88
PTEN	O	88-92
-	O	92-93
wild	O	93-97
type	O	98-102
)	O	102-103
to	O	104-106
taxol	O	107-112
.  	O	112-115

The	O	0-3
50	O	4-6
%	O	6-7
inhibitory	O	8-18
concentration	O	19-32
and	O	33-36
cell	O	37-41
viability	O	42-51
were	O	52-56
determined	O	57-67
by	O	68-70
the	O	71-74
MTT	O	75-78
assay	O	79-84
. 	O	84-86

METHODS	O	0-7
:	O	7-8
Human	O	9-14
glioblastoma	O	15-27
U251	O	28-32
(	O	33-34
PTEN	O	34-38
-	O	38-39
mutant	O	39-45
)	O	45-46
and	O	47-50
LN229	O	51-56
(	O	57-58
PTEN	O	58-62
wild	O	63-67
-	O	67-68
type	O	68-72
)	O	72-73
cells	O	74-79
were	O	80-84
treated	O	85-92
with	O	93-97
taxol	O	98-103
and	O	104-107
the	O	108-111
miR	O	112-115
-	O	115-116
21	O	116-118
inhibitor	O	119-128
(	O	129-130
in	O	130-132
a	O	133-134
poly	O	135-139
(	O	140-141
amidoamine	O	141-151
)	O	151-152
(	O	153-154
PAMAM	O	154-159
)	O	159-160
dendrimer	O	161-170
)	O	170-171
,	O	171-172
alone	O	173-178
or	O	179-181
in	O	182-184
combination	O	185-196
. 	O	196-198

So	O	0-2
far	O	3-6
,	O	6-7
the	O	8-11
effect	O	12-18
of	O	19-21
downregulating	O	22-36
miR	B	37-40
-	I	40-41
21	I	41-43
to	O	44-46
enhance	O	47-54
the	O	55-58
chemotherapeutic	O	59-75
effect	O	76-82
to	O	83-85
taxol	O	86-91
has	O	92-95
not	O	96-99
been	O	100-104
studied	O	105-112
in	O	113-115
human	O	116-121
GBM	O	122-125
. 	O	125-127

Thus	O	0-4
,	O	4-5
miR	B	6-9
-	I	9-10
21	I	10-12
can	O	13-16
theoretically	O	17-30
become	O	31-37
a	O	38-39
target	O	40-46
to	O	47-49
enhance	O	50-57
the	O	58-61
chemotherapeutic	O	62-78
effect	O	79-85
in	O	86-88
cancer	O	89-95
therapy	O	96-103
. 	O	103-105

MicroRNAs	O	0-9
:	O	9-10
biology	O	11-18
and	O	19-22
roles	O	23-28
in	O	29-31
neurodegeneration	O	32-49
and	O	50-53
brain	O	54-59
tumours	O	60-67
. 	O	67-69

Introduction	O	0-12
and	O	13-16
historical	O	17-27
background	O	28-38
.     	O	38-44

Ectopic	O	0-7
expression	O	8-18
of	O	19-21
miR	B	22-25
-	I	25-26
29b	I	26-29
decreased	O	30-39
hPGRN	O	40-45
expression	O	46-56
at	O	57-59
the	O	60-63
both	O	64-68
mRNA	O	69-73
and	O	74-77
protein	O	78-85
levels	O	86-92
. 	O	92-94

To	O	0-2
examine	O	3-10
the	O	11-14
direct	O	15-21
effect	O	22-28
of	O	29-31
manipulating	O	32-44
endogenous	O	45-55
miR	B	56-59
-	I	59-60
29b	I	60-63
on	O	64-66
hPGRN	O	67-72
expression	O	73-83
,	O	83-84
we	O	85-87
established	O	88-99
a	O	100-101
stable	O	102-108
NIH3T3	O	109-115
cell	O	116-120
line	O	121-125
that	O	126-130
expresses	O	131-140
hPGRN	O	141-146
under	O	147-152
the	O	153-156
control	O	157-164
of	O	165-167
the	O	168-171
cytomegalovirus	O	172-187
promoter	O	188-196
. 	O	196-198

Endogenous	O	0-10
hPGRN	O	11-16
in	O	17-19
HEK	O	20-23
293	O	24-27
cells	O	28-33
was	O	34-37
also	O	38-42
regulated	O	43-52
by	O	53-55
miR	B	56-59
-	I	59-60
29b	I	60-63
. 	O	63-65

Conversely	O	0-10
,	O	10-11
knockdown	O	12-21
of	O	22-24
endogenous	O	25-35
miR	B	36-39
-	I	39-40
29b	I	40-43
with	O	44-48
locked	O	49-55
nucleic	O	56-63
acid	O	64-68
increased	O	69-78
the	O	79-82
production	O	83-93
and	O	94-97
secretion	O	98-107
of	O	108-110
hPGRN	O	111-116
in	O	117-119
NIH3T3	O	120-126
cells	O	127-132
. 	O	132-134

How	O	0-3
progranulin	O	4-15
(	O	16-17
PGRN	O	17-21
)	O	21-22
expression	O	23-33
is	O	34-36
regulated	O	37-46
is	O	47-49
largely	O	50-57
unknown	O	58-65
. 	O	65-67

Progranulin	O	0-11
deficiency	O	12-22
is	O	23-25
thought	O	26-33
to	O	34-36
cause	O	37-42
some	O	43-47
forms	O	48-53
of	O	54-56
frontotemporal	O	57-71
dementia	O	72-80
(	O	81-82
FTD	O	82-85
)	O	85-86
,	O	86-87
a	O	88-89
major	O	90-95
early	O	96-101
-	O	101-102
onset	O	102-107
age	O	108-111
-	O	111-112
dependent	O	112-121
neurodegenerative	O	122-139
disease	O	140-147
. 	O	147-149

miR	B	0-3
-	I	3-4
29b	I	4-7
downregulates	O	8-21
the	O	22-25
expression	O	26-36
of	O	37-39
luciferase	O	40-50
through	O	51-58
hPGRN	O	59-64
or	O	65-67
mouse	O	68-73
PGRN	O	74-78
(	O	79-80
mPGRN	O	80-85
)	O	85-86
3	O	87-88
'	O	88-89
UTRs	O	89-93
,	O	93-94
and	O	95-98
the	O	99-102
regulation	O	103-113
was	O	114-117
abolished	O	118-127
by	O	128-130
mutations	O	131-140
in	O	141-143
the	O	144-147
miR	B	148-151
-	I	151-152
29b	I	152-155
binding	O	156-163
site	O	164-168
. 	O	168-170

We	O	0-2
identified	O	3-13
an	O	14-16
evolutionarily	O	17-31
conserved	O	32-41
binding	O	42-49
site	O	50-54
for	O	55-58
microRNA	B	59-67
-	I	67-68
29b	I	68-71
(	O	72-73
miR	B	73-76
-	I	76-77
29b	I	77-80
)	O	80-81
in	O	82-84
the	O	85-88
3	O	89-90
'	O	90-91
untranslated	O	92-104
region	O	105-111
(	O	112-113
3	O	113-114
'	O	114-115
UTR	O	115-118
)	O	118-119
of	O	120-122
the	O	123-126
human	O	127-132
PGRN	O	133-137
(	O	138-139
hPGRN	O	139-144
)	O	144-145
mRNA	O	146-150
. 	O	150-152

MicroRNA	B	0-8
-	I	8-9
29b	I	9-12
regulates	O	13-22
the	O	23-26
expression	O	27-37
level	O	38-43
of	O	44-46
human	O	47-52
progranulin	O	53-64
,	O	64-65
a	O	66-67
secreted	O	68-76
glycoprotein	O	77-89
implicated	O	90-100
in	O	101-103
frontotemporal	O	104-118
dementia	O	119-127
.  	O	127-130

These	O	0-5
findings	O	6-14
identify	O	15-23
miR	B	24-27
-	I	27-28
29b	I	28-31
as	O	32-34
a	O	35-36
novel	O	37-42
posttranscriptional	O	43-62
regulator	O	63-72
of	O	73-75
PGRN	O	76-80
expression	O	81-91
,	O	91-92
raising	O	93-100
the	O	101-104
possibility	O	105-116
that	O	117-121
miR	B	122-125
-	I	125-126
29b	I	126-129
or	O	130-132
other	O	133-138
miRNAs	O	139-145
might	O	146-151
be	O	152-154
targeted	O	155-163
therapeutically	O	164-179
to	O	180-182
increase	O	183-191
hPGRN	O	192-197
levels	O	198-204
in	O	205-207
some	O	208-212
FTD	O	213-216
patients	O	217-225
.   	O	225-229

These	O	0-5
novel	O	6-11
findings	O	12-20
suggest	O	21-28
that	O	29-33
miR	B	34-37
-	I	37-38
21	I	38-40
may	O	41-44
be	O	45-47
an	O	48-50
attractive	O	51-61
therapeutic	O	62-73
molecule	O	74-82
for	O	83-86
treatment	O	87-96
of	O	97-99
stroke	O	100-106
.   	O	106-110

MicroRNAs	O	0-9
are	O	10-13
small	O	14-19
RNAs	O	20-24
that	O	25-29
attenuate	O	30-39
protein	O	40-47
expression	O	48-58
by	O	59-61
complementary	O	62-75
binding	O	76-83
to	O	84-86
the	O	87-90
3	O	91-92
'	O	92-93
-	O	93-94
UTR	O	94-97
of	O	98-100
a	O	101-102
target	O	103-109
mRNA	O	110-114
. 	O	114-116

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
protects	O	12-20
neurons	O	21-28
from	O	29-33
ischemic	O	34-42
death	O	43-48
.  	O	48-51

In	O	0-2
particular	O	3-13
,	O	13-14
microRNA	B	15-23
-	I	23-24
21	I	24-26
(	O	27-28
miR	B	28-31
-	I	31-32
21	I	32-34
)	O	34-35
is	O	36-38
a	O	39-40
strong	O	41-47
antiapoptotic	O	48-61
factor	O	62-68
in	O	69-71
some	O	72-76
biological	O	77-87
systems	O	88-95
. 	O	95-97

Currently	O	0-9
,	O	9-10
very	O	11-15
little	O	16-22
is	O	23-25
known	O	26-31
about	O	32-37
microRNAs	O	38-47
after	O	48-53
cerebral	O	54-62
ischemia	O	63-71
. 	O	71-73

We	O	0-2
employed	O	3-11
in	O	12-14
situ	O	15-19
hybridization	O	20-33
and	O	34-37
laser	O	38-43
capture	O	44-51
microdissection	O	52-67
in	O	68-70
combination	O	71-82
with	O	83-87
real	O	88-92
-	O	92-93
time	O	93-97
RT	O	98-100
-	O	100-101
PCR	O	101-104
to	O	105-107
investigate	O	108-119
the	O	120-123
expression	O	124-134
of	O	135-137
miR	B	138-141
-	I	141-142
21	I	142-144
after	O	145-150
stroke	O	151-157
. 	O	157-159

We	O	0-2
investigated	O	3-15
the	O	16-19
role	O	20-24
of	O	25-27
miR	B	28-31
-	I	31-32
21	I	32-34
after	O	35-40
stroke	O	41-47
in	O	48-50
the	O	51-54
rat	O	55-58
. 	O	58-60

In	O	0-2
vitro	O	3-8
,	O	8-9
overexpression	O	10-24
of	O	25-27
miR	B	28-31
-	I	31-32
21	I	32-34
in	O	35-37
cultured	O	38-46
cortical	O	47-55
neurons	O	56-63
substantially	O	64-77
suppressed	O	78-88
oxygen	O	89-95
and	O	96-99
glucose	O	100-107
deprivation	O	108-119
-	O	119-120
induced	O	120-127
apoptotic	O	128-137
cell	O	138-142
death	O	143-148
,	O	148-149
whereas	O	150-157
attenuation	O	158-169
of	O	170-172
endogenous	O	173-183
miR	B	184-187
-	I	187-188
21	I	188-190
by	O	191-193
antisense	O	194-203
inhibition	O	204-214
exacerbated	O	215-226
cell	O	227-231
death	O	232-237
after	O	238-243
oxygen	O	244-250
and	O	251-254
glucose	O	255-262
deprivation	O	263-274
. 	O	274-276

In	O	0-2
situ	O	3-7
hybridization	O	8-21
revealed	O	22-30
that	O	31-35
miR	B	36-39
-	I	39-40
21	I	40-42
expression	O	43-53
was	O	54-57
upregulated	O	58-69
in	O	70-72
neurons	O	73-80
of	O	81-83
the	O	84-87
ischemic	O	88-96
boundary	O	97-105
zone	O	106-110
,	O	110-111
and	O	112-115
quantitative	O	116-128
real	O	129-133
-	O	133-134
time	O	134-138
RT	O	139-141
-	O	141-142
PCR	O	142-145
analysis	O	146-154
revealed	O	155-163
that	O	164-168
stroke	O	169-175
increased	O	176-185
mature	O	186-192
miR	B	193-196
-	I	196-197
21	I	197-199
levels	O	200-206
by	O	207-209
approximately	O	210-223
threefold	O	224-233
in	O	234-236
neurons	O	237-244
isolated	O	245-253
from	O	254-258
the	O	259-262
ischemic	O	263-271
boundary	O	272-280
zone	O	281-285
by	O	286-288
laser	O	289-294
capture	O	295-302
microdissection	O	303-318
as	O	319-321
compared	O	322-330
with	O	331-335
homologous	O	336-346
contralateral	O	347-360
neurons	O	361-368
2	O	369-370
days	O	371-375
(	O	376-377
n	O	377-378
=	O	379-380
4	O	381-382
;	O	382-383
P	O	384-385
<	O	386-387
0	O	388-389
.	O	389-390
05	O	390-392
)	O	392-393
and	O	394-397
7	O	398-399
days	O	400-404
(	O	405-406
n	O	406-407
=	O	408-409
3	O	410-411
;	O	411-412
P	O	413-414
<	O	415-416
0	O	417-418
.	O	418-419
05	O	419-421
)	O	421-422
after	O	423-428
stroke	O	429-435
. 	O	435-437

Our	O	0-3
data	O	4-8
indicate	O	9-17
that	O	18-22
overexpression	O	23-37
of	O	38-40
miR	B	41-44
-	I	44-45
21	I	45-47
protects	O	48-56
against	O	57-64
ischemic	O	65-73
neuronal	O	74-82
death	O	83-88
,	O	88-89
and	O	90-93
that	O	94-98
downregulation	O	99-113
of	O	114-116
FASLG	O	117-122
,	O	122-123
a	O	124-125
tumor	O	126-131
necrosis	O	132-140
factor	O	141-147
-	O	147-148
α	O	148-150
family	O	151-157
member	O	158-164
and	O	165-168
an	O	169-171
important	O	172-181
cell	O	182-186
death	O	187-192
-	O	192-193
inducing	O	193-201
ligand	O	202-208
whose	O	209-214
gene	O	215-219
is	O	220-222
targeted	O	223-231
by	O	232-234
miR	I	235-238
-	I	238-239
21	I	239-241
,	O	241-242
probably	O	243-251
mediates	O	252-260
the	O	261-264
neuroprotective	O	265-280
effect	O	281-287
. 	O	287-289

Moreover	O	0-8
,	O	8-9
overexpression	O	10-24
of	O	25-27
miR	B	28-31
-	I	31-32
21	I	32-34
in	O	35-37
neurons	O	38-45
significantly	O	46-59
reduced	O	60-67
FASLG	O	68-73
levels	O	74-80
,	O	80-81
and	O	82-85
introduction	O	86-98
of	O	99-101
an	O	102-104
miR	B	105-108
-	I	108-109
21	I	109-111
mimic	O	112-117
into	O	118-122
293	O	123-126
-	O	126-127
HEK	O	127-130
cells	O	131-136
substantially	O	137-150
reduced	O	151-158
luciferase	O	159-169
activity	O	170-178
in	O	179-181
a	O	182-183
reporter	O	184-192
system	O	193-199
containing	O	200-210
the	O	211-214
3	O	215-216
'	O	216-217
-	O	217-218
UTR	O	218-221
of	O	222-224
Faslg	O	225-230
. 	O	230-232

[	O	0-1
Genetic	O	1-8
and	O	9-12
molecular	O	13-22
abnormalities	O	23-36
of	O	37-39
glioblastomas	O	40-53
(	O	54-55
GBM	O	55-58
)	O	58-59
]	O	59-60
.  	O	60-63

This	O	0-4
presentation	O	5-17
reports	O	18-25
a	O	26-27
series	O	28-34
of	O	35-37
data	O	38-42
dealing	O	43-50
with	O	51-55
recurrent	O	56-65
genetic	O	66-73
abnormalities	O	74-87
and	O	88-91
gene	O	92-96
expression	O	97-107
profiles	O	108-116
that	O	117-121
characterize	O	122-134
primary	O	135-142
glioblastomas	O	143-156
and	O	157-160
secondary	O	161-170
glioblastomas	O	171-184
resulting	O	185-194
from	O	195-199
the	O	200-203
transformation	O	204-218
of	O	219-221
low	O	222-225
grade	O	226-231
tumors	O	232-238
(	O	239-240
grade	O	240-245
II	O	246-248
and	O	249-252
III	O	253-256
astrocytomas	O	257-269
and	O	270-273
oligodendrogliomas	O	274-292
)	O	292-293
. 	O	293-295

Finally	O	0-7
,	O	7-8
a	O	9-10
short	O	11-16
description	O	17-28
of	O	29-31
exosomes	O	32-40
as	O	41-43
vectors	O	44-51
of	O	52-54
tumor	O	55-60
information	O	61-72
will	O	73-77
be	O	78-80
presented	O	81-90
.   	O	90-94

The	O	0-3
most	O	4-8
recent	O	9-15
aspects	O	16-23
of	O	24-26
the	O	27-30
concept	O	31-38
of	O	39-41
tumor	O	42-47
stem	O	48-52
cells	O	53-58
that	O	59-63
may	O	64-67
explain	O	68-75
the	O	76-79
relentless	O	80-90
growth	O	91-97
of	O	98-100
GBM	O	101-104
will	O	105-109
be	O	110-112
reported	O	113-121
. 	O	121-123

Molecular	O	0-9
features	O	10-18
of	O	19-21
tumor	O	22-27
neoangiogenesis	O	28-43
will	O	44-48
be	O	49-51
described	O	52-61
. 	O	61-63

Epigenetic	O	0-10
alterations	O	11-22
and	O	23-26
deregulation	O	27-39
of	O	40-42
gene	O	43-47
expression	O	48-58
by	O	59-61
microRNAs	O	62-71
(	O	72-73
miRs	O	73-77
)	O	77-78
will	O	79-83
be	O	84-86
also	O	87-91
included	O	92-100
. 	O	100-102

Some	O	0-4
aspects	O	5-12
of	O	13-15
tumor	O	16-21
predisposition	O	22-36
will	O	37-41
be	O	42-44
also	O	45-49
discussed	O	50-59
. 	O	59-61

This	O	0-4
mechanism	O	5-14
may	O	15-18
have	O	19-23
broad	O	24-29
implications	O	30-42
for	O	43-46
microRNA	O	47-55
-	O	55-56
regulated	O	56-65
macrophage	O	66-76
activation	O	77-87
in	O	88-90
inflammatory	O	91-103
diseases	O	104-112
.   	O	112-116

Our	O	0-3
findings	O	4-12
suggest	O	13-20
that	O	21-25
microRNA	O	26-34
dysregulated	O	35-47
in	O	48-50
multiple	O	51-59
sclerosis	O	60-69
lesions	O	70-77
reduce	O	78-84
CD47	O	85-89
in	O	90-92
brain	O	93-98
resident	O	99-107
cells	O	108-113
,	O	113-114
releasing	O	115-124
macrophages	O	125-136
from	O	137-141
inhibitory	O	142-152
control	O	153-160
,	O	160-161
thereby	O	162-169
promoting	O	170-179
phagocytosis	O	180-192
of	O	193-195
myelin	O	196-202
. 	O	202-204

Three	O	0-5
microRNA	O	6-14
upregulated	O	15-26
in	O	27-29
active	O	30-36
multiple	O	37-45
sclerosis	O	46-55
lesions	O	56-63
(	O	64-65
microRNA	B	65-73
-	I	73-74
34a	I	74-77
,	O	77-78
microRNA	B	79-87
-	I	87-88
155	I	88-91
and	O	92-95
microRNA	B	96-104
-	I	104-105
326	I	105-108
)	O	108-109
targeted	O	110-118
the	O	119-122
3	O	123-124
'	O	124-125
-	O	125-126
untranslated	O	126-138
region	O	139-145
of	O	146-148
CD47	O	149-153
in	O	154-156
reporter	O	157-165
assays	O	166-172
,	O	172-173
with	O	174-178
microRNA	B	179-187
-	I	187-188
155	I	188-191
even	O	192-196
at	O	197-199
two	O	200-203
distinct	O	204-212
sites	O	213-218
. 	O	218-220

This	O	0-4
converged	O	5-14
on	O	15-17
CD47	O	18-22
,	O	22-23
which	O	24-29
functions	O	30-39
as	O	40-42
a	O	43-44
'	O	45-46
don	O	46-49
'	O	49-50
t	O	50-51
eat	O	52-55
me	O	56-58
'	O	58-59
signal	O	60-66
inhibiting	O	67-77
macrophage	O	78-88
activity	O	89-97
. 	O	97-99

We	O	0-2
established	O	3-14
microRNA	O	15-23
profiles	O	24-32
from	O	33-37
active	O	38-44
and	O	45-48
inactive	O	49-57
multiple	O	58-66
sclerosis	O	67-76
lesions	O	77-84
. 	O	84-86

Using	O	0-5
laser	O	6-11
capture	O	12-19
microdissection	O	20-35
from	O	36-40
multiple	O	41-49
sclerosis	O	50-59
lesions	O	60-67
to	O	68-70
pool	O	71-75
single	O	76-82
cells	O	83-88
and	O	89-92
in	O	93-95
vitro	O	96-101
cultures	O	102-110
,	O	110-111
we	O	112-114
assigned	O	115-123
differentially	O	124-138
expressed	O	139-148
microRNA	O	149-157
to	O	158-160
specific	O	161-169
cell	O	170-174
types	O	175-180
. 	O	180-182

MicroRNA	O	0-8
profiling	O	9-18
of	O	19-21
multiple	O	22-30
sclerosis	O	31-40
lesions	O	41-48
identifies	O	49-59
modulators	O	60-70
of	O	71-73
the	O	74-77
regulatory	O	78-88
protein	O	89-96
CD47	O	97-101
.  	O	101-104

This	O	0-4
was	O	5-8
confirmed	O	9-18
with	O	19-23
astrocyte	O	24-33
cultures	O	34-42
from	O	43-47
microRNA	B	48-56
-	I	56-57
155	I	57-60
-	O	60-61
|	O	61-62
-	O	62-63
lacZ	O	63-67
mice	O	68-72
. 	O	72-74

We	O	0-2
matched	O	3-10
microRNA	O	11-19
upregulated	O	20-31
in	O	32-34
phagocytically	O	35-49
active	O	50-56
multiple	O	57-65
sclerosis	O	66-75
lesions	O	76-83
with	O	84-88
downregulated	O	89-102
protein	O	103-110
coding	O	111-117
transcripts	O	118-129
. 	O	129-131

Astrocytes	O	0-10
contained	O	11-20
all	O	21-24
10	O	25-27
microRNA	O	28-36
that	O	37-41
were	O	42-46
most	O	47-51
strongly	O	52-60
upregulated	O	61-72
in	O	73-75
active	O	76-82
multiple	O	83-91
sclerosis	O	92-101
lesions	O	102-109
,	O	109-110
including	O	111-120
microRNA	B	121-129
-	I	129-130
155	I	130-133
,	O	133-134
which	O	135-140
is	O	141-143
known	O	144-149
to	O	150-152
modulate	O	153-161
immune	O	162-168
responses	O	169-178
in	O	179-181
different	O	182-191
ways	O	192-196
but	O	197-200
so	O	201-203
far	O	204-207
had	O	208-211
not	O	212-215
been	O	216-220
assigned	O	221-229
to	O	230-232
central	O	233-240
nervous	O	241-248
system	O	249-255
resident	O	256-264
cells	O	265-270
. 	O	270-272

MicroRNA	B	0-8
-	I	8-9
155	I	9-12
was	O	13-16
expressed	O	17-26
in	O	27-29
human	O	30-35
astrocytes	O	36-46
in	O	47-49
situ	O	50-54
,	O	54-55
and	O	56-59
further	O	60-67
induced	O	68-75
with	O	76-80
cytokines	O	81-90
in	O	91-93
human	O	94-99
astrocytes	O	100-110
in	O	111-113
vitro	O	114-119
. 	O	119-121

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
predominantly	O	19-32
induce	O	33-39
translational	O	40-53
repression	O	54-64
and	O	65-68
are	O	69-72
emerging	O	73-81
as	O	82-84
a	O	85-86
major	O	87-92
regulators	O	93-103
of	O	104-106
mRNA	O	107-111
and	O	112-115
subsequent	O	116-126
protein	O	127-134
expression	O	135-145
after	O	146-151
ischemia	O	152-160
. 	O	160-162

The	O	0-3
miRNA	O	4-9
miR	B	10-13
-	I	13-14
23a	I	14-17
was	O	18-21
predicted	O	22-31
to	O	32-34
bind	O	35-39
XIAP	O	40-44
mRNA	O	45-49
. 	O	49-51

miR	B	0-3
-	I	3-4
23a	I	4-7
directly	O	8-16
bound	O	17-22
the	O	23-26
3	O	27-28
'	O	28-29
UTR	O	30-33
of	O	34-36
XIAP	O	37-41
,	O	41-42
and	O	43-46
miR	B	47-50
-	I	50-51
23a	I	51-54
inhibition	O	55-65
led	O	66-69
to	O	70-72
an	O	73-75
increase	O	76-84
in	O	85-87
XIAP	O	88-92
mRNA	O	93-97
in	O	98-100
vitro	O	101-106
,	O	106-107
demonstrating	O	108-121
that	O	122-126
XIAP	O	127-131
is	O	132-134
a	O	135-136
previously	O	137-147
uncharacterized	O	148-163
target	O	164-170
for	O	171-174
miR	B	175-178
-	I	178-179
23a	I	179-182
. 	O	182-184

Embelin	O	0-7
treatment	O	8-17
significantly	O	18-31
exacerbated	O	32-43
stroke	O	44-50
-	O	50-51
induced	O	51-58
injury	O	59-65
in	O	66-68
females	O	69-76
but	O	77-80
had	O	81-84
no	O	85-87
effect	O	88-94
in	O	95-97
males	O	98-103
,	O	103-104
demonstrating	O	105-118
that	O	119-123
XIAP	O	124-128
is	O	129-131
an	O	132-134
important	O	135-144
mediator	O	145-153
of	O	154-156
sex	O	157-160
-	O	160-161
specific	O	161-169
responses	O	170-179
after	O	180-185
stroke	O	186-192
.   	O	192-196

miR	B	0-3
-	I	3-4
23a	I	4-7
levels	O	8-14
differed	O	15-23
in	O	24-26
male	O	27-31
and	O	32-35
female	O	36-42
ischemic	O	43-51
brains	O	52-58
,	O	58-59
providing	O	60-69
evidence	O	70-78
for	O	79-82
sex	O	83-86
-	O	86-87
specific	O	87-95
miRNA	O	96-101
expression	O	102-112
in	O	113-115
stroke	O	116-122
. 	O	122-124

Embelin	O	0-7
,	O	7-8
a	O	9-10
small	O	11-16
-	O	16-17
molecule	O	17-25
inhibitor	O	26-35
of	O	36-38
XIAP	O	39-43
,	O	43-44
decreased	O	45-54
the	O	55-58
interaction	O	59-70
between	O	71-78
XIAP	O	79-83
and	O	84-87
caspase	O	88-95
-	O	95-96
3	O	96-97
and	O	98-101
led	O	102-105
to	O	106-108
enhanced	O	109-117
caspase	O	118-125
activity	O	126-134
. 	O	134-136

It	O	0-2
is	O	3-5
increasingly	O	6-18
recognized	O	19-29
that	O	30-34
the	O	35-38
mechanisms	O	39-49
underlying	O	50-60
ischemic	O	61-69
cell	O	70-74
death	O	75-80
are	O	81-84
sexually	O	85-93
dimorphic	O	94-103
. 	O	103-105

miR	B	0-3
-	I	3-4
23a	I	4-7
regulation	O	8-18
of	O	19-21
X	O	22-23
-	O	23-24
linked	O	24-30
inhibitor	O	31-40
of	O	41-43
apoptosis	O	44-53
(	O	54-55
XIAP	O	55-59
)	O	59-60
contributes	O	61-72
to	O	73-75
sex	O	76-79
differences	O	80-91
in	O	92-94
the	O	95-98
response	O	99-107
to	O	108-110
cerebral	O	111-119
ischemia	O	120-128
.  	O	128-131

In	O	0-2
contrast	O	3-11
,	O	11-12
ischemic	O	13-21
cell	O	22-26
death	O	27-32
in	O	33-35
females	O	36-43
is	O	44-46
primarily	O	47-56
triggered	O	57-66
by	O	67-69
mitochondrial	O	70-83
cytochrome	O	84-94
c	O	95-96
release	O	97-104
with	O	105-109
subsequent	O	110-120
caspase	O	121-128
activation	O	129-139
. 	O	139-141

Stroke	O	0-6
-	O	6-7
induced	O	7-14
cell	O	15-19
death	O	20-25
in	O	26-28
males	O	29-34
is	O	35-37
initiated	O	38-47
by	O	48-50
the	O	51-54
mitochondrial	O	55-68
release	O	69-76
of	O	77-79
apoptosis	O	80-89
-	O	89-90
inducing	O	90-98
factor	O	99-105
,	O	105-106
resulting	O	107-116
in	O	117-119
caspase	O	120-127
-	O	127-128
independent	O	128-139
cell	O	140-144
death	O	145-150
. 	O	150-152

XIAP	O	0-4
mRNA	O	5-9
levels	O	10-16
were	O	17-21
higher	O	22-28
in	O	29-31
females	O	32-39
at	O	40-42
baseline	O	43-51
. 	O	51-53

Because	O	0-7
X	O	8-9
-	O	9-10
linked	O	10-16
inhibitor	O	17-26
of	O	27-29
apoptosis	O	30-39
(	O	40-41
XIAP	O	41-45
)	O	45-46
is	O	47-49
the	O	50-53
primary	O	54-61
endogenous	O	62-72
inhibitor	O	73-82
of	O	83-85
caspases	O	86-94
,	O	94-95
its	O	96-99
regulation	O	100-110
may	O	111-114
play	O	115-119
a	O	120-121
unique	O	122-128
role	O	129-133
in	O	134-136
the	O	137-140
response	O	141-149
to	O	150-152
injury	O	153-159
in	O	160-162
females	O	163-170
. 	O	170-172

However	O	0-7
,	O	7-8
XIAP	O	9-13
protein	O	14-21
levels	O	22-28
were	O	29-33
decreased	O	34-43
in	O	44-46
both	O	47-51
sexes	O	52-57
after	O	58-63
stroke	O	64-70
. 	O	70-72

Stroke	O	0-6
induced	O	7-14
a	O	15-16
significant	O	17-28
decrease	O	29-37
in	O	38-40
XIAP	O	41-45
mRNA	O	46-50
in	O	51-53
females	O	54-61
,	O	61-62
whereas	O	63-70
no	O	71-73
changes	O	74-81
were	O	82-86
seen	O	87-91
in	O	92-94
the	O	95-98
male	O	99-103
brain	O	104-109
. 	O	109-111

We	O	0-2
also	O	3-7
demonstrate	O	8-19
that	O	20-24
the	O	25-28
single	O	29-35
-	O	35-36
nucleotide	O	36-46
polymorphism	O	47-59
(	O	60-61
SNP	O	61-64
)	O	64-65
that	O	66-70
is	O	71-73
located	O	74-81
immediately	O	82-93
adjacent	O	94-102
(	O	103-104
3	O	104-105
'	O	105-106
)	O	106-107
to	O	108-110
the	O	111-114
repeats	O	115-122
of	O	123-125
the	O	126-129
SCA3	O	130-134
transcript	O	135-145
modulates	O	146-155
the	O	156-159
structures	O	160-170
formed	O	171-177
by	O	178-180
these	O	181-186
sequences	O	187-196
,	O	196-197
and	O	198-201
may	O	202-205
have	O	206-210
functional	O	211-221
significance	O	222-234
,	O	234-235
as	O	236-238
only	O	239-243
one	O	244-247
of	O	248-250
its	O	251-254
variants	O	255-263
is	O	264-266
selected	O	267-275
in	O	276-278
human	O	279-284
evolution	O	285-294
.     	O	294-300

We	O	0-2
provide	O	3-10
evidence	O	11-19
that	O	20-24
the	O	25-28
hairpin	O	29-36
structure	O	37-46
formed	O	47-53
by	O	54-56
CAG	O	57-60
repeats	O	61-68
in	O	69-71
mRNA	O	72-76
fragments	O	77-86
is	O	87-89
preserved	O	90-99
in	O	100-102
full	O	103-107
-	O	107-108
length	O	108-114
mRNA	O	115-119
. 	O	119-121

Here	O	0-4
,	O	4-5
we	O	6-8
show	O	9-13
that	O	14-18
the	O	19-22
structures	O	23-33
formed	O	34-40
by	O	41-43
the	O	44-47
repeats	O	48-55
and	O	56-59
their	O	60-65
natural	O	66-73
flanking	O	74-82
sequences	O	83-92
in	O	93-95
the	O	96-99
spinocerebellar	O	100-115
ataxia	O	116-122
(	O	123-124
SCA	O	124-127
)	O	127-128
type	O	129-133
3	O	134-135
and	O	136-139
type	O	140-144
6	O	145-146
,	O	146-147
and	O	148-151
dentatorubral	O	152-165
-	O	165-166
palidoluysian	O	166-179
atrophy	O	180-187
(	O	188-189
DRPLA	O	189-194
)	O	194-195
transcripts	O	196-207
have	O	208-212
different	O	213-222
molecular	O	223-232
architectures	O	233-246
which	O	247-252
may	O	253-256
have	O	257-261
functional	O	262-272
meaning	O	273-280
. 	O	280-282

The	O	0-3
expanded	O	4-12
CAG	O	13-16
repeats	O	17-24
are	O	25-28
present	O	29-36
in	O	37-39
transcripts	O	40-51
from	O	52-56
several	O	57-64
mutant	O	65-71
genes	O	72-77
associated	O	78-88
with	O	89-93
hereditary	O	94-104
neurodegenerative	O	105-122
diseases	O	123-131
but	O	132-135
their	O	136-141
contribution	O	142-154
to	O	155-157
pathogenesis	O	158-170
has	O	171-174
not	O	175-178
been	O	179-183
documented	O	184-194
convincingly	O	195-207
. 	O	207-209

CAG	O	0-3
repeats	O	4-11
are	O	12-15
present	O	16-23
in	O	24-26
numerous	O	27-35
human	O	36-41
transcripts	O	42-53
but	O	54-57
neither	O	58-65
their	O	66-71
structures	O	72-82
nor	O	83-86
physiological	O	87-100
functions	O	101-110
have	O	111-115
been	O	116-120
satisfactorily	O	121-135
recognized	O	136-146
. 	O	146-148

Molecular	O	0-9
architecture	O	10-22
of	O	23-25
CAG	O	26-29
repeats	O	30-37
in	O	38-40
human	O	41-46
disease	O	47-54
related	O	55-62
transcripts	O	63-74
.   	O	74-78

The	O	0-3
rapid	O	4-9
and	O	10-13
exciting	O	14-22
pace	O	23-27
of	O	28-30
advances	O	31-39
in	O	40-42
glioblastoma	O	43-55
genetics	O	56-64
has	O	65-68
prompted	O	69-77
this	O	78-82
up	O	83-85
-	O	85-86
to	O	86-88
-	O	88-89
date	O	89-93
review	O	94-100
.   	O	100-104

The	O	0-3
likely	O	4-10
impact	O	11-17
on	O	18-20
care	O	21-25
delivery	O	26-34
in	O	35-37
the	O	38-41
clinic	O	42-48
may	O	49-52
only	O	53-57
be	O	58-60
a	O	61-62
few	O	63-66
years	O	67-72
away	O	73-77
. 	O	77-79

Within	O	0-6
the	O	7-10
last	O	11-15
few	O	16-19
years	O	20-25
,	O	25-26
high	O	27-31
-	O	31-32
throughput	O	32-42
efforts	O	43-50
such	O	51-55
as	O	56-58
The	O	59-62
Cancer	O	63-69
Genome	O	70-76
Atlas	O	77-82
and	O	83-86
a	O	87-88
massive	O	89-96
sequencing	O	97-107
project	O	108-115
have	O	116-120
yielded	O	121-128
novel	O	129-134
insights	O	135-143
and	O	144-147
classifications	O	148-163
of	O	164-166
this	O	167-171
dreaded	O	172-179
cancer	O	180-186
. 	O	186-188

It	O	0-2
has	O	3-6
been	O	7-11
hoped	O	12-17
that	O	18-22
dissection	O	23-33
of	O	34-36
the	O	37-40
genetics	O	41-49
of	O	50-52
this	O	53-57
cancer	O	58-64
would	O	65-70
lead	O	71-75
to	O	76-78
more	O	79-83
targeted	O	84-92
and	O	93-96
effective	O	97-106
treatments	O	107-117
,	O	117-118
and	O	119-122
new	O	123-126
advances	O	127-135
may	O	136-139
finally	O	140-147
be	O	148-150
bringing	O	151-159
this	O	160-164
closer	O	165-171
to	O	172-174
fruition	O	175-183
. 	O	183-185

Glioblastoma	O	0-12
genetics	O	13-21
:	O	21-22
in	O	23-25
rapid	O	26-31
flux	O	32-36
.  	O	36-39

Glioblastoma	O	0-12
is	O	13-15
the	O	16-19
most	O	20-24
common	O	25-31
and	O	32-35
most	O	36-40
lethal	O	41-47
primary	O	48-55
brain	O	56-61
tumor	O	62-67
. 	O	67-69

While	O	0-5
small	O	6-11
progress	O	12-20
has	O	21-24
been	O	25-29
made	O	30-34
in	O	35-37
treating	O	38-46
this	O	47-51
cancer	O	52-58
in	O	59-61
recent	O	62-68
years	O	69-74
,	O	74-75
glioblastoma	O	76-88
remains	O	89-96
largely	O	97-104
resistant	O	105-114
to	O	115-117
all	O	118-121
existing	O	122-130
therapies	O	131-140
. 	O	140-142

Biomarkers	O	0-10
associated	O	11-21
with	O	22-26
metastasis	O	27-37
of	O	38-40
lung	O	41-45
cancer	O	46-52
to	O	53-55
brain	O	56-61
predict	O	62-69
patient	O	70-77
survival	O	78-86
.  	O	86-89

This	O	0-4
research	O	5-13
involves	O	14-22
comprehensive	O	23-36
miRNA	O	37-42
expression	O	43-53
profiling	O	54-63
,	O	63-64
evaluation	O	65-75
of	O	76-78
normalisation	O	79-92
techniques	O	93-103
and	O	104-107
combination	O	108-119
of	O	120-122
miRNA	O	123-128
with	O	129-133
imaging	O	134-141
features	O	142-150
FDG	O	151-154
-	O	154-155
PET	O	155-158
/	O	158-159
CT	O	159-161
and	O	162-165
CT	O	166-168
Scan	O	169-173
. 	O	173-175

We	O	0-2
combine	O	3-10
validated	O	11-20
miRNA	O	21-26
expression	O	27-37
values	O	38-44
with	O	45-49
imaging	O	50-57
features	O	58-66
to	O	67-69
classify	O	70-78
NSCLC	O	79-84
brain	O	85-90
mets	O	91-95
from	O	96-100
non	O	101-104
-	O	104-105
brain	O	105-110
mets	O	111-115
and	O	116-119
identify	O	120-128
possible	O	129-137
biomarkers	O	138-148
of	O	149-151
brain	O	152-157
mets	O	158-162
. 	O	162-164

Generally	O	0-9
,	O	9-10
one	O	11-14
miRNA	O	15-20
is	O	21-23
predicted	O	24-33
to	O	34-36
regulate	O	37-45
several	O	46-53
hundred	O	54-61
genes	O	62-67
,	O	67-68
and	O	69-72
as	O	73-75
a	O	76-77
result	O	78-84
,	O	84-85
miRNAs	O	86-92
could	O	93-98
serve	O	99-104
as	O	105-107
a	O	108-109
better	O	110-116
classifier	O	117-127
than	O	128-132
gene	O	133-137
expression	O	138-148
. 	O	148-150

MicroRNAs	O	0-9
influence	O	10-19
cell	O	20-24
physiology	O	25-35
;	O	35-36
alteration	O	37-47
in	O	48-50
miRNA	O	51-56
regulation	O	57-67
can	O	68-71
be	O	72-74
implicated	O	75-85
in	O	86-88
carcinogenesis	O	89-103
and	O	104-107
disease	O	108-115
progression	O	116-127
. 	O	127-129

The	O	0-3
biomarkers	O	4-14
were	O	15-19
validated	O	20-29
on	O	30-32
an	O	33-35
independent	O	36-47
data	O	48-52
set	O	53-56
to	O	57-59
predict	O	60-67
potential	O	68-77
brain	O	78-83
mets	O	84-88
.   	O	88-92

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNAs	O	39-43
comprising	O	44-54
21	O	55-57
-	O	57-58
23	O	58-60
nucleotides	O	61-72
that	O	73-77
regulate	O	78-86
gene	O	87-91
expression	O	92-102
by	O	103-105
transcriptionally	O	106-123
repressing	O	124-134
their	O	135-140
complementary	O	141-154
mRNAs	O	155-160
. 	O	160-162

Let	B	0-3
-	I	3-4
7	I	4-5
microRNA	O	6-14
inhibits	O	15-23
the	O	24-27
proliferation	O	28-41
of	O	42-44
human	O	45-50
glioblastoma	O	51-63
cells	O	64-69
.  	O	69-72

Transfection	O	0-12
of	O	13-15
let	B	16-19
-	I	19-20
7	I	20-21
miRNA	O	22-27
reduced	O	28-35
expression	O	36-46
of	O	47-49
pan	O	50-53
-	O	53-54
RAS	O	54-57
,	O	57-58
N	O	59-60
-	O	60-61
RAS	O	61-64
,	O	64-65
and	O	66-69
K	O	70-71
-	O	71-72
RAS	O	72-75
in	O	76-78
the	O	79-82
glioblastoma	O	83-95
cells	O	96-101
. 	O	101-103

Human	O	0-5
glioblastoma	O	6-18
cells	O	19-24
(	O	25-26
U251	O	26-30
or	O	31-33
U87	O	34-37
cells	O	38-43
)	O	43-44
were	O	45-49
transfected	O	50-61
with	O	62-66
let	B	67-70
-	I	70-71
7	I	71-72
miRNA	O	73-78
and	O	79-82
assayed	O	83-90
for	O	91-94
in	O	95-97
-	O	97-98
vitro	O	98-103
proliferation	O	104-117
,	O	117-118
migration	O	119-128
,	O	128-129
and	O	130-133
in	O	134-136
-	O	136-137
vivo	O	137-141
tumor	O	142-147
formation	O	148-157
. 	O	157-159

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
investigated	O	18-30
the	O	31-34
anti	O	35-39
-	O	39-40
tumorigenic	O	40-51
effect	O	52-58
of	O	59-61
let	B	62-65
-	I	65-66
7	I	66-67
miRNA	O	68-73
in	O	74-76
glioblastoma	O	77-89
cells	O	90-95
. 	O	95-97

In	O	0-2
particular	O	3-13
,	O	13-14
let	B	15-18
-	I	18-19
7	I	19-20
miRNA	O	21-26
has	O	27-30
been	O	31-35
postulated	O	36-46
to	O	47-49
function	O	50-58
as	O	59-61
a	O	62-63
tumor	O	64-69
suppressor	O	70-80
in	O	81-83
various	O	84-91
cancer	O	92-98
cells	O	99-104
,	O	104-105
but	O	106-109
not	O	110-113
yet	O	114-117
in	O	118-120
glioblastoma	O	121-133
. 	O	133-135

These	O	0-5
results	O	6-13
indicate	O	14-22
that	O	23-27
let	B	28-31
-	I	31-32
7	I	32-33
miRNA	O	34-39
has	O	40-43
an	O	44-46
anti	O	47-51
-	O	51-52
tumorigenic	O	52-63
effect	O	64-70
on	O	71-73
glioblastoma	O	74-86
cells	O	87-92
,	O	92-93
and	O	94-97
suggest	O	98-105
possible	O	106-114
use	O	115-118
of	O	119-121
let	B	122-125
-	I	125-126
7	I	126-127
miRNA	O	128-133
for	O	134-137
treating	O	138-146
glioblastoma	O	147-159
.   	O	159-163

However	O	0-7
,	O	7-8
let	B	9-12
-	I	12-13
7	I	13-14
miRNA	O	15-20
exerted	O	21-28
no	O	29-31
effect	O	32-38
on	O	39-41
the	O	42-45
proliferation	O	46-59
of	O	60-62
normal	O	63-69
human	O	70-75
astrocytes	O	76-86
. 	O	86-88

Let	B	0-3
-	I	3-4
7	I	4-5
miRNA	O	6-11
also	O	12-16
reduced	O	17-24
the	O	25-28
in	O	29-31
-	O	31-32
vitro	O	32-37
proliferation	O	38-51
and	O	52-55
migration	O	56-65
of	O	66-68
the	O	69-72
cells	O	73-78
,	O	78-79
and	O	80-83
reduced	O	84-91
the	O	92-95
sizes	O	96-101
of	O	102-104
the	O	105-108
tumors	O	109-115
produced	O	116-124
after	O	125-130
transplantation	O	131-146
into	O	147-151
nude	O	152-156
mice	O	157-161
. 	O	161-163

Proteasomal	O	0-11
degradation	O	12-23
of	O	24-26
myocardin	O	27-36
is	O	37-39
required	O	40-48
for	O	49-52
its	O	53-56
transcriptional	O	57-72
activity	O	73-81
in	O	82-84
vascular	O	85-93
smooth	O	94-100
muscle	O	101-107
cells	O	108-113
.  	O	113-116

Myocardin	O	0-9
is	O	10-12
a	O	13-14
transcriptional	O	15-30
co	O	31-33
-	O	33-34
activator	O	34-43
of	O	44-46
serum	O	47-52
response	O	53-61
factor	O	62-68
(	O	69-70
SRF	O	70-73
)	O	73-74
and	O	75-78
can	O	79-82
be	O	83-85
degraded	O	86-94
through	O	95-102
ubiquitin	O	103-112
-	O	112-113
proteasome	O	113-123
system	O	124-130
. 	O	130-132

Our	O	0-3
preliminary	O	4-15
studies	O	16-23
unexpectedly	O	24-36
revealed	O	37-45
that	O	46-50
accumulation	O	51-63
of	O	64-66
myocardin	O	67-76
in	O	77-79
response	O	80-88
to	O	89-91
proteasome	O	92-102
inhibition	O	103-113
by	O	114-116
MG132	O	117-122
or	O	123-125
lactacystin	O	126-137
resulted	O	138-146
in	O	147-149
decrease	O	150-158
of	O	159-161
transcriptional	O	162-177
activity	O	178-186
of	O	187-189
myocardin	O	190-199
as	O	200-202
indicated	O	203-212
by	O	213-215
reduced	O	216-223
expression	O	224-234
of	O	235-237
SMC	O	238-241
contractile	O	242-253
marker	O	254-260
genes	O	261-266
(	O	267-268
SM	O	268-270
α	O	271-273
-	O	273-274
actin	O	274-279
,	O	279-280
SM22	O	281-285
,	O	285-286
and	O	287-290
calponin	O	291-299
)	O	299-300
and	O	301-304
muscle	O	305-311
-	O	311-312
enriched	O	312-320
microRNAs	O	321-330
(	B	331-332
miR	I	332-335
-	I	335-336
143	I	336-339
/	I	339-340
145	I	340-343
and	O	344-347
miR	I	348-351
-	I	351-352
1	I	352-353
/	I	353-354
133a	I	354-358
)	O	358-359
,	O	359-360
and	O	361-364
reduced	O	365-372
contractility	O	373-386
of	O	387-389
human	O	390-395
vascular	O	396-404
smooth	O	405-411
muscle	O	412-418
cells	O	419-424
(	O	425-426
SMCs	O	426-430
)	O	430-431
embedded	O	432-440
in	O	441-443
collagen	O	444-452
gel	O	453-456
lattices	O	457-465
,	O	465-466
suggesting	O	467-477
that	O	478-482
myocardin	O	483-492
degradation	O	493-504
is	O	505-507
required	O	508-516
for	O	517-520
its	O	521-524
transcriptional	O	525-540
activity	O	541-549
. 	O	549-551

Further	O	0-7
studies	O	8-15
using	O	16-21
chromatin	O	22-31
immunoprecipitation	O	32-51
assay	O	52-57
revealed	O	58-66
that	O	67-71
proteasome	O	72-82
inhibition	O	83-93
,	O	93-94
although	O	95-103
increased	O	104-113
the	O	114-117
occupancy	O	118-127
of	O	128-130
myocardin	O	131-140
and	O	141-144
SRF	O	145-148
on	O	149-151
the	O	152-155
promoter	O	156-164
of	O	165-167
SM	O	168-170
α	O	171-173
-	O	173-174
actin	O	174-179
gene	O	180-184
,	O	184-185
abolished	O	186-195
myocardin	O	196-205
-	O	205-206
dependent	O	206-215
recruitment	O	216-227
of	O	228-230
RNA	O	231-234
polymerase	O	235-245
II	O	246-248
. 	O	248-250

We	O	0-2
further	O	3-10
examined	O	11-19
the	O	20-23
degradation	O	24-35
of	O	36-38
myocardin	O	39-48
in	O	49-51
epithelioid	O	52-63
and	O	64-67
spindle	O	68-75
-	O	75-76
shaped	O	76-82
SMCs	O	83-87
and	O	88-91
revealed	O	92-100
that	O	101-105
myocardin	O	106-115
in	O	116-118
more	O	119-123
differentiated	O	124-138
spindle	O	139-146
-	O	146-147
shaped	O	147-153
SMCs	O	154-158
was	O	159-162
more	O	163-167
quickly	O	168-175
degraded	O	176-184
and	O	185-188
had	O	189-192
shorter	O	193-200
half	O	201-205
-	O	205-206
life	O	206-210
than	O	211-215
in	O	216-218
epithelioid	O	219-230
SMCs	O	231-235
. 	O	235-237

In	O	0-2
neointimal	O	3-13
lesions	O	14-21
,	O	21-22
we	O	23-25
found	O	26-31
that	O	32-36
stabilization	O	37-50
of	O	51-53
myocardin	O	54-63
protein	O	64-71
was	O	72-75
companied	O	76-85
by	O	86-88
downregulation	O	89-103
of	O	104-106
transcripts	O	107-118
of	O	119-121
ubiquitin	O	122-131
and	O	132-135
proteasome	O	136-146
subunits	O	147-155
,	O	155-156
further	O	157-164
illustrating	O	165-177
the	O	178-181
mechanism	O	182-191
underlying	O	192-202
reduction	O	203-212
of	O	213-215
myocardin	O	216-225
transcriptional	O	226-241
activity	O	242-250
. 	O	250-252

In	O	0-2
summary	O	3-10
,	O	10-11
our	O	12-15
results	O	16-23
have	O	24-28
suggested	O	29-38
that	O	39-43
proteasomal	O	44-55
degradation	O	56-67
of	O	68-70
myocardin	O	71-80
is	O	81-83
required	O	84-92
for	O	93-96
its	O	97-100
transcriptional	O	101-116
activity	O	117-125
.   	O	125-129

These	O	0-5
findings	O	6-14
reveal	O	15-21
a	O	22-23
significant	O	24-35
additional	O	36-46
mechanism	O	47-56
by	O	57-59
which	O	60-65
alpha	O	66-71
-	O	71-72
synuclein	O	72-81
is	O	82-84
regulated	O	85-94
and	O	95-98
point	O	99-104
toward	O	105-111
new	O	112-115
therapeutic	O	116-127
regimes	O	128-135
for	O	136-139
lowering	O	140-148
endogenous	O	149-159
alpha	O	160-165
-	O	165-166
synuclein	O	166-175
levels	O	176-182
in	O	183-185
patients	O	186-194
with	O	195-199
familial	O	200-208
or	O	209-211
sporadic	O	212-220
Parkinson	O	221-230
disease	O	231-238
.   	O	238-242

Overexpression	O	0-14
of	O	15-17
mir	B	18-21
-	I	21-22
7	I	22-23
and	O	24-27
mir	B	28-31
-	I	31-32
153	I	32-35
significantly	O	36-49
reduces	O	50-57
endogenous	O	58-68
alpha	O	69-74
-	O	74-75
synuclein	O	75-84
levels	O	85-91
,	O	91-92
whereas	O	93-100
inhibition	O	101-111
of	O	112-114
mir	B	115-118
-	I	118-119
7	I	119-120
and	O	121-124
mir	B	125-128
-	I	128-129
153	I	129-132
enhances	O	133-141
translation	O	142-153
of	O	154-156
a	O	157-158
luciferase	O	159-169
construct	O	170-179
bearing	O	180-187
the	O	188-191
alpha	O	192-197
-	O	197-198
synuclein	O	198-207
3	O	208-209
'	O	209-210
-	O	210-211
untranslated	O	211-223
region	O	224-230
in	O	231-233
primary	O	234-241
neurons	O	242-249
. 	O	249-251

They	O	0-4
are	O	5-8
expressed	O	9-18
predominantly	O	19-32
in	O	33-35
the	O	36-39
brain	O	40-45
with	O	46-50
a	O	51-52
pattern	O	53-60
that	O	61-65
mirrors	O	66-73
synuclein	O	74-83
expression	O	84-94
in	O	95-97
different	O	98-107
tissues	O	108-115
as	O	116-118
well	O	119-123
as	O	124-126
during	O	127-133
neuronal	O	134-142
development	O	143-154
,	O	154-155
indicating	O	156-166
that	O	167-171
they	O	172-176
play	O	177-181
a	O	182-183
tuning	O	184-190
role	O	191-195
in	O	196-198
the	O	199-202
amount	O	203-209
of	O	210-212
alpha	O	213-218
-	O	218-219
synuclein	O	219-228
produced	O	229-237
. 	O	237-239

These	O	0-5
microRNAs	O	6-15
bind	O	16-20
specifically	O	21-33
to	O	34-36
the	O	37-40
3	O	41-42
'	O	42-43
-	O	43-44
untranslated	O	44-56
region	O	57-63
of	O	64-66
alpha	O	67-72
-	O	72-73
synuclein	O	73-82
and	O	83-86
down	O	87-91
-	O	91-92
regulate	O	92-100
its	O	101-104
mRNA	O	105-109
and	O	110-113
protein	O	114-121
levels	O	122-128
,	O	128-129
with	O	130-134
their	O	135-140
effect	O	141-147
being	O	148-153
additive	O	154-162
. 	O	162-164

Here	O	0-4
,	O	4-5
two	O	6-9
microRNAs	O	10-19
,	O	19-20
namely	O	21-27
mir	B	28-31
-	I	31-32
7	I	32-33
and	O	34-37
mir	B	38-41
-	I	41-42
153	I	42-45
,	O	45-46
have	O	47-51
been	O	52-56
identified	O	57-67
to	O	68-70
regulate	O	71-79
alpha	O	80-85
-	O	85-86
synuclein	O	86-95
levels	O	96-102
post	O	103-107
-	O	107-108
transcriptionally	O	108-125
. 	O	125-127

Genetic	O	0-7
and	O	8-11
biochemical	O	12-23
studies	O	24-31
have	O	32-36
established	O	37-48
a	O	49-50
central	O	51-58
role	O	59-63
for	O	64-67
alpha	O	68-73
-	O	73-74
synuclein	O	74-83
accumulation	O	84-96
in	O	97-99
the	O	100-103
pathogenesis	O	104-116
of	O	117-119
Parkinson	O	120-129
disease	O	130-137
. 	O	137-139

Post	O	0-4
-	O	4-5
transcriptional	O	5-20
regulation	O	21-31
of	O	32-34
alpha	O	35-40
-	O	40-41
synuclein	O	41-50
expression	O	51-61
by	O	62-64
mir	B	65-68
-	I	68-69
7	I	69-70
and	O	71-74
mir	B	75-78
-	I	78-79
153	I	79-82
.  	O	82-85

The	O	0-3
findings	O	4-12
also	O	13-17
indicate	O	18-26
that	O	27-31
allopregnanolone	O	32-48
and	O	49-52
perhaps	O	53-60
other	O	61-66
neurosteroid	O	67-79
-	O	79-80
like	O	80-84
compounds	O	85-94
might	O	95-100
represent	O	101-110
potential	O	111-120
biomarkers	O	121-131
or	O	132-134
therapies	O	135-144
for	O	145-148
multiple	O	149-157
sclerosis	O	158-167
. 	O	167-169

These	O	0-5
multi	O	6-11
-	O	11-12
platform	O	12-20
studies	O	21-28
point	O	29-34
to	O	35-37
impaired	O	38-46
neurosteroidogenesis	O	47-67
in	O	68-70
both	O	71-75
multiple	O	76-84
sclerosis	O	85-94
and	O	95-98
experimental	O	99-111
autoimmune	O	112-122
encephalomyelitis	O	123-140
. 	O	140-142

Allopregnanolone	O	0-16
treatment	O	17-26
of	O	27-29
the	O	30-33
experimental	O	34-46
autoimmune	O	47-57
encephalomyelitis	O	58-75
mouse	O	76-81
model	O	82-87
limited	O	88-95
the	O	96-99
associated	O	100-110
neuropathology	O	111-125
,	O	125-126
including	O	127-136
neuroinflammation	O	137-154
,	O	154-155
myelin	O	156-162
and	O	163-166
axonal	O	167-173
injury	O	174-180
and	O	181-184
reduced	O	185-192
neurobehavioral	O	193-208
deficits	O	209-217
(	O	218-219
P	O	219-220
<	O	221-222
0	O	223-224
.	O	224-225
05	O	225-227
)	O	227-228
. 	O	228-230

Levels	O	0-6
of	O	7-9
important	O	10-19
neurosteroids	O	20-33
,	O	33-34
including	O	35-44
allopregnanolone	O	45-61
,	O	61-62
were	O	63-67
suppressed	O	68-78
in	O	79-81
the	O	82-85
white	O	86-91
matter	O	92-98
of	O	99-101
patients	O	102-110
with	O	111-115
multiple	O	116-124
sclerosis	O	125-134
(	O	135-136
P	O	136-137
<	O	138-139
0	O	140-141
.	O	141-142
05	O	142-144
)	O	144-145
. 	O	145-147

Induction	O	0-9
of	O	10-12
the	O	13-16
murine	O	17-23
micro	O	24-29
-	O	29-30
RNAs	O	30-34
,	O	34-35
miR	B	36-39
-	I	39-40
338	I	40-43
and	O	44-47
miR	B	48-51
-	I	51-52
155	I	52-55
,	O	55-56
accompanied	O	57-68
by	O	69-71
diminished	O	72-82
expression	O	83-93
of	O	94-96
neurosteroidogenic	O	97-115
enzymes	O	116-123
and	O	124-127
allopregnanolone	O	128-144
,	O	144-145
was	O	146-149
also	O	150-154
observed	O	155-163
in	O	164-166
the	O	167-170
brains	O	171-177
of	O	178-180
mice	O	181-185
with	O	186-190
experimental	O	191-203
autoimmune	O	204-214
encephalomyelitis	O	215-232
(	O	233-234
P	O	234-235
<	O	236-237
0	O	238-239
.	O	239-240
05	O	240-242
)	O	242-243
. 	O	243-245

Analysis	O	0-8
of	O	9-11
the	O	12-15
neurosteroidogenic	O	16-34
pathways	O	35-43
targeted	O	44-52
by	O	53-55
micro	O	56-61
-	O	61-62
RNAs	O	62-66
revealed	O	67-75
suppression	O	76-87
of	O	88-90
enzyme	O	91-97
transcript	O	98-108
and	O	109-112
protein	O	113-120
levels	O	121-127
in	O	128-130
the	O	131-134
white	O	135-140
matter	O	141-147
of	O	148-150
patients	O	151-159
with	O	160-164
multiple	O	165-173
sclerosis	O	174-183
(	O	184-185
P	O	185-186
<	O	187-188
0	O	189-190
.	O	190-191
05	O	191-193
)	O	193-194
. 	O	194-196

This	O	0-4
was	O	5-8
confirmed	O	9-18
by	O	19-21
firefly	O	22-29
/	O	29-30
Renilla	O	30-37
luciferase	O	38-48
micro	O	49-54
-	O	54-55
RNA	O	55-58
target	O	59-65
knockdown	O	66-75
experiments	O	76-87
(	O	88-89
P	O	89-90
<	O	91-92
0	O	93-94
.	O	94-95
05	O	95-97
)	O	97-98
and	O	99-102
detection	O	103-112
of	O	113-115
specific	O	116-124
micro	O	125-130
-	O	130-131
RNAs	O	131-135
by	O	136-138
in	O	139-141
situ	O	142-146
hybridization	O	147-160
in	O	161-163
the	O	164-167
brains	O	168-174
of	O	175-177
patients	O	178-186
with	O	187-191
or	O	192-194
without	O	195-202
multiple	O	203-211
sclerosis	O	212-221
. 	O	221-223

These	O	0-5
observations	O	6-18
were	O	19-23
verified	O	24-32
using	O	33-38
the	O	39-42
in	O	43-45
vivo	O	46-50
multiple	O	51-59
sclerosis	O	60-69
model	O	70-75
,	O	75-76
experimental	O	77-89
autoimmune	O	90-100
encephalomyelitis	O	101-118
. 	O	118-120

Brains	O	0-6
of	O	7-9
patients	O	10-18
with	O	19-23
or	O	24-26
without	O	27-34
multiple	O	35-43
sclerosis	O	44-53
demonstrated	O	54-66
differential	O	67-79
expression	O	80-90
of	O	91-93
multiple	O	94-102
micro	O	103-108
-	O	108-109
RNAs	O	109-113
,	O	113-114
but	O	115-118
expression	O	119-129
of	O	130-132
three	O	133-138
neurosteroid	O	139-151
synthesis	O	152-161
enzyme	O	162-168
-	O	168-169
specific	O	169-177
micro	O	178-183
-	O	183-184
RNAs	O	184-188
(	O	189-190
miR	B	190-193
-	I	193-194
338	I	194-197
,	O	197-198
miR	B	199-202
-	I	202-203
155	I	203-206
and	O	207-210
miR	B	211-214
-	I	214-215
491	I	215-218
)	O	218-219
showed	O	220-226
a	O	227-228
bias	O	229-233
towards	O	234-241
induction	O	242-251
in	O	252-254
patients	O	255-263
with	O	264-268
multiple	O	269-277
sclerosis	O	278-287
(	O	288-289
P	O	289-290
<	O	291-292
0	O	293-294
.	O	294-295
05	O	295-297
)	O	297-298
. 	O	298-300

High	O	0-4
-	O	4-5
throughput	O	5-15
technologies	O	16-28
have	O	29-33
led	O	34-37
to	O	38-40
advances	O	41-49
in	O	50-52
the	O	53-56
recognition	O	57-68
of	O	69-71
disease	O	72-79
pathways	O	80-88
and	O	89-92
their	O	93-98
underlying	O	99-109
mechanisms	O	110-120
. 	O	120-122

To	O	0-2
investigate	O	3-14
the	O	15-18
impact	O	19-25
of	O	26-28
micro	O	29-34
-	O	34-35
RNAs	O	35-39
on	O	40-42
the	O	43-46
disease	O	47-54
process	O	55-62
in	O	63-65
multiple	O	66-74
sclerosis	O	75-84
,	O	84-85
a	O	86-87
prototypic	O	88-98
inflammatory	O	99-111
neurological	O	112-124
disorder	O	125-133
,	O	133-134
we	O	135-137
examined	O	138-146
cerebral	O	147-155
white	O	156-161
matter	O	162-168
from	O	169-173
patients	O	174-182
with	O	183-187
or	O	188-190
without	O	191-198
the	O	199-202
disease	O	203-210
by	O	211-213
micro	O	214-219
-	O	219-220
RNA	O	220-223
profiling	O	224-233
,	O	233-234
together	O	235-243
with	O	244-248
confirmatory	O	249-261
reverse	O	262-269
transcription	O	270-283
-	O	283-284
polymerase	O	284-294
chain	O	295-300
reaction	O	301-309
analysis	O	310-318
,	O	318-319
immunoblotting	O	320-334
and	O	335-338
gas	O	339-342
chromatography	O	343-357
-	O	357-358
mass	O	358-362
spectrometry	O	363-375
. 	O	375-377

Impaired	O	0-8
neurosteroid	O	9-21
synthesis	O	22-31
in	O	32-34
multiple	O	35-43
sclerosis	O	44-53
.  	O	53-56

Since	O	0-5
neuron	O	6-12
-	O	12-13
specific	O	13-21
microRNA	B	22-30
-	I	30-31
7	I	31-32
is	O	33-35
downregulated	O	36-49
in	O	50-52
gliomas	O	53-60
but	O	61-64
highly	O	65-71
expressed	O	72-81
in	O	82-84
normal	O	85-91
brain	O	92-97
tissue	O	98-104
,	O	104-105
we	O	106-108
engineered	O	109-119
a	O	120-121
microRNA	O	122-130
-	O	130-131
sensitive	O	131-140
virus	O	141-146
containing	O	147-157
target	O	158-164
sites	O	165-170
for	O	171-174
microRNA	B	175-183
-	I	183-184
7	I	184-185
in	O	186-188
the	O	189-192
3	O	193-194
'	O	194-195
-	O	195-196
untranslated	O	196-208
region	O	209-215
of	O	216-218
the	O	219-222
viral	O	223-228
fusion	O	229-235
gene	O	236-240
. 	O	240-242

Recent	O	0-6
preclinical	O	7-18
studies	O	19-26
have	O	27-31
shown	O	32-37
that	O	38-42
the	O	43-46
cellular	O	47-55
tropism	O	56-63
of	O	64-66
several	O	67-74
viruses	O	75-82
can	O	83-86
be	O	87-89
controlled	O	90-100
by	O	101-103
inserting	O	104-113
microRNA	O	114-122
-	O	122-123
target	O	123-129
sequences	O	130-139
into	O	140-144
their	O	145-150
genomes	O	151-158
,	O	158-159
thereby	O	160-167
inhibiting	O	168-178
spread	O	179-185
in	O	186-188
tissues	O	189-196
expressing	O	197-207
cognate	O	208-215
microRNAs	O	216-225
. 	O	225-227

Oncolytic	O	0-9
measles	O	10-17
viruses	O	18-25
(	O	26-27
MV	O	27-29
)	O	29-30
derived	O	31-38
from	O	39-43
the	O	44-47
live	O	48-52
attenuated	O	53-63
vaccine	O	64-71
strain	O	72-78
have	O	79-83
been	O	84-88
engineered	O	89-99
for	O	100-103
increased	O	104-113
tumor	O	114-119
-	O	119-120
cell	O	120-124
specificity	O	125-136
,	O	136-137
and	O	138-141
are	O	142-145
currently	O	146-155
under	O	156-161
investigation	O	162-175
in	O	176-178
clinical	O	179-187
trials	O	188-194
including	O	195-204
a	O	205-206
phase	O	207-212
I	O	213-214
study	O	215-220
for	O	221-224
glioblastoma	O	225-237
multiforme	O	238-248
(	O	249-250
GBM	O	250-253
)	O	253-254
. 	O	254-256

MicroRNA	O	0-8
-	O	8-9
sensitive	O	9-18
oncolytic	O	19-28
measles	O	29-36
viruses	O	37-44
for	O	45-48
cancer	O	49-55
-	O	55-56
specific	O	56-64
vector	O	65-71
tropism	O	72-79
.  	O	79-82

This	O	0-4
is	O	5-7
proof	O	8-13
-	O	13-14
of	O	14-16
-	O	16-17
concept	O	17-24
that	O	25-29
tropism	O	30-37
restriction	O	38-49
by	O	50-52
tissue	O	53-59
-	O	59-60
specific	O	60-68
microRNAs	O	69-78
can	O	79-82
be	O	83-85
adapted	O	86-93
to	O	94-96
oncolytic	O	97-106
MV	O	107-109
to	O	110-112
regulate	O	113-121
viral	O	122-127
replication	O	128-139
and	O	140-143
gene	O	144-148
expression	O	149-159
to	O	160-162
maximize	O	163-171
tumor	O	172-177
specificity	O	178-189
without	O	190-197
compromising	O	198-210
oncolytic	O	211-220
efficacy	O	221-229
.   	O	229-233

Furthermore	O	0-11
,	O	11-12
microRNA	O	13-21
-	O	21-22
mediated	O	22-30
inhibition	O	31-41
protected	O	42-51
genetically	O	52-63
modified	O	64-72
mice	O	73-77
susceptible	O	78-89
to	O	90-92
MV	O	93-95
infection	O	96-105
from	O	106-110
a	O	111-112
potentially	O	113-124
lethal	O	125-131
intracerebral	O	132-145
challenge	O	146-155
. 	O	155-157

Importantly	O	0-11
,	O	11-12
endogenous	O	13-23
microRNA	B	24-32
-	I	32-33
7	I	33-34
expression	O	35-45
in	O	46-48
primary	O	49-56
human	O	57-62
brain	O	63-68
resections	O	69-79
tightly	O	80-87
restricted	O	88-98
replication	O	99-110
and	O	111-114
spread	O	115-121
of	O	122-124
microRNA	O	125-133
-	O	133-134
sensitive	O	134-143
virus	O	144-149
. 	O	149-151

In	O	0-2
presence	O	3-11
of	O	12-14
microRNA	B	15-23
-	I	23-24
7	I	24-25
this	O	26-30
modification	O	31-43
inhibits	O	44-52
translation	O	53-64
of	O	65-67
envelope	O	68-76
proteins	O	77-85
,	O	85-86
restricts	O	87-96
viral	O	97-102
spread	O	103-109
,	O	109-110
and	O	111-114
progeny	O	115-122
production	O	123-133
. 	O	133-135

Even	O	0-4
though	O	5-11
highly	O	12-18
attenuated	O	19-29
in	O	30-32
presence	O	33-41
of	O	42-44
microRNA	B	45-53
-	I	53-54
7	I	54-55
,	O	55-56
this	O	57-61
virus	O	62-67
retained	O	68-76
full	O	77-81
efficacy	O	82-90
against	O	91-98
glioblastoma	O	99-111
xenografts	O	112-122
. 	O	122-124

Finally	O	0-7
,	O	7-8
the	O	9-12
association	O	13-24
of	O	25-27
the	O	28-31
variant	O	32-39
with	O	40-44
stroke	O	45-51
was	O	52-55
tested	O	56-62
in	O	63-65
438	O	66-69
stroke	O	70-76
patients	O	77-85
and	O	86-89
890	O	90-93
controls	O	94-102
,	O	102-103
and	O	104-107
replicated	O	108-118
in	O	119-121
an	O	122-124
independent	O	125-136
population	O	137-147
of	O	148-150
1791	O	151-155
stroke	O	156-162
patients	O	163-171
and	O	172-175
1843	O	176-180
controls	O	181-189
. 	O	189-191

The	O	0-3
TT	O	4-6
genotype	O	7-15
resulted	O	16-24
in	O	25-27
a	O	28-29
significant	O	30-41
reduction	O	42-51
in	O	52-54
overall	O	55-62
stroke	O	63-69
risk	O	70-74
{	O	75-76
OR	O	76-78
,	O	78-79
0	O	80-81
.	O	81-82
51	O	82-84
[	O	85-86
95	O	86-88
%	O	88-89
confidence	O	90-100
interval	O	101-109
(	O	110-111
CI	O	111-113
)	O	113-114
,	O	114-115
0	O	116-117
.	O	117-118
36	O	118-120
-	O	120-121
0	O	121-122
.	O	122-123
74	O	123-125
]	O	125-126
,	O	126-127
P	O	128-129
=	O	130-131
0	O	132-133
.	O	133-134
0003	O	134-138
}	O	138-139
,	O	139-140
ischemic	O	141-149
stroke	O	150-156
[	O	157-158
OR	O	158-160
,	O	160-161
0	O	162-163
.	O	163-164
56	O	164-166
(	O	167-168
95	O	168-170
%	O	170-171
CI	O	172-174
,	O	174-175
0	O	176-177
.	O	177-178
36	O	178-180
-	O	180-181
0	O	181-182
.	O	182-183
85	O	183-185
)	O	185-186
,	O	186-187
P	O	188-189
=	O	190-191
0	O	192-193
.	O	193-194
007	O	194-197
]	O	197-198
and	O	199-202
hemorrhagic	O	203-214
stroke	O	215-221
[	O	222-223
OR	O	223-225
,	O	225-226
0	O	227-228
.	O	228-229
46	O	229-231
(	O	232-233
95	O	233-235
%	O	235-236
CI	O	237-239
,	O	239-240
0	O	241-242
.	O	242-243
26	O	243-245
-	O	245-246
0	O	246-247
.	O	247-248
80	O	248-250
)	O	250-251
,	O	251-252
P	O	253-254
=	O	255-256
0	O	257-258
.	O	258-259
007	O	259-262
]	O	262-263
. 	O	263-265

We	O	0-2
found	O	3-8
that	O	9-13
the	O	14-17
A	O	18-19
allele	O	20-26
of	O	27-29
rs2507800	O	30-39
suppressed	O	40-50
angiopoietin	O	51-63
-	O	63-64
1	O	64-65
translation	O	66-77
by	O	78-80
facilitating	O	81-93
miR	B	94-97
-	I	97-98
211	I	98-101
binding	O	102-109
,	O	109-110
but	O	111-114
not	O	115-118
the	O	119-122
T	O	123-124
allele	O	125-131
. 	O	131-133

Subjects	O	0-8
carrying	O	9-17
the	O	18-21
TT	O	22-24
genotype	O	25-33
had	O	34-37
higher	O	38-44
plasma	O	45-51
angiopoietin	O	52-64
-	O	64-65
1	O	65-66
levels	O	67-73
than	O	74-78
those	O	79-84
with	O	85-89
the	O	90-93
A	O	94-95
allele	O	96-102
. 	O	102-104

To	O	0-2
test	O	3-7
our	O	8-11
hypothesis	O	12-22
,	O	22-23
a	O	24-25
predicted	O	26-35
microRNA	O	36-44
-	O	44-45
binding	O	45-52
site	O	53-57
was	O	58-61
found	O	62-67
in	O	68-70
the	O	71-74
3	O	75-76
'	O	76-77
-	O	77-78
UTR	O	78-81
of	O	82-84
angiopoietin	O	85-97
-	O	97-98
1	O	98-99
using	O	100-105
bioinformatics	O	106-120
;	O	120-121
variant	O	122-129
rs2507800	O	130-139
was	O	140-143
identified	O	144-154
to	O	155-157
be	O	158-160
located	O	161-168
in	O	169-171
the	O	172-175
miR	B	176-179
-	I	179-180
211	I	180-183
-	O	183-184
binding	O	184-191
site	O	192-196
of	O	197-199
angiopoietin	O	200-212
-	O	212-213
1	O	213-214
. 	O	214-216

Secondly	O	0-8
,	O	8-9
the	O	10-13
effects	O	14-21
of	O	22-24
the	O	25-28
identified	O	29-39
variant	O	40-47
on	O	48-50
angiopoietin	O	51-63
-	O	63-64
1	O	64-65
translation	O	66-77
were	O	78-82
assessed	O	83-91
using	O	92-97
a	O	98-99
luciferase	O	100-110
reporter	O	111-119
assay	O	120-125
and	O	126-129
ELISA	O	130-135
. 	O	135-137

Angiopoietin	O	0-12
-	O	12-13
1	O	13-14
is	O	15-17
a	O	18-19
vascular	O	20-28
strengthening	O	29-42
factor	O	43-49
during	O	50-56
vascular	O	57-65
development	O	66-77
and	O	78-81
a	O	82-83
protective	O	84-94
factor	O	95-101
for	O	102-105
pathological	O	106-118
vascular	O	119-127
inflammation	O	128-140
and	O	141-144
leakage	O	145-152
. 	O	152-154

Brain	O	0-5
vascular	O	6-14
leaking	O	15-22
and	O	23-26
inflammation	O	27-39
are	O	40-43
two	O	44-47
important	O	48-57
pathological	O	58-70
processes	O	71-80
of	O	81-83
stroke	O	84-90
;	O	90-91
therefore	O	92-101
,	O	101-102
we	O	103-105
hypothesized	O	106-118
that	O	119-123
variants	O	124-132
of	O	133-135
the	O	136-139
microRNA	O	140-148
-	O	148-149
binding	O	149-156
site	O	157-161
in	O	162-164
angiopoietin	O	165-177
-	O	177-178
1	O	178-179
would	O	180-185
affect	O	186-192
its	O	193-196
expression	O	197-207
and	O	208-211
confer	O	212-218
a	O	219-220
risk	O	221-225
of	O	226-228
stroke	O	229-235
. 	O	235-237

A	O	0-1
functional	O	2-12
variant	O	13-20
in	O	21-23
the	O	24-27
3	O	28-29
'	O	29-30
-	O	30-31
UTR	O	31-34
of	O	35-37
angiopoietin	O	38-50
-	O	50-51
1	O	51-52
might	O	53-58
reduce	O	59-65
stroke	O	66-72
risk	O	73-77
by	O	78-80
interfering	O	81-92
with	O	93-97
the	O	98-101
binding	O	102-109
efficiency	O	110-120
of	O	121-123
microRNA	B	124-132
211	I	133-136
.  	O	136-139

Our	O	0-3
results	O	4-11
provide	O	12-19
evidence	O	20-28
that	O	29-33
the	O	34-37
TT	O	38-40
genotype	O	41-49
(	O	50-51
rs2507800	O	51-60
)	O	60-61
in	O	62-64
the	O	65-68
3	O	69-70
'	O	70-71
-	O	71-72
UTR	O	72-75
of	O	76-78
angiopoietin	O	79-91
-	O	91-92
1	O	92-93
might	O	94-99
reduce	O	100-106
the	O	107-110
risk	O	111-115
of	O	116-118
stroke	O	119-125
by	O	126-128
interfering	O	129-140
with	O	141-145
miR	B	146-149
-	I	149-150
211	I	150-153
binding	O	154-161
.   	O	161-165

These	O	0-5
results	O	6-13
were	O	14-18
confirmed	O	19-28
in	O	29-31
an	O	32-34
independent	O	35-46
study	O	47-52
. 	O	52-54

Does	O	0-4
the	O	5-8
effect	O	9-15
of	O	16-18
microRNAs	O	19-28
in	O	29-31
vascular	O	32-40
neointimal	O	41-51
formation	O	52-61
depend	O	62-68
on	O	69-71
cell	O	72-76
cycle	O	77-82
phase	O	83-88
?     	O	88-94

The	O	0-3
characteristics	O	4-19
of	O	20-22
tumors	O	23-29
induced	O	30-37
in	O	38-40
NG2	O	41-44
-	O	44-45
KO	O	45-47
were	O	48-52
compared	O	53-61
to	O	62-64
those	O	65-70
of	O	71-73
tumors	O	74-80
induced	O	81-88
in	O	89-91
wild	O	92-96
type	O	97-101
mice	O	102-106
by	O	107-109
immunostaining	O	110-124
for	O	125-128
different	O	129-138
cell	O	139-143
lineage	O	144-151
markers	O	152-159
and	O	160-163
by	O	164-166
transplantation	O	167-182
assays	O	183-189
in	O	190-192
adult	O	193-198
mice	O	199-203
. 	O	203-205

METHODS	O	0-7
:	O	7-8
The	O	9-12
survival	O	13-21
curves	O	22-28
of	O	29-31
NG2	O	32-35
-	O	35-36
KO	O	36-38
mice	O	39-43
overexpressing	O	44-58
PDGF	O	59-63
-	O	63-64
B	O	64-65
were	O	66-70
compared	O	71-79
to	O	80-82
controls	O	83-91
by	O	92-94
using	O	95-100
a	O	101-102
Log	O	103-106
-	O	106-107
rank	O	107-111
test	O	112-116
. 	O	116-118

We	O	0-2
have	O	3-7
recently	O	8-16
generated	O	17-26
a	O	27-28
glioma	O	29-35
model	O	36-41
based	O	42-47
on	O	48-50
the	O	51-54
overexpression	O	55-69
of	O	70-72
PDGF	O	73-77
-	O	77-78
B	O	78-79
in	O	80-82
neural	O	83-89
progenitors	O	90-101
and	O	102-105
here	O	106-110
we	O	111-113
investigated	O	114-126
the	O	127-130
possible	O	131-139
relevance	O	140-149
of	O	150-152
NG2	O	153-156
during	O	157-163
PDGF	O	164-168
-	O	168-169
driven	O	169-175
gliomagenesis	O	176-189
. 	O	189-191

NG2	O	0-3
has	O	4-7
been	O	8-12
shown	O	13-18
to	O	19-21
function	O	22-30
as	O	31-33
a	O	34-35
co	O	36-38
-	O	38-39
receptor	O	39-47
for	O	48-51
PDGF	O	52-56
ligands	O	57-64
whose	O	65-70
aberrant	O	71-79
expression	O	80-90
is	O	91-93
common	O	94-100
in	O	101-103
gliomas	O	104-111
. 	O	111-113

BACKGROUND	O	0-10
:	O	10-11
In	O	12-14
the	O	15-18
last	O	19-23
years	O	24-29
,	O	29-30
the	O	31-34
transmembrane	O	35-48
proteoglycan	O	49-61
NG2	O	62-65
has	O	66-69
gained	O	70-76
interest	O	77-85
as	O	86-88
a	O	89-90
therapeutic	O	91-102
target	O	103-109
for	O	110-113
the	O	114-117
treatment	O	118-127
of	O	128-130
diverse	O	131-138
tumor	O	139-144
types	O	145-150
,	O	150-151
including	O	152-161
gliomas	O	162-169
,	O	169-170
because	O	171-178
increases	O	179-188
of	O	189-191
its	O	192-195
expression	O	196-206
correlate	O	207-216
with	O	217-221
dismal	O	222-228
prognosis	O	229-238
. 	O	238-240

PDGF	O	0-4
-	O	4-5
B	O	5-6
-	O	6-7
driven	O	7-13
gliomagenesis	O	14-27
can	O	28-31
occur	O	32-37
in	O	38-40
the	O	41-44
absence	O	45-52
of	O	53-55
the	O	56-59
proteoglycan	O	60-72
NG2	O	73-76
.  	O	76-79

On	O	0-2
the	O	3-6
basis	O	7-12
of	O	13-15
the	O	16-19
data	O	20-24
obtained	O	25-33
,	O	33-34
we	O	35-37
therefore	O	38-47
suggest	O	48-55
that	O	56-60
the	O	61-64
role	O	65-69
of	O	70-72
NG2	O	73-76
as	O	77-79
a	O	80-81
target	O	82-88
molecule	O	89-97
for	O	98-101
glioma	O	102-108
treatment	O	109-118
should	O	119-125
be	O	126-128
carefully	O	129-138
reconsidered	O	139-151
.   	O	151-155

CONCLUSIONS	O	0-11
:	O	11-12
Our	O	13-16
analysis	O	17-25
,	O	25-26
using	O	27-32
both	O	33-37
NG2	O	38-41
-	O	41-42
KO	O	42-44
mice	O	45-49
and	O	50-53
a	O	54-55
miRNA	O	56-61
based	O	62-67
silencing	O	68-77
approach	O	78-86
,	O	86-87
clearly	O	88-95
demonstrates	O	96-108
that	O	109-113
NG2	O	114-117
is	O	118-120
not	O	121-124
required	O	125-133
for	O	134-137
PDGF	O	138-142
-	O	142-143
B	O	143-144
to	O	145-147
efficiently	O	148-159
induce	O	160-166
and	O	167-170
maintain	O	171-179
gliomas	O	180-187
from	O	188-192
neural	O	193-199
progenitors	O	200-211
. 	O	211-213

RESULTS	O	0-7
:	O	7-8
We	O	9-11
showed	O	12-18
that	O	19-23
the	O	24-27
lack	O	28-32
of	O	33-35
NG2	O	36-39
does	O	40-44
not	O	45-48
appreciably	O	49-60
affect	O	61-67
any	O	68-71
of	O	72-74
the	O	75-78
characterized	O	79-92
steps	O	93-98
of	O	99-101
PDGF	O	102-106
-	O	106-107
driven	O	107-113
brain	O	114-119
tumorigenesis	O	120-133
,	O	133-134
such	O	135-139
as	O	140-142
oligodendrocyte	O	143-158
progenitor	O	159-169
cells	O	170-175
(	O	176-177
OPC	O	177-180
)	O	180-181
induction	O	182-191
,	O	191-192
the	O	193-196
recruitment	O	197-208
of	O	209-211
bystander	O	212-221
OPCs	O	222-226
and	O	227-230
the	O	231-234
progression	O	235-246
to	O	247-249
full	O	250-254
malignancy	O	255-265
,	O	265-266
which	O	267-272
take	O	273-277
place	O	278-283
as	O	284-286
in	O	287-289
wild	O	290-294
type	O	295-299
animals	O	300-307
. 	O	307-309

These	O	0-5
findings	O	6-14
indicate	O	15-23
that	O	24-28
miR	B	29-32
-	I	32-33
107	I	33-36
contributes	O	37-48
to	O	49-51
GRN	O	52-55
expression	O	56-66
regulation	O	67-77
with	O	78-82
implications	O	83-95
for	O	96-99
brain	O	100-105
disorders	O	106-115
.   	O	115-119

In	O	0-2
brain	O	3-8
tissue	O	9-15
subjacent	O	16-25
to	O	26-28
1	O	29-30
.	O	30-31
0	O	31-32
mm	O	33-35
depth	O	36-41
controlled	O	42-52
cortical	O	53-61
impact	O	62-68
,	O	68-69
surviving	O	70-79
hippocampal	O	80-91
neurons	O	92-99
show	O	100-104
decreased	O	105-114
miR	B	115-118
-	I	118-119
107	I	119-122
with	O	123-127
augmentation	O	128-140
of	O	141-143
neuronal	O	144-152
GRN	O	153-156
expression	O	157-167
. 	O	167-169

We	O	0-2
also	O	3-7
tested	O	8-14
a	O	15-16
mouse	O	17-22
model	O	23-28
where	O	29-34
miR	B	35-38
-	I	38-39
107	I	39-42
has	O	43-46
been	O	47-51
shown	O	52-57
to	O	58-60
be	O	61-63
down	O	64-68
-	O	68-69
regulated	O	69-78
. 	O	78-80

However	O	0-7
,	O	7-8
GRN	O	9-12
regulation	O	13-23
expression	O	24-34
is	O	35-37
poorly	O	38-44
understood	O	45-55
. 	O	55-57

A	O	0-1
high	O	2-6
-	O	6-7
throughput	O	7-17
experimental	O	18-30
microRNA	O	31-39
assay	O	40-45
showed	O	46-52
that	O	53-57
GRN	O	58-61
is	O	62-64
the	O	65-68
strongest	O	69-78
target	O	79-85
for	O	86-89
miR	B	90-93
-	I	93-94
107	I	94-97
in	O	98-100
human	O	101-106
H4	O	107-109
neuroglioma	O	110-121
cells	O	122-127
. 	O	127-129

miR	B	0-3
-	I	3-4
107	I	4-7
has	O	8-11
been	O	12-16
implicated	O	17-27
in	O	28-30
Alzheimer	O	31-40
'	O	40-41
s	O	41-42
disease	O	43-50
pathogenesis	O	51-63
,	O	63-64
and	O	65-68
sequence	O	69-77
elements	O	78-86
in	O	87-89
the	O	90-93
open	O	94-98
reading	O	99-106
frame	O	107-112
-	O	112-113
rather	O	113-119
than	O	120-124
the	O	125-128
3	O	129-130
'	O	130-131
untranslated	O	132-144
region	O	145-151
-	O	151-152
of	O	152-154
GRN	O	155-158
mRNA	O	159-163
are	O	164-167
recognized	O	168-178
by	O	179-181
miR	B	182-185
-	I	185-186
107	I	186-189
and	O	190-193
are	O	194-197
highly	O	198-204
conserved	O	205-214
among	O	215-220
vertebrate	O	221-231
species	O	232-239
. 	O	239-241

To	O	0-2
better	O	3-9
understand	O	10-20
the	O	21-24
mechanism	O	25-34
of	O	35-37
this	O	38-42
interaction	O	43-54
,	O	54-55
FLAG	O	56-60
-	O	60-61
tagged	O	61-67
Argonaute	O	68-77
constructs	O	78-88
were	O	89-93
used	O	94-98
following	O	99-108
miR	B	109-112
-	I	112-113
107	I	113-116
transfection	O	117-129
. 	O	129-131

miR	B	0-3
-	I	3-4
107	I	4-7
regulates	O	8-17
granulin	O	18-26
/	O	26-27
progranulin	O	27-38
with	O	39-43
implications	O	44-56
for	O	57-60
traumatic	O	61-70
brain	O	71-76
injury	O	77-83
and	O	84-87
neurodegenerative	O	88-105
disease	O	106-113
.  	O	113-116

Granulin	O	0-8
(	O	9-10
GRN	O	10-13
,	O	13-14
or	O	15-17
progranulin	O	18-29
)	O	29-30
is	O	31-33
a	O	34-35
protein	O	36-43
involved	O	44-52
in	O	53-55
wound	O	56-61
repair	O	62-68
,	O	68-69
inflammation	O	70-82
,	O	82-83
and	O	84-87
neoplasia	O	88-97
. 	O	97-99

GRN	O	0-3
has	O	4-7
also	O	8-12
been	O	13-17
directly	O	18-26
implicated	O	27-37
in	O	38-40
frontotemporal	O	41-55
dementia	O	56-64
and	O	65-68
may	O	69-72
contribute	O	73-83
to	O	84-86
Alzheimer	O	87-96
'	O	96-97
s	O	97-98
disease	O	99-106
pathogenesis	O	107-119
. 	O	119-121

GRN	O	0-3
mRNA	O	4-8
interacts	O	9-18
preferentially	O	19-33
with	O	34-38
Argonaute	O	39-48
2	O	49-50
.	O	50-51
In	O	52-54
vitro	O	55-60
and	O	61-64
in	O	65-67
vivo	O	68-72
studies	O	73-80
indicate	O	81-89
that	O	90-94
regulation	O	95-105
of	O	106-108
GRN	O	109-112
by	O	113-115
miR	B	116-119
-	I	119-120
107	I	120-123
may	O	124-127
be	O	128-130
functionally	O	131-143
important	O	144-153
. 	O	153-155

Glucose	O	0-7
supplementation	O	8-23
in	O	24-26
cultured	O	27-35
cells	O	36-41
that	O	42-46
leads	O	47-52
to	O	53-55
increased	O	56-65
miR	B	66-69
-	I	69-70
107	I	70-73
levels	O	74-80
also	O	81-85
results	O	86-93
in	O	94-96
decreased	O	97-106
GRN	O	107-110
expression	O	111-121
,	O	121-122
including	O	123-132
changes	O	133-140
in	O	141-143
cell	O	144-148
compartmentation	O	149-165
and	O	166-169
decreased	O	170-179
secretion	O	180-189
of	O	190-192
GRN	O	193-196
protein	O	197-204
. 	O	204-206

This	O	0-4
effect	O	5-11
was	O	12-15
eliminated	O	16-26
following	O	27-36
miR	B	37-40
-	I	40-41
107	I	41-44
transfection	O	45-57
. 	O	57-59

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNA	O	39-42
molecules	O	43-52
that	O	53-57
regulate	O	58-66
protein	O	67-74
expression	O	75-85
by	O	86-88
cleaving	O	89-97
or	O	98-100
repressing	O	101-111
the	O	112-115
translation	O	116-127
of	O	128-130
target	O	131-137
mRNAs	O	138-143
. 	O	143-145

MiR	B	0-3
-	I	3-4
21	I	4-6
protected	O	7-16
human	O	17-22
glioblastoma	O	23-35
U87MG	O	36-41
cells	O	42-47
from	O	48-52
chemotherapeutic	O	53-69
drug	O	70-74
temozolomide	O	75-87
induced	O	88-95
apoptosis	O	96-105
by	O	106-108
decreasing	O	109-119
Bax	O	120-123
/	O	123-124
Bcl	O	124-127
-	O	127-128
2	O	128-129
ratio	O	130-135
and	O	136-139
caspase	O	140-147
-	O	147-148
3	O	148-149
activity	O	150-158
.  	O	158-161

Several	O	0-7
miRNAs	O	8-14
have	O	15-19
been	O	20-24
recently	O	25-33
reported	O	34-42
to	O	43-45
be	O	46-48
involved	O	49-57
in	O	58-60
modulation	O	61-71
of	O	72-74
glioma	O	75-81
development	O	82-93
,	O	93-94
especially	O	95-105
some	O	106-110
up	O	111-113
-	O	113-114
regulated	O	114-123
miRNAs	O	124-130
,	O	130-131
such	O	132-136
as	O	137-139
microRNA	B	140-148
-	I	148-149
21	I	149-151
(	O	152-153
miR	B	153-156
-	I	156-157
21	I	157-159
)	O	159-160
,	O	160-161
which	O	162-167
has	O	168-171
been	O	172-176
found	O	177-182
to	O	183-185
function	O	186-194
as	O	195-197
an	O	198-200
oncogene	O	201-209
in	O	210-212
cultured	O	213-221
glioblastoma	O	222-234
multiforme	O	235-245
cells	O	246-251
. 	O	251-253

In	O	0-2
mammal	O	3-9
animals	O	10-17
,	O	17-18
their	O	19-24
function	O	25-33
mainly	O	34-40
represses	O	41-50
the	O	51-54
target	O	55-61
mRNAs	O	62-67
transcripts	O	68-79
via	O	80-83
imperfectly	O	84-95
complementary	O	96-109
to	O	110-112
the	O	113-116
3	O	117-118
'	O	118-119
UTR	O	119-122
of	O	123-125
target	O	126-132
mRNAs	O	133-138
. 	O	138-140

However	O	0-7
,	O	7-8
resistance	O	9-19
develops	O	20-28
quickly	O	29-36
and	O	37-40
with	O	41-45
high	O	46-50
frequency	O	51-60
. 	O	60-62

Temozolomide	O	0-12
(	O	13-14
TMZ	O	14-17
)	O	17-18
,	O	18-19
an	O	20-22
alkylating	O	23-33
agent	O	34-39
,	O	39-40
is	O	41-43
a	O	44-45
promising	O	46-55
chemotherapeutic	O	56-72
agent	O	73-78
for	O	79-82
treating	O	83-91
glioblastoma	O	92-104
. 	O	104-106

Our	O	0-3
studies	O	4-11
showed	O	12-18
that	O	19-23
TMZ	O	24-27
markedly	O	28-36
enhanced	O	37-45
apoptosis	O	46-55
in	O	56-58
U87MG	O	59-64
cells	O	65-70
compared	O	71-79
with	O	80-84
untreated	O	85-94
cells	O	95-100
(	O	101-102
P	O	102-103
<	O	103-104
0	O	104-105
.	O	105-106
05	O	106-108
)	O	108-109
. 	O	109-111

To	O	0-2
explore	O	3-10
the	O	11-14
mechanism	O	15-24
of	O	25-27
resistance	O	28-38
,	O	38-39
we	O	40-42
found	O	43-48
that	O	49-53
miR	B	54-57
-	I	57-58
21	I	58-60
could	O	61-66
protect	O	67-74
human	O	75-80
glioblastoma	O	81-93
U87MG	O	94-99
cells	O	100-105
from	O	106-110
TMZ	O	111-114
induced	O	115-122
apoptosis	O	123-132
. 	O	132-134

However	O	0-7
,	O	7-8
over	O	9-13
-	O	13-14
express	O	14-21
miR	B	22-25
-	I	25-26
21	I	26-28
in	O	29-31
U87MG	O	32-37
cells	O	38-43
could	O	44-49
significantly	O	50-63
reduce	O	64-70
TMZ	O	71-74
-	O	74-75
induced	O	75-82
apoptosis	O	83-92
(	O	93-94
P	O	94-95
<	O	95-96
0	O	96-97
.	O	97-98
05	O	98-100
)	O	100-101
. 	O	101-103

Pro	O	0-3
-	O	3-4
apoptotic	O	4-13
Bax	O	14-17
and	O	18-21
anti	O	22-26
-	O	26-27
apoptotic	O	27-36
Bcl	O	37-40
-	O	40-41
2	O	41-42
proteins	O	43-51
are	O	52-55
known	O	56-61
to	O	62-64
regulate	O	65-73
the	O	74-77
apoptosis	O	78-87
of	O	88-90
glioma	O	91-97
cells	O	98-103
. 	O	103-105

Further	O	0-7
research	O	8-16
demonstrated	O	17-29
that	O	30-34
the	O	35-38
mechanism	O	39-48
was	O	49-52
associated	O	53-63
with	O	64-68
a	O	69-70
shift	O	71-76
in	O	77-79
Bax	O	80-83
/	O	83-84
Bcl	O	84-87
-	O	87-88
2	O	88-89
ratio	O	90-95
and	O	96-99
change	O	100-106
in	O	107-109
caspase	O	110-117
-	O	117-118
3	O	118-119
activity	O	120-128
. 	O	128-130

Bax	O	0-3
is	O	4-6
shown	O	7-12
to	O	13-15
correlate	O	16-25
with	O	26-30
an	O	31-33
increased	O	34-43
survival	O	44-52
of	O	53-55
glioblastoma	O	56-68
multiforme	O	69-79
patients	O	80-88
. 	O	88-90

However	O	0-7
,	O	7-8
such	O	9-13
effect	O	14-20
was	O	21-24
partly	O	25-31
prevented	O	32-41
by	O	42-44
treatment	O	45-54
of	O	55-57
cells	O	58-63
with	O	64-68
miR	B	69-72
-	I	72-73
21	I	73-75
overexpression	O	76-90
before	O	91-97
,	O	97-98
which	O	99-104
appeared	O	105-113
to	O	114-116
downregulate	O	117-129
the	O	130-133
Bax	O	134-137
expression	O	138-148
,	O	148-149
upregulate	O	150-160
the	O	161-164
Bcl	O	165-168
-	O	168-169
2	O	169-170
expression	O	171-181
and	O	182-185
decrease	O	186-194
caspase	O	195-202
-	O	202-203
3	O	203-204
activity	O	205-213
. 	O	213-215

Compared	O	0-8
to	O	9-11
control	O	12-19
cells	O	20-25
,	O	25-26
cells	O	27-32
treated	O	33-40
with	O	41-45
TMZ	O	46-49
showed	O	50-56
a	O	57-58
significant	O	59-70
increase	O	71-79
in	O	80-82
the	O	83-86
Bax	O	87-90
/	O	90-91
Bcl	O	91-94
-	O	94-95
2	O	95-96
ratio	O	97-102
and	O	103-106
caspase	O	107-114
-	O	114-115
3	O	115-116
activity	O	117-125
(	O	126-127
P	O	127-128
<	O	128-129
0	O	129-130
.	O	130-131
01	O	131-133
)	O	133-134
. 	O	134-136

Taken	O	0-5
together	O	6-14
,	O	14-15
these	O	16-21
results	O	22-29
suggested	O	30-39
that	O	40-44
over	O	45-49
-	O	49-50
express	O	50-57
miR	B	58-61
-	I	61-62
21	I	62-64
could	O	65-70
inhibit	O	71-78
TMZ	O	79-82
-	O	82-83
induced	O	83-90
apoptosis	O	91-100
in	O	101-103
U87MG	O	104-109
cells	O	110-115
,	O	115-116
at	O	117-119
least	O	120-125
in	O	126-128
part	O	129-133
,	O	133-134
by	O	135-137
decreasing	O	138-148
Bax	O	149-152
/	O	152-153
Bcl	O	153-156
-	O	156-157
2	O	157-158
ratio	O	159-164
and	O	165-168
caspase	O	169-176
-	O	176-177
3	O	177-178
activity	O	179-187
,	O	187-188
which	O	189-194
highlighted	O	195-206
the	O	207-210
possibility	O	211-222
of	O	223-225
miR	B	226-229
-	I	229-230
21	I	230-232
overexpression	O	233-247
in	O	248-250
the	O	251-254
clinical	O	255-263
resistance	O	264-274
to	O	275-277
chemotherapeutic	O	278-294
therapy	O	295-302
of	O	303-305
TMZ	O	306-309
.   	O	309-313

Bcl	O	0-3
-	O	3-4
2	O	4-5
,	O	5-6
resistance	O	7-17
to	O	18-20
induction	O	21-30
of	O	31-33
apoptosis	O	34-43
,	O	43-44
constitutes	O	45-56
one	O	57-60
major	O	61-66
obstacle	O	67-75
to	O	76-78
chemotherapy	O	79-91
in	O	92-94
many	O	95-99
cancer	O	100-106
cells	O	107-112
. 	O	112-114

Hypoxia	O	0-7
induces	O	8-15
microRNA	O	16-24
miR	B	25-28
-	I	28-29
210	I	29-32
in	O	33-35
vitro	O	36-41
and	O	42-45
in	O	46-48
vivo	O	49-53
ephrin	O	54-60
-	O	60-61
A3	O	61-63
and	O	64-67
neuronal	O	68-76
pentraxin	O	77-86
1	O	87-88
are	O	89-92
potentially	O	93-104
regulated	O	105-114
by	O	115-117
miR	B	118-121
-	I	121-122
210	I	122-125
.  	O	125-128

Shortage	O	0-8
of	O	9-11
oxygen	O	12-18
is	O	19-21
one	O	22-25
of	O	26-28
the	O	29-32
prime	O	33-38
stress	O	39-45
conditions	O	46-56
in	O	57-59
tissues	O	60-67
. 	O	67-69

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
looked	O	18-24
for	O	25-28
microRNAs	O	29-38
expressed	O	39-48
during	O	49-55
hypoxia	O	56-63
and	O	64-67
showed	O	68-74
that	O	75-79
miR	B	80-83
-	I	83-84
210	I	84-87
expression	O	88-98
was	O	99-102
upregulated	O	103-114
in	O	115-117
response	O	118-126
to	O	127-129
hypoxia	O	130-137
in	O	138-140
vitro	O	141-146
and	O	147-150
in	O	151-153
vivo	O	154-158
. 	O	158-160

An	O	0-2
active	O	3-9
form	O	10-14
of	O	15-17
the	O	18-21
HIF	O	22-25
-	O	25-26
1alpha	O	26-32
induced	O	33-40
the	O	41-44
expression	O	45-55
of	O	56-58
miR	B	59-62
-	I	62-63
210	I	63-66
,	O	66-67
showing	O	68-75
the	O	76-79
involvement	O	80-91
of	O	92-94
the	O	95-98
HIF	O	99-102
-	O	102-103
1	O	103-104
signaling	O	105-114
pathway	O	115-122
in	O	123-125
miR	B	126-129
-	I	129-130
210	I	130-133
gene	O	134-138
transcription	O	139-152
. 	O	152-154

Furthermore	O	0-11
,	O	11-12
miR	B	13-16
-	I	16-17
210	I	17-20
was	O	21-24
shown	O	25-30
to	O	31-33
bind	O	34-38
to	O	39-41
the	O	42-45
predicted	O	46-55
target	O	56-62
sites	O	63-68
of	O	69-71
ephrin	O	72-78
-	O	78-79
A3	O	79-81
or	O	82-84
neuronal	O	85-93
pentraxin	O	94-103
1	O	104-105
,	O	105-106
causing	O	107-114
repression	O	115-125
in	O	126-128
luciferase	O	129-139
reporter	O	140-148
activity	O	149-157
. 	O	157-159

Thus	O	0-4
,	O	4-5
the	O	6-9
regulatory	O	10-20
effects	O	21-28
of	O	29-31
miR	B	32-35
-	I	35-36
210	I	36-39
on	O	40-42
its	O	43-46
targets	O	47-54
in	O	55-57
vivo	O	58-62
need	O	63-67
to	O	68-70
be	O	71-73
further	O	74-81
characterized	O	82-95
.   	O	95-99

Contrary	O	0-8
to	O	9-11
the	O	12-15
microRNA	O	16-24
-	O	24-25
mediated	O	25-33
repression	O	34-44
hypothesis	O	45-55
,	O	55-56
ephrin	O	57-63
-	O	63-64
A3	O	64-66
was	O	67-70
expressed	O	71-80
at	O	81-83
very	O	84-88
high	O	89-93
levels	O	94-100
in	O	101-103
post	O	104-108
-	O	108-109
ischemic	O	109-117
mouse	O	118-123
hippocampus	O	124-135
in	O	136-138
vivo	O	139-143
. 	O	143-145

Cells	O	0-5
stably	O	6-12
transfected	O	13-24
with	O	25-29
LAT	O	30-33
or	O	34-36
trigeminal	O	37-47
ganglionic	O	48-58
neurons	O	59-66
of	O	67-69
mice	O	70-74
infected	O	75-83
with	O	84-88
a	O	89-90
LAT	O	91-94
expressing	O	95-105
virus	O	106-111
appeared	O	112-120
to	O	121-123
express	O	124-131
the	O	132-135
L2	O	136-138
or	O	139-141
L8	O	142-144
ORF	O	145-148
. 	O	148-150

Peptide	O	0-7
-	O	7-8
specific	O	8-16
immunoglobulin	O	17-31
G	O	32-33
(	O	34-35
IgG	O	35-38
)	O	38-39
was	O	40-43
generated	O	44-53
against	O	54-61
open	O	62-66
reading	O	67-74
frames	O	75-81
(	O	82-83
ORFs	O	83-87
)	O	87-88
that	O	89-93
are	O	94-97
located	O	98-105
within	O	106-112
the	O	113-116
first	O	117-122
1	O	123-124
.	O	124-125
5	O	125-126
kb	O	127-129
of	O	130-132
LAT	O	133-136
coding	O	137-143
sequences	O	144-153
. 	O	153-155

Only	O	0-4
L2	O	5-7
ORF	O	8-11
expression	O	12-22
was	O	23-26
readily	O	27-34
detected	O	35-43
in	O	44-46
trigeminal	O	47-57
ganglionic	O	58-68
neurons	O	69-76
of	O	77-79
latently	O	80-88
infected	O	89-97
mice	O	98-102
.   	O	102-106

Expression	O	0-10
of	O	11-13
the	O	14-17
first	O	18-23
1	O	24-25
.	O	25-26
5	O	26-27
kb	O	28-30
of	O	31-33
the	O	34-37
latency	O	38-45
-	O	45-46
associated	O	46-56
transcript	O	57-67
(	O	68-69
LAT	O	69-72
)	O	72-73
that	O	74-78
is	O	79-81
encoded	O	82-89
by	O	90-92
herpes	O	93-99
simplex	O	100-107
virus	O	108-113
type	O	114-118
1	O	119-120
(	O	121-122
HSV	O	122-125
-	O	125-126
1	O	126-127
)	O	127-128
is	O	129-131
sufficient	O	132-142
for	O	143-146
wild	O	147-151
-	O	151-152
type	O	152-156
(	O	157-158
wt	O	158-160
)	O	160-161
levels	O	162-168
of	O	169-171
reactivation	O	172-184
from	O	185-189
latency	O	190-197
in	O	198-200
small	O	201-206
animal	O	207-213
models	O	214-220
. 	O	220-222

Identification	O	0-14
of	O	15-17
herpes	O	18-24
simplex	O	25-32
virus	O	33-38
type	O	39-43
1	O	44-45
proteins	O	46-54
encoded	O	55-62
within	O	63-69
the	O	70-73
first	O	74-79
1	O	80-81
.	O	81-82
5	O	82-83
kb	O	84-86
of	O	87-89
the	O	90-93
latency	O	94-101
-	O	101-102
associated	O	102-112
transcript	O	113-123
.  	O	123-126

Our	O	0-3
study	O	4-9
shows	O	10-15
that	O	16-20
one	O	21-24
aspect	O	25-31
of	O	32-34
miR	B	35-38
-	I	38-39
155	I	39-42
function	O	43-51
is	O	52-54
the	O	55-58
promotion	O	59-68
of	O	69-71
T	O	72-73
cell	O	74-78
-	O	78-79
dependent	O	79-88
tissue	O	89-95
inflammation	O	96-108
,	O	108-109
suggesting	O	110-120
that	O	121-125
miR	B	126-129
-	I	129-130
155	I	130-133
might	O	134-139
be	O	140-142
a	O	143-144
promising	O	145-154
therapeutic	O	155-166
target	O	167-173
for	O	174-177
the	O	178-181
treatment	O	182-191
of	O	192-194
autoimmune	O	195-205
disorders	O	206-215
.   	O	215-219

miR	B	0-3
-	I	3-4
155	I	4-7
functions	O	8-17
in	O	18-20
the	O	21-24
hematopoietic	O	25-38
compartment	O	39-50
to	O	51-53
promote	O	54-61
the	O	62-65
development	O	66-77
of	O	78-80
inflammatory	O	81-93
T	O	94-95
cells	O	96-101
including	O	102-111
the	O	112-115
T	O	116-117
helper	O	118-124
17	O	125-127
(	O	128-129
Th17	O	129-133
)	O	133-134
cell	O	135-139
and	O	140-143
Th1	O	144-147
cell	O	148-152
subsets	O	153-160
. 	O	160-162

Furthermore	O	0-11
,	O	11-12
the	O	13-16
major	O	17-22
contribution	O	23-35
of	O	36-38
miR	B	39-42
-	I	42-43
155	I	43-46
to	O	47-49
EAE	O	50-53
was	O	54-57
CD4	O	58-61
(	O	61-62
+	O	62-63
)	O	63-64
T	O	65-66
cell	O	67-71
intrinsic	O	72-81
,	O	81-82
whereas	O	83-90
miR	B	91-94
-	I	94-95
155	I	95-98
was	O	99-102
also	O	103-107
required	O	108-116
for	O	117-120
optimum	O	121-128
dendritic	O	129-138
cell	O	139-143
production	O	144-154
of	O	155-157
cytokines	O	158-167
that	O	168-172
promoted	O	173-181
Th17	O	182-186
cell	O	187-191
formation	O	192-201
. 	O	201-203

Here	O	0-4
,	O	4-5
we	O	6-8
have	O	9-13
investigated	O	14-26
the	O	27-30
role	O	31-35
of	O	36-38
miR	B	39-42
-	I	42-43
155	I	43-46
during	O	47-53
an	O	54-56
autoimmune	O	57-67
inflammatory	O	68-80
disease	O	81-88
. 	O	88-90

Consistent	O	0-10
with	O	11-15
a	O	16-17
positive	O	18-26
role	O	27-31
for	O	32-35
miR	B	36-39
-	I	39-40
155	I	40-43
in	O	44-46
mediating	O	47-56
inflammatory	O	57-69
responses	O	70-79
,	O	79-80
Mir155	B	81-87
(	O	87-88
-	O	88-89
/	O	89-90
-	O	90-91
)	O	91-92
mice	O	93-97
were	O	98-102
highly	O	103-109
resistant	O	110-119
to	O	120-122
experimental	O	123-135
autoimmune	O	136-146
encephalomyelitis	O	147-164
(	O	165-166
EAE	O	166-169
)	O	169-170
. 	O	170-172

MicroRNA	B	0-8
-	I	8-9
155	I	9-12
promotes	O	13-21
autoimmune	O	22-32
inflammation	O	33-45
by	O	46-48
enhancing	O	49-58
inflammatory	O	59-71
T	O	72-73
cell	O	74-78
development	O	79-90
.  	O	90-93

Mammalian	O	0-9
noncoding	O	10-19
microRNAs	O	20-29
(	O	30-31
miRNAs	O	31-37
)	O	37-38
are	O	39-42
a	O	43-44
class	O	45-50
of	O	51-53
gene	O	54-58
regulators	O	59-69
that	O	70-74
have	O	75-79
been	O	80-84
linked	O	85-91
to	O	92-94
immune	O	95-101
system	O	102-108
function	O	109-117
. 	O	117-119

During	O	0-6
experimental	O	7-19
autoimmune	O	20-30
encephalomyelitis	O	31-48
(	O	49-50
EAE	O	50-53
)	O	53-54
,	O	54-55
miR	B	56-59
-	I	59-60
124	I	60-63
was	O	64-67
downregulated	O	68-81
in	O	82-84
activated	O	85-94
microglia	O	95-104
. 	O	104-106

Peripheral	O	0-10
administration	O	11-25
of	O	26-28
miR	B	29-32
-	I	32-33
124	I	33-36
in	O	37-39
EAE	O	40-43
caused	O	44-50
systemic	O	51-59
deactivation	O	60-72
of	O	73-75
macrophages	O	76-87
,	O	87-88
reduced	O	89-96
activation	O	97-107
of	O	108-110
myelin	O	111-117
-	O	117-118
specific	O	118-126
T	O	127-128
cells	O	129-134
and	O	135-138
marked	O	139-145
suppression	O	146-157
of	O	158-160
disease	O	161-168
. 	O	168-170

Conversely	O	0-10
,	O	10-11
knockdown	O	12-21
of	O	22-24
miR	B	25-28
-	I	28-29
124	I	29-32
in	O	33-35
microglia	O	36-45
and	O	46-49
macrophages	O	50-61
resulted	O	62-70
in	O	71-73
activation	O	74-84
of	O	85-87
these	O	88-93
cells	O	94-99
in	O	100-102
vitro	O	103-108
and	O	109-112
in	O	113-115
vivo	O	116-120
. 	O	120-122

These	O	0-5
findings	O	6-14
identify	O	15-23
miR	B	24-27
-	I	27-28
124	I	28-31
both	O	32-36
as	O	37-39
a	O	40-41
key	O	42-45
regulator	O	46-55
of	O	56-58
microglia	O	59-68
quiescence	O	69-79
in	O	80-82
the	O	83-86
central	O	87-94
nervous	O	95-102
system	O	103-109
and	O	110-113
as	O	114-116
a	O	117-118
previously	O	119-129
unknown	O	130-137
modulator	O	138-147
of	O	148-150
monocyte	O	151-159
and	O	160-163
macrophage	O	164-174
activation	O	175-185
.   	O	185-189

MicroRNA	B	0-8
-	I	8-9
124	I	9-12
promotes	O	13-21
microglia	O	22-31
quiescence	O	32-42
and	O	43-46
suppresses	O	47-57
EAE	O	58-61
by	O	62-64
deactivating	O	65-77
macrophages	O	78-89
via	O	90-93
the	O	94-97
C	O	98-99
/	O	99-100
EBP	O	100-103
-	O	103-104
α	O	104-106
-	O	106-107
PU	O	107-109
.	O	109-110
1	O	110-111
pathway	O	112-119
.  	O	119-122

MicroRNAs	O	0-9
are	O	10-13
a	O	14-15
family	O	16-22
of	O	23-25
regulatory	O	26-36
molecules	O	37-46
involved	O	47-55
in	O	56-58
many	O	59-63
physiological	O	64-77
processes	O	78-87
,	O	87-88
including	O	89-98
differentiation	O	99-114
and	O	115-118
activation	O	119-129
of	O	130-132
cells	O	133-138
of	O	139-141
the	O	142-145
immune	O	146-152
system	O	153-159
. 	O	159-161

We	O	0-2
found	O	3-8
that	O	9-13
brain	O	14-19
-	O	19-20
specific	O	20-28
miR	B	29-32
-	I	32-33
124	I	33-36
is	O	37-39
expressed	O	40-49
in	O	50-52
microglia	O	53-62
but	O	63-66
not	O	67-70
in	O	71-73
peripheral	O	74-84
monocytes	O	85-94
or	O	95-97
macrophages	O	98-109
. 	O	109-111

When	O	0-4
overexpressed	O	5-18
in	O	19-21
macrophages	O	22-33
,	O	33-34
miR	B	35-38
-	I	38-39
124	I	39-42
directly	O	43-51
inhibited	O	52-61
the	O	62-65
transcription	O	66-79
factor	O	80-86
CCAAT	O	87-92
/	O	92-93
enhancer	O	93-101
-	O	101-102
binding	O	102-109
protein	O	110-117
-	O	117-118
α	O	118-120
(	O	121-122
C	O	122-123
/	O	123-124
EBP	O	124-127
-	O	127-128
α	O	128-130
)	O	130-131
and	O	132-135
its	O	136-139
downstream	O	140-150
target	O	151-157
PU	O	158-160
.	O	160-161
1	O	161-162
,	O	162-163
resulting	O	164-173
in	O	174-176
transformation	O	177-191
of	O	192-194
these	O	195-200
cells	O	201-206
from	O	207-211
an	O	212-214
activated	O	215-224
phenotype	O	225-234
into	O	235-239
a	O	240-241
quiescent	O	242-251
CD45	O	252-256
(	O	256-257
low	O	257-260
)	O	260-261
,	O	261-262
major	O	263-268
histocompatibility	O	269-287
complex	O	288-295
(	O	296-297
MHC	O	297-300
)	O	300-301
class	O	302-307
II	O	308-310
(	O	310-311
low	O	311-314
)	O	314-315
phenotype	O	316-325
resembling	O	326-336
resting	O	337-344
microglia	O	345-354
. 	O	354-356

Mutations	O	0-9
in	O	10-12
the	O	13-16
Drosophila	O	17-27
gene	O	28-32
lethal	O	33-39
(	O	40-41
3	O	41-42
)	O	42-43
malignant	O	44-53
brain	O	54-59
tumor	O	60-65
cause	O	66-71
malignant	O	72-81
growth	O	82-88
in	O	89-91
the	O	92-95
larval	O	96-102
brain	O	103-108
. 	O	108-110

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
l	O	18-19
(	O	19-20
3	O	20-21
)	O	21-22
mbt	O	22-25
tumors	O	26-32
exhibited	O	33-42
a	O	43-44
soma	O	45-49
-	O	49-50
to	O	50-52
-	O	52-53
germline	O	53-61
transformation	O	62-76
through	O	77-84
the	O	85-88
ectopic	O	89-96
expression	O	97-107
of	O	108-110
genes	O	111-116
normally	O	117-125
required	O	126-134
for	O	135-138
germline	O	139-147
stemness	O	148-156
,	O	156-157
fitness	O	158-165
,	O	165-166
or	O	167-169
longevity	O	170-179
. 	O	179-181

Orthologs	O	0-9
of	O	10-12
some	O	13-17
of	O	18-20
these	O	21-26
genes	O	27-32
were	O	33-37
also	O	38-42
expressed	O	43-52
in	O	53-55
human	O	56-61
somatic	O	62-69
tumors	O	70-76
. 	O	76-78

In	O	0-2
addition	O	3-11
,	O	11-12
inactivation	O	13-25
of	O	26-28
any	O	29-32
of	O	33-35
the	O	36-39
germline	O	40-48
genes	O	49-54
nanos	O	55-60
,	O	60-61
vasa	O	62-66
,	O	66-67
piwi	O	68-72
,	O	72-73
or	O	74-76
aubergine	O	77-86
suppressed	O	87-97
l	O	98-99
(	O	99-100
3	O	100-101
)	O	101-102
mbt	O	102-105
malignant	O	106-115
growth	O	116-122
. 	O	122-124

Ectopic	O	0-7
expression	O	8-18
of	O	19-21
germline	O	22-30
genes	O	31-36
drives	O	37-43
malignant	O	44-53
brain	O	54-59
tumor	O	60-65
growth	O	66-72
in	O	73-75
Drosophila	O	76-86
.  	O	86-89

Model	O	0-5
organisms	O	6-15
such	O	16-20
as	O	21-23
the	O	24-27
fruit	O	28-33
fly	O	34-37
Drosophila	O	38-48
melanogaster	O	49-61
can	O	62-65
help	O	66-70
to	O	71-73
elucidate	O	74-83
the	O	84-87
molecular	O	88-97
basis	O	98-103
of	O	104-106
complex	O	107-114
diseases	O	115-123
such	O	124-128
as	O	129-131
cancer	O	132-138
. 	O	138-140

Our	O	0-3
results	O	4-11
demonstrate	O	12-23
that	O	24-28
germline	O	29-37
traits	O	38-44
are	O	45-48
necessary	O	49-58
for	O	59-62
tumor	O	63-68
growth	O	69-75
in	O	76-78
this	O	79-83
Drosophila	O	84-94
model	O	95-100
and	O	101-104
suggest	O	105-112
that	O	113-117
inactivation	O	118-130
of	O	131-133
germline	O	134-142
genes	O	143-148
might	O	149-154
have	O	155-159
tumor	O	160-165
-	O	165-166
suppressing	O	166-177
effects	O	178-185
in	O	186-188
other	O	189-194
species	O	195-202
.   	O	202-206

We	O	0-2
also	O	3-7
identified	O	8-18
a	O	19-20
potential	O	21-30
feedback	O	31-39
loop	O	40-44
between	O	45-52
LKB1	O	53-57
and	O	58-61
miR	B	62-65
-	I	65-66
451	I	66-69
,	O	69-70
which	O	71-76
allows	O	77-83
a	O	84-85
sustained	O	86-95
and	O	96-99
robust	O	100-106
response	O	107-115
to	O	116-118
glucose	O	119-126
deprivation	O	127-138
. 	O	138-140

We	O	0-2
then	O	3-7
found	O	8-13
that	O	14-18
by	O	19-21
targeting	O	22-31
the	O	32-35
LKB1	O	36-40
kinase	O	41-47
complex	O	48-55
miR	B	56-59
-	I	59-60
451	I	60-63
suppresses	O	64-74
the	O	75-78
activity	O	79-87
of	O	88-90
downstream	O	91-101
protein	O	102-109
kinases	O	110-117
including	O	118-127
the	O	128-131
major	O	132-137
energy	O	138-144
biosensor	O	145-154
AMPK	O	155-159
. 	O	159-161

We	O	0-2
initially	O	3-12
identified	O	13-23
miR	B	24-27
-	I	27-28
451	I	28-31
due	O	32-35
to	O	36-38
its	O	39-42
downregulation	O	43-57
in	O	58-60
a	O	61-62
glioma	O	63-69
cell	O	70-74
migration	O	75-84
assay	O	85-90
. 	O	90-92

Under	O	0-5
conditions	O	6-16
of	O	17-19
glucose	O	20-27
withdrawal	O	28-38
,	O	38-39
miR	B	40-43
-	I	43-44
451	I	44-47
downregulation	O	48-62
is	O	63-65
necessary	O	66-75
for	O	76-79
AMPK	O	80-84
pathway	O	85-92
activation	O	93-103
,	O	103-104
leading	O	105-112
to	O	113-115
suppressed	O	116-126
proliferation	O	127-140
rates	O	141-146
,	O	146-147
increased	O	148-157
cell	O	158-162
survival	O	163-171
and	O	172-175
migration	O	176-185
. 	O	185-187

MiR	B	0-3
-	I	3-4
451	I	4-7
levels	O	8-14
are	O	15-18
regulated	O	19-28
by	O	29-31
glucose	O	32-39
;	O	39-40
under	O	41-46
conditions	O	47-57
of	O	58-60
abundant	O	61-69
energy	O	70-76
miR	B	77-80
-	I	80-81
451	I	81-84
expression	O	85-95
is	O	96-98
high	O	99-103
,	O	103-104
and	O	105-108
the	O	109-112
suppression	O	113-124
of	O	125-127
AMPK	O	128-132
signaling	O	133-142
allows	O	143-149
cells	O	150-155
to	O	156-158
maintain	O	159-167
elevated	O	168-176
proliferation	O	177-190
rates	O	191-196
via	O	197-200
unrestrained	O	201-213
mTOR	O	214-218
activation	O	219-229
. 	O	229-231

Incomplete	O	0-10
knowledge	O	11-20
of	O	21-23
the	O	24-27
molecular	O	28-37
biology	O	38-45
,	O	45-46
genetics	O	47-55
,	O	55-56
causes	O	57-63
and	O	64-67
cellular	O	68-76
origin	O	77-83
of	O	84-86
these	O	87-92
tumors	O	93-99
may	O	100-103
limit	O	104-109
the	O	110-113
development	O	114-125
of	O	126-128
improved	O	129-137
therapeutics	O	138-150
. 	O	150-152

Glioblastoma	O	0-12
,	O	12-13
the	O	14-17
most	O	18-22
common	O	23-29
and	O	30-33
aggressive	O	34-44
primary	O	45-52
brain	O	53-58
tumor	O	59-64
,	O	64-65
is	O	66-68
rapidly	O	69-76
growing	O	77-84
and	O	85-88
highly	O	89-95
infiltrative	O	96-108
. 	O	108-110

Here	O	0-4
we	O	5-7
will	O	8-12
discuss	O	13-20
further	O	21-28
our	O	29-32
recently	O	33-41
published	O	42-51
data	O	52-56
on	O	57-59
the	O	60-63
role	O	64-68
of	O	69-71
miR	B	72-75
-	I	75-76
451	I	76-79
in	O	80-82
the	O	83-86
biology	O	87-94
of	O	95-97
glioblastoma	O	98-110
. 	O	110-112

A	O	0-1
major	O	2-7
and	O	8-11
fundamental	O	12-23
advance	O	24-31
in	O	32-34
recent	O	35-41
years	O	42-47
has	O	48-51
been	O	52-56
the	O	57-60
identification	O	61-75
of	O	76-78
microRNAs	O	79-88
as	O	89-91
highly	O	92-98
conserved	O	99-108
regulators	O	109-119
of	O	120-122
gene	O	123-127
expression	O	128-138
. 	O	138-140

microRNA	B	0-8
-	I	8-9
451	I	9-12
:	O	12-13
A	O	14-15
conditional	O	16-27
switch	O	28-34
controlling	O	35-46
glioma	O	47-53
cell	O	54-58
proliferation	O	59-72
and	O	73-76
migration	O	77-86
.  	O	86-89

This	O	0-4
data	O	5-9
will	O	10-14
be	O	15-17
discussed	O	18-27
in	O	28-30
the	O	31-34
context	O	35-42
of	O	43-45
potential	O	46-55
biological	O	56-66
significance	O	67-79
and	O	80-83
therapeutic	O	84-95
implications	O	96-108
.   	O	108-112

Thus	O	0-4
,	O	4-5
miR	B	6-9
-	I	9-10
206	I	10-13
slows	O	14-19
ALS	O	20-23
progression	O	24-35
by	O	36-38
sensing	O	39-46
motor	O	47-52
neuron	O	53-59
injury	O	60-66
and	O	67-70
promoting	O	71-80
the	O	81-84
compensatory	O	85-97
regeneration	O	98-110
of	O	111-113
neuromuscular	O	114-127
synapses	O	128-136
.   	O	136-140

Here	O	0-4
,	O	4-5
we	O	6-8
show	O	9-13
that	O	14-18
a	O	19-20
key	O	21-24
regulator	O	25-34
of	O	35-37
this	O	38-42
signaling	O	43-52
is	O	53-55
miR	B	56-59
-	I	59-60
206	I	60-63
,	O	63-64
a	O	65-66
skeletal	O	67-75
muscle	O	76-82
-	O	82-83
specific	O	83-91
microRNA	O	92-100
that	O	101-105
is	O	106-108
dramatically	O	109-121
induced	O	122-129
in	O	130-132
a	O	133-134
mouse	O	135-140
model	O	141-146
of	O	147-149
ALS	O	150-153
. 	O	153-155

Mice	O	0-4
that	O	5-9
are	O	10-13
genetically	O	14-25
deficient	O	26-35
in	O	36-38
miR	B	39-42
-	I	42-43
206	I	43-46
form	O	47-51
normal	O	52-58
neuromuscular	O	59-72
synapses	O	73-81
during	O	82-88
development	O	89-100
,	O	100-101
but	O	102-105
deficiency	O	106-116
of	O	117-119
miR	B	120-123
-	I	123-124
206	I	124-127
in	O	128-130
the	O	131-134
ALS	O	135-138
mouse	O	139-144
model	O	145-150
accelerates	O	151-162
disease	O	163-170
progression	O	171-182
. 	O	182-184

miR	B	0-3
-	I	3-4
206	I	4-7
is	O	8-10
required	O	11-19
for	O	20-23
efficient	O	24-33
regeneration	O	34-46
of	O	47-49
neuromuscular	O	50-63
synapses	O	64-72
after	O	73-78
acute	O	79-84
nerve	O	85-90
injury	O	91-97
,	O	97-98
which	O	99-104
probably	O	105-113
accounts	O	114-122
for	O	123-126
its	O	127-130
salutary	O	131-139
effects	O	140-147
in	O	148-150
ALS	O	151-154
. 	O	154-156

miR	B	0-3
-	I	3-4
206	I	4-7
mediates	O	8-16
these	O	17-22
effects	O	23-30
at	O	31-33
least	O	34-39
in	O	40-42
part	O	43-47
through	O	48-55
histone	O	56-63
deacetylase	O	64-75
4	O	76-77
and	O	78-81
fibroblast	O	82-92
growth	O	93-99
factor	O	100-106
signaling	O	107-116
pathways	O	117-125
. 	O	125-127

MicroRNA	B	0-8
-	I	8-9
206	I	9-12
delays	O	13-19
ALS	O	20-23
progression	O	24-35
and	O	36-39
promotes	O	40-48
regeneration	O	49-61
of	O	62-64
neuromuscular	O	65-78
synapses	O	79-87
in	O	88-90
mice	O	91-95
.  	O	95-98

Amyotrophic	O	0-11
lateral	O	12-19
sclerosis	O	20-29
(	O	30-31
ALS	O	31-34
)	O	34-35
is	O	36-38
a	O	39-40
neurodegenerative	O	41-58
disease	O	59-66
characterized	O	67-80
by	O	81-83
loss	O	84-88
of	O	89-91
motor	O	92-97
neurons	O	98-105
,	O	105-106
denervation	O	107-118
of	O	119-121
target	O	122-128
muscles	O	129-136
,	O	136-137
muscle	O	138-144
atrophy	O	145-152
,	O	152-153
and	O	154-157
paralysis	O	158-167
. 	O	167-169

Understanding	O	0-13
ALS	O	14-17
pathogenesis	O	18-30
may	O	31-34
require	O	35-42
a	O	43-44
fuller	O	45-51
understanding	O	52-65
of	O	66-68
the	O	69-72
bidirectional	O	73-86
signaling	O	87-96
between	O	97-104
motor	O	105-110
neurons	O	111-118
and	O	119-122
skeletal	O	123-131
muscle	O	132-138
fibers	O	139-145
at	O	146-148
neuromuscular	O	149-162
synapses	O	163-171
. 	O	171-173

In	O	0-2
gliomas	O	3-10
,	O	10-11
microRNA	B	12-20
-	I	20-21
21	I	21-23
(	O	24-25
miR	B	25-28
-	I	28-29
21	I	29-31
)	O	31-32
levels	O	33-39
have	O	40-44
been	O	45-49
reported	O	50-58
to	O	59-61
be	O	62-64
elevated	O	65-73
and	O	74-77
their	O	78-83
knockdown	O	84-93
is	O	94-96
associated	O	97-107
with	O	108-112
increased	O	113-122
apoptotic	O	123-132
activity	O	133-141
. 	O	141-143

We	O	0-2
hypothesized	O	3-15
that	O	16-20
suppression	O	21-32
of	O	33-35
miR	B	36-39
-	I	39-40
21	I	40-42
might	O	43-48
sensitize	O	49-58
gliomas	O	59-66
for	O	67-70
cytotoxic	O	71-80
tumor	O	81-86
therapy	O	87-94
. 	O	94-96

With	O	0-4
the	O	5-8
use	O	9-12
of	O	13-15
locked	O	16-22
nucleic	O	23-30
acid	O	31-35
(	O	36-37
LNA	O	37-40
)	O	40-41
-	O	41-42
antimiR	O	42-49
-	O	49-50
21	O	50-52
oligonucleotides	O	53-69
,	O	69-70
bimodal	O	71-78
imaging	O	79-86
vectors	O	87-94
,	O	94-95
and	O	96-99
neural	O	100-106
precursor	O	107-116
cells	O	117-122
(	O	123-124
NPC	O	124-127
)	O	127-128
expressing	O	129-139
a	O	140-141
secretable	O	142-152
variant	O	153-160
of	O	161-163
the	O	164-167
cytotoxic	O	168-177
agent	O	178-183
tumor	O	184-189
necrosis	O	190-198
factor	O	199-205
-	O	205-206
related	O	206-213
apoptosis	O	214-223
inducing	O	224-232
ligand	O	233-239
(	O	240-241
S	O	241-242
-	O	242-243
TRAIL	O	243-248
)	O	248-249
,	O	249-250
we	O	251-253
show	O	254-258
that	O	259-263
the	O	264-267
combined	O	268-276
suppression	O	277-288
of	O	289-291
miR	B	292-295
-	I	295-296
21	I	296-298
and	O	299-302
NPC	O	303-306
-	O	306-307
S	O	307-308
-	O	308-309
TRAIL	O	309-314
leads	O	315-320
to	O	321-323
a	O	324-325
synergistic	O	326-337
increase	O	338-346
in	O	347-349
caspase	O	350-357
activity	O	358-366
and	O	367-370
significantly	O	371-384
decreased	O	385-394
cell	O	395-399
viability	O	400-409
in	O	410-412
human	O	413-418
glioma	O	419-425
cells	O	426-431
in	O	432-434
vitro	O	435-440
. 	O	440-442

This	O	0-4
phenomenon	O	5-15
persists	O	16-24
in	O	25-27
vivo	O	28-32
,	O	32-33
as	O	34-36
we	O	37-39
observed	O	40-48
complete	O	49-57
eradication	O	58-69
of	O	70-72
LNA	O	73-76
-	O	76-77
antimiR	O	77-84
-	O	84-85
21	O	85-87
-	O	87-88
treated	O	88-95
gliomas	O	96-103
subjected	O	104-113
to	O	114-116
the	O	117-120
presence	O	121-129
of	O	130-132
NPC	O	133-136
-	O	136-137
S	O	137-138
-	O	138-139
TRAIL	O	139-144
in	O	145-147
the	O	148-151
murine	O	152-158
brain	O	159-164
. 	O	164-166

Our	O	0-3
results	O	4-11
reveal	O	12-18
the	O	19-22
efficacy	O	23-31
of	O	32-34
miR	B	35-38
-	I	38-39
21	I	39-41
antagonism	O	42-52
in	O	53-55
murine	O	56-62
glioma	O	63-69
models	O	70-76
and	O	77-80
implicate	O	81-90
miR	B	91-94
-	I	94-95
21	I	95-97
as	O	98-100
a	O	101-102
target	O	103-109
for	O	110-113
therapeutic	O	114-125
intervention	O	126-138
. 	O	138-140

Furthermore	O	0-11
,	O	11-12
our	O	13-16
findings	O	17-25
provide	O	26-33
the	O	34-37
basis	O	38-43
for	O	44-47
developing	O	48-58
combination	O	59-70
therapies	O	71-80
using	O	81-86
miRNA	O	87-92
modulation	O	93-103
and	O	104-107
cytotoxic	O	108-117
tumor	O	118-123
therapies	O	124-133
.   	O	133-137

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
knockdown	O	12-21
disrupts	O	22-30
glioma	O	31-37
growth	O	38-44
in	O	45-47
vivo	O	48-52
and	O	53-56
displays	O	57-65
synergistic	O	66-77
cytotoxicity	O	78-90
with	O	91-95
neural	O	96-102
precursor	O	103-112
cell	O	113-117
delivered	O	118-127
S	O	128-129
-	O	129-130
TRAIL	O	130-135
in	O	136-138
human	O	139-144
gliomas	O	145-152
.  	O	152-155

Mounting	O	0-8
evidence	O	9-17
indicates	O	18-27
that	O	28-32
microRNAs	O	33-42
(	O	43-44
miRNA	O	44-49
)	O	49-50
might	O	51-56
play	O	57-61
a	O	62-63
fundamental	O	64-75
role	O	76-80
in	O	81-83
tumorigenesis	O	84-97
,	O	97-98
controlling	O	99-110
cell	O	111-115
proliferation	O	116-129
and	O	130-133
apoptosis	O	134-143
. 	O	143-145

Despite	O	0-7
the	O	8-11
development	O	12-23
of	O	24-26
new	O	27-30
glioma	O	31-37
therapies	O	38-47
that	O	48-52
allow	O	53-58
for	O	59-62
tumor	O	63-68
-	O	68-69
targeted	O	69-77
in	O	78-80
situ	O	81-85
delivery	O	86-94
of	O	95-97
cytotoxic	O	98-107
drugs	O	108-113
,	O	113-114
tumor	O	115-120
resistance	O	121-131
to	O	132-134
apoptosis	O	135-144
remains	O	145-152
a	O	153-154
key	O	155-158
impediment	O	159-169
to	O	170-172
effective	O	173-182
treatment	O	183-192
. 	O	192-194

We	O	0-2
therefore	O	3-12
sought	O	13-19
to	O	20-22
determine	O	23-32
whether	O	33-40
microRNA	O	41-49
targets	O	50-57
could	O	58-63
be	O	64-66
engineered	O	67-77
into	O	78-82
VSV	O	83-86
to	O	87-89
ameliorate	O	90-100
its	O	101-104
neuropathogenicity	O	105-123
. 	O	123-125

Using	O	0-5
a	O	6-7
panel	O	8-13
of	O	14-16
recombinant	O	17-28
VSVs	O	29-33
incorporating	O	34-47
microRNA	O	48-56
target	O	57-63
sequences	O	64-73
corresponding	O	74-87
to	O	88-90
neuron	O	91-97
-	O	97-98
specific	O	98-106
or	O	107-109
control	O	110-117
microRNAs	O	118-127
(	O	128-129
in	O	129-131
forward	O	132-139
and	O	140-143
reverse	O	144-151
orientations	O	152-164
)	O	164-165
,	O	165-166
we	O	167-169
tested	O	170-176
viral	O	177-182
replication	O	183-194
kinetics	O	195-203
in	O	204-206
cell	O	207-211
lines	O	212-217
treated	O	218-225
with	O	226-230
microRNA	O	231-239
mimics	O	240-246
,	O	246-247
neurotoxicity	O	248-261
after	O	262-267
direct	O	268-274
intracerebral	O	275-288
inoculation	O	289-300
in	O	301-303
mice	O	304-308
,	O	308-309
and	O	310-313
antitumor	O	314-323
efficacy	O	324-332
. 	O	332-334

Compared	O	0-8
to	O	9-11
picornaviruses	O	12-26
and	O	27-30
adenoviruses	O	31-43
,	O	43-44
the	O	45-48
engineered	O	49-59
VSVs	O	60-64
were	O	65-69
relatively	O	70-80
resistant	O	81-90
to	O	91-93
microRNA	O	94-102
-	O	102-103
mediated	O	103-111
inhibition	O	112-122
,	O	122-123
but	O	124-127
neurotoxicity	O	128-141
could	O	142-147
nevertheless	O	148-160
be	O	161-163
ameliorated	O	164-175
significantly	O	176-189
using	O	190-195
this	O	196-200
approach	O	201-209
,	O	209-210
without	O	211-218
compromise	O	219-229
to	O	230-232
antitumor	O	233-242
efficacy	O	243-251
. 	O	251-253

Neurotoxicity	O	0-13
was	O	14-17
most	O	18-22
profoundly	O	23-33
reduced	O	34-41
in	O	42-44
a	O	45-46
virus	O	47-52
carrying	O	53-61
four	O	62-66
tandem	O	67-73
copies	O	74-80
of	O	81-83
a	O	84-85
neuronal	O	86-94
mir125	B	95-101
target	O	102-108
sequence	O	109-117
inserted	O	118-126
in	O	127-129
the	O	130-133
3	O	134-135
'	O	135-136
-	O	136-137
untranslated	O	137-149
region	O	150-156
of	O	157-159
the	O	160-163
viral	O	164-169
polymerase	O	170-180
(	O	181-182
L	O	182-183
)	O	183-184
gene	O	185-189
.   	O	189-193

Attenuation	O	0-11
of	O	12-14
vesicular	O	15-24
stomatitis	O	25-35
virus	O	36-41
encephalitis	O	42-54
through	O	55-62
microRNA	O	63-71
targeting	O	72-81
.  	O	81-84

Vesicular	O	0-9
stomatitis	O	10-20
virus	O	21-26
(	O	27-28
VSV	O	28-31
)	O	31-32
has	O	33-36
long	O	37-41
been	O	42-46
regarded	O	47-55
as	O	56-58
a	O	59-60
promising	O	61-70
recombinant	O	71-82
vaccine	O	83-90
platform	O	91-99
and	O	100-103
oncolytic	O	104-113
agent	O	114-119
but	O	120-123
has	O	124-127
not	O	128-131
yet	O	132-135
been	O	136-140
tested	O	141-147
in	O	148-150
humans	O	151-157
because	O	158-165
it	O	166-168
causes	O	169-175
encephalomyelitis	O	176-193
in	O	194-196
rodents	O	197-204
and	O	205-208
primates	O	209-217
. 	O	217-219

Recent	O	0-6
studies	O	7-14
have	O	15-19
shown	O	20-25
that	O	26-30
specific	O	31-39
tropisms	O	40-48
of	O	49-51
several	O	52-59
viruses	O	60-67
could	O	68-73
be	O	74-76
eliminated	O	77-87
by	O	88-90
engineering	O	91-102
microRNA	O	103-111
target	O	112-118
sequences	O	119-128
into	O	129-133
their	O	134-139
genomes	O	140-147
,	O	147-148
thereby	O	149-156
inhibiting	O	157-167
spread	O	168-174
in	O	175-177
tissues	O	178-185
expressing	O	186-196
cognate	O	197-204
microRNAs	O	205-214
. 	O	214-216

Furthermore	O	0-11
,	O	11-12
in	O	13-15
patient	O	16-23
samples	O	24-31
expression	O	32-42
of	O	43-45
miR	B	46-49
124a	I	50-54
is	O	55-57
significantly	O	58-71
decreased	O	72-81
. 	O	81-83

Our	O	0-3
data	O	4-8
strongly	O	9-17
indicate	O	18-26
that	O	27-31
CDK6	O	32-36
is	O	37-39
regulated	O	40-49
by	O	50-52
microRNA	B	53-61
124	I	62-65
in	O	66-68
medulloblastoma	O	69-84
and	O	85-88
that	O	89-93
miR	B	94-97
124	I	98-101
modulates	O	102-111
medulloblastoma	O	112-127
cell	O	128-132
growth	O	133-139
.   	O	139-143

We	O	0-2
hypothesized	O	3-15
that	O	16-20
CDK6	O	21-25
expression	O	26-36
is	O	37-39
also	O	40-44
regulated	O	45-54
by	O	55-57
microRNAs	O	58-67
in	O	68-70
medulloblastoma	O	71-86
. 	O	86-88

Genomic	O	0-7
amplification	O	8-21
accounts	O	22-30
for	O	31-34
some	O	35-39
,	O	39-40
but	O	41-44
not	O	45-48
all	O	49-52
of	O	53-55
the	O	56-59
CDK6	O	60-64
over	O	65-69
-	O	69-70
expression	O	70-80
. 	O	80-82

Expression	O	0-10
of	O	11-13
miR	B	14-17
124a	I	18-22
was	O	23-26
significantly	O	27-40
decreased	O	41-50
in	O	51-53
medulloblastoma	O	54-69
cells	O	70-75
compared	O	76-84
to	O	85-87
normal	O	88-94
adult	O	95-100
cerebellum	O	101-111
. 	O	111-113

We	O	0-2
identified	O	3-13
putative	O	14-22
miR	O	23-26
sites	O	27-32
in	O	33-35
the	O	36-39
CDK6	O	40-44
including	O	45-54
microRNA	B	55-63
124a	I	64-68
,	O	68-69
a	O	70-71
brain	O	72-77
enriched	O	78-86
microRNA	O	87-95
. 	O	95-97

Additionally	O	0-12
,	O	12-13
re	O	14-16
-	O	16-17
expression	O	17-27
of	O	28-30
miR	B	31-34
124a	I	35-39
in	O	40-42
medulloblastoma	O	43-58
cells	O	59-64
decreased	O	65-74
expression	O	75-85
of	O	86-88
CDK6	O	89-93
protein	O	94-101
. 	O	101-103

Functional	O	0-10
association	O	11-22
between	O	23-30
miR	B	31-34
124a	I	35-39
and	O	40-43
CDK6	O	44-48
in	O	49-51
medulloblastoma	O	52-67
was	O	68-71
established	O	72-83
using	O	84-89
luciferase	O	90-100
assays	O	101-107
. 	O	107-109

Transfection	O	0-12
of	O	13-15
miR	B	16-19
124	I	20-23
significantly	O	24-37
decreases	O	38-47
medulloblastoma	O	48-63
cell	O	64-68
growth	O	69-75
but	O	76-79
does	O	80-84
not	O	85-88
alter	O	89-94
apoptosis	O	95-104
. 	O	104-106

Regulation	O	0-10
of	O	11-13
cyclin	O	14-20
dependent	O	21-30
kinase	O	31-37
6	O	38-39
by	O	40-42
microRNA	B	43-51
124	I	52-55
in	O	56-58
medulloblastoma	O	59-74
.  	O	74-77

Despite	O	0-7
recent	O	8-14
advances	O	15-23
in	O	24-26
treatment	O	27-36
medulloblastoma	O	37-52
continues	O	53-62
to	O	63-65
remain	O	66-72
a	O	73-74
vexing	O	75-81
problem	O	82-89
. 	O	89-91

Recently	O	0-8
increased	O	9-18
expression	O	19-29
of	O	30-32
cyclin	O	33-39
dependent	O	40-49
kinase	O	50-56
6	O	57-58
(	O	59-60
CDK6	O	60-64
)	O	64-65
was	O	66-69
identified	O	70-80
as	O	81-83
an	O	84-86
adverse	O	87-94
prognostic	O	95-105
marker	O	106-112
in	O	113-115
medulloblastoma	O	116-131
. 	O	131-133

An	O	0-2
association	O	3-14
study	O	15-20
of	O	21-23
rs9897526	O	24-33
and	O	34-37
rs5848	O	38-44
was	O	45-48
carried	O	49-56
out	O	57-60
in	O	61-63
an	O	64-66
Italian	O	67-74
population	O	75-85
and	O	86-89
in	O	90-92
a	O	93-94
replication	O	95-106
population	O	107-117
of	O	118-120
European	O	121-129
American	O	130-138
patients	O	139-147
and	O	148-151
controls	O	152-160
. 	O	160-162

The	O	0-3
influence	O	4-13
of	O	14-16
GRN	O	17-20
genetic	O	21-28
variability	O	29-40
on	O	41-43
susceptibility	O	44-58
to	O	59-61
AD	O	62-64
and	O	65-68
on	O	69-71
expression	O	72-82
levels	O	83-89
in	O	90-92
a	O	93-94
series	O	95-101
of	O	102-104
neuropathologically	O	105-124
-	O	124-125
confirmed	O	125-134
AD	O	135-137
patients	O	138-146
as	O	147-149
well	O	150-154
as	O	155-157
in	O	158-160
peripheral	O	161-171
mononuclear	O	172-183
cells	O	184-189
(	O	190-191
PBMC	O	191-195
)	O	195-196
and	O	197-200
in	O	201-203
cells	O	204-209
isolated	O	210-218
from	O	219-223
cerebrospinal	O	224-237
fluid	O	238-243
(	O	244-245
CSF	O	245-248
)	O	248-249
was	O	250-253
investigated	O	254-266
. 	O	266-268

Mutations	O	0-9
in	O	10-12
the	O	13-16
progranulin	O	17-28
gene	O	29-33
(	O	34-35
GRN	O	35-38
)	O	38-39
,	O	39-40
causative	O	41-50
for	O	51-54
Frontotemporal	O	55-69
Lobar	O	70-75
Degeneration	O	76-88
with	O	89-93
ubiquitin	O	94-103
-	O	103-104
immunoreactive	O	104-118
neuronal	O	119-127
inclusions	O	128-138
(	O	139-140
FTLD	O	140-144
-	O	144-145
U	O	145-146
)	O	146-147
,	O	147-148
could	O	149-154
also	O	155-159
be	O	160-162
associated	O	163-173
with	O	174-178
Alzheimer	O	179-188
'	O	188-189
s	O	189-190
disease	O	191-198
(	O	199-200
AD	O	200-202
)	O	202-203
. 	O	203-205

Rs5848	O	0-6
variant	O	7-14
influences	O	15-25
GRN	O	26-29
mRNA	O	30-34
levels	O	35-41
in	O	42-44
brain	O	45-50
and	O	51-54
peripheral	O	55-65
mononuclear	O	66-77
cells	O	78-83
in	O	84-86
patients	O	87-95
with	O	96-100
Alzheimer	O	101-110
'	O	110-111
s	O	111-112
disease	O	113-120
.  	O	120-123

Despite	O	0-7
no	O	8-10
significant	O	11-22
differences	O	23-34
were	O	35-39
found	O	40-45
in	O	46-48
the	O	49-52
relative	O	53-61
PBMC	O	62-66
and	O	67-70
CSF	O	71-74
GRN	O	75-78
expression	O	79-89
in	O	90-92
patients	O	93-101
compared	O	102-110
to	O	111-113
controls	O	114-122
,	O	122-123
stratifying	O	124-135
patients	O	136-144
according	O	145-154
to	O	155-157
the	O	158-161
presence	O	162-170
of	O	171-173
rs5848	O	174-180
T	O	181-182
allele	O	183-189
,	O	189-190
a	O	191-192
0	O	193-194
.	O	194-195
57	O	195-197
-	O	197-198
fold	O	198-202
decrease	O	203-211
in	O	212-214
GRN	O	215-218
mRNA	O	219-223
levels	O	224-230
over	O	231-235
C	O	236-237
carriers	O	238-246
was	O	247-250
found	O	251-256
in	O	257-259
PBMC	O	260-264
(	O	265-266
1	O	266-267
.	O	267-268
22	O	268-270
+	O	271-272
/	O	272-273
-	O	273-274
0	O	275-276
.	O	276-277
23	O	277-279
versus	O	280-286
0	O	287-288
.	O	288-289
70	O	289-291
+	O	292-293
/	O	293-294
-	O	294-295
0	O	296-297
.	O	297-298
12	O	298-300
,	O	300-301
P	O	302-303
=	O	304-305
0	O	306-307
.	O	307-308
04	O	308-310
)	O	310-311
. 	O	311-313

Patients	O	0-8
carrying	O	9-17
the	O	18-21
rs5848	O	22-28
TT	O	29-31
genotype	O	32-40
had	O	41-44
the	O	45-48
lowest	O	49-55
GRN	O	56-59
expression	O	60-70
levels	O	71-77
(	O	78-79
0	O	79-80
.	O	80-81
96	O	81-83
+	O	84-85
/	O	85-86
-	O	86-87
0	O	88-89
.	O	89-90
12	O	90-92
,	O	92-93
P	O	94-95
=	O	96-97
0	O	98-99
.	O	99-100
014	O	100-103
)	O	103-104
. 	O	104-106

GRN	O	0-3
expression	O	4-14
in	O	15-17
the	O	18-21
parietal	O	22-30
lobe	O	31-35
of	O	36-38
AD	O	39-41
cases	O	42-47
showed	O	48-54
a	O	55-56
0	O	57-58
.	O	58-59
76	O	59-61
-	O	61-62
fold	O	62-66
decrease	O	67-75
compared	O	76-84
with	O	85-89
controls	O	90-98
(	O	99-100
1	O	100-101
.	O	101-102
31	O	102-104
+	O	105-106
/	O	106-107
-	O	107-108
0	O	109-110
.	O	110-111
07	O	111-113
versus	O	114-120
1	O	121-122
.	O	122-123
73	O	123-125
+	O	126-127
/	O	127-128
-	O	128-129
0	O	130-131
.	O	131-132
12	O	132-134
,	O	134-135
P	O	136-137
=	O	138-139
0	O	140-141
.	O	141-142
0025	O	142-146
)	O	146-147
. 	O	147-149

None	O	0-4
of	O	5-7
the	O	8-11
variants	O	12-20
tested	O	21-27
act	O	28-31
as	O	32-34
unequivocal	O	35-46
susceptibility	O	47-61
factor	O	62-68
in	O	69-71
both	O	72-76
populations	O	77-88
although	O	89-97
rs9897526	O	98-107
anticipated	O	108-119
the	O	120-123
onset	O	124-129
of	O	130-132
the	O	133-136
disease	O	137-144
in	O	145-147
the	O	148-151
Italian	O	152-159
population	O	160-170
. 	O	170-172

Similarly	O	0-9
to	O	10-12
data	O	13-17
obtained	O	18-26
in	O	27-29
brain	O	30-35
samples	O	36-43
,	O	43-44
patients	O	45-53
carrying	O	54-62
the	O	63-66
TT	O	67-69
genotype	O	70-78
showed	O	79-85
the	O	86-89
lowest	O	90-96
GRN	O	97-100
mRNA	O	101-105
levels	O	106-112
(	O	113-114
TT	O	114-116
=	O	117-118
0	O	119-120
.	O	120-121
46	O	121-123
+	O	124-125
/	O	125-126
-	O	126-127
0	O	128-129
.	O	129-130
14	O	130-132
,	O	132-133
CC	O	134-136
=	O	137-138
1	O	139-140
.	O	140-141
22	O	141-143
+	O	144-145
/	O	145-146
-	O	146-147
0	O	148-149
.	O	149-150
23	O	150-152
;	O	152-153
P	O	154-155
=	O	156-157
0	O	158-159
.	O	159-160
013	O	160-163
)	O	163-164
. 	O	164-166

These	O	0-5
data	O	6-10
argue	O	11-16
against	O	17-24
a	O	25-26
direct	O	27-33
role	O	34-38
of	O	39-41
GRN	O	42-45
as	O	46-48
a	O	49-50
susceptibility	O	51-65
factor	O	66-72
for	O	73-76
sporadic	O	77-85
AD	O	86-88
but	O	89-92
support	O	93-100
a	O	101-102
role	O	103-107
of	O	108-110
GRN	O	111-114
as	O	115-117
a	O	118-119
disease	O	120-127
-	O	127-128
modifying	O	128-137
gene	O	138-142
,	O	142-143
possibly	O	144-152
contributing	O	153-165
to	O	166-168
the	O	169-172
failure	O	173-180
of	O	181-183
neuronal	O	184-192
survival	O	193-201
.   	O	201-205

Thrombolytic	O	0-12
therapy	O	13-20
involving	O	21-30
recombinant	O	31-42
tissue	O	43-49
plasminogen	O	50-61
activator	O	62-71
(	O	72-73
rtPA	O	73-77
)	O	77-78
has	O	79-82
been	O	83-87
shown	O	88-93
to	O	94-96
be	O	97-99
beneficial	O	100-110
only	O	111-115
when	O	116-120
used	O	121-125
within	O	126-132
4	O	133-134
.	O	134-135
5	O	135-136
hours	O	137-142
of	O	143-145
onset	O	146-151
of	O	152-154
acute	O	155-160
ischemic	O	161-169
stroke	O	170-176
. 	O	176-178

There	O	0-5
are	O	6-9
two	O	10-13
major	O	14-19
types	O	20-25
of	O	26-28
stroke	O	29-35
:	O	35-36
cerebral	O	37-45
ischemia	O	46-54
caused	O	55-61
by	O	62-64
obstruction	O	65-76
of	O	77-79
blood	O	80-85
vessels	O	86-93
in	O	94-96
the	O	97-100
brain	O	101-106
and	O	107-110
haemorrhagic	O	111-123
stroke	O	124-130
that	O	131-135
is	O	136-138
triggered	O	139-148
by	O	149-151
the	O	152-155
disruption	O	156-166
of	O	167-169
blood	O	170-175
vessels	O	176-183
. 	O	183-185

Stroke	O	0-6
is	O	7-9
one	O	10-13
of	O	14-16
the	O	17-20
leading	O	21-28
causes	O	29-35
of	O	36-38
death	O	39-44
and	O	45-48
disability	O	49-59
worldwide	O	60-69
. 	O	69-71

microRNAs	O	0-9
in	O	10-12
stroke	O	13-19
pathogenesis	O	20-32
.  	O	32-35

Although	O	0-8
the	O	9-12
biochemistry	O	13-25
of	O	26-28
stroke	O	29-35
and	O	36-39
related	O	40-47
diseases	O	48-56
is	O	57-59
quite	O	60-65
well	O	66-70
understood	O	71-81
,	O	81-82
the	O	83-86
knowledge	O	87-96
on	O	97-99
the	O	100-103
molecular	O	104-113
mechanisms	O	114-124
underlying	O	125-135
these	O	136-141
diseases	O	142-150
is	O	151-153
still	O	154-159
at	O	160-162
its	O	163-166
infancy	O	167-174
. 	O	174-176

microRNAs	O	0-9
that	O	10-14
form	O	15-19
a	O	20-21
unique	O	22-28
class	O	29-34
of	O	35-37
endogenous	O	38-48
riboregulators	O	49-63
of	O	64-66
gene	O	67-71
function	O	72-80
,	O	80-81
offer	O	82-87
tremendous	O	88-98
potential	O	99-108
in	O	109-111
unraveling	O	112-122
the	O	123-126
mechanisms	O	127-137
underlying	O	138-148
stroke	O	149-155
pathogenesis	O	156-168
. 	O	168-170

rtPA	O	0-4
treatment	O	5-14
beyond	O	15-21
this	O	22-26
time	O	27-31
window	O	32-38
has	O	39-42
been	O	43-47
found	O	48-53
to	O	54-56
be	O	57-59
unsuitable	O	60-70
and	O	71-74
usually	O	75-82
resulting	O	83-92
in	O	93-95
haemorrhagic	O	96-108
transformation	O	109-123
. 	O	123-125

Stroke	O	0-6
is	O	7-9
a	O	10-11
multifactorial	O	12-26
disease	O	27-34
that	O	35-39
forms	O	40-45
a	O	46-47
possible	O	48-56
end	O	57-60
state	O	61-66
for	O	67-70
majority	O	71-79
of	O	80-82
patients	O	83-91
suffering	O	92-101
from	O	102-106
diabetes	O	107-115
,	O	115-116
atherosclerosis	O	117-132
and	O	133-136
hypertension	O	137-149
which	O	150-155
are	O	156-159
known	O	160-165
risk	O	166-170
factors	O	171-178
. 	O	178-180

microRNA	O	0-8
expression	O	9-19
also	O	20-24
reflects	O	25-33
the	O	34-37
response	O	38-46
of	O	47-49
individuals	O	50-61
to	O	62-64
drugs	O	65-70
and	O	71-74
therapy	O	75-82
. 	O	82-84

Several	O	0-7
microRNAs	O	8-17
and	O	18-21
their	O	22-27
target	O	28-34
genes	O	35-40
,	O	40-41
known	O	42-47
to	O	48-50
be	O	51-53
involved	O	54-62
in	O	63-65
endothelial	O	66-77
dysfunction	O	78-89
,	O	89-90
dysregulation	O	91-104
of	O	105-107
neurovascular	O	108-121
integrity	O	122-131
,	O	131-132
edema	O	133-138
formation	O	139-148
,	O	148-149
pro	O	150-153
-	O	153-154
apoptosis	O	154-163
,	O	163-164
inflammation	O	165-177
and	O	178-181
extra	O	182-187
-	O	187-188
cellular	O	188-196
matrix	O	197-203
remodeling	O	204-214
contribute	O	215-225
to	O	226-228
the	O	229-232
critical	O	233-241
processes	O	242-251
in	O	252-254
the	O	255-258
pathogenesis	O	259-271
of	O	272-274
stroke	O	275-281
. 	O	281-283

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
will	O	19-23
also	O	24-28
be	O	29-31
discussing	O	32-42
the	O	43-46
role	O	47-51
of	O	52-54
microRNAs	O	55-64
as	O	65-67
possible	O	68-76
diagnostic	O	77-87
and	O	88-91
prognostic	O	92-102
biomarkers	O	103-113
as	O	114-116
well	O	117-121
as	O	122-124
potential	O	125-134
therapeutic	O	135-146
targets	O	147-154
in	O	155-157
stroke	O	158-164
pathogenesis	O	165-177
.   	O	177-181

Molecular	O	0-9
biology	O	10-17
. 	O	17-19

miRNAs	O	0-6
in	O	7-9
neurodegeneration	O	10-27
.     	O	27-33

These	O	0-5
cellular	O	6-14
responses	O	15-24
are	O	25-28
mediated	O	29-37
by	O	38-40
augmented	O	41-50
expression	O	51-61
of	O	62-64
the	O	65-68
direct	O	69-75
targets	O	76-83
of	O	84-86
miR	B	87-90
-	I	90-91
10b	I	91-94
,	O	94-95
including	O	96-105
BCL2L11	O	106-113
/	O	113-114
Bim	O	114-117
,	O	117-118
TFAP2C	O	119-125
/	O	125-126
AP	O	126-128
-	O	128-129
2γ	O	129-132
,	O	132-133
CDKN1A	O	134-140
/	O	140-141
p21	O	141-144
,	O	144-145
and	O	146-149
CDKN2A	O	150-156
/	O	156-157
p16	O	157-160
,	O	160-161
which	O	162-167
normally	O	168-176
protect	O	177-184
cells	O	185-190
from	O	191-195
uncontrolled	O	196-208
growth	O	209-215
. 	O	215-217

Analysis	O	0-8
of	O	9-11
The	O	12-15
Cancer	O	16-22
Genome	O	23-29
Atlas	O	30-35
expression	O	36-46
data	O	47-51
set	O	52-55
reveals	O	56-63
a	O	64-65
strong	O	66-72
positive	O	73-81
correlation	O	82-93
between	O	94-101
numerous	O	102-110
genes	O	111-116
sustaining	O	117-127
cellular	O	128-136
growth	O	137-143
and	O	144-147
miR	B	148-151
-	I	151-152
10b	I	152-155
levels	O	156-162
in	O	163-165
human	O	166-171
glioblastomas	O	172-185
,	O	185-186
while	O	187-192
proapoptotic	O	193-205
genes	O	206-211
anticorrelate	O	212-225
with	O	226-230
the	O	231-234
expression	O	235-245
of	O	246-248
miR	B	249-252
-	I	252-253
10b	I	253-256
. 	O	256-258

Molecular	O	0-9
functions	O	10-19
of	O	20-22
these	O	23-28
miRNAs	O	29-35
in	O	36-38
gliomagenesis	O	39-52
are	O	53-56
mainly	O	57-63
unknown	O	64-71
. 	O	71-73

We	O	0-2
show	O	3-7
that	O	8-12
inhibition	O	13-23
of	O	24-26
miR	B	27-30
-	I	30-31
10b	I	31-34
,	O	34-35
a	O	36-37
miRNA	O	38-43
not	O	44-47
expressed	O	48-57
in	O	58-60
human	O	61-66
brain	O	67-72
and	O	73-76
strongly	O	77-85
upregulated	O	86-97
in	O	98-100
both	O	101-105
low	O	106-109
-	O	109-110
grade	O	110-115
and	O	116-119
high	O	120-124
-	O	124-125
grade	O	125-130
gliomas	O	131-138
,	O	138-139
reduces	O	140-147
glioma	O	148-154
cell	O	155-159
growth	O	160-166
by	O	167-169
cell	O	170-174
-	O	174-175
cycle	O	175-180
arrest	O	181-187
and	O	188-191
apoptosis	O	192-201
. 	O	201-203

Human	O	0-5
glioma	O	6-12
growth	O	13-19
is	O	20-22
controlled	O	23-33
by	O	34-36
microRNA	B	37-45
-	I	45-46
10b	I	46-49
.  	O	49-52

MicroRNA	O	0-8
(	O	9-10
miRNA	O	10-15
)	O	15-16
expression	O	17-27
profiling	O	28-37
studies	O	38-45
revealed	O	46-54
a	O	55-56
number	O	57-63
of	O	64-66
miRNAs	O	67-73
dysregulated	O	74-86
in	O	87-89
the	O	90-93
malignant	O	94-103
brain	O	104-109
tumor	O	110-115
glioblastoma	O	116-128
. 	O	128-130

Altogether	O	0-10
,	O	10-11
our	O	12-15
experiments	O	16-27
validate	O	28-36
an	O	37-39
important	O	40-49
role	O	50-54
of	O	55-57
miR	B	58-61
-	I	61-62
10b	I	62-65
in	O	66-68
gliomagenesis	O	69-82
,	O	82-83
reveal	O	84-90
a	O	91-92
novel	O	93-98
mechanism	O	99-108
of	O	109-111
miR	B	112-115
-	I	115-116
10b	I	116-119
-	O	119-120
mediated	O	120-128
regulation	O	129-139
,	O	139-140
and	O	141-144
suggest	O	145-152
the	O	153-156
possibility	O	157-168
of	O	169-171
its	O	172-175
future	O	176-182
use	O	183-186
as	O	187-189
a	O	190-191
therapeutic	O	192-203
target	O	204-210
in	O	211-213
gliomas	O	214-221
.   	O	221-225

Furthermore	O	0-11
,	O	11-12
survival	O	13-21
of	O	22-24
glioblastoma	O	25-37
patients	O	38-46
expressing	O	47-57
high	O	58-62
levels	O	63-69
of	O	70-72
miR	B	73-76
-	I	76-77
10	I	77-79
family	O	80-86
members	O	87-94
is	O	95-97
significantly	O	98-111
reduced	O	112-119
in	O	120-122
comparison	O	123-133
to	O	134-136
patients	O	137-145
with	O	146-150
low	O	151-154
miR	B	155-158
-	I	158-159
10	I	159-161
levels	O	162-168
,	O	168-169
indicating	O	170-180
that	O	181-185
miR	B	186-189
-	I	189-190
10	I	190-192
may	O	193-196
contribute	O	197-207
to	O	208-210
glioma	O	211-217
growth	O	218-224
in	O	225-227
vivo	O	228-232
. 	O	232-234

Finally	O	0-7
,	O	7-8
inhibition	O	9-19
of	O	20-22
miR	B	23-26
-	I	26-27
10b	I	27-30
in	O	31-33
a	O	34-35
mouse	O	36-41
model	O	42-47
of	O	48-50
human	O	51-56
glioma	O	57-63
results	O	64-71
in	O	72-74
significant	O	75-86
reduction	O	87-96
of	O	97-99
tumor	O	100-105
growth	O	106-112
. 	O	112-114

Adult	O	0-5
-	O	5-6
onset	O	6-11
autosomal	O	12-21
dominant	O	22-30
leukodystrophy	O	31-45
:	O	45-46
linking	O	47-54
nuclear	O	55-62
envelope	O	63-71
to	O	72-74
myelin	O	75-81
.     	O	81-87

The	O	0-3
advent	O	4-10
of	O	11-13
next	O	14-18
-	O	18-19
generation	O	19-29
sequencing	O	30-40
technologies	O	41-53
promises	O	54-62
to	O	63-65
greatly	O	66-73
transform	O	74-83
our	O	84-87
understanding	O	88-101
of	O	102-104
medulloblastoma	O	105-120
pathogenesis	O	121-133
in	O	134-136
the	O	137-140
next	O	141-145
few	O	146-149
years	O	150-155
,	O	155-156
permitting	O	157-167
comprehensive	O	168-181
analyses	O	182-190
of	O	191-193
all	O	194-197
aspects	O	198-205
of	O	206-208
the	O	209-212
genome	O	213-219
and	O	220-223
increasing	O	224-234
the	O	235-238
likelihood	O	239-249
that	O	250-254
genomic	O	255-262
medicine	O	263-271
will	O	272-276
become	O	277-283
part	O	284-288
of	O	289-291
the	O	292-295
routine	O	296-303
diagnosis	O	304-313
and	O	314-317
treatment	O	318-327
of	O	328-330
medulloblastoma	O	331-346
.   	O	346-350

The	O	0-3
application	O	4-15
of	O	16-18
high	O	19-23
-	O	23-24
resolution	O	24-34
microarray	O	35-45
platforms	O	46-55
to	O	56-58
the	O	59-62
study	O	63-68
of	O	69-71
medulloblastoma	O	72-87
has	O	88-91
revealed	O	92-100
new	O	101-104
oncogenes	O	105-114
and	O	115-118
tumor	O	119-124
suppressors	O	125-136
and	O	137-140
has	O	141-144
implicated	O	145-155
changes	O	156-163
in	O	164-166
DNA	O	167-170
copy	O	171-175
number	O	176-182
,	O	182-183
gene	O	184-188
expression	O	189-199
,	O	199-200
and	O	201-204
methylation	O	205-216
state	O	217-222
in	O	223-225
its	O	226-229
etiology	O	230-238
. 	O	238-240

Additionally	O	0-12
,	O	12-13
the	O	14-17
integration	O	18-29
of	O	30-32
medulloblastoma	O	33-48
genomics	O	49-57
with	O	58-62
patient	O	63-70
clinical	O	71-79
data	O	80-84
has	O	85-88
confirmed	O	89-98
molecular	O	99-108
markers	O	109-116
of	O	117-119
prognostic	O	120-130
significance	O	131-143
and	O	144-147
highlighted	O	148-159
the	O	160-163
potential	O	164-173
utility	O	174-181
of	O	182-184
molecular	O	185-194
disease	O	195-202
stratification	O	203-217
. 	O	217-219

Genomics	O	0-8
of	O	9-11
medulloblastoma	O	12-27
:	O	27-28
from	O	29-33
Giemsa	O	34-40
-	O	40-41
banding	O	41-48
to	O	49-51
next	O	52-56
-	O	56-57
generation	O	57-67
sequencing	O	68-78
in	O	79-81
20	O	82-84
years	O	85-90
.  	O	90-93

Advances	O	0-8
in	O	9-11
the	O	12-15
field	O	16-21
of	O	22-24
genomics	O	25-33
have	O	34-38
recently	O	39-47
enabled	O	48-55
the	O	56-59
unprecedented	O	60-73
characterization	O	74-90
of	O	91-93
the	O	94-97
cancer	O	98-104
genome	O	105-111
,	O	111-112
providing	O	113-122
novel	O	123-128
insight	O	129-136
into	O	137-141
the	O	142-145
molecular	O	146-155
mechanisms	O	156-166
underlying	O	167-177
malignancies	O	178-190
in	O	191-193
humans	O	194-200
. 	O	200-202

Here	O	0-4
,	O	4-5
we	O	6-8
report	O	9-15
an	O	16-18
elegant	O	19-26
mechanism	O	27-36
of	O	37-39
Tau	O	40-43
degradation	O	44-55
involving	O	56-65
the	O	66-69
cochaperone	O	70-81
BAG2	O	82-86
. 	O	86-88

The	O	0-3
BAG2	O	4-8
/	O	8-9
Hsp70	O	9-14
complex	O	15-22
is	O	23-25
tethered	O	26-34
to	O	35-37
the	O	38-41
microtubule	O	42-53
and	O	54-57
this	O	58-62
complex	O	63-70
can	O	71-74
capture	O	75-82
and	O	83-86
deliver	O	87-94
Tau	O	95-98
to	O	99-101
the	O	102-105
proteasome	O	106-116
for	O	117-120
ubiquitin	O	121-130
-	O	130-131
independent	O	131-142
degradation	O	143-154
. 	O	154-156

The	O	0-3
components	O	4-14
of	O	15-17
a	O	18-19
Tau	O	20-23
protein	O	24-31
triage	O	32-38
system	O	39-45
consisting	O	46-56
of	O	57-59
CHIP	O	60-64
/	O	64-65
Hsp70	O	65-70
and	O	71-74
other	O	75-80
chaperones	O	81-91
have	O	92-96
begun	O	97-102
to	O	103-105
emerge	O	106-112
. 	O	112-114

However	O	0-7
,	O	7-8
the	O	9-12
site	O	13-17
of	O	18-20
triage	O	21-27
and	O	28-31
the	O	32-35
master	O	36-42
regulatory	O	43-53
elements	O	54-62
are	O	63-66
unknown	O	67-74
. 	O	74-76

Tau	O	0-3
inclusions	O	4-14
are	O	15-18
a	O	19-20
prominent	O	21-30
feature	O	31-38
of	O	39-41
many	O	42-46
neurodegenerative	O	47-64
diseases	O	65-73
including	O	74-83
Alzheimer	O	84-93
'	O	93-94
s	O	94-95
disease	O	96-103
. 	O	103-105

Their	O	0-5
accumulation	O	6-18
in	O	19-21
neurons	O	22-29
as	O	30-32
ubiquitinated	O	33-46
filaments	O	47-56
suggests	O	57-65
a	O	66-67
failure	O	68-75
in	O	76-78
the	O	79-82
degradation	O	83-94
limb	O	95-99
of	O	100-102
the	O	103-106
Tau	O	107-110
pathway	O	111-118
. 	O	118-120

The	O	0-3
cochaperone	O	4-15
BAG2	O	16-20
sweeps	O	21-27
paired	O	28-34
helical	O	35-42
filament	O	43-51
-	O	51-52
insoluble	O	53-62
tau	O	63-66
from	O	67-71
the	O	72-75
microtubule	O	76-87
.  	O	87-90

Thus	O	0-4
,	O	4-5
we	O	6-8
propose	O	9-16
that	O	17-21
ubiquitinated	O	22-35
Tau	O	36-39
inclusions	O	40-50
arise	O	51-56
due	O	57-60
to	O	61-63
shunting	O	64-72
of	O	73-75
Tau	O	76-79
degradation	O	80-91
toward	O	92-98
a	O	99-100
less	O	101-105
efficient	O	106-115
ubiquitin	O	116-125
-	O	125-126
dependent	O	126-135
pathway	O	136-143
.   	O	143-147

This	O	0-4
complex	O	5-12
preferentially	O	13-27
degrades	O	28-36
Sarkosyl	O	37-45
insoluble	O	46-55
Tau	O	56-59
and	O	60-63
phosphorylated	O	64-78
Tau	O	79-82
. 	O	82-84

BAG2	O	0-4
levels	O	5-11
in	O	12-14
cells	O	15-20
are	O	21-24
under	O	25-30
the	O	31-34
physiological	O	35-48
control	O	49-56
of	O	57-59
the	O	60-63
microRNA	O	64-72
miR	B	73-76
-	I	76-77
128a	I	77-81
,	O	81-82
which	O	83-88
can	O	89-92
tune	O	93-97
paired	O	98-104
helical	O	105-112
filament	O	113-121
Tau	O	122-125
levels	O	126-132
in	O	133-135
neurons	O	136-143
. 	O	143-145

miR	B	0-3
-	I	3-4
15a	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
16	I	16-18
-	I	18-19
1	I	19-20
down	O	21-25
-	O	25-26
regulation	O	26-36
in	O	37-39
pituitary	O	40-49
adenomas	O	50-58
.  	O	58-61

We	O	0-2
found	O	3-8
that	O	9-13
miR	B	14-17
-	I	17-18
15a	I	18-21
and	O	22-25
miR	B	26-29
-	I	29-30
16	I	30-32
-	I	32-33
1	I	33-34
are	O	35-38
expressed	O	39-48
at	O	49-51
lower	O	52-57
levels	O	58-64
in	O	65-67
pituitary	O	68-77
adenomas	O	78-86
as	O	87-89
compared	O	90-98
to	O	99-101
normal	O	102-108
pituitary	O	109-118
tissue	O	119-125
. 	O	125-127

We	O	0-2
explored	O	3-11
miR	B	12-15
-	I	15-16
15a	I	16-19
and	O	20-23
miR	B	24-27
-	I	27-28
16	I	28-30
-	I	30-31
1	I	31-32
expression	O	33-43
in	O	44-46
10	O	47-49
GH	O	50-52
-	O	52-53
secreting	O	53-62
and	O	63-66
in	O	67-69
10	O	70-72
PRL	O	73-76
-	O	76-77
secreting	O	77-86
pituitary	O	87-96
macroadenomas	O	97-110
by	O	111-113
Northern	O	114-122
blot	O	123-127
,	O	127-128
and	O	129-132
investigated	O	133-145
the	O	146-149
possible	O	150-158
correlation	O	159-170
with	O	171-175
in	O	176-178
vivo	O	179-183
and	O	184-187
in	O	188-190
vitro	O	191-196
characteristics	O	197-212
. 	O	212-214

Therefore	O	0-9
,	O	9-10
miR15	B	11-16
and	O	17-20
miR16	B	21-26
down	O	27-31
-	O	31-32
regulation	O	32-42
in	O	43-45
pituitary	O	46-55
adenomas	O	56-64
correlates	O	65-75
with	O	76-80
a	O	81-82
greater	O	83-90
tumor	O	91-96
diameter	O	97-105
and	O	106-109
a	O	110-111
lower	O	112-117
p43	O	118-121
secretion	O	122-131
,	O	131-132
suggesting	O	133-143
that	O	144-148
these	O	149-154
genes	O	155-160
may	O	161-164
,	O	164-165
at	O	166-168
least	O	169-174
in	O	175-177
part	O	178-182
,	O	182-183
influence	O	184-193
tumor	O	194-199
growth	O	200-206
.   	O	206-210

Moreover	O	0-8
,	O	8-9
their	O	10-15
expression	O	16-26
inversely	O	27-36
correlates	O	37-47
with	O	48-52
tumor	O	53-58
diameter	O	59-67
and	O	68-71
with	O	72-76
RARS	O	77-81
expression	O	82-92
(	O	93-94
P	O	94-95
<	O	96-97
0	O	98-99
.	O	99-100
05	O	100-102
)	O	102-103
,	O	103-104
but	O	105-108
directly	O	109-117
correlates	O	118-128
with	O	129-133
p43	O	134-137
secretion	O	138-147
(	O	148-149
P	O	149-150
<	O	151-152
0	O	153-154
.	O	154-155
02	O	155-157
)	O	157-158
. 	O	158-160

miR	B	0-3
-	I	3-4
15a	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
16	I	16-18
-	I	18-19
1	I	19-20
genes	O	21-26
are	O	27-30
located	O	31-38
at	O	39-41
chromosome	O	42-52
13q14	O	53-58
,	O	58-59
a	O	60-61
region	O	62-68
which	O	69-74
is	O	75-77
frequently	O	78-88
deleted	O	89-96
in	O	97-99
pituitary	O	100-109
tumors	O	110-116
. 	O	116-118

Micro	O	0-5
RNAs	O	6-10
(	O	11-12
miRs	O	12-16
)	O	16-17
are	O	18-21
small	O	22-27
noncoding	O	28-37
RNAs	O	38-42
,	O	42-43
functioning	O	44-55
as	O	56-58
antisense	O	59-68
regulators	O	69-79
of	O	80-82
other	O	83-88
RNAs	O	89-93
. 	O	93-95

When	O	0-4
secreted	O	5-13
,	O	13-14
p43	O	15-18
regulates	O	19-28
local	O	29-34
inflammatory	O	35-47
response	O	48-56
and	O	57-60
macrophage	O	61-71
chemotaxis	O	72-82
,	O	82-83
and	O	84-87
seems	O	88-93
to	O	94-96
have	O	97-101
anti	O	102-106
-	O	106-107
neoplastic	O	107-117
properties	O	118-128
in	O	129-131
mice	O	132-136
. 	O	136-138

An	O	0-2
inverse	O	3-10
correlation	O	11-22
has	O	23-26
been	O	27-31
shown	O	32-37
in	O	38-40
B	O	41-42
cell	O	43-47
chronic	O	48-55
lymphocytic	O	56-67
leukemia	O	68-76
(	O	77-78
B	O	78-79
-	O	79-80
CLL	O	80-83
)	O	83-84
between	O	85-92
miR	B	93-96
-	I	96-97
15a	I	97-100
and	O	101-104
miR	B	105-108
-	I	108-109
16	I	109-111
-	I	111-112
1	I	112-113
expression	O	114-124
and	O	125-128
the	O	129-132
expression	O	133-143
levels	O	144-150
of	O	151-153
arginyl	O	154-161
-	O	161-162
tRNA	O	162-166
synthetase	O	167-177
(	O	178-179
RARS	O	179-183
)	O	183-184
,	O	184-185
an	O	186-188
enzyme	O	189-195
which	O	196-201
associates	O	202-212
with	O	213-217
the	O	218-221
cofactor	O	222-230
p43	O	231-234
in	O	235-237
the	O	238-241
aminoacyl	O	242-251
-	O	251-252
tRNA	O	252-256
synthetase	O	257-267
complex	O	268-275
. 	O	275-277

The	O	0-3
emerging	O	4-12
role	O	13-17
of	O	18-20
epigenetics	O	21-32
in	O	33-35
stroke	O	36-42
:	O	42-43
II	O	44-46
.	O	46-47
RNA	O	48-51
regulatory	O	52-62
circuitry	O	63-72
. 	O	72-74

These	O	0-5
non	O	6-9
-	O	9-10
protein	O	10-17
-	O	17-18
coding	O	18-24
RNAs	O	25-29
(	O	30-31
ncRNAs	O	31-37
)	O	37-38
include	O	39-46
subclasses	O	47-57
that	O	58-62
are	O	63-66
well	O	67-71
known	O	72-77
,	O	77-78
such	O	79-83
as	O	84-86
transfer	O	87-95
RNAs	O	96-100
and	O	101-104
ribosomal	O	105-114
RNAs	O	115-119
,	O	119-120
as	O	121-123
well	O	124-128
as	O	129-131
those	O	132-137
that	O	138-142
have	O	143-147
more	O	148-152
recently	O	153-161
been	O	162-166
characterized	O	167-180
,	O	180-181
such	O	182-186
as	O	187-189
microRNAs	O	190-199
,	O	199-200
small	O	201-206
nucleolar	O	207-216
RNAs	O	217-221
,	O	221-222
and	O	223-226
long	O	227-231
ncRNAs	O	232-238
. 	O	238-240

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
examine	O	19-26
the	O	27-30
role	O	31-35
of	O	36-38
these	O	39-44
novel	O	45-50
ncRNAs	O	51-57
in	O	58-60
the	O	61-64
nervous	O	65-72
system	O	73-79
and	O	80-83
highlight	O	84-93
emerging	O	94-102
evidence	O	103-111
that	O	112-116
implicates	O	117-127
RNA	O	128-131
-	O	131-132
based	O	132-137
networks	O	138-146
in	O	147-149
the	O	150-153
molecular	O	154-163
pathogenesis	O	164-176
of	O	177-179
stroke	O	180-186
. 	O	186-188

Recent	O	0-6
scientific	O	7-17
advances	O	18-26
have	O	27-31
demonstrated	O	32-44
the	O	45-48
existence	O	49-58
of	O	59-61
extensive	O	62-71
RNA	O	72-75
-	O	75-76
based	O	76-81
regulatory	O	82-92
networks	O	93-101
involved	O	102-110
in	O	111-113
orchestrating	O	114-127
nearly	O	128-134
every	O	135-140
cellular	O	141-149
process	O	150-157
in	O	158-160
health	O	161-167
and	O	168-171
various	O	172-179
disease	O	180-187
states	O	188-194
. 	O	194-196

This	O	0-4
previously	O	5-15
hidden	O	16-22
layer	O	23-28
of	O	29-31
functional	O	32-42
RNAs	O	43-47
is	O	48-50
derived	O	51-58
largely	O	59-66
from	O	67-71
non	O	72-75
-	O	75-76
protein	O	76-83
-	O	83-84
coding	O	84-90
DNA	O	91-94
sequences	O	95-104
that	O	105-109
constitute	O	110-120
more	O	121-125
than	O	126-130
98	O	131-133
%	O	133-134
of	O	135-137
the	O	138-141
genome	O	142-148
in	O	149-151
humans	O	152-158
. 	O	158-160

These	O	0-5
novel	O	6-11
approaches	O	12-22
for	O	23-26
neural	O	27-33
cell	O	34-38
-	O	38-39
and	O	40-43
tissue	O	44-50
-	O	50-51
selective	O	51-60
reprogramming	O	61-74
of	O	75-77
epigenetic	O	78-88
regulatory	O	89-99
mechanisms	O	100-110
are	O	111-114
likely	O	115-121
to	O	122-124
promote	O	125-132
more	O	133-137
effective	O	138-147
neuroprotective	O	148-163
and	O	164-167
neural	O	168-174
regenerative	O	175-187
responses	O	188-197
for	O	198-201
safeguarding	O	202-214
and	O	215-218
even	O	219-223
restoring	O	224-233
central	O	234-241
nervous	O	242-249
system	O	250-256
function	O	257-265
.   	O	265-269

We	O	0-2
also	O	3-7
describe	O	8-16
RNA	O	17-20
editing	O	21-28
,	O	28-29
a	O	30-31
related	O	32-39
epigenetic	O	40-50
mechanism	O	51-60
that	O	61-65
is	O	66-68
partly	O	69-75
responsible	O	76-87
for	O	88-91
generating	O	92-102
the	O	103-106
exquisite	O	107-116
degrees	O	117-124
of	O	125-127
environmental	O	128-141
responsiveness	O	142-156
and	O	157-160
molecular	O	161-170
diversity	O	171-180
that	O	181-185
characterize	O	186-198
ncRNAs	O	199-205
. 	O	205-207

In	O	0-2
addition	O	3-11
,	O	11-12
we	O	13-15
discuss	O	16-23
the	O	24-27
development	O	28-39
of	O	40-42
future	O	43-49
therapeutic	O	50-61
strategies	O	62-72
for	O	73-76
locus	O	77-82
-	O	82-83
specific	O	83-91
and	O	92-95
genome	O	96-102
-	O	102-103
wide	O	103-107
regulation	O	108-118
of	O	119-121
genes	O	122-127
and	O	128-131
functional	O	132-142
gene	O	143-147
networks	O	148-156
through	O	157-164
the	O	165-168
modulation	O	169-179
of	O	180-182
RNA	O	183-186
transcription	O	187-200
,	O	200-201
posttranscriptional	O	202-221
RNA	O	222-225
processing	O	226-236
(	O	237-238
eg	O	238-240
,	O	240-241
RNA	O	242-245
modifications	O	246-259
,	O	259-260
quality	O	261-268
control	O	269-276
,	O	276-277
intracellular	O	278-291
trafficking	O	292-303
,	O	303-304
and	O	305-308
local	O	309-314
and	O	315-318
long	O	319-323
-	O	323-324
distance	O	324-332
intercellular	O	333-346
transport	O	347-356
)	O	356-357
,	O	357-358
and	O	359-362
RNA	O	363-366
translation	O	367-378
. 	O	378-380

Keystone	O	0-8
symposium	O	9-18
,	O	18-19
Neurodegenerative	O	20-37
Diseases	O	38-46
:	O	46-47
New	O	48-51
Molecular	O	52-61
Mechanisms	O	62-72
17	O	73-75
-	O	75-76
22	O	76-78
February	O	79-87
2009	O	88-92
.     	O	92-98

Diseases	O	0-8
potentially	O	9-20
mediated	O	21-29
by	O	30-32
alterations	O	33-44
in	O	45-47
RNA	O	48-51
processes	O	52-61
include	O	62-69
tauopathies	O	70-81
,	O	81-82
myotonic	O	83-91
dystrophy	O	92-101
,	O	101-102
Alzheimer	O	103-112
disease	O	113-120
,	O	120-121
brain	O	122-127
cancer	O	128-134
,	O	134-135
and	O	136-139
many	O	140-144
others	O	145-151
. 	O	151-153

Some	O	0-4
noncoding	O	5-14
RNAs	O	15-19
have	O	20-24
been	O	25-29
shown	O	30-35
to	O	36-38
be	O	39-41
involved	O	42-50
in	O	51-53
human	O	54-59
brain	O	60-65
diseases	O	66-74
. 	O	74-76

Furthermore	O	0-11
,	O	11-12
there	O	13-18
is	O	19-21
poor	O	22-26
correlation	O	27-38
between	O	39-46
mRNA	O	47-51
levels	O	52-58
and	O	59-62
protein	O	63-70
levels	O	71-77
in	O	78-80
mammalian	O	81-90
cells	O	91-96
,	O	96-97
due	O	98-101
partly	O	102-108
to	O	109-111
complicated	O	112-123
post	O	124-128
-	O	128-129
transcriptional	O	129-144
regulation	O	145-155
by	O	156-158
hitherto	O	159-167
unknown	O	168-175
noncoding	O	176-185
RNAs	O	186-190
. 	O	190-192

For	O	0-3
example	O	4-11
,	O	11-12
neurologic	O	13-23
illnesses	O	24-33
may	O	34-37
arise	O	38-43
because	O	44-51
of	O	52-54
perturbations	O	55-68
in	O	69-71
distinct	O	72-80
but	O	81-84
interrelated	O	85-97
tiers	O	98-103
of	O	104-106
RNA	O	107-110
-	O	110-111
based	O	111-116
genetic	O	117-124
regulation	O	125-135
:	O	135-136
pre	O	137-140
-	O	140-141
mRNA	O	141-145
splicing	O	146-154
;	O	154-155
nonsplicing	O	156-167
RNA	O	168-171
modifications	O	172-185
;	O	185-186
and	O	187-190
mRNA	O	191-195
translational	O	196-209
regulation	O	210-220
. 	O	220-222

A	O	0-1
variety	O	2-9
of	O	10-12
unforeseen	O	13-23
complexities	O	24-36
have	O	37-41
been	O	42-46
identified	O	47-57
,	O	57-58
many	O	59-63
with	O	64-68
relevance	O	69-78
to	O	79-81
human	O	82-87
brain	O	88-93
disease	O	94-101
. 	O	101-103

RNA	O	0-3
research	O	4-12
has	O	13-16
made	O	17-21
great	O	22-27
progress	O	28-36
in	O	37-39
recent	O	40-46
years	O	47-52
. 	O	52-54

RNA	O	0-3
in	O	4-6
brain	O	7-12
disease	O	13-20
:	O	20-21
no	O	22-24
longer	O	25-31
just	O	32-36
"	O	37-38
the	O	38-41
messenger	O	42-51
in	O	52-54
the	O	55-58
middle	O	59-65
"	O	65-66
.  	O	66-69

Here	O	0-4
we	O	5-7
present	O	8-15
an	O	16-18
overview	O	19-27
of	O	28-30
new	O	31-34
research	O	35-43
highlighting	O	44-56
functions	O	57-66
for	O	67-70
RNA	O	71-74
that	O	75-79
far	O	80-83
surpass	O	84-91
the	O	92-95
"	O	96-97
messenger	O	97-106
in	O	107-109
the	O	110-113
middle	O	114-120
"	O	120-121
role	O	122-126
and	O	127-130
that	O	131-135
identify	O	136-144
RNA	O	145-148
molecules	O	149-158
as	O	159-161
important	O	162-171
agents	O	172-178
in	O	179-181
the	O	182-185
human	O	186-191
brain	O	192-197
in	O	198-200
health	O	201-207
and	O	208-211
in	O	212-214
disease	O	215-222
states	O	223-229
.   	O	229-233

Gliomas	O	0-7
display	O	8-15
a	O	16-17
microRNA	O	18-26
expression	O	27-37
profile	O	38-45
reminiscent	O	46-57
of	O	58-60
neural	O	61-67
precursor	O	68-77
cells	O	78-83
.  	O	83-86

Gliomas	O	0-7
express	O	8-15
many	O	16-20
genes	O	21-26
that	O	27-31
play	O	32-36
a	O	37-38
role	O	39-43
in	O	44-46
neural	O	47-53
precursor	O	54-63
cells	O	64-69
(	O	70-71
NPCs	O	71-75
)	O	75-76
,	O	76-77
but	O	78-81
no	O	82-84
direct	O	85-91
comparison	O	92-102
between	O	103-110
glioma	O	111-117
and	O	118-121
stem	O	122-126
cell	O	127-131
(	O	132-133
SC	O	133-135
)	O	135-136
gene	O	137-141
expression	O	142-152
profiles	O	153-161
has	O	162-165
been	O	166-170
performed	O	171-180
. 	O	180-182

To	O	0-2
investigate	O	3-14
the	O	15-18
similarities	O	19-31
and	O	32-35
differences	O	36-47
between	O	48-55
gliomas	O	56-63
and	O	64-67
SCs	O	68-71
,	O	71-72
we	O	73-75
compared	O	76-84
the	O	85-88
microRNA	O	89-97
(	O	98-99
miRNA	O	99-104
)	O	104-105
expression	O	106-116
signatures	O	117-127
of	O	128-130
glial	O	131-136
tumors	O	137-143
,	O	143-144
embryonic	O	145-154
SCs	O	155-158
(	O	159-160
ESCs	O	160-164
)	O	164-165
,	O	165-166
NPCs	O	167-171
,	O	171-172
and	O	173-176
normal	O	177-183
adult	O	184-189
brains	O	190-196
from	O	197-201
both	O	202-206
human	O	207-212
and	O	213-216
mouse	O	217-222
tissues	O	223-230
. 	O	230-232

We	O	0-2
demonstrated	O	3-15
that	O	16-20
both	O	21-25
human	O	26-31
gliomas	O	32-39
(	O	40-41
regardless	O	41-51
of	O	52-54
their	O	55-60
grade	O	61-66
)	O	66-67
and	O	68-71
methylcholanthrene	O	72-90
-	O	90-91
induced	O	91-98
mouse	O	99-104
glioma	O	105-111
shared	O	112-118
an	O	119-121
miRNA	O	122-127
expression	O	128-138
profile	O	139-146
that	O	147-151
is	O	152-154
reminiscent	O	155-166
of	O	167-169
NPCs	O	170-174
. 	O	174-176

About	O	0-5
half	O	6-10
of	O	11-13
the	O	14-17
miRNAs	O	18-24
expressed	O	25-34
in	O	35-37
the	O	38-41
shared	O	42-48
profile	O	49-56
clustered	O	57-66
in	O	67-69
seven	O	70-75
genomic	O	76-83
regions	O	84-91
susceptible	O	92-103
to	O	104-106
genetic	O	107-114
/	O	114-115
epigenetic	O	115-125
alterations	O	126-137
in	O	138-140
various	O	141-148
cancers	O	149-156
. 	O	156-158

These	O	0-5
clusters	O	6-14
comprised	O	15-24
the	O	25-28
miR17	B	29-34
family	O	35-41
,	O	41-42
mir183	B	43-49
-	I	49-50
182	I	50-53
,	O	53-54
and	O	55-58
the	O	59-62
SC	O	63-65
-	O	65-66
specific	O	66-74
clusters	O	75-83
mir367	B	84-90
-	I	90-91
302	I	91-94
and	O	95-98
mir371	B	99-105
-	I	105-106
373	I	106-109
,	O	109-110
which	O	111-116
are	O	117-120
upregulated	O	121-132
in	O	133-135
gliomas	O	136-143
,	O	143-144
ESCs	O	145-149
,	O	149-150
and	O	151-154
NPCs	O	155-159
. 	O	159-161

The	O	0-3
bipartite	O	4-13
cluster	O	14-21
of	O	22-24
7	O	25-26
+	O	27-28
46	O	29-31
miRNAs	O	32-38
on	O	39-41
chromosome	O	42-52
14q32	O	53-58
.	O	58-59
31	O	59-61
, 	O	61-63

which	O	0-5
might	O	6-11
represent	O	12-21
the	O	22-25
largest	O	26-33
tumor	O	34-39
suppressor	O	40-50
miRNA	O	51-56
cluster	O	57-64
,	O	64-65
was	O	66-69
downregulated	O	70-83
in	O	84-86
the	O	87-90
shared	O	91-97
expression	O	98-108
profile	O	109-116
. 	O	116-118

This	O	0-4
study	O	5-10
provides	O	11-19
the	O	20-23
first	O	24-29
evidence	O	30-38
for	O	39-42
association	O	43-54
between	O	55-62
these	O	63-68
clusters	O	69-77
and	O	78-81
gliomas	O	82-89
. 	O	89-91

Despite	O	0-7
the	O	8-11
broad	O	12-17
similarity	O	18-28
in	O	29-31
the	O	32-35
miRNA	O	36-41
expression	O	42-52
profiles	O	53-61
,	O	61-62
15	O	63-65
miRNAs	O	66-72
showed	O	73-79
disparate	O	80-89
expression	O	90-100
between	O	101-108
SC	O	109-111
and	O	112-115
gliomas	O	116-123
. 	O	123-125

Ten	O	0-3
miRNAs	O	4-10
belong	O	11-17
to	O	18-20
the	O	21-24
2	O	25-26
SC	O	27-29
-	O	29-30
specific	O	30-38
clusters	O	39-47
and	O	48-51
the	O	52-55
remaining	O	56-65
(	O	66-67
mir135b	B	67-74
,	O	74-75
mir141	B	76-82
,	O	82-83
mir205	B	84-90
,	O	90-91
mir200C	B	92-99
,	O	99-100
and	O	101-104
mir301a	B	105-112
)	O	112-113
have	O	114-118
been	O	119-123
previously	O	124-134
shown	O	135-140
to	O	141-143
associate	O	144-153
with	O	154-158
malignancies	O	159-171
. 	O	171-173

Our	O	0-3
finding	O	4-11
showed	O	12-18
that	O	19-23
all	O	24-27
gliomas	O	28-35
displayed	O	36-45
NPC	O	46-49
-	O	49-50
like	O	50-54
miRNA	O	55-60
signatures	O	61-71
,	O	71-72
which	O	73-78
may	O	79-82
have	O	83-87
implications	O	88-100
for	O	101-104
studies	O	105-112
of	O	113-115
glioma	O	116-122
origins	O	123-130
. 	O	130-132

Furthermore	O	0-11
,	O	11-12
careful	O	13-20
study	O	21-26
of	O	27-29
the	O	30-33
15	O	34-36
miRNAs	O	37-43
that	O	44-48
differ	O	49-55
in	O	56-58
expression	O	59-69
between	O	70-77
SCs	O	78-81
and	O	82-85
gliomas	O	86-93
,	O	93-94
particularly	O	95-107
those	O	108-113
5	O	114-115
that	O	116-120
are	O	121-124
not	O	125-128
SC	O	129-131
-	O	131-132
specific	O	132-140
,	O	140-141
may	O	142-145
enhance	O	146-153
our	O	154-157
understanding	O	158-171
of	O	172-174
gliomagenesis	O	175-188
.   	O	188-192

Finally	O	0-7
,	O	7-8
we	O	9-11
will	O	12-16
discuss	O	17-24
fundamental	O	25-36
issues	O	37-43
to	O	44-46
be	O	47-49
considered	O	50-60
in	O	61-63
study	O	64-69
design	O	70-76
when	O	77-81
targeting	O	82-91
the	O	92-95
epigenome	O	96-105
.   	O	105-109

Pharmacology	O	0-12
of	O	13-15
epigenetics	O	16-27
in	O	28-30
brain	O	31-36
disorders	O	37-46
.  	O	46-49

Epigenetics	O	0-11
is	O	12-14
a	O	15-16
rapidly	O	17-24
growing	O	25-32
field	O	33-38
and	O	39-42
holds	O	43-48
great	O	49-54
promise	O	55-62
for	O	63-66
a	O	67-68
range	O	69-74
of	O	75-77
human	O	78-83
diseases	O	84-92
,	O	92-93
including	O	94-103
brain	O	104-109
disorders	O	110-119
such	O	120-124
as	O	125-127
Rett	O	128-132
syndrome	O	133-141
,	O	141-142
anxiety	O	143-150
and	O	151-154
depressive	O	155-165
disorders	O	166-175
,	O	175-176
schizophrenia	O	177-190
,	O	190-191
Alzheimer	O	192-201
disease	O	202-209
and	O	210-213
Huntington	O	214-224
disease	O	225-232
. 	O	232-234

This	O	0-4
review	O	5-11
is	O	12-14
concerned	O	15-24
with	O	25-29
the	O	30-33
pharmacology	O	34-46
of	O	47-49
epigenetics	O	50-61
to	O	62-64
treat	O	65-70
disorders	O	71-80
of	O	81-83
the	O	84-87
epigenome	O	88-97
whether	O	98-105
induced	O	106-113
developmentally	O	114-129
or	O	130-132
manifested	O	133-143
/	O	143-144
acquired	O	144-152
later	O	153-158
in	O	159-161
life	O	162-166
. 	O	166-168

In	O	0-2
particular	O	3-13
,	O	13-14
we	O	15-17
will	O	18-22
focus	O	23-28
on	O	29-31
brain	O	32-37
disorders	O	38-47
and	O	48-51
their	O	52-57
treatment	O	58-67
by	O	68-70
drugs	O	71-76
that	O	77-81
modify	O	82-88
the	O	89-92
epigenome	O	93-102
. 	O	102-104

While	O	0-5
the	O	6-9
use	O	10-13
of	O	14-16
DNA	O	17-20
methyl	O	21-27
transferase	O	28-39
inhibitors	O	40-50
and	O	51-54
histone	O	55-62
deacetylase	O	63-74
inhibitors	O	75-85
in	O	86-88
in	O	89-91
vitro	O	92-97
and	O	98-101
in	O	102-104
vivo	O	105-109
models	O	110-116
have	O	117-121
demonstrated	O	122-134
improvements	O	135-147
in	O	148-150
disease	O	151-158
-	O	158-159
related	O	159-166
deficits	O	167-175
,	O	175-176
clinical	O	177-185
trials	O	186-192
in	O	193-195
humans	O	196-202
have	O	203-207
been	O	208-212
less	O	213-217
promising	O	218-227
. 	O	227-229

We	O	0-2
will	O	3-7
address	O	8-15
recent	O	16-22
advances	O	23-31
in	O	32-34
our	O	35-38
understanding	O	39-52
of	O	53-55
the	O	56-59
complexity	O	60-70
of	O	71-73
the	O	74-77
epigenome	O	78-87
with	O	88-92
its	O	93-96
many	O	97-101
molecular	O	102-111
players	O	112-119
,	O	119-120
and	O	121-124
discuss	O	125-132
evidence	O	133-141
for	O	142-145
a	O	146-147
compromised	O	148-159
epigenome	O	160-169
in	O	170-172
the	O	173-176
context	O	177-184
of	O	185-187
an	O	188-190
ageing	O	191-197
or	O	198-200
diseased	O	201-209
brain	O	210-215
. 	O	215-217

We	O	0-2
will	O	3-7
also	O	8-12
draw	O	13-17
on	O	18-20
examples	O	21-29
of	O	30-32
species	O	33-40
differences	O	41-52
that	O	53-57
may	O	58-61
exist	O	62-67
between	O	68-75
humans	O	76-82
and	O	83-86
model	O	87-92
systems	O	93-100
,	O	100-101
emphasizing	O	102-113
the	O	114-117
need	O	118-122
for	O	123-126
more	O	127-131
robust	O	132-138
pre	O	139-142
-	O	142-143
clinical	O	143-151
testing	O	152-159
. 	O	159-161

This	O	0-4
review	O	5-11
discusses	O	12-21
potential	O	22-31
RNAi	O	32-36
-	O	36-37
based	O	37-42
targets	O	43-50
that	O	51-55
are	O	56-59
of	O	60-62
interest	O	63-71
for	O	72-75
epilepsy	O	76-84
therapy	O	85-92
,	O	92-93
including	O	94-103
adenosine	O	104-113
kinase	O	114-120
(	O	121-122
ADK	O	122-125
)	O	125-126
,	O	126-127
the	O	128-131
key	O	132-135
negative	O	136-144
regulator	O	145-154
of	O	155-157
the	O	158-161
brain	O	162-167
'	O	167-168
s	O	168-169
endogenous	O	170-180
anticonvulsant	O	181-195
adenosine	O	196-205
. 	O	205-207

Therapeutic	O	0-11
RNAi	O	12-16
has	O	17-20
been	O	21-25
widely	O	26-32
explored	O	33-41
for	O	42-45
dominant	O	46-54
targets	O	55-62
involved	O	63-71
in	O	72-74
neurodegenerative	O	75-92
diseases	O	93-101
;	O	101-102
however	O	103-110
,	O	110-111
their	O	112-117
use	O	118-121
for	O	122-125
epilepsy	O	126-134
therapy	O	135-142
has	O	143-146
received	O	147-155
less	O	156-160
attention	O	161-170
. 	O	170-172

Therefore	O	0-9
,	O	9-10
RNAi	O	11-15
-	O	15-16
strategies	O	16-26
aimed	O	27-32
at	O	33-35
reducing	O	36-44
ADK	O	45-48
(	O	49-50
and	O	50-53
increasing	O	54-64
adenosine	O	65-74
)	O	74-75
are	O	76-79
based	O	80-85
on	O	86-88
a	O	89-90
direct	O	91-97
neurochemical	O	98-111
rationale	O	112-121
that	O	122-126
has	O	127-130
recently	O	131-139
been	O	140-144
explored	O	145-153
experimentally	O	154-168
using	O	169-174
ex	O	175-177
vivo	O	178-182
and	O	183-186
in	O	187-189
vivo	O	190-194
gene	O	195-199
therapy	O	200-207
approaches	O	208-218
. 	O	218-220

Overexpression	O	0-14
of	O	15-17
ADK	O	18-21
,	O	21-22
and	O	23-26
the	O	27-30
resulting	O	31-40
adenosine	O	41-50
deficiency	O	51-61
,	O	61-62
are	O	63-66
pathologic	O	67-77
hallmarks	O	78-87
of	O	88-90
the	O	91-94
sclerotic	O	95-104
epileptic	O	105-114
brain	O	115-120
,	O	120-121
and	O	122-125
have	O	126-130
been	O	131-135
implicated	O	136-146
in	O	147-149
seizure	O	150-157
generation	O	158-168
. 	O	168-170

Inhibitory	O	0-10
RNA	O	11-14
in	O	15-17
epilepsy	O	18-26
:	O	26-27
research	O	28-36
tools	O	37-42
and	O	43-46
therapeutic	O	47-58
perspectives	O	59-71
.  	O	71-74

In	O	0-2
contrast	O	3-11
to	O	12-14
conventional	O	15-27
antiepileptic	O	28-41
drugs	O	42-47
(	O	48-49
AEDs	O	49-53
)	O	53-54
that	O	55-59
target	O	60-66
specific	O	67-75
proteins	O	76-84
such	O	85-89
as	O	90-92
ion	O	93-96
channels	O	97-105
or	O	106-108
receptors	O	109-118
,	O	118-119
RNAi	O	120-124
-	O	124-125
based	O	125-130
therapeutics	O	131-143
exploit	O	144-151
an	O	152-154
endogenous	O	155-165
regulatory	O	166-176
mechanism	O	177-186
of	O	187-189
gene	O	190-194
expression	O	195-205
and	O	206-209
thereby	O	210-217
are	O	218-221
poised	O	222-228
to	O	229-231
prevent	O	232-239
or	O	240-242
reverse	O	243-250
pathogenetic	O	251-263
mechanisms	O	264-274
involved	O	275-283
in	O	284-286
seizure	O	287-294
development	O	295-306
. 	O	306-308

Since	O	0-5
its	O	6-9
discovery	O	10-19
a	O	20-21
decade	O	22-28
ago	O	29-32
,	O	32-33
RNA	O	34-37
interference	O	38-50
(	O	51-52
RNAi	O	52-56
)	O	56-57
has	O	58-61
been	O	62-66
developed	O	67-76
not	O	77-80
only	O	81-85
into	O	86-90
powerful	O	91-99
experimental	O	100-112
tools	O	113-118
but	O	119-122
also	O	123-127
into	O	128-132
promising	O	133-142
novel	O	143-148
therapeutics	O	149-161
. 	O	161-163

Technical	O	0-9
issues	O	10-16
and	O	17-20
challenges	O	21-31
remain	O	32-38
before	O	39-45
those	O	46-51
promising	O	52-61
tools	O	62-67
can	O	68-71
be	O	72-74
developed	O	75-84
into	O	85-89
future	O	90-96
therapeutics	O	97-109
for	O	110-113
epilepsy	O	114-122
.   	O	122-126

A	O	0-1
series	O	2-8
of	O	9-11
novel	O	12-17
and	O	18-21
established	O	22-33
medulloblastoma	O	34-49
defects	O	50-57
were	O	58-62
detected	O	63-71
(	O	72-73
MYC	O	73-76
amplification	O	77-90
(	O	91-92
n	O	92-93
=	O	94-95
4	O	96-97
)	O	97-98
,	O	98-99
17q21	O	100-105
.	O	105-106
31	O	106-108
high	O	109-113
-	O	113-114
level	O	114-119
gain	O	120-124
(	O	125-126
n	O	126-127
=	O	128-129
1	O	130-131
)	O	131-132
;	O	132-133
9p21	O	134-138
.	O	138-139
1	O	139-140
-	O	140-141
p21	O	141-144
.	O	144-145
3	O	145-146
(	O	147-148
n	O	148-149
=	O	150-151
1	O	152-153
)	O	153-154
and	O	155-158
6q23	O	159-163
.	O	163-164
1	O	164-165
(	O	166-167
n	O	167-168
=	O	169-170
1	O	171-172
)	O	172-173
homozygous	O	174-184
deletion	O	185-193
)	O	193-194
. 	O	194-196

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
We	O	32-34
performed	O	35-44
a	O	45-46
SNP	O	47-50
-	O	50-51
array	O	51-56
based	O	57-62
genome	O	63-69
-	O	69-70
wide	O	70-74
copy	O	75-79
number	O	80-86
analysis	O	87-95
in	O	96-98
medulloblastoma	O	99-114
cell	O	115-119
lines	O	120-125
,	O	125-126
to	O	127-129
identify	O	130-138
regions	O	139-146
of	O	147-149
genomic	O	150-157
amplification	O	158-171
and	O	172-175
homozygous	O	176-186
deletion	O	187-195
,	O	195-196
which	O	197-202
may	O	203-206
harbour	O	207-214
critical	O	215-223
disease	O	224-231
genes	O	232-237
. 	O	237-239

Most	O	0-4
notably	O	5-12
,	O	12-13
a	O	14-15
novel	O	16-21
recurrent	O	22-31
region	O	32-38
of	O	39-41
genomic	O	42-49
amplification	O	50-63
at	O	64-66
8q24	O	67-71
.	O	71-72
22	O	72-74
-	O	74-75
q24	O	75-78
.	O	78-79
23	O	79-81
was	O	82-85
identified	O	86-96
(	O	97-98
n	O	98-99
=	O	100-101
2	O	102-103
)	O	103-104
,	O	104-105
and	O	106-109
selected	O	110-118
for	O	119-122
further	O	123-130
investigation	O	131-144
. 	O	144-146

Amplification	O	0-13
and	O	14-17
overexpression	O	18-32
of	O	33-35
Hsa	B	36-39
-	I	39-40
miR	I	40-43
-	I	43-44
30b	I	44-47
,	O	47-48
Hsa	B	49-52
-	I	52-53
miR	I	53-56
-	I	56-57
30d	I	57-60
and	O	61-64
KHDRBS3	O	65-72
at	O	73-75
8q24	O	76-80
.	O	80-81
22	O	81-83
-	O	83-84
q24	O	84-87
.	O	87-88
23	O	88-90
in	O	91-93
medulloblastoma	O	94-109
.  	O	109-112

The	O	0-3
identification	O	4-18
of	O	19-21
critical	O	22-30
genes	O	31-36
involved	O	37-45
in	O	46-48
its	O	49-52
pathogenesis	O	53-65
will	O	66-70
be	O	71-73
central	O	74-81
to	O	82-84
advances	O	85-93
in	O	94-96
our	O	97-100
understanding	O	101-114
of	O	115-117
its	O	118-121
molecular	O	122-131
basis	O	132-137
,	O	137-138
and	O	139-142
the	O	143-146
development	O	147-158
of	O	159-161
improved	O	162-170
therapeutic	O	171-182
approaches	O	183-193
. 	O	193-195

BACKGROUND	O	0-10
:	O	10-11
Medulloblastoma	O	12-27
is	O	28-30
the	O	31-34
most	O	35-39
common	O	40-46
malignant	O	47-56
brain	O	57-62
tumour	O	63-69
of	O	70-72
childhood	O	73-82
. 	O	82-84

Of	O	0-2
these	O	3-8
,	O	8-9
only	O	10-14
expression	O	15-25
of	O	26-28
hsa	B	29-32
-	I	32-33
miR	I	33-36
-	I	36-37
30b	I	37-40
,	O	40-41
hsa	B	42-45
-	I	45-46
miR	I	46-49
-	I	49-50
30d	I	50-53
and	O	54-57
KHDRBS3	O	58-65
correlated	O	66-76
with	O	77-81
copy	O	82-86
number	O	87-93
status	O	94-100
,	O	100-101
and	O	102-105
all	O	106-109
three	O	110-115
of	O	116-118
these	O	119-124
transcripts	O	125-136
also	O	137-141
displayed	O	142-151
evidence	O	152-160
of	O	161-163
elevated	O	164-172
expression	O	173-183
in	O	184-186
sub	O	187-190
-	O	190-191
sets	O	191-195
of	O	196-198
primary	O	199-206
medulloblastomas	O	207-223
,	O	223-224
measured	O	225-233
relative	O	234-242
to	O	243-245
the	O	246-249
normal	O	250-256
cerebellum	O	257-267
. 	O	267-269

Additional	O	0-10
analysis	O	11-19
by	O	20-22
interphase	O	23-33
fluorescence	O	34-46
in	O	47-49
situ	O	50-54
hybridisation	O	55-68
(	O	69-70
iFISH	O	70-75
)	O	75-76
,	O	76-77
PCR	O	78-81
-	O	81-82
based	O	82-87
mapping	O	88-95
and	O	96-99
SNP	O	100-103
-	O	103-104
array	O	104-109
revealed	O	110-118
this	O	119-123
novel	O	124-129
amplification	O	130-143
at	O	144-146
8q24	O	147-151
.	O	151-152
22	O	152-154
-	O	154-155
q24	O	155-158
.	O	158-159
23	O	159-161
is	O	162-164
independent	O	165-176
of	O	177-179
MYC	O	180-183
amplification	O	184-197
at	O	198-200
8q24	O	201-205
.	O	205-206
21	O	206-208
,	O	208-209
and	O	210-213
is	O	214-216
unique	O	217-223
to	O	224-226
medulloblastoma	O	227-242
in	O	243-245
over	O	246-250
800	O	251-254
cancer	O	255-261
cell	O	262-266
lines	O	267-272
assessed	O	273-281
from	O	282-286
different	O	287-296
tumour	O	297-303
types	O	304-309
,	O	309-310
suggesting	O	311-321
it	O	322-324
contains	O	325-333
key	O	334-337
genes	O	338-343
specifically	O	344-356
involved	O	357-365
in	O	366-368
medulloblastoma	O	369-384
development	O	385-396
. 	O	396-398

Detailed	O	0-8
mapping	O	9-16
identified	O	17-27
a	O	28-29
3Mb	O	30-33
common	O	34-40
minimal	O	41-48
region	O	49-55
of	O	56-58
amplification	O	59-72
harbouring	O	73-83
3	O	84-85
coding	O	86-92
genes	O	93-98
(	O	99-100
ZFAT1	O	100-105
,	O	105-106
LOC286094	O	107-116
,	O	116-117
KHDRBS3	O	118-125
)	O	125-126
and	O	127-130
two	O	131-134
genes	O	135-140
encoding	O	141-149
micro	O	150-155
-	O	155-156
RNAs	O	156-160
(	O	161-162
hsa	B	162-165
-	I	165-166
miR	I	166-169
-	I	169-170
30b	I	170-173
,	O	173-174
hsa	B	175-178
-	I	178-179
miR	I	179-182
-	I	182-183
30d	I	183-186
)	O	186-187
. 	O	187-189

Our	O	0-3
findings	O	4-12
suggest	O	13-20
critical	O	21-29
roles	O	30-35
for	O	36-39
these	O	40-45
genes	O	46-51
in	O	52-54
medulloblastoma	O	55-70
development	O	71-82
,	O	82-83
and	O	84-87
further	O	88-95
support	O	96-103
the	O	104-107
contribution	O	108-120
of	O	121-123
micro	O	124-129
-	O	129-130
RNA	O	130-133
species	O	134-141
to	O	142-144
medulloblastoma	O	145-160
pathogenesis	O	161-173
.   	O	173-177

CONCLUSIONS	O	0-11
/	O	11-12
SIGNIFICANCE	O	12-24
:	O	24-25
These	O	26-31
data	O	32-36
implicate	O	37-46
hsa	B	47-50
-	I	50-51
miR	I	51-54
-	I	54-55
30b	I	55-58
,	O	58-59
hsa	B	60-63
-	I	63-64
miR	I	64-67
-	I	67-68
30d	I	68-71
and	O	72-75
KHDRBS3	O	76-83
as	O	84-86
putative	O	87-95
oncogenic	O	96-105
target	O	106-112
(	O	112-113
s	O	113-114
)	O	114-115
of	O	116-118
a	O	119-120
novel	O	121-126
recurrent	O	127-136
medulloblastoma	O	137-152
amplicon	O	153-161
at	O	162-164
8q24	O	165-169
.	O	169-170
22	O	170-172
-	O	172-173
q24	O	173-176
.	O	176-177
23	O	177-179
. 	O	179-181

Recently	O	0-8
,	O	8-9
it	O	10-12
was	O	13-16
demonstrated	O	17-29
that	O	30-34
podoplanin	O	35-45
membrane	O	46-54
sialo	O	55-60
-	O	60-61
glycoprotein	O	61-73
encoded	O	74-81
by	O	82-84
PDPN	O	85-89
gene	O	90-94
is	O	95-97
over	O	98-102
-	O	102-103
expressed	O	103-112
and	O	113-116
related	O	117-124
to	O	125-127
cellular	O	128-136
invasion	O	137-145
in	O	146-148
astrocytic	O	149-159
tumors	O	160-166
;	O	166-167
however	O	168-175
the	O	176-179
mechanisms	O	180-190
of	O	191-193
regulation	O	194-204
are	O	205-208
still	O	209-214
unknown	O	215-222
. 	O	222-224

Glioblastoma	O	0-12
is	O	13-15
the	O	16-19
most	O	20-24
frequent	O	25-33
and	O	34-37
malignant	O	38-47
brain	O	48-53
tumor	O	54-59
,	O	59-60
characterized	O	61-74
by	O	75-77
an	O	78-80
elevated	O	81-89
capacity	O	90-98
for	O	99-102
cellular	O	103-111
proliferation	O	112-125
and	O	126-129
invasion	O	130-138
. 	O	138-140

miR	B	0-3
-	I	3-4
29b	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
125a	I	16-20
regulate	O	21-29
podoplanin	O	30-40
and	O	41-44
suppress	O	45-53
invasion	O	54-62
in	O	63-65
glioblastoma	O	66-78
.  	O	78-81

Taken	O	0-5
together	O	6-14
,	O	14-15
these	O	16-21
results	O	22-29
suggest	O	30-37
that	O	38-42
miR	B	43-46
-	I	46-47
29b	I	47-50
and	O	51-54
miR	B	55-58
-	I	58-59
125a	I	59-63
represent	O	64-73
potential	O	74-83
therapeutic	O	84-95
targets	O	96-103
in	O	104-106
glioblastoma	O	107-119
.   	O	119-123

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
focused	O	18-25
on	O	26-28
miR	B	29-32
-	I	32-33
29b	I	33-36
and	O	37-40
miR	B	41-44
-	I	44-45
125a	I	45-49
,	O	49-50
which	O	51-56
were	O	57-61
predicted	O	62-71
to	O	72-74
regulate	O	75-83
PDPN	O	84-88
,	O	88-89
and	O	90-93
demonstrated	O	94-106
that	O	107-111
these	O	112-117
microRNAs	O	118-127
directly	O	128-136
target	O	137-143
the	O	144-147
3	O	148-149
'	O	149-150
untranslated	O	151-163
region	O	164-170
of	O	171-173
PDPN	O	174-178
and	O	179-182
inhibit	O	183-190
invasion	O	191-199
,	O	199-200
apoptosis	O	201-210
,	O	210-211
and	O	212-215
proliferation	O	216-229
of	O	230-232
glioblastomas	O	233-246
. 	O	246-248

Furthermore	O	0-11
,	O	11-12
we	O	13-15
report	O	16-22
that	O	23-27
miR	B	28-31
-	I	31-32
29b	I	32-35
and	O	36-39
miR	B	40-43
-	I	43-44
125a	I	44-48
are	O	49-52
downregulated	O	53-66
in	O	67-69
glioblastomas	O	70-83
and	O	84-87
also	O	88-92
in	O	93-95
CD133	O	96-101
-	O	101-102
positive	O	102-110
cells	O	111-116
. 	O	116-118

MicroRNAs	O	0-9
are	O	10-13
noncoding	O	14-23
RNAs	O	24-28
that	O	29-33
regulate	O	34-42
gene	O	43-47
expression	O	48-58
and	O	59-62
several	O	63-70
biological	O	71-81
processes	O	82-91
and	O	92-95
diseases	O	96-104
,	O	104-105
including	O	106-115
cancer	O	116-122
. 	O	122-124

Nevertheless	O	0-12
,	O	12-13
their	O	14-19
roles	O	20-25
in	O	26-28
invasion	O	29-37
,	O	37-38
proliferation	O	39-52
,	O	52-53
and	O	54-57
apoptosis	O	58-67
of	O	68-70
glioblastoma	O	71-83
are	O	84-87
not	O	88-91
completely	O	92-102
understood	O	103-113
. 	O	113-115

We	O	0-2
also	O	3-7
found	O	8-13
that	O	14-18
miR	B	19-22
-	I	22-23
326	I	23-26
promoted	O	27-35
T	O	36-37
(	O	37-38
H	O	38-39
)	O	39-40
-	O	40-41
17	O	41-43
differentiation	O	44-59
by	O	60-62
targeting	O	63-72
Ets	O	73-76
-	O	76-77
1	O	77-78
,	O	78-79
a	O	80-81
negative	O	82-90
regulator	O	91-100
of	O	101-103
T	O	104-105
(	O	105-106
H	O	106-107
)	O	107-108
-	O	108-109
17	O	109-111
differentiation	O	112-127
. 	O	127-129

Our	O	0-3
data	O	4-8
show	O	9-13
a	O	14-15
critical	O	16-24
role	O	25-29
for	O	30-33
microRNA	O	34-42
in	O	43-45
T	O	46-47
(	O	47-48
H	O	48-49
)	O	49-50
-	O	50-51
17	O	51-53
differentiation	O	54-69
and	O	70-73
the	O	74-77
pathogenesis	O	78-90
of	O	91-93
multiple	O	94-102
sclerosis	O	103-112
.   	O	112-116

Interleukin	O	0-11
17	O	12-14
(	O	15-16
IL	O	16-18
-	O	18-19
17	O	19-21
)	O	21-22
-	O	22-23
producing	O	23-32
T	O	33-34
helper	O	35-41
cells	O	42-47
(	O	48-49
T	O	49-50
(	O	50-51
H	O	51-52
)	O	52-53
-	O	53-54
17	O	54-56
cells	O	57-62
)	O	62-63
are	O	64-67
increasingly	O	68-80
recognized	O	81-91
as	O	92-94
key	O	95-98
participants	O	99-111
in	O	112-114
various	O	115-122
autoimmune	O	123-133
diseases	O	134-142
,	O	142-143
including	O	144-153
multiple	O	154-162
sclerosis	O	163-172
. 	O	172-174

Although	O	0-8
sets	O	9-13
of	O	14-16
transcription	O	17-30
factors	O	31-38
and	O	39-42
cytokines	O	43-52
are	O	53-56
known	O	57-62
to	O	63-65
regulate	O	66-74
T	O	75-76
(	O	76-77
H	O	77-78
)	O	78-79
-	O	79-80
17	O	80-82
differentiation	O	83-98
,	O	98-99
the	O	100-103
role	O	104-108
of	O	109-111
noncoding	O	112-121
RNA	O	122-125
is	O	126-128
poorly	O	129-135
understood	O	136-146
. 	O	146-148

Here	O	0-4
we	O	5-7
identify	O	8-16
a	O	17-18
T	O	19-20
(	O	20-21
H	O	21-22
)	O	22-23
-	O	23-24
17	O	24-26
cell	O	27-31
-	O	31-32
associated	O	32-42
microRNA	O	43-51
,	O	51-52
miR	B	53-56
-	I	56-57
326	I	57-60
,	O	60-61
whose	O	62-67
expression	O	68-78
was	O	79-82
highly	O	83-89
correlated	O	90-100
with	O	101-105
disease	O	106-113
severity	O	114-122
in	O	123-125
patients	O	126-134
with	O	135-139
multiple	O	140-148
sclerosis	O	149-158
and	O	159-162
mice	O	163-167
with	O	168-172
experimental	O	173-185
autoimmune	O	186-196
encephalomyelitis	O	197-214
(	O	215-216
EAE	O	216-219
)	O	219-220
. 	O	220-222

In	O	0-2
vivo	O	3-7
silencing	O	8-17
of	O	18-20
miR	B	21-24
-	I	24-25
326	I	25-28
resulted	O	29-37
in	O	38-40
fewer	O	41-46
T	O	47-48
(	O	48-49
H	O	49-50
)	O	50-51
-	O	51-52
17	O	52-54
cells	O	55-60
and	O	61-64
mild	O	65-69
EAE	O	70-73
,	O	73-74
and	O	75-78
its	O	79-82
overexpression	O	83-97
led	O	98-101
to	O	102-104
more	O	105-109
T	O	110-111
(	O	111-112
H	O	112-113
)	O	113-114
-	O	114-115
17	O	115-117
cells	O	118-123
and	O	124-127
severe	O	128-134
EAE	O	135-138
. 	O	138-140

MicroRNA	O	0-8
miR	B	9-12
-	I	12-13
326	I	13-16
regulates	O	17-26
TH	O	27-29
-	O	29-30
17	O	30-32
differentiation	O	33-48
and	O	49-52
is	O	53-55
associated	O	56-66
with	O	67-71
the	O	72-75
pathogenesis	O	76-88
of	O	89-91
multiple	O	92-100
sclerosis	O	101-110
.  	O	110-113

Parkinson	O	0-9
disease	O	10-17
(	O	18-19
PD	O	19-21
)	O	21-22
is	O	23-25
a	O	26-27
common	O	28-34
neurodegenerative	O	35-52
disorder	O	53-61
caused	O	62-68
by	O	69-71
environmental	O	72-85
and	O	86-89
genetic	O	90-97
factors	O	98-105
. 	O	105-107

Variation	O	0-9
in	O	10-12
the	O	13-16
miRNA	B	17-22
-	I	22-23
433	I	23-26
binding	O	27-34
site	O	35-39
of	O	40-42
FGF20	O	43-48
confers	O	49-56
risk	O	57-61
for	O	62-65
Parkinson	O	66-75
disease	O	76-83
by	O	84-86
overexpression	O	87-101
of	O	102-104
alpha	O	105-110
-	O	110-111
synuclein	O	111-120
.  	O	120-123

Subsequently	O	0-12
,	O	12-13
fibroblast	O	14-24
growth	O	25-31
factor	O	32-38
20	O	39-41
(	O	42-43
FGF20	O	43-48
)	O	48-49
at	O	50-52
8p21	O	53-57
.	O	57-58
3	O	58-59
-	O	59-60
22	O	60-62
was	O	63-66
identified	O	67-77
as	O	78-80
a	O	81-82
risk	O	83-87
factor	O	88-94
in	O	95-97
several	O	98-105
association	O	106-117
studies	O	118-125
. 	O	125-127

We	O	0-2
have	O	3-7
previously	O	8-18
shown	O	19-24
linkage	O	25-32
of	O	33-35
PD	O	36-38
to	O	39-41
chromosome	O	42-52
8p	O	53-55
. 	O	55-57

In	O	0-2
a	O	3-4
sample	O	5-11
of	O	12-14
729	O	15-18
nuclear	O	19-26
families	O	27-35
with	O	36-40
1089	O	41-45
affected	O	46-54
and	O	55-58
1165	O	59-63
unaffected	O	64-74
individuals	O	75-86
,	O	86-87
the	O	88-91
strongest	O	92-101
evidence	O	102-110
of	O	111-113
association	O	114-125
came	O	126-130
from	O	131-135
rs12720208	O	136-146
in	O	147-149
the	O	150-153
3	O	154-155
'	O	155-156
untranslated	O	157-169
region	O	170-176
of	O	177-179
FGF20	O	180-185
. 	O	185-187

To	O	0-2
identify	O	3-11
the	O	12-15
risk	O	16-20
-	O	20-21
conferring	O	21-31
polymorphism	O	32-44
in	O	45-47
FGF20	O	48-53
,	O	53-54
we	O	55-57
performed	O	58-67
genetic	O	68-75
and	O	76-79
functional	O	80-90
analysis	O	91-99
of	O	100-102
single	O	103-109
-	O	109-110
nucleotide	O	110-120
polymorphisms	O	121-134
within	O	135-141
the	O	142-145
gene	O	146-150
. 	O	150-152

In	O	0-2
a	O	3-4
cell	O	5-9
-	O	9-10
based	O	10-15
system	O	16-22
and	O	23-26
in	O	27-29
PD	O	30-32
brains	O	33-39
,	O	39-40
this	O	41-45
increase	O	46-54
in	O	55-57
translation	O	58-69
of	O	70-72
FGF20	O	73-78
is	O	79-81
correlated	O	82-92
with	O	93-97
increased	O	98-107
alpha	O	108-113
-	O	113-114
synuclein	O	114-123
expression	O	124-134
,	O	134-135
which	O	136-141
has	O	142-145
previously	O	146-156
been	O	157-161
shown	O	162-167
to	O	168-170
cause	O	171-176
PD	O	177-179
through	O	180-187
both	O	188-192
overexpression	O	193-207
and	O	208-211
point	O	212-217
mutations	O	218-227
. 	O	227-229

We	O	0-2
show	O	3-7
in	O	8-10
several	O	11-18
functional	O	19-29
assays	O	30-36
that	O	37-41
the	O	42-45
risk	O	46-50
allele	O	51-57
for	O	58-61
rs12720208	O	62-72
disrupts	O	73-81
a	O	82-83
binding	O	84-91
site	O	92-96
for	O	97-100
microRNA	B	101-109
-	I	109-110
433	I	110-113
,	O	113-114
increasing	O	115-125
translation	O	126-137
of	O	138-140
FGF20	O	141-146
in	O	147-149
vitro	O	150-155
and	O	156-159
in	O	160-162
vivo	O	163-167
. 	O	167-169

We	O	0-2
propose	O	3-10
this	O	11-15
is	O	16-18
likely	O	19-25
to	O	26-28
be	O	29-31
a	O	32-33
common	O	34-40
mechanism	O	41-50
of	O	51-53
genetic	O	54-61
modulation	O	62-72
of	O	73-75
individual	O	76-86
susceptibility	O	87-101
to	O	102-104
complex	O	105-112
disease	O	113-120
.   	O	120-124

We	O	0-2
suggest	O	3-10
a	O	11-12
novel	O	13-18
mechanism	O	19-28
of	O	29-31
action	O	32-38
for	O	39-42
PD	O	43-45
risk	O	46-50
in	O	51-53
which	O	54-59
the	O	60-63
modulation	O	64-74
of	O	75-77
the	O	78-81
susceptibility	O	82-96
gene	O	97-101
'	O	101-102
s	O	102-103
translation	O	104-115
by	O	116-118
common	O	119-125
variations	O	126-136
interfere	O	137-146
with	O	147-151
the	O	152-155
regulation	O	156-166
mechanisms	O	167-177
of	O	178-180
microRNA	O	181-189
. 	O	189-191

The	O	0-3
reason	O	4-10
why	O	11-14
a	O	15-16
mild	O	17-21
TBI	O	22-25
results	O	26-33
in	O	34-36
varying	O	37-44
clinical	O	45-53
symptoms	O	54-62
is	O	63-65
currently	O	66-75
unknown	O	76-83
. 	O	83-85

Based	O	0-5
on	O	6-8
evidence	O	9-17
that	O	18-22
microRNA	O	23-31
species	O	32-39
in	O	40-42
peripheral	O	43-53
blood	O	54-59
mononuclear	O	60-71
cells	O	72-77
(	O	78-79
PBMCs	O	79-84
)	O	84-85
may	O	86-89
reflect	O	90-97
molecular	O	98-107
alterations	O	108-119
in	O	120-122
neurodegenerative	O	123-140
disorders	O	141-150
,	O	150-151
it	O	152-154
can	O	155-158
be	O	159-161
hypothesized	O	162-174
that	O	175-179
at	O	180-182
early	O	183-188
,	O	188-189
preclinical	O	190-201
phases	O	202-208
of	O	209-211
the	O	212-215
disease	O	216-223
,	O	223-224
PBMC	O	225-229
may	O	230-233
provide	O	234-241
an	O	242-244
ideal	O	245-250
and	O	251-254
clinically	O	255-265
assessable	O	266-276
"	O	277-278
window	O	278-284
"	O	284-285
into	O	286-290
the	O	291-294
brain	O	295-300
. 	O	300-302

Patients	O	0-8
who	O	9-12
have	O	13-17
sustained	O	18-27
a	O	28-29
mild	O	30-34
traumatic	O	35-44
brain	O	45-50
injury	O	51-57
(	O	58-59
TBI	O	59-62
)	O	62-63
from	O	64-68
both	O	69-73
civilian	O	74-82
and	O	83-86
military	O	87-95
populations	O	96-107
exhibit	O	108-115
clinical	O	116-124
symptoms	O	125-133
of	O	134-136
varying	O	137-144
severity	O	145-153
with	O	154-158
minimal	O	159-166
to	O	167-169
profound	O	170-178
impact	O	179-185
on	O	186-188
their	O	189-194
daily	O	195-200
functioning	O	201-212
. 	O	212-214

Although	O	0-8
most	O	9-13
patients	O	14-22
make	O	23-27
a	O	28-29
full	O	30-34
recovery	O	35-43
,	O	43-44
a	O	45-46
subgroup	O	47-55
of	O	56-58
mild	O	59-63
TBI	O	64-67
patients	O	68-76
develop	O	77-84
cognitive	O	85-94
,	O	94-95
somatic	O	96-103
,	O	103-104
and	O	105-108
neurobehavioral	O	109-124
sequelae	O	125-133
that	O	134-138
generally	O	139-148
resolve	O	149-156
over	O	157-161
3	O	162-163
to	O	164-166
6	O	167-168
months	O	169-175
;	O	175-176
a	O	177-178
smaller	O	179-186
subgroup	O	187-195
develop	O	196-203
persisting	O	204-214
symptoms	O	215-223
. 	O	223-225

Personalized	O	0-12
medicine	O	13-21
in	O	22-24
traumatic	O	25-34
brain	O	35-40
injury	O	41-47
.  	O	47-50

Thus	O	0-4
,	O	4-5
it	O	6-8
is	O	9-11
conceivable	O	12-23
that	O	24-28
changes	O	29-36
in	O	37-39
the	O	40-43
expression	O	44-54
profile	O	55-62
of	O	63-65
clinically	O	66-76
accessible	O	77-87
biological	O	88-98
indices	O	99-106
(	O	107-108
biomarkers	O	108-118
)	O	118-119
,	O	119-120
such	O	121-125
as	O	126-128
microRNA	O	129-137
in	O	138-140
PBMC	O	141-145
,	O	145-146
may	O	147-150
reflect	O	151-158
molecular	O	159-168
alterations	O	169-180
following	O	181-190
TBI	O	191-194
that	O	195-199
contribute	O	200-210
to	O	211-213
the	O	214-217
onset	O	218-223
and	O	224-227
progression	O	228-239
of	O	240-242
TBI	O	243-246
phenotypes	O	247-257
including	O	258-267
chronic	O	268-275
traumatic	O	276-285
encephalopathy	O	286-300
. 	O	300-302

It	O	0-2
is	O	3-5
possible	O	6-14
that	O	15-19
the	O	20-23
availability	O	24-36
of	O	37-39
TBI	O	40-43
biomarkers	O	44-54
may	O	55-58
provide	O	59-66
potential	O	67-76
elements	O	77-85
with	O	86-90
clinical	O	91-99
relevance	O	100-109
to	O	110-112
prevention	O	113-123
,	O	123-124
prognosis	O	125-134
,	O	134-135
and	O	136-139
treatment	O	140-149
of	O	150-152
postconcussive	O	153-167
disorders	O	168-177
.   	O	177-181

